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Abstract 
Ultraviolet radiation (UVR) is immunosuppressive, particularly to antigen-specific ce ll -mediated 
processes, acting via direct and indirect (e.g. vitamin D-mediated) pathways. This research 
aimed to examine the influence of acute and cumulative solar UVR exposure, at doses relevant 
to day-to-day activities, on the primary immune response to immunisation in humans. 
The Australian Ultraviolet Radiation and Immunity (AusUVI) Study was a prospective, 
longitudinal, twin-centre immunotoxicological study. Healthy adults were immunised 
subcutaneously with the T-cell dependent antigen, keyhole limpet haemocyanin (KLH). Acute 
personal UVR exposure was measured by electron ic UVR dosimeter worn on the wrist for ten 
days centred on the day of immunisation; and by sun diary. Cumulative UVR exposure was 
quantified by microtopographic analysis of silicone impressions of sun exposed skin. Variables 
that might confound the association between UVR and vaccine immune respon se were 
measured, including serum vitamin D (2S(OH)D) level. Participants attended for five study 
visits over a period of 31 days, with recruitment spread over one year. Immune function 
outcomes were : anti-KLH lgGl antibody levels measured by enzyme linked immunoassay; 
delayed-type hypersensitivity (DTH) response to KLH antigen (reflecting T helper cell-1 (Thl) 
processes); and quantification ofT-helper ce ll subsets by flow cytometry-based methods. A 
pilot study trialled many components of the AusUVI Study protocol .and immune assays. 
The AusUVI Study was conducted in the Australian cities of Canberra (35°2'5) and Townsville 
(19°1'5) from July 2010 to August 2011 . Two hundr~d and twenty two healthy participants 
were recruited (Canberra : 110; Townsville: 112). Participants' average age was 27.9 years 
(range: 18-40 years) and 63.5% were female . Participants with both parents of northern 
European ancestry (70.0%) predominated. 2S(OH)D levels and personal UVR exposure varied 
by season and by site of enrolment. Townsville participants had higher 10-day clothing-
adjusted UVR exposure compared with Canberra participants (2.5 vs.l.8 standard erythemal 
dose (SED); p=0.003). Higher cumulative UVR exposure was strongly associated with age, male 
sex, Townsvil le residence and northern European ancestry. 
In multiple linear regression models, anti-KLH lgGl response at day 21 post-immunisation was 
associated with age (antibody titre reduced by 1.6% per year of age; p=0.001) and sex (14.6% 
higher titre in females compared with males (p=0.004)). No association between KLH lgGl 
response and acute or cumulative UVR exposure, or serum 25(OH)D levels was demonstrated. 
Reduced DTH response to KLH recall challenge at day 21 post-immunisation was associated 
with higher acute UVR exposure on the day prior ('Day S' ) to immunisation (p=0.015), and Days 
5-8 and 5-9 (p=0.039 and p=0.025, respectively) that spanned the pre- and post-immunisation 
period. No association with cumulative UVR or serum 25(OH)D levels was demonstrated. 
Change in T-helper 17 (Th17) cell percentage between pre- and post-vaccination time points 
differed in direction when comparing the low and high UVR exposure groups (-0.39% vs. 
0.31%; p=0.004). 
In conclusion, acute personal solar UVR exposure, at doses relevant to day-to-day activities, 
modulated the primary cell-mediated immune responses to KLH immunisation. Cumulative 
UVR exposure and serum 25(OH)D levels were not associated with immune function 
outcomes. 
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Introduction 
Solar ultraviolet radiation (UVR) is an important environmental exposure for terrestrial and 
aquatic life (1). UVR exposure is the major contributor to stores of vitamin Din humans; the 
active form of vitamin Dis required for calcium metabolism, optimal musculoskeletal health 
and other critical physiological processes (2). Vitamin D deficiency has been associated with 
numerous disease states, including osteomalacia, autoimmune diseases and solid-organ 
cancers (3) . Conversely, high UVR exposure leads to sunburn and is the strongest risk factor 
for several skin cancers and eye diseases (4) . These adverse health effects are likely related, at 
least in part, to the immunomodulatory effects of UVR exposure. 
What is known about photoimmunology? 
The study of the effects of non-ionising radiation on the immune system is known as 
'photoimmunology' (5) - in this thesis the term will be restricted to the effects of UVR 
(wavelengths 100nm - 400nm). The origins of this field can be traced to a series of seminal 
experiments conducted by Professor Margaret Kripke and colleagues in the 1970s relating to 
the control of skin tumours in mice. They elegantly demonstrated that irradiation with UVR 
induced an antigen-specific, cell-mediated and systemic immunosuppressive effect (6) . Since 
that time, UVR-induced immunomodulatory effects have been demonstrated using different 
antigens and in numerous contexts, including contact hypersensitivity and delayed-type 
hypersensitivity responses, infection and vaccination (7,8). 
Absorption of UVR by specific elements within the epidermis of the skin sets in train a complex 
cascade of processes that ultimately leads to both local and systemic immunosuppression. 
These steps include release of numerous chemical mediators (e.g. cytokines) and migration of 
immune cells (e.g. Langerhans cells) that lead to an immuno-tolerant environment within the 
draining lymph node (9). Regulatory T-cell lymphocytes have been shown to play an important 
mediatory role in this setting (10) . Calcitriol - the biologically active form of vitamin D - has 
also been shown to influence both innate and adaptive immune processes and constitutes 
another (indirect) pathway for UVR-induced immunomodulation (11). The overall effects of 
both UVR exposure and calcitriol on adaptive immunity are to suppress antigen-specific cell-
mediated ("Thl") immune processes and promote a regulatory immune environment (12) . 
Although the potential adverse clinical consequences for UVR-induced immunosuppression are 
obvious, namely increased risk of infection and cancer, the postulated benefits include 
reduced cutaneous reactivity (i.e. dermatitis) to non-pathogenic commensal organisms, 
increased time for cellular DNA repair and reduced rates of autoimmune disease (13,14). 
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These advantages constitute at least some of the evolutionary rationale for the human 
immune system's complex adaptations to a ubiquitous environmental exposure. 
Limitations in current models used in photoimmunology 
Much of what is currently known about photoimmunology has resulted from studies that have 
simulated conditions that are not relevant to typical UVR exposures experienced by humans. 
Many studies have used animal models of the immune system where UVR exposure has been 
derived from artificial sources, at non-solar spectra and/or delivered at supra-normal doses 
(8). Studies involving humans have often suffered from similar limitations, but additionally 
have been restricted by sma ll numbers and/or non-consideration of other potential 
immunomodulatory factors (e.g. vitamin D status) (15,16). Many ecological studies have not 
directly measured UVR exposure at an individual level but instead used surrogates of UVR 
exposure such as latitude of residence or season (17,18), which can potentially lead to 
misleading inferences. 
There has been very limited research assessing whether UVR exposure adversely affects the 
immune response to vaccination, despite this having important public health implications. In 
humans, there has been only one clinica l trial involving vaccination that has taken into account 
UVR exposure at an individual level {19). Although wel l designed and assessing a range of 
immune outcomes, methodological limitations of this study that related to the vaccine used in 
particular narrowed the conclusions that could be drawn (7). 
lmmunotoxicology can inform human photoimmunological research 
lmmunotoxicology relates to the study of adverse influences of putative toxins on immune 
function and the resultant risks posed to health (20). The principles and practices 
underpinning this relatively nascent research field lend themselves well to better 
understanding the effects of UVR exposure on human immune function. 
lmmunotoxicological literature and guidelines emphasise the accurate quantification of both 
toxin exposure (at an individual level) and immune outcome (using a combination of immune 
tests), with measurement of potential confounding factors (21,22). Immunisation with a T-cell 
dependent antigen has been promoted as a safe, reliable tool for characterising and 
quantifying alterations in the human immune response to putative toxins (23). Processing of a 
novel vaccine antigen allows for primary cell-mediated and humoral responses to be 
generated, and, importantly, quantified using ex vivo and in vivo assays. Recent advances in 
UVR measurement with electronic dosimeters, in conjunction with diary data, enables the 
accurate quantification of personal UVR exposure (24,25). 
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Aims of this doctoral research 
The aim of the doctoral research was to examine the effect of naturally-acquired solar UVR 
exposure, at doses relevant to day-to-day activity, on the primary immune response to 
immunisation in humans. The research relied heavily on the principles and methods espoused 
by the fields of immunotoxicology and clinical epidemiology, to robustly examine the 
association between UVR exposure and immune responses under 'real life' conditions. A 
major emphasis of this work was to measure and adjust for other potential 
immunomodulatory factors, a significant deficiency in previous studies. Additionally, the role 
of vitamin D status on immune response and the possible differential effects of acute versus 
cumulative UVR exposure were examined. 
Research Hypotheses 
Based on the current literature, the following hypotheses were generated : 
• Higher persona l acute UVR exposure is associated with impaired cell-mediated and/or 
humeral immune response to primary immunisation. 
• Higher cumu lative personal UVR exposure does not lead to photoadaptation to the 
immunomodulatory effects of UVR 
• Vitamin D status modulates the antigen-specific response to immunisation 
Specific research questions: 
In the context of primary immunisation with a T-cell dependent antigen: 
• Does acute personal UVR dose at the time of immunisation affect subsequent ce ll -
mediated and/ or humeral vaccine response? 
• Does cumulative (long-term) personal UVR dose modulate the effect of acute personal 
UVR exposure on cell-mediated and/ or humeral vaccine response? 
• Does season or latitude of residence at the time of immunisation affect subsequent 
cel l-mediated and/ or humeral vaccine response? 
• Does vitamin D status affect subsequent cell-mediated and/ or humeral vaccine 
response? 
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Outline of thesis 
A brief outline of the eight chapters contained within this thesis is provided here. 
Chapter 1 introduces UVR concepts and terminology as they relate to terrestrial exposure, 
biologically relevant doses and effects on human health. The synthesis, physiological actions 
and the health effects of vitamin D are also discussed. 
Chapter 2 reviews the current literature on photoimmunology, with particular emphasis on 
postulated mechanisms of immunomodulation and highlighting host resistance and clinical 
studies. Evidence supporting vitamin D-associated immunomodulation is also reviewed. 
Chapter 3 out lines the field of immunotoxicology and discusses how it can inform an 
assessment of the effect of so lar UVR exposure on human immune response. Important 
clinical epidemiology elements of conducting an immunotoxicological study are discussed. 
Chapter 4 describes the choice of an appropriate T-ce ll dependent vaccine antigen for use in 
an immunotoxicology study, the development of immunisation and immune assay protocols, 
and the results of a pilot study. 
Chapter 5 introduces the Australian Ultraviolet Radiation and Immunity (AusUVI) Study, a 
prospective, longitudinal, twin-city study that constitutes the main r~search vehicle for this 
thesis. This chapter discusses recruitment strategies, tools for measuring personal UVR 
exposure and othe r potential immunomodu latory variables, statistical considerations and 
study protocol. 
Chapter 6 describes the results from the AusUVI Study including demographic details, 
participant characteristics, examination findings, vitamin D status and personal UVR exposure. 
Chapter 7 describes the outcomes of immune function testing and their associations with 
personal UVR exposure and potential confounding variab les. Multiple linear regression models 
examine their overa ll associations. 
Chapter 8 discusses the findings of the AusUVI Study and their significance in the context of 
the broader literature. Limitations of the study and potential new avenues for investigation 
are canvassed. 
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Relevance of this research 
It is hoped that a robustly designed and rigorously conducted epidemiological 
immunotoxicology study using a reliable vaccine antigen, comprehensive immune testing 
strategy and innovative UVR exposure monitoring can provide an original and valuable 
contributi on to the field of photoimmunology. Conducting this study in a high ambient so lar 
UVR environment such as Australia under real life conditions will additionally inform our 
understanding of appropriate sun exposure in this setting. This may have added relevance in 
the future if, under global change (especially climate change) conditions, the levels and 
patterns of solar UVR exposure change within and between populations. 
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Chapter 1: Ultraviolet radiation 
Synopsis 
This chapter reviews the literature on solar ultraviolet radiation (UVR) with particular attention 
given to its relevance to human health. Vitamin D, a steroid pro-hormone that relies on UVR 
radiation for syn thesis and whose active metabolite has numerous critical physiological 
functions in humans, will also be discussed. 
1.1 Ultraviolet Radiation 
1.1.1 Classification 
Ultraviolet radiation (UVR) constitutes a small component of electromagnetic radiation beyond 
the visible spectrum, with a wavelength spectrum ranging from 100 to 400 nanometers (nm) 
(26). In 1932, the Second International Congress on Light proposed a further sub-classification 
of UVR in recognition of varying biological effects observed at different spectral regions (27). 
These sub-divisions were: UVA (400-3 15nm), UVB (315-280nm) and UVC (280 -100nm). 
Photobiologists have further refined these spectral definitions to better match photobiological 
phenomena: UVA (400- 320nm), UVB (320- 290nm) and UVC (290 - 200nm) (28). A 
wavelength of 290nm corresponds to the shortest wavelength of UVR present in terrestrial 
sunlight, whilst the UVA/ UVB cut-off is more arbitrary. UVA is further divided into UVAI (340-
400nm) and UVAII (320-340nm) in recognition of the greater photobiological activity of the 
shorter wavelengths (28). Table 1.1 describes the properties of the various UVR sub-types. 
1.1.2 Factors influencing terrestrial UVR levels 
The spectrum and intensity of ambient UVR that reaches Earth's surface ("terrestrial UVR") is 
dependent on the "solar altitude", defined as the elevation of the sun above the horizon. Solar 
altitude varies with latitude, season and time of day. In addition, differential absorption of 
UVR by the atmosphere also affects the spectral com position of terrestrial UVR (28). 
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Table 1.1 UVR subtypes and their properties 
UVR sub-type General Properties Biological Properties 
UVA . Not filtered by atmospheric ozone . Passes deeper into skin (dermis) 
(320-400nm) . Constitutes ~gs% of terrestrial UVR . Contributes to photo-ageing and 
. Passes through most glass tanning 
. lmmunosuppressive 
. Possible role in carcinogenesis 
UVB . Extensively filtered by atmospheric . Superficia l penetration (epidermis) 
(290 - 320nm) ozone . Catalyses synthesis of vitamin D pre-
. Constitutes~ 5% of terrestrial UVR cursors 
. Does not pass through glass . Causes sunburn, tanning, photo-
ageing, immunosuppression 
. Carcinogenic - induces skin cancer 
uvc . Completely filtered by atmospheric . Carcinogenic 
(200 - 290nm) ozone and oxygen . Cau ses sun burn 
. Artificial sources only 
Adapted from: (26,29) 
Atmospheric influences 
Ozone (03) , 0 2 and N2 molecules within the stratosphere (~10 - 50 k.m above sea level) absorb 
all UVC and the vast majority of UVB. In the troposphere (O -10 km above sea level) , further 
absorption and/ or scattering by pollutants such as ozone, NO 2, 502, soot and clouds occurs 
(30,31). Terrestrial UVR therefore is comprised mainly of UVA (~95%) w ith UVB making up the 
remainder, with some modest variation in proportion dependent on solar altitude (See Fig 1.1) 
(28). 
Solar altitude and zenith angle 
A measure of solar altitude is the 'solar zenith angle' (SZA). The SZA is the angle between the 
local vertical and the instantaneous position of the sun (32). A SZA of 0° indicates that the sun 
is directly overhead and represents the shortest travel distance for UVR to Earth's surface (See 
Figure 1.2). The likelihood of low SZA increases at low latitude, in su mmer months and the 
four hours centred around local or 'solar' noon (when 50-60% of summer UVR is received), and 
therefore terrestrial UVR is at its most intense under these conditions (28,30) . 
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Figure 1.1 Electromagnetic spectrum and the filtering of ultraviolet radiation by Earth's 
atmosphere 
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Figure 1.2: Solar zenith angle determines the length of the path ultraviolet radiation travels 
to the point of observation 
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The spectral composition of terrestrial UVR also varies with solar zenith angle (and therefore 
with latitude, season and time of day) . Terrestrial UVR has a higher proportion of UVB at 
smaller SZA since there is less atmospheric filtering of these shorter UVR wavelengths {28) . 
Figures 1.3 and 1.4 il lustrate the influence of SZA on the spectral composition of terrestrial 
UVR by time of day (Figure 1.3) and time of year (Figure 1.4). 
Figure 1.3: Variation in spectral composition of terrestrial UVR by time of day. 
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Figure 1.4: Variation in spectral composition of terrestrial UVR by time of year 
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Again, due to reduced distances for solar UVR to travel through the atmosphere, regions 
located at lower latitude have higher terrestrial UVR levels (4) . In addition, as the sun is 
approximately 3% closer to the earth in January compared with July, the Southern Hemisphere 
receives approximately 7% greater UVR intensity than the Northern Hemisphere (35). 
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Cloud cover 
Clouds, which are composed of ice crystals or water, tend to sca tter rather than absorb UVR 
and constitute the most important factor affecting UVR for a given SZA (36). Even in cool and 
cloudy summer conditions, there can be significant terrestrial levels of UVR as clouds are more 
efficient at absorbing infra-red radiation (heat) than absorbing UVR. As an approximation, 
cloud cover reduces annual terrestrial levels of UVR to two thirds of estimated clear sky levels 
in temperate latitudes, and 75% in tropical latitudes (30) . Figure 1.5 demonstrates the effect 
of cloudy conditions on dai ly terrestrial UVR levels in an Australian temperate city (35). 
Other factors 
Terrestrial UVR levels are more intense at higher altitudes due to decreased atmospheric 
thickness (37,38) . 
The reflectance of ground surfaces (or 'albedo') can also affect terrestrial UVR. The reflectance 
of most ground surfaces is less than 10%, but gypsum sand (15-30%), choppy water (20%) and 
snow (90%) can reflect significant amounts of UVR (30). 
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1.1.3 Personal UVR exposure and dose 
For the purposes of this thesis, the following terms will be used to describe UVR exposure: 
• Terrestrial (or ambient) UVR- The intensity of UVR reaching Earth's surface which is 
related to solar zenith angle, altitude and cloud cover. 
• Personal UVR exposure -A function of the terrestrial (or artificial) UVR and the 
duration of exposure, e.g. time outdoors. 
• Personal UVR dose - The dose of UVR a person receives which depends on personal 
UVR exposure and the area of skin exposed (which differs by clothing and sun 
protective strategies used, e.g. sunscreen, sunglasses). 
Terrestrial UVR is measured as part of atmospheric monitoring in many locations around the 
world and in Australia using ground-based spectroradiometers (35). In addition, sa tellite data 
on atmospheric ozone is used to calculate clear-sky and cloud-corrected terrestrial UVR 
globally (NASA) . Numerous studies have quantified personal UVR exposure using personal sun 
exposure diaries and/or dosimeters (e.g. polysulphone, digital) (24). Personal UVR dose relies 
on measurement of personal UVR exposure coupled with data on the nature of outdoor 
activity (e.g. use of shade), the coverage and type of sun protective r;_iothing worn, and sun 
protective strategies utilised (30). 
Due to behavioural and clothing differences, males generally receive higher personal doses of 
UVR than females (up to 50-100% more) (40-42), though this difference is less pronounced in 
children (43). 
Dosimeter measurements indicate that average personal UVR exposure is approximately 3-
15% of terrestrial UVR levels, although this proportion can be markedly higher in certain sub-
populations (i.e. outdoor workers, holiday-makers), and in different seasons and regions 
(38,40,42,44). Variation in personal UVR exposure between individuals within a population 
can be large, from one-tenth to ten times the mean (40). 
1.1.4 Effect of sun protective behaviour on received UVR dose 
The Sun Protection Factor (SPF) is a measure of sunscreen efficacy. This is a laboratory derived 
ratio describing the relative protection from UVR-induced erythema provided by sunscreen 
applicat ion to the wearer above that offered by natural pigmentat ion (45) . For example, an 
SPF rating of 15 indicates that sunscreen-applied skin could be exposed to 15 times the dose of 
UVR compared with no sunscreen, before erythema becomes evident. Indeed, an SPF 15 
sunscreen would theoretically offer all day protection even under tropical sun conditions on 
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single application (46). However, SPF ratings are based on laboratory testing where sunscreen 
is applied at a concentration of 2 mg/cm'. Application of lmg/cm' or O.Smg/cm' gives an 
exponentially lower level of protection (square or fourth-root, respectively) compared with 
baseline (47) . Indeed, studies show that the actual amount of sunscreen applied varies from 0 
to 1.2 mg/cm' after one application (48). In real-life situations therefore, a useful 'rule-of-
thumb' is that the 'expected SPF' of applied sunscreen is typically one-third of 'laboratory 
tested SPF' (30). In addition, UVR protection from sunscreen is compromised by haphazard 
application and removal by water immersion, abrasion or towelling (30,46,49) . Regular re-
application of sunscreen or following water immersion or towelling is advised to compensate 
for initial under-application and/ or to replace sunscreen removed with activity (30). 
Sunscreen was initially developed to provide protection against erythema inducing UVB 
radiation, although broad spectrum (UVA and UVB) sunscreens are now common (SO). A 
limitation of the traditional SPF rating is that it gives only an indication of the relative 
protection against a single erythema-inducing UVR dose, and as such, the degree of protection 
against sub-erythemal UVR doses or UVA exposure is not afforded by this measure (48). 
Recently however, standardised methods for also assessing UVA protection have been 
developed (51). In the United States, regulations are being introduced to ensure that there is 
comparable UVA and UVB protection offered by broad-spectrum sunscreen (52). 
The regular use of sunscreen can reduce the incidence of several UVR-related diseases, 
including actinic keratosis and squamous cell carcinoma in organ transplant recipients (48). 
There are conflicting reports of a protective effect of sunscreen on the incidence of melanoma 
(53-55). Currently there is no evidence of a sunscreen protective effect against basal cell 
carcinoma, although this is based on data from a single study (56). Vitamin D deficiency does 
not appear to be more prevalent amongst those who regularly use sunscreen (57,58). 
Clothing and hats 
Clothing offers UVR protection, however the protective effectiveness is dependent on fabric 
weave, colour, weight, stretch and wetness (30). Some textiles have a greater 'ultraviolet 
protective factor' (UPF; analogous to SPF) than others - for example, polyester blends offer 
more protection than pure cotton, linen, acetate or rayon fabrics (59). 
Driscoll et al found that 80% of summer clothing had a UPF of greater than 15, whilst another 
resea rcher reported one third of commercial summer clothing to have a UPF < 15 (60,61). The 
differences are likely to be explained by differing measurement methodologies (62). Clearly 
the skin coverage of clothing will also affect the received personal UVR dose, with long sleeve 
length attire offering greater protection than shorter length attire for the same fabric. Hats 
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can offer variable protection depending on type - legionnaire's hats (with coverage of the neck 
and ears) provide the best overa ll protection, whilst broad brimmed hats and baseball caps 
offer less (30,63). 
1.1.5 Biologically-relevant UVR spectra 
UVR induces different biological effects at different wavelengths (38). In general, higher 
energy wave lengths of UVR have greater biological activity (i.e. UVB > UVA); however the 
penetration of UVR into the skin is greater at longer wavelengths (i.e. UVA> UVB) (26,64). An 
"action spectrum" describes the relative effectiveness of energy at different wavelengths in 
producing a specific biologica l response (65). Action spectra have been described for skin 
erythema (sun burn), squamous cell skin cancer, immunosuppression and vitamin D synthesis 
(66,67). 
Erythema action spectrum 
The McKinlay-Diffey erythema l action spectrum has been endorsed as the International 
standard (with minor modifications) and represents the erythema-inducing effectiveness of 
UVR at various wavelengths (68). This action spectrum is graphically represented as three 
linear lines (see Figure 1.6, lines in red) on a sem i-log plot which was derived from 
mathematical equations to fit experimental data (69). This action spectrum is the basis for 
commonly used measures of erythemally-weighted energy in photobiology - minimal 
erythemal dose, standard erythemal dose and ultraviolet index; and against wh ich default 
response spectra for UVR monitors are compared (68). 
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Figure 1.6: Action spectra for various UVR-associated biological responses 
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Minimal Erythemal Dose 
Minimal erythemal dose (MED) is the erythemally effective UVR sufficient to cause faint 
erythema at 24-hours post irradiation (70). As the development of sl<in erythema depends on 
numerous factors including skin pigmentation, anatomical site and previous UVR exposure, the 
MED can vary significantly between individuals (even of the same complexion) (71). 
Standard Erythemal Dose 
The standard erythemal dose (SED) was proposed in an effort to standardise reporting of 
erythemally effective UVR dosing (B. L. Diffey et al, 1997). One SED is equivalent to an 
erythemal effective radiant exposure of 100 J/m 2 and is independent of skin pigmentation. 
Therefore, for fair skin (skin phototypes I to IV (see Section 1.1.6), 1 MED is equivalent to 
between 1.5 - 6 SED (71). 
UV Index 
The UV Index (UVI) was developed to describe the intensity of terrestrial UVR (at erythemally 
effective wavelengths) in a manner that could be easily understood by the public (72). The 
forecast UVI is calculated by multiplying the biologically effective solar UVR (UVR,tt) by 40 (73) . 
UVR,tt (Watts/m' ) is calculated by spectra l-weighting of incident solar UVR with the erythemal 
response of human skin (based on the erythemal action spectrum) across the wavelengths 280 
-400nm and summating the effects (35). The UVI, when used as a forecast, is calculated using 
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computer models which input various atmospheric parameters such as ozone, potential cloud 
cover, water vapour and aerosols. The UVI as measured on the ground is often less than that 
forecast, due to cloud cover (26). 
In Australian southern cities such as Melbourne (38°5) and Sydney (33°5), the average monthly 
measured UVI ranges from between 2 (in winter months) to 10 (in summer), although the 
maximal measured UVI can be much higher. In Darwin (12°5), the average monthly UVI ranges 
from 8 (winter) to 12 (summer) (35). 
1.1.6 The modifying effect of skin pigmentation on the biological action of UVR exposure 
Melanin, produced by melanocytes in the basal layer (stratum basa/e) of the epidermis, 
provides an effective barrier to UVR across a wide wavelength spectrum (UVC (200-280nm) 
into the visible range (>700nm)) (74). Melanin-containing granules or 'melanosomes' are 
transferred to adjacent keratinocytes which migrate towards the surface. It is the density, 
distribution and size of melanosomes in keratinocytes that determines skin pigmentation, as 
the number of melanocytes remains fairly constant across different ethnic populations (75). 
Constitutive skin pigmentation is controlled by a number of genes (e.g. human melanocortin-1-
receptor (MClR) gene, melanocyte differentiation antigen (MATP), HERC2 gene) (76). 
Tanning (or induced pigmentation) is the process of skin darkening r~sulting from UVR 
exposure, and is also influenced by genetic make-up (See also Fitzpatrick skin phototypes 
below) (77). Although both UVB and UVA lead to tanning, they induce different melanin 
responses characterised by differing time kinetics (78). Immediate pigment darkening (IPD) 
following sun exposure is due to UVA-induced oxidation of pre-existing melanin and melanin 
precursors (79). IPD typically lasts for 10-20 minutes but higher UVA doses (>10 J/cm 2) can 
lead to 'persistent pigment darkening' (PPD) which can remain for some days. Importantly, 
IPD and PPD are not protective against subsequent UVB-induced erythema (79). Delayed 
tanning (DT) is visible 72 hours post-UVR exposure, is responsive to wavelengths similar to the 
erythema -action spectrum (i.e. UVB > UVA) and, in fair skinned individuals, follows erythema 
(78-80). UVR-induced DNA damage is thought to activate key enzymes required for 
melanocyte growth and proliferation, and increased transfer of melanosomes to keratinocytes 
(75,79). 
The Fitzpatrick Skin Phototype scale is a practical and commonly used tool to classify skin types 
according to pigmentation and skin response to solar or artificial UVR exposure (see Table 1.2) 
(81,82). Individuals with low phototype classifications (i.e. fair complexions) are at increased 
risk of melanoma and non-melanoma skin cancers. Phototypes are also useful for estimating 
doses for UVR, PUVA treatment (for psoriasis) and laser therapy (83). 
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Table 1.2: Fitzpatrick's Skin Phototypes 
Sunburn & Tan ning Cons titutitve color UV-B 
history {defines the Immediate pigment (une-xposed UV-A MED MEO 
Phototype phototype} darkening Delayed tanning buttock skin) (mJ/cm2) (mJ/cm2) 
I Bums easily, never Nore [-) Nore(-} Ivory White 20-35 15-30 
tans 
II Bums easily, tans Weak ±[± to + ) Minimal to weak 'Mlite 30--45 25-40 
mi1irnally with diffi - [ ± to +} 
culty 
Ill Bums mcxlerately, tans Definite + Low + 1/vhite 40-55 30-60 
mcx:lerately and uni-
to1TT1 ~ 
" 
Burns minimally, tans Moderate + + Moderate + + Beige-Oive, Lghtly 50-80 40-60 
mcx:lerately and easily tanred 
V Rarely bums, tans Intense (brown) Strong, intense Moderate brown or 70-100 60-90 
profusely + + + brown +++ tanred 
VI Never burns, tans Intense [dark brown) Stroog, intense Dark brown or black 100 90-150 
profusely + + + brown + + + 
Source (83) 
Increased skin pigmentation confers better erythema protection from UVR - an individual 
with high melanin density (e.g. Fitzpatrick phototype VI) has an MED 6 to 33-fold higher than a 
fair-skinned counterpart and corresponding inherent sun protection fa ctor of up to 13.4 
(64,84). Epidermal melanin in black skin filters 93% of UVB and 83% of UVA compared with 
76% and 45% for Caucasian skin (84) . Intermediate phototypes have_step-wise lower levels of 
protection . 
Section 1.2.4 discusses the relationship between vitamin D synthesis and skin pigmentation . 
1.1.7 Health effects of UVR exposure 
UVR exposure is associated with both beneficial and adverse health outcomes (extensively 
reviewed in (4)) . UVR is required for the synthesis of vitamin D which influences a wide range 
of essential physiological functions (discussed in Section 1.2.6). Artificial sources of UVR (e.g. 
sun lamps) are used as effective therapeutic measures for certain inflammatory dermatological 
conditions including psoriasis, lupus vulgaris and dermatitis (85,86). Either via a direct effect of 
UVR, or indirectly via vitamin D synthesis, a number of cancers (e.g. bowel , breast, prostate), 
infectious diseases (e.g. tuberculosis), metabolic, cardiovascular and psychiatric disorders have 
been associated with low UVR exposure (3,4). However, the majority of direct health effects 
from cumulative UVR exposure are negative and primarily affect the skin and the eyes (87). An 
apparent 'U-shaped' relationship exists between burden of disease and UVR exposure, with 
both low and high exposures leading to increased risk of illness (see Figure 1. 7) (33) . 
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Figure 1. 7 Relationship between ultraviolet radiation exposure and burden of disease 
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Adverse effects of UVR on human health 
UVR and skin disease 
The potential adverse effects of UVR exposure on human health are most commonly and 
obviously seen in the skin. UVR penetrates approximately 0.1 to 1mm into human skin, with 
UVA radiation penetrating further than UVB radiation (26,88). 
Acute UVR exposure can cause erythema leadi ng to painful sunbu rn and peeling, and blistering 
in the most severe manifestation (79). Recurrent acute UVR exposure leads to damage to 
DNA, decreased DNA repair and apoptosis of damaged cells (via mutations to tumou r 
suppression genes (e.g. p53)), oxidative cell stress, local immunosuppression (including of 
immune surveillance cells) and pro-inflammatory responses. All of these mechanisms 
contribute to skin cancer development and photo-ageing (29,89). 
There is convincing biological and epidemiological ev idence linking UVR exposure and the 
development of malignant melanoma and non-melanoma ski n cancer (NMSC). Squamous cel l 
carcinoma (SCC) and basal cell carcinoma (BCC) are the most common fo rms of NMSC, and 
indeed are the most common form of cancer amongst Caucasians in the western world (29). A 
recent estimate using Australian population data, showed th at around 434,000 persons 
(253,000 males, 180,000 females) would be diagnosed wi th one or more NMSC in the year 
2008 alone (90). In 2006, 410 Australians died from NMSC (Australian Bureau of Statistics, 
2008).The ratio of BCC to sec is approximately 4:1, although the risk of metastases and 
mortality is >10-fo ld greater with SCC. Melanoma causes 75% of skin cancer-related mortality 
in the USA despite constituting only ~3% of all skin cancers (29) . 
17 
Studies have linked intermittent and severe UVR exposure (i.e. painful su nburn) in childhood 
and adolescence with later development of malignant melanoma and BCC (84,91). Cumulative 
UVR exposure is associated with SCC formation. Outdoor occupational exposure also confers a 
significantly higher risk of NMSC development (4,29). 
The incidence of skin cancers varies by skin pigmentation of the population. Caucasian 
populations have a much higher rate of skin cancer development than more deeply pigmented 
populations. In the USA, skin cancer (all types) constitutes 20-30% of all cancers in Caucasians, 
2-4% in (east) Asians and 1-2% in African American and (south) Asian Indians (84). 
Cumulative sun damage can also lead to "photo-ageing", a process distinct from, but additive 
to, chronological ageing (92). Repeated sub-erythemal exposure to UVA with or without UVB 
induces most of the histological changes observed in the epidermis of photo-aged skin (93). 
Photo-ageing is characterised by deep, coarse wrinkles, mottled hyper-pigmentation and loss 
of elasticity and ski n recoil. The most affected areas are those chronically exposed to UVR -
face, hands, arms and nape of the neck (92,94). There are numerous macro- and micro-scopic 
differences between intrinsic (chronological) ageing and extrinsic (photo-) ageing, summarised 
in Table 1.3. Recent evidence suggests that longer infra-red wavelengths of light may also 
contribute to the process of photo-ageing (95). 
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Table 1.3: Features of intrinsic and extrinsic causes of skin ageing 
Intrinsic Ageing Extrinsic Ageing 
Aetiology • Chronological age • UVR exposure 
• Smoking 
Macroscopic • Fine wrinkling • Coarse wrinkling 
Appearance* • Smooth texture • Roughened texture 
• Clear complexion • Sallow complexion 
. Uniform pigmentation • Mottled pigmentation 
• Gradual loss of elasticity • Marked loss of elasticity 
• Generalised process • Sun-exposed areas affected most 
Histological • Epidermal and derma l • Epidermis: atrophy & disrupted 
Appearance atrophy keratinocyte maturat ion 
• Flattened epidermis • Dermis: Hyperplastic disordered 
• Reduced number of mast elastic fibre network 
cells • Loss of fibrillin-rich microfibrils at 
• Reduced fibroblast numbers the dermo-epidermal junction 
w ith less co llagen and 
increased matrix meta llo-
proteinases 
Adapted from (92) 
UVR and the eye 
UVR exposure has been causal ly linked to the deve lopment cortica l cataracts (96), pterygium 
(97,98), acute solar retinopathy (99), squamous cel l cancer of the cornea and conjunctiva 
(100), and acute photo-kerati t is and photo-conjunctivitis (101,102). Weaker evidence suggests 
an association between UVR and climatic droplet keratopathy, non-cortical cataracts and 
ocular me lanomas (4) . 
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1.2 Vitamin D 
UVB exposure is the major contributor to vitamin D stores in humans, with the remainder 
coming from dietary sources (103). This section discusses the synthesis of vitamin D, sources 
and its biological roles. 
1.2.1 Endogenous synthesis of vitamin D 
The synthesis of vitamin D begins in the skin (Figure 1.8). Provitamin-D3 (7-dehydrocholesterol 
(7-DHC)) produced by epidermal and dermal cells absorbs UVB, resulting in the formation of 
pre-vitamin D3 (9,10-secosterol) . Pre-vitamin D3 undergoes immediate heat induced 
transformation into vitamin D3 before entering the venous circulation via the lymphatics 
where it is tightly bound to vitamin D-binding protein. Within 12 to 24 hours of UVB exposure, 
maximal vitamin D3 levels are achieved. On passage through the liver, vitamin D3 is converted 
by 25-hydroxylase into 25-hydroxyvitamin D (2S(OH)D) which is the major circulating form of 
vitamin D and has a half-life of 15 days. Although 25(OH)D is not biologically active, its 
concentration is used by clinicians to assess an individual's vitamin D stores. 2S(OH)D is 
converted to the biologically active form, calcitriol (1,25-dihydroxyvitamin D (1,2S(OH),D)), in 
the kidney by the enzyme la-hydroxylase (encoded by the gene CYP2781). Of note, UVR 
exposures less than that required to produce erythema can maximise vitamin D3 synthesis 
(only a few minutes of summer su n in fair skinned persons). Excess loca l production of pre-
vitamin D3 is itself eliminated by UVB (via conversion to inert photoproducts), so that longer 
sun exposure does not increase vitamin D3 levels but adds to the risk of erythema and DNA 
damage (2,3,104-106). 
Calcitriol can also be produced extra-renally in many tissues including bone, placenta, 
keratinocytes, macrophages, T-lymphocytes and dendritic ce lls. Many of the constitutive cells 
in these tissues express both 25-hydroxylase and la-hydroxylase allowing the synthesis of 
25(OH)D and/or 1,2S(OH),D. However, only 0.03% of total 2S(OH)D is freely available in the 
tissues with the remainder being tightly bound to D-binding protein in the circulation (2) . 
There is increasing evidence of an autocrine (i.e. an effect on the 1,2S(OH)D producing cell 
itself) and paracrine (i.e. local effect on neighbouring cells) influence of 1,2S(OH)D (107). This 
may be particularly relevant in the skin where many cell types (including keratinocytes, 
fibroblasts, macrophages, dendritic cells) express the vitamin-D receptor, essential for the 
genomic effects (including immunological) of vitamin D exposure (104). 
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Figure 1.8: Production, metabolism, regulation and action of vitamin D 
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1.2.2 UVR action spectrum for pre-vitamin D3 synthesis 
As described in the previous section, pre-vitamin D3 is formed following the absorption of UVB 
photons by pro-vitamin D3 (7-DHC). The UVR action spectrum that is effective for this 
biological response was first described by Maclaughlin in 1982 following studies invo lving 
irradiation of neonata l foreskins {108), and formed the basis for the 'official' CIE action 
spectrum (109). The effective wavelengths are essentially within the UVB band (280nm -
320nm) with peak effectiveness of UVR at a wavelength of 297nm, (see Figure 1.6) . There is an 
additional minor contribution from shorter wavelength UVA (<1% of total production at 
wavelengths 320-330nm) (104). Of note, there is significant overlap between the action 
spectra for erythema and pre-vitamin D3 synthesis, however with some important differences, 
including: pre-vitamin D3 is more sensitive to the UVB wavelengths whilst erythema has a 
higher weighting coefficient in the UVA part of the spectrum (66) . 
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There has been recent debate regarding the validity of the CIE pre-vitamin D3 action spectrum. 
Norval et al (110) argue that the original Maclaughlin experiments suffered from 
methodological issues, particularly with regard to not detailing the doses used at each 
wavelength and minimal testing at the extremes of the action spectrum (particularly> 315nm). 
They note that the CIE action spectrum extrapolated the Maclaughlin data at wavelengths 
below 260nm and between 315 - 330nm using mathematical decay functions . Further 
experimentation, particularly to clarify the relative contribution of wavelengths at the 
UVB/UVA margin and further into the UVA band, has been called for. 
1.2.3 Regulation of vitamin D metabolism 
The conversion of 25(OH)D to calcitriol in the kidney is strictly regulated by plasma parathyroid 
hormone (PTH), calcium, phosphate, calcitonin and fibroblast growth factor 23 (3,104). PTH is 
secreted by the parathyroid gland in response to low serum calcium (or very low serum 
phosphate), which in turn up-regulates transcription of CYP2781 to promote production of 
calcitriol (106). Calcitriol is transported by the vitamin D binding protein to various target cells 
and tissues where it exerts its effect via genomic and non-genomic pathways. Calcitriol and 
PTH work in concert to increase serum calcium and phosphate levels by: i) increasing intestinal 
calcium and phosphate absorption, ii) increasing distal renal tubular reabsorption of calcium, 
and iii) secretion of 'receptor activator of nuclear factor-KB ligand' (RP,NKl) which acts on 
osteoclasts to promote bone resorption. Resultant increases in serum calcium act to suppress 
further PTH secretion, thus completing the negative feedback loop (106). Calcitriol also self-
regulates via stimulation of the enzyme 25-hydroxyvitamin D-24-hydroxylase which catabolises 
calcitriol and 25(OH)D (3,111). 
1.2.4 Effect of skin pigmentation and sunscreen on vitamin D synthesis 
Melanin competes with 7-DHC in the epidermis to absorb UVB photons. Therefore darker 
skinned individuals are less efficient at synthesising vitamin D than fairer skinned individuals 
for the same UVR dose (74). Persons with Fitzpatrick phototype VI require 10-50 times the 
amount of solar UVR exposure of a fairer person (Type 11-111 phototype) to produce equivalent 
amounts of vitamin D (112). 
The latitudinal gradient in population skin pigmentation (i.e. darker skinned populations near 
the equator, and lighter skinned populations at higher latitudes) has long been attributed to 
the latitudinal gradient in ambient UVR levels, such that under evolutionary selection pressure, 
darker skinned persons are 'photo-protected' from intense UVR exposure, whilst fairer skinned 
persons have adapted to require less UVR to synthesise vitamin D (113) . However, doubts 
regarding the potency of evolutionary selection pressure arising from some adverse effects of 
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excess UVR exposure (erythema, skin cancer) or low vitamin D levels (apart from rickets) to 
drive changes in skin pigmentation have led to other theories being proposed (76). One 
alternative hypothesis is that dark pigmentation evolved in high ambient UVR environments to 
protect against photolysis of folate in cutaneous blood vessels which has potential implications 
for foetal abnormalities (such as neural tube defects) and fertility (in males and females) (114). 
1.2.5 Sources of vitamin D 
The primary sources of vitamin Dare exposure to sunlight and diet. For most human 
populations, sunlight exposure contributes ~90% to vitamin D stores, however the relative 
contributions can change considerably by season, skin type, diet and culture (103,105,115). 
The recommended duration of exposure to solar UVR to achieve adequate 25(OH)D levels is 
the subject of considerable ongoing research. Skin pigmentation, solar altitude (season, 
latitude, altitude) and sun protection behaviours determine the amount of sun exposure 
required (105). Local guidelines recommend safe levels of sun exposure that can promote 
adequate vitamin D stores whilst minimising the risk of erythema. For example, in Australia 
recommendations for persons with fair skin (Fitzpatrick type II skin) for exposure depending on 
season, region and time of day have been suggested (see Table 1.4) (116). Due to the low 
solar altitude in winter months at high latitudes (e.g. > 40°), there is insufficient UVB in sun light 
to produce adequate quantities of vitamin D3 . The body therefore re.lies on mobilisation of 
stores in body fat produced during sunnier seasons, as well as fortified diets or 
supplementation (74,117). 
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Table 1.4: Recommended solar UVR exposure for Australian regions 
Region October to March April to September 
At 12:00 
Northern 2- 5 mins* 3-10 mins# 
(Townsville / Cairns) 
Central (Brisbane/ Perth) 2-6mins* 4-17mins# 
Southern (Adelaide/ 2-10 mins* 5- 34 mins# 
Sydney/Melbourne) 
At 10:00 & lS:00 
Northern $10 mins# $16 mins# 
(Townsville / Cairns) 
Central (Brisbane/ Perth) ~ 10 mins# 14-44 mins* 
Southern (Adelaide/ :;;15 mins• 21 mins to ~1 hr.* 
Sydney/Melbourne) 
To 15% of the body at 12:00, 10:00 & 15:00, for fair skin people to produce 25(0H)O 
levels equivalent to current recommended intakes in Australia, if exposure occurs 
three to four times per week (Adapted from (116)) 
*With extreme care - sun protection highly recommended 
.. 
# With care - sun protection recommended if times exceeded 
Vitamin O ca n also be derived from the diet and/ or dietary supplements. There are two oral 
forms: vitamin 0 2 (or ergocalciferol) derived from UV irradiation of the yeast sterol, ergosterol; 
and vitamin 03 (cholecalciferol) formed through UV irradiation of 7-0HC. Vitamin 0 2 and 0 3 
differ only in a side chain of the sterol skeleton and both forms undergo hydroxylation in the 
liver to form 25(0H)O. Vitamin 0 3 is found in only a few foods, including fatty fish (e.g. salmon, 
mackerel, sardines), fish liver oil, fish liver and egg yolks. Vitamin 0 2 is present in some 
mushrooms (e.g. sh itake) and egg yolk although it has been the predominant form in 
manufactured supplements (3,118) . Recent studies have indicated that vitamin 03 may be 
more efficient that vitamin o, in increasing vitamin O status (measured as serum 25(0H)O 
concentration), although there is some conflicting evidence (104,118) . 
There is ongoing debate as to what constitutes adequate dietary intake of vitamin O (either 
vitamin 0 2 or 03) . It has been estimated that whole body exposure to 1 MED of UVR results in 
a rise in serum 25(0H)O that is equivalent to 20,000IU of vitam in 0 2 supplementation (74) . 
Recent American consensus guidelines report evidence that maintaining adequate 25(0H)O 
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levels (>S0nmol/L) was beneficial for skeletal health, and this could be achieved by oral vitamin 
D dosing of 600 IU per day for all age groups, except the elderly(> 70 years: 800 IU/day) and 
infants below 12 months (400 IU/day) in the context of little or no UVR exposure (119). British 
consensus guidelines recommend that groups that are at increased risk of vitamin D deficiency 
due to low UVR exposure shou ld fortify or supplement their diet with vitamin D (400 - 800 
IU/day) (117). 
1.2.6 Biological action of vitamin D 
Calcitriol can have biological actions mediated by genomic (i.e. altering gene expression) or 
non-genomic mechanisms (e.g. opening ca lcium channels, activation of phospholipase C) (2). 
Genomic processes occur in cells that express the vitamin D receptor (VDR) (120). When 
binding with calcitriol in the cell nucleus, the VDR is phosphorylated and combines with the 
transcription factor 9-cis-retinoid X receptor (RXR). This complex interacts with specific 
promoter regions of DNA ('Vitamin D response elements') which regulate the transcription of 
gene products (e.g. cytokines, anti -microbial peptides) (120,121). Genomic effects generally 
take place over a period of hours, whereas non-genomic actions occur in seconds to minutes 
(2,104). The range of actions of calcitrio l are summarised in Table 1.5. 
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Table 1.5: Biological actions of calcitriol 
Target Organ/ Genomic (G) or non-genomic (NG) Action 
Cell 
Kidney G:1'expression of Ca ++ selective 1'trans-cellular Ca++ transport in 
channel & calbindin (Ca ++ binding distal tubule 
protein) Negative feedback to 1' 25-
hydroxyvitamin D-24-hydroxylase to 
catabolise calcitriol 
Gut G:1'expression of epithelial Ca ++ 1'intestinal absorption of calcium by 
channel & calbindin (Ca ++ binding 30-40% and phosphate by 80% 
protein) 
Bone G: 1'osteoblast expression of 'i'Osteoclastic activity which 
RAN KL, inducing preosteoclasts to increases serum Ca++ and PO/ 
form osteoclasts 
Parathyroid G: '1,,-transcription of genes '1,,-PTH / PTHrP synthesis 
gland encoding PTH & PTHrP 
Miscellaneous NG: Activates Ca ++ influx and 1'Intracellular Ca++ levels; 
cells release from intracellular stores; Stimulation of intestinal Ca++ & 
(keratinocytes, adenylate cyclise, phospholipase C, phosphate transport fluxes; 
enterocytes, protein kinases C & D modulation; elevation of cGMP levels; Rapid 
myocytes, modulates mitogen activated changes in phosphoinositide 
osteoblasts, protein & rapidly growing metabolism 
chondrocytes) fibrosarcoma kinase pathways 
RAN KL - receptor activator of nuclear factor-KB ligand 
PTHrP - parathyroid hormone related hormone 
cGMP - cyclic guanosine monophosphate 
Sources: (2,3,104,122) 
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1.2.7 Health outcomes associated with vitamin D deficiency 
Vitamin D deficiency is associated with a number of clinical diseases, as summarised below. 
Immune system-mediated diseases (e.g. autoimmune disease, infection) that are associated 
with low vitamin D status, will be discussed in the next chapter. 
Musculoskeletal health 
Extended periods of vitamin D deficiency can lead to secondary hyperparathyroidism and 
subsequent decreased calcium and phosphate mineralisation of the ske leton (105,123). When 
this occurs in utero or in childhood, the bone deforming condition 'rickets' can result (124). In 
adults, this condition is termed 'osteomalacia ' (3). 
Osteopaenia and osteoporosis are conditions of decreased bone mass often associated with 
fracture. They are common conditions of multi -factorial aetiology where vitamin D deficiency 
plays a role {125,126) . A number of studies have shown a benefit in terms of reduced 
fractures in osteoporotic patients in those who take vitamin D and calcium supplementation 
(rather than either exclusively) {106,119) 
Vitamin D deficiency is also associated with skeleta l muscle weakness. Studies have shown 
that muscle strength and speed increases with correction of vitamin D deficiency, and falls 
risks amongst elderly patients are significantly reduced (127). 
Cancer 
The genomic influences of calcitriol - including regulation of cell growth and division, 
differentiation, apoptosis and angiogenesis - can supp'ress tumour cell genesis and 
proliferation (3). Many observational studies have demonstrated a favourable association 
between vitamin D status (measured directly by serum 2S(OH)D level or indirectly by duration 
of sunlight exposure, latitude of residence, dietary intake) and the incidence of colon, breast, 
prostate and ovarian cancer {128). However the role of oral vitamin D supplementation as a 
preventative measure or as an intervention in patients with cancer, is presently unclear 
{106,119). 
Other conditions 
Vitamin D deficiency has been associated with congestive cardiac failure, increased 
inflammatory markers associated with cardiovascular disease (e.g. (-reactive protein, IL-10) 
and hypertension (via modulation of the rennin-angiotensin system) (3,129). Reduced mental 
health well-being and increased risk of psychiatric illnesses (e.g. schizophrenia, autism and 
depression) have also been epidemiologically associated with low vitamin D status (3,130,131). 
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1.3 Summary 
Ultraviolet radiation is a component of the electromagnetic radiation spectrum emitted by the 
sun. Terrestrial UVR levels vary by solar zenith angle (which is determined by time of day, 
season and latitude), cloud cover and altitude. Extra -terrestrial UVR is differentially filtered by 
atmospheric gases (primarily ozone), such that ground level UVR comprises mainly longer-
wavelength UVA with a smaller (but varying) component of shorter-wavelength UVB. UVA and 
UVB are biologically active, although UVB possesses disproportionate biological potency 
because of its inherent higher energy. An individual's personal UVR dose is dependent on their 
UVR exposure (a function of terrestrial UVR intensity and duration of exposure) and the area of 
skin exposed (which varies by clothing, sunscreen). Individuals typically are exposed to only a 
small fraction of terrestrial levels but there is wide variation within a population. Clothing and 
sunscreen provide varying degrees of protection from UVR exposure. The accepted units of 
personal UVR dose are the standard erythemal dose (SED) and minimal erythemal dose (MED), 
which are linked to erythema effective wavelengths of UVR (i.e. erythema action spectrum) . 
The UV Index is a convenient measure of biologically-relevant terrestrial UVR intensity. Skin 
pigmentation modifies the biological activity of UVR exposure . High or cumulative UVR 
exposure is associated with a number of adverse health outcomes particu larly affecting the 
eye and skin, including photo-ageing, sunburn, skin cancer and cataracts. 
UVR plays a critical role in the local synthesis of vitamin D precursors within the skin and 
constitutes the major vitamin D source in humans . Dietary intake plays a secondary role in 
maintaining overall vitamin D stores. UVR catalysed production of pre-v itamin D precursors in 
the epidermis sets in train a complex multi -organ process that ultimately results in the 
production of the biologically active form of vitamin D, calcitriol (1,2S(OH),D). The pre-vitamin 
D3 UVR action spectrum is si milar to the erythema action spectrum (i.e. UVB wavelengths are 
largely responsible) . Calcitriol is produced by the kidney, but importantly also by other tissues 
(including immune cells and keratinocytes). The main function of calcitriol (often acting in 
concert with parathyroid hormone) is to maintain serum calcium levels within narrow limits, 
with influences on gut, kidney and bone via genomic and non-genomic actions. Low 25(0H)D 
levels (the preferred measu re of vita min D stores) are associated with a number of adverse 
health outcomes including low bone mass, sol id organ cancers, autoimmune, cardiovascular 
and psychiatric disorders. 
As adverse health outcomes are related to excessive and insufficient UVR exposure, the most 
appropriate levels of UVR exposure at individual and population levels are unclear. This is the 
subject of considerable current research activity. 
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The following chapter will discuss the literature pertaining to the influence of UVR and vitamin 
D status on human immune function . 
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Chapter 2: Ultraviolet radiation and immune function 
Synopsis 
This chapter is presented in three parts. The first section provides a genera l overview of the 
immune system, with particular emphasis on the adaptive immune system. The remaining 
sections review the known and postulated influences of UVR on immune function, both 
directly, and indirectly via induction of vitamin D synthesis. 
2.1 An overview of the human immune system 
The immune system defends against microbial infection and plays a significant role in the 
detection and deletion of cancer cells . Our understanding of the mammalian immune system 
has become increasingly sophisticated, yet still remains incomplete. Evolution of the immune 
system within the animal kingdom has occurred over aeons, such that in humans there has 
developed two parallel but interacting systems: the 'innate' or primitive immune system, 
components of which are seen even in the simplest organisms; and the 'adaptive' immune 
system, unique to vertebrates (132). 
Innate immunity provides a first line of defence against microbial invaders. It consists of 
physical barriers (i.e . skin, mucous membranes, gastric acid, sa livary enzymes, cough reflex), 
cellular components (e.g. neutrophils, Natural Killer (NK) cells) and proteins (e.g. complement, 
Toll-like receptors). These produce a generic, non-specific response that does not change or 
evolve ove r an individual's life - that is, there is no 'memory' of previous exposure. When 
activated, cellular components release chemical signals (e.g. cytokines) which interact with the 
adaptive immune system, so that the two operate in concert (133). 
Adaptive immunity is a more sophisticated response, entai ling the ability to recognise, attack 
and remember specific foreign antigens. It is this capacity for "immune memory" that protects 
a host from re-infection and which provides the scientific rationale for immunisation . The 
adaptive immune system is comprised of specia lised white blood cells - "B" and "T" - cell 
lymphocytes. Activation of B cells results in antibody production - either for opsonising 
(coating) or neutralising targets. T cells are subdivided into T-helper cells (Th or CD4+ cells1) 
and cytotoxic T cells (Tc or CD 8+ cells). Upon presentation of foreign antigen by specialised 
"antigen presenting cells" (APCs i.e. dendritic cells, macrophages, B cells), T-helper cells further 
differentiate into effector cel ls : Thl, Th2, Th17 and regulatory T (Treg) ce lls (134,135). 
1CD: Cluster of differentiation 
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Functionally, the adaptive immune system is again further divided into cell-mediated and 
humoral immunity, referring to pathogen elim ination by either cellular components or 
antibodies, respectively. Cell-mediated immunity (CMI) is regulated largely by Thl ce lls: upon 
activation, these cells release specific cytokines (i.e. interferon y, TNF ~) that i) activate 
macrophages; ii) induce B cells to produce opsonising antibodies (i.e. lgGl, lgG3) that coat the 
invading pathogen for killing by other phagocytic cells; and iii) stimu late cytotoxic T cells. 
Humoral immunity is principally mediated by Th2 cells, which release cytokines (i.e. IL-4, IL-5, 
IL-10) that activate B cells to make neutralising antibodies. The adaptive immune response 
following the first (or primary) exposure to antigen can take several days; however, this 
stimulates the development of 'memory' Band T cells. These long-lived cells allow humans to 
develop a rapid immune response on subsequent exposure to the same antigen (133-135) . 
CMI (Thl) is particularly important for combating intracellular infections (i.e. viruses and 
certain bacteria such as Mycobacteria tuberculosis, Listeria sp.), whilst humoral immunity (Th2) 
primarily deals with extracellular infections (i.e. bacteria, parasites). Nevertheless, immune 
responses against infection generally comprise aspects of innate and adaptive immunity, and 
cell-mediated and humoral immunity (135). 
Disease can occur from both overactivity (up-regulation) of the immune system and immune 
suppression (down-regulation). Up-regulation of Th2 pathways is imJ_Jlicated in the 
pathogenesis of allergy (particularly lgE-mediated), whereas up-regulated Thl responses are 
implicated in specific autoimmune diseases (such as Type 1 diabetes, scleroderma and multiple 
sclerosis) {136,137). As the immune system defends against microbial pathogens and aberrant 
host cells, down-regu lation may increase vulnerabi lity to infection and neoplastic disease, and 
reduce the protective efficacy of immunisation. 
Impairment of specific immune components predisposes to specific types of infection and 
disease. For example, individuals with very low CD4+ (T-helper) cell counts (e .g. HIV/AIDS 
patients) are at much higher risk of specific opportunistic infections such as Pneumocystis 
jiroveci pneumonia, mycobacterial infection and toxoplasmosis than those with higher CD4+ T 
cell counts (138). Primary humoral immunodeficiency - manifest by low or absent levels of 
circulating antibody (i.e. lgG subclass deficiency, lgA deficiency or common variable 
immunodeficiency) - is associated with recurrent respiratory and gastrointestinal infections of 
varying severity (139). Additionally, studies of cancer patients (140) and acutely ill surgical 
patients (141,142) have shown that impaired cell-mediated immunity (demonstrated by 
reduced delayed-type hypersensitivity skin reactions) is associated with poorer prognosis 
and/or higher mortality. 
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At an individual level, it is these profound impairments of immune function that are associated 
with significant (i.e. clinically manifest) health consequences. However, at a population level, 
less profound impairment of specific immune processes occurring with high prevalence may 
manifest as an increased incidence of infection (e.g. influenza, otitis media or the common 
cold) (22) and reduced vaccine effectiveness (143). For vulnerable sub-populations -the old, 
young, ill and in the developing world - these outcomes may be even more pronounced. This 
thesis postulates that UVR exposure is an environmental agent that can impair aspects of the 
human immune response, thereby altering the level and distribution of vulnerability within the 
population. 
2.2 Immune response elements of the skin 
The skin represents the interface between the human immune system and UVR exposure. 
Figure 2.1 illustrates the layers of the skin and the immune cells that reside within them in the 
non-inflamed state. The epidermis is the most superficial layer of the skin and consists 
primarily of 'keratinocytes', which are epithelial cells able to produce keratin, an extra-cellular 
protein. Within the epidermis also reside Langerhans cells - which are long-living, immature, 
bone marrow-derived dendritic cells that act as important 'sentinel' antigen presenting cells; 
and melanocytes. Below the epidermis, the dermis is comprised mainly of fibroblast-
produced, extra-cellular connective tissue, as well as other immune cells, including mast cells, 
dermal dendritic cells and memory T cells . Keratinocytes and resident immune cells express 
pattern recognition receptors (such as Toll-like receptors) that recognise specific pathogen 
components and which can initiate innate immune pro·cesses. The dermal post-capillary 
venule(s) are able to take chemical signals (chemokines and cytokines) produced by immune 
cells in the skin to the systemic circulation attracting other immune cells to the site of tissue 
injury or infection. Immune cells such as Langerhans cells, dermal dendritic cells and mast cells 
can migrate to draining lymph nodes via afferent lymphatic vessels (144). 
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Figure 2.1 Immune components of the skin 
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Immune-response elements in non-
inflamed skin: Human skin is composed 
of three distinct compartments relevant 
to its immune functions. First, the 
epidermis is composed of keratinized 
epithelial cells and functions as both a 
physical barrier and an early warning 
system. Immune cells resident in the 
epidermis include special ized dendritic 
ce lls (DCs) known as Langerhans cells 
and intra-epithelial lymphocytes. 
Second, the dermis is mainly composed 
of connective tissue produced by 
dermal fibroblasts. Immune system cells 
resident in non-inflamed dermis include 
dermal DCs, mast cells and a small 
number of cutaneous lymphocyte 
ant igen (CLA)-positive memory T cells. 
Third, dermal post-capillary venules 
constitutively express low levels of E-
selectin, CC-chemokine ligand 17 
(CCL17) and intercellular adhesion 
molecule 1 (ICAMl). These support the 
margination and baseline emigration of 
CLA+ memory T cells into non-inflamed 
skin. CLA--T cells, including both naive 
cells and memory/effector cells that are 
targeted to other tissues, as well as 
granu locytes (e.g. neutrophils) and 
other immune cells, lack the 
appropriate receptors to attach to 
dermal vessels and emigrate into non-
inflamed skin. Text adapted from (144). 
2.3 The influence of UVR on immune function 
2.3.1 Introduction 
The genesis of photoimmunology can be traced to the seminal experiments conducted by 
Margaret Kripke and colleagues in the 1970s. They found that skin cancers transplanted into 
normal, genetically-identical mice were rejected, but grew progressively in 
immunocompromised hosts. It also became apparent that transplanted skin cancers would 
grow in mice that had been irradiated with UVR. Furthermore, transfer ofT-cell lymphocytes 
from UVR-exposed mice also conferred ' immunotolerance' to transplanted tumours in non-
irradiated mice (6,145,146). These findings led to the following conclusions: skin cancers were 
highly antigenic; host immune responses played a critical role in tumour control; UVR was 
immunosuppressive (including systemically) and this was regulated by T-cel l mediated 
processes. 
There has since been considerable progress in the elucidation of the underlying mechanisms 
leading to UVR-induced immunosuppression, although much remains unresolved. 
2.3.2 Postulated mechanisms of UVR-induced immunomodulation 
The degree and characteristics of immune system modulation vary considerably depending on 
the nature of UVR exposure (i.e. timing, dose, spectrum, body site exposed) and immune 
challenge (i.e. type of antigen, dose, site and method of administration, primary or recall 
response) (7). Much of our knowledge in this area is ba sed on work that has been conducted 
using rodent models, single or few doses of UVR exposu re, erythemal doses of UVR and/or a 
source emitting non-solar UVR spectrum (e.g. frequently with a high UVB component) (8). The 
prevailing view, however, is that UVR exposure is immunosuppressive to cell-mediated 
immune processes in an antigen-specific manner. 
The following section will describe the postulated pathways leading from absorption of UVR 
photons by skin components through to changes in cutaneous cellular and inflammatory 
mediators, development of a regulatory and tolerogenic immune environment in the draining 
lymph node and dissemination of loca l and syste mic mediators of immunomodulation. 
2.3.3 UVR chromophores 
Energy from UVR exposure is part-reflected and part-absorbed by the skin. Absorption occurs 
via cutaneous chromophores - photon-absorbing molecules that change their structure on 
exposure to UVR (147). More is currently known about chromophores likely relevant for UVB 
immunomodulation than for UVA wave lengths (13). UVB chromophores are located 
superficially in the skin, reflecting the poor cutaneous penetration of UVB (88), and include 
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DNA, urocanic acid (UCA) and membrane lipid components. DNA within keratinocytes and 
Langerhans cells (epidermal antigen presenting cells) acts as the major UVB chromophore and 
DNA damage is a crucial mediator of UVR-induced immunosuppression . 
DNA is maximally degraded at 260nm, but UVB wavelengths (290-320nm) are also effective, 
resulting in photoproducts such as cyclobutane pyrimidine dimers (CPD) and pyrimidine (6-4) 
pyrimidone (148,149) . UVA also induces DNA damage directly but at much higher doses than 
for UVB; and indirectly through the generation of reactive oxygen species causing DNA strand 
damage and mutagenic changes to purines (e.g. 8-oxo-7,8-dihydro-2' -deoxyguanosine) (93). It 
has been recently shown that oral or topical replacement with nicotinamide (precursor of 
keratinocyte-produced nicotinamide adenine dinucleotide (NAD), important for cellular 
metabolic energy) can reduce DNA damage and limit subsequent UVR-induced 
immunosuppression (150,151) . The cytokines IL-12, IL-18 and IL-23 are also important for DNA 
repair, but UVR reduces the production of these mediators within UVR-damaged Langerhans 
cells (9). 
UCA undergoes UVR-dose dependent isomerisation from trans-UCA to cis-UCA in the stratum 
corneum (superficial epidermis), with peak transformation occurring at the shorter UVB 
wavelengths 280 - 310nm, but also into the UVA spectrum (152,153). cis-UCA is thought to be 
an important mediator of cell-mediated immune responses (via TNF-q in particular (154)) . For 
example, higher cis-UCA levels have been implicated in lower antigen specific cellular immune 
responses to immunisation in UVB exposed humans (155). Finally, various cellular membrane 
components (e.g. phospholipids, surface receptors) are.susceptible to changes in redox 
equilibrium (e .g. lipid peroxidation) following UVB-induced reactive oxygen species synthesis 
(147,156). 
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2.3.4 Cellular trafficking and signalling 
Keratinocytes, mast cells, macrophages, dendritic cells and sensory nerve cells are induced by 
UVR-transformed chromophores to synthesise and release a set of chemical signals which 
mediate local inflammation (i.e. chemotactic signals to attract neutrophils and macrophages to 
the skin) and set in train subsequent immune modulating processes. Table 2.1 details the main 
chemical mediators that play a role in this setting. 
Table 2.1: Chemical mediators affected by cutaneous UVR-irradiation 
Cytokine Producer cells Action UVR effect 
on mediator 
Platelet Keratinocytes, Activates platelets, monocytes, Increased 
activating CDllb+ macrophage neutrophils; increases PGE2 
factor production; increases DNA damage; 
promotes regu latory B cells 
IL-1 Keratinocytes, Stimulates inflammation, chemotactic Increased 
macrophages agent, 1'PGE2 
IL-4 T cells, mast cells Promotes Th2 differentiation; B cell Increased 
activation; lgE antibody switch 
IL-6 Keratinocytes, T B- cell activation - Increased 
cells, macrophages 
IL-10 CDllb+ '1,,LC & DC stimulation of na'fve T cells Increased 
macrophages, mast and Thl cytokine production 
cells, neutrophils 
(keratinocytes) 
IL-12 Langerhans cells, Promotes Thl cell proliferation; Reduced 
dendritic cells, repairs UVR-induced DNA damage; 
macrophages inhibits Treg cell activity 
IL-18 Macrophages Induces IFN-y by T cells and NK cells; Reduced 
promotes Thl processes 
IL-23 Dendritic cel ls Reduces DNA damage; induces IFN-y Reduced 
by T cells; promotes memory T-cells; 
inhibits Treg cell activity 
IL-33 Keratinocyte, dermal lmmunosuppressive effect (t CHS Increased 
fibroblasts response); UVB shown to j IL-33 
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TNF-a Keratinocytes, mast Recruits inflammatory cells to injured Increased 
cells, activated area, mediates immune effect of cis-
dendritic cells UCA, 1'PGE2, promotes migration of 
dendritic cells to lymph node, 
Histamine Mast cells Stimulate prostanoid production, Increased 
j PGE2 (associated with (-!, CHS 
responses) 
PGE2 = prostaglandin E2; LC= Langerhans ce lls; DC= dendritic cells; CHS= contact 
hypersensitivity; UCA = urocanic acid; Sources: (147,157-160) 
Chemical mediators can also be found in the systemic circulation after UVR exposure 
potentially contributing to system ic immunomodulation. These include histam ine, platelet-
activating factor, prostaglandins, cis-UCA, IL-1, IL-10, IL-4, TN Fa, neuropeptides and 
neuroendocrine hormones (7,156). 
In response to cutaneous UVR exposure and release of the aforementioned chemical 
mediators, several populations of immune cells migrate to and from the skin . Within two 
hours of UVR-induced epidermal ce ll damage, macrophages, mast cells and neutrophils are 
attracted to the site of cell injury; peak infiltration occurs by four to si~ hours and the 
inflammatory cell recruitment has largely concluded by 48 hours (64). Macrophages and 
neutrophils are responsible for phagocytosis of apoptotic cells and also secrete the potent 
immunosuppressive cytokine IL-10 (161,162) . 
2.3.5 Influence of UVR on the adaptive immune response 
UVB radiation leads to migration of epidermal Langerhans cells and dermal dendritic cells to 
the draining lymph node, albeit in an impaired fashion (163-165). In addition, UVR affects the 
ability of dendritic cells to present antigen to T ce lls in the lymph node by reducing the 
expression of surface co-stimulatory molecules (e.g. B7, ICAM-1) (166) and MHC class II 
molecules {147). Furthermore, it appears that UVR-exposed dendritic cells preferentially 
promote CD4+ T helper cell differentiation into a Th2 pattern rather than Thl {167,168). 
Secreted IL-10 (by mast cells that have migrated to the lymph node on stimulation by antigen 
and CDllb+ macrophages in the skin) is likely to be an important cytokine driving Th2 
differentiation (162,169). The contribution of Langerhans cells in promoting a regulatory 
environment in the draining lymph node, is also receiving increased attention (9,170). 
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Since Kripke's initial experiments, it has been shown that the immunosuppressive effect of 
UVR exposure is antigen-specific rather than of a general nature. That is, not only is the 
immune response to primary cutaneous exposure to antigen affected following UVR exposure 
(due to the processes mentioned above), but re-exposure to the same antigen at a later time is 
also impaired, even if exposed at a distant site (systemic immunosuppression) (171). Although 
initially hypothesised to be the result of 'suppressor' T cells, it is now known that there exists a 
subset of antigen-specific T-helper cells - regulatory T cells (Treg) that are promoted in the 
lymph node upon interaction with UVR-affected APC. The phenotype of the UVR-induced Treg 
lymphocyte is CD4+ CD25hi CD127'° Foxp3+ CTLA-4+ although there are likely to be 
heterogeneous populations of these cells . They appear to produce IL-10 but not IL-4 or IFN-y 
(172). UVR-induced Treg lymphocytes have been shown to be inhibitors of the immune 
stimulatory cytokine IL-12, inhibit APC function (173) and also switch APCs from a stimulatory 
to a regulatory (or tolerogenic) phenotype (174). 
Other cells have been implicated in the development and maintenance of a local 
immunosuppressive environment. Following cutaneous UVR exposure, increased local IL-10 
concentrations have been shown to induce 'regulatory B cells' which act to inhibit the ability of 
dendritic cells to activate (particularlyThl) cell-mediated processes within the lymph node 
(175,176). A population of IL-4 producing Natural Killer T (NKT) cells are also thought to down-
regulate immune responses following interaction with UVR exposed Langerhans cells that have 
migrated to the lymph node (177). 
Given that Thl cell-mediated processes are primarily affected by UVR exposure, assessment of 
the T-dependent antibody response would be informative. However, the limited number of 
studies examining this specific question have demonstrated conflicting results (178,179). 
Nevertheless, a series of recent experiments in mice has demonstrated that UVR exposure 
following immunisation suppressed the antigen-specific antibody response to T-dependent 
antigens but not T-independent antigen, and suppression was related to the generation of IL-
10 producing regulatory T cells (178,180,181). T follicular helper (Tfh) cells, a specialised 
subset of CD4+ T cells, are important in providing an environment for B cells to produce 
antibody in the germinal centre of lymph nodes. Recent evidence suggests that IL-10 
producing mast cells that have migrated from UVR-irradiated skin to lymph nodes (169) can 
suppress T follicular helper cells, formation of germinal centres and subsequent antibody 
formation (182). 
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2.3.6 UVR and in vivo cell-mediated immune response testing 
Contact hypersensitivity (CHS) or delayed-type hypersensitivity (DTH) responses are functiona l 
in vivo assays of cell-mediated immune function. They have been utilised in a number of 
contro lled studies in humans to assess the local and systemic immunomodu latory influence of 
UVR exposure (183). Both the CHS and the DTH responses are mediated by antigen-specific 
effector T cells and require: i) sensitisation of na'fve CD4+ T helper cells with antigen (i.e. by 
immunisation or natural exposure) and ii) elicitation of a quantifiable inflammatory response 
by re-exposure to antigen (usually several weeks after sensitisation). The elicitation phase 
results in a delayed inflammatory response (which is primari ly made up of macrophages, 
phagocytes and plasma) that can be measured usua lly 24-72 hours fo llowing antigen re-
exposure (134). Exposing volunteers to UVR before antigen sensitisation assesses suppression 
of the induction arm. Assessment of the elicitation arm is made by exposing participants to 
UVR sometime after initial sensitization, then re-cha llenging with the relevant antigens or 
contact allergen (184). Local immunosuppression is detected when there is reduced response 
to antigen applied to UVR exposed skin, and systemic (or distal) immunosuppression occurs 
when there is reduced response fo llowing antigen exposu re to a site remote from the UVR 
exposure (184) . Differences between _CHS and DTH responses are summarised in Table 2.2 and 
further details rega rd ing the mechanisms of DTH response are given in Section 3.1.6. 
Table 2.2 Features of contact hypersensitivity and delayed type hypersensitivity responses 
Immune Site of antigen Major antigen Example of Description of typical 
response exposure presenting antigens skin response 
cell involved 
Contact Epicutaneous Langerhans Nickel, Local epidermal 
hypersensitivity (i.e. topical ly ce ll chromate, reaction : redness, 
applied to Poison ivy swelling, cellular 
skin) infiltrate, vesicles 
Delayed type Intra- Dermal Tuberculin, Local skin induration: 
hypersensitivity cutaneous (i.e. dendritic cel l lepromin, insect redness, swe lling, 
intra-derma l venom, Candida, cellular infiltrate 
injection) Trichophyton 
Sources: (134,183) 
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UVR exposure has been shown to be immunosuppressive in humans using various 
experimental designs. Studies utilising DTH responses have used tuberculin antigen (185,186), 
lepromin antigen (187), and the Multitest kit (containing seven commonly encountered 
proteins) (15,16,188). Antigens used for CHS testing have included nickel (189,190) and 
dinitrochlorobenzene (DNCB) (191-193). Experimental design has varied according to the 
DTH/CHS phase being investigated (i.e. sensitisation vs. elicitation); source of UVR exposure 
(i.e. UVR lamp vs. natural sun exposure); UVR spectrum (i.e. UVA vs. UVB vs. solar UVR (+/-
simulated)); dose (erythemal vs. sub-erythemal) and timing of UVR exposure; site of testing 
(i.e. buttock vs. back vs. arm); and use of sunscreen (reviewed in: 61,62) . Some examples of 
these studies are shown in Table 2.3. 
These studies, taken in total, have consistently shown that UVR is immunosuppressive to 
antigen-specific in vivo cell-mediated immune responses, and have been the basis for the 
ascertainment of the immunosuppression UVR action spectrum (Section 2.3.7) and the 
immune-protective properties of sunscreen. Some important findings from these studies are 
outlined below: 
UVR wavelength - lmmunosuppression was induced in studies using UVB (190,194,195), UVA 
{188,190,196,197) and solar simulated (55)-UVR wavelengths (15,185,192) but there were 
differences in the respective time courses of suppression. (See sectiq_n 2.3.7) 
UVR exposure dose - UVR influenced immune function at even low levels of exposure. A 
single sub-erythemal dose of 55- UVR at 0.25 - 0.5 MED was sufficient to suppress the 
induction phase of the CHS response to DNCB by 50-80% (192) . Sub-erythemal doses of UVR 
(~0.6 MED; equiva lent to six minutes midday summer sun exposure) significantly suppressed 
nickel CHS elicitation responses in participants after a single dose of 55-UVR and UVA, and 
after two doses with UVB (190). 
Local vs. systemic response - There was strong evidence for UVR-induced local 
immunosuppression, but also evidence of a systemic effect. DTH elicitation responses to 
Multitest kit antigens were reduced at the site of UVA, 55-UVR and/or natural UVR exposure 
and distally in two studies assessing the immune-protective efficacy of sunscreen (15,16). In 
another study, participants irradiated with a single dose of 55-UVR (3 MED) to a small area of 
skin, demonstrated both local (12/12) and systemic (10/12) immunosuppression using CHS 
assays (198). Sleijffers et al {19) demonstrated that five days of 1 x MED UVB was su fficient to 
cause a slight but significant reduction in the concentration of circulating NK cells, compared 
with a non-irradiated control group . 
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Table 2.3 Examples of in vivo cell-mediated immunity testing: Assessing the immunomodulatory effects of UVR exposure in humans 
First Author Participant UVR Doses In vivo immune Antigen Outcome 
(Year) characteristics spectrum parameter 
Moyal D Fitzpatrick skin UVA; 55- Variable dosing- sub- DTH - elicitation Multitest kit * Reduction in local & systemic DTH 
(2008) type 11-111; aged UVR; natural erythema l and phase response in all groups. Sunscreen 
18-40yrs UVR erythema l doses, both protective if UVA range included 
with sunscreen 
Damian D Fitzpatrick skin 55-UVR Sub-erythema l and DTH - elicitation Tuberculin Dose respon se UVR-
(1998) type I-V; aged 21- erythemal doses; 5 day phase immunosuppression. Wea k 
53 yrs protocol; 4-5 week evidence of adaptive response to 
protocol chronic UVR 
Damian D Fitzpatrick skin 55-UVR; Sub-e rythema l doses; CHS - elicitation Nickel 55-UVR, UVB, UVA 
(1999) type I-V; aged 18- UVA; UVB Short (<5 days) and long phase immunosuppressive . UVB & UVA 
62 yrs . (4 week) protocols maximal effects at different 
times. UVA transient effect 
Kelly D Fitzpat rick skin 55-UVR 0.25 -3 MED CHS- DNCB Low dose 55-UVR 
(2000) type I-IV; aged 18 sensitisation immunosuppressive. Differentia l 
-35 yrs. phase response by sk in type-Type 1/11 
skin > Type Il l/IV 
* Multitest kit (Pasteur/ Merieux) - containing teta nus toxoid, diphtheri a toxoid, Proteus mirabilis, Trichophyton mentagrophytes, Candida albicans, streptococcus, 
tuberculin 55-UVR: sim ulated so lar UVR; 0TH: delayed type hypersensitivity; CHS: contact hypersensitivity; ON CB: dinitrochlorobenzene 
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2.3.7 UVR-induced immunosuppression action spectrum 
Recent research has delineated the immunosuppressive potency of UVR at different 
wavelengths by assessing the effect of narrow-band UVR irradiation on the nickel CHS 
response (67). UVB radiation is immunosuppressive in a linear dose-dependent manner, with 
maximal suppression occurring at a wavelength of 300nm (195) . By contrast, the 
immunosuppressive effect of UVA is more complex, with maximal suppression occurring at 
370nm and not being apparent following exposures of ~23 minutes or greater of midday 
summer sunlight (196,199). The postulated action spectrum for UVR-induced 
immunosuppress ion is shown in Figure 2.2a. 
Given that the majority of ground level UVR from sunlight is comprised of UVA, and that there 
is ~go times the level of UVA at 370nm than UVB at 300nm in sunlight, UVA has a far greater 
immunosuppressive effect than UVB at incidental doses of sun light (i.e. less than ~ 20 minutes) 
(67,199). The immunosuppressive potency of UVR from sunlight is shown in Figure 2.2b. 
Figure 2.2a UVR action spectrum for immunosuppression 
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This graph was generated following experiments assessi ng nickel contact hypersensitivity 
responses following narrowband UVR exposure at 11 wavebands from 289nm to 392nm and 
comparing w ith responses in adjacent unirradiated skin. Peak immunosuppression occurs in 
the UVB wavelengths (300nm), with a much sma ller peak occuring in the UVA waveband 
(370nm). Adapted from (67) . 
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Figure 2.2b Solar UVR action spectrum for immunosuppression 
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This graph is derived by multiplying the wavelength dependency for UVR-induced 
immunosuppression at each waveband by the irradiance of each wavelength in solar UVR (at 
standard noon). Given the abundance of UVA relative to UVB in solar UVR at ground level, 
UVA contributes the most to the overall immunosuppressive properties of solar UVR. 
Adapted from (67). 
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2.3.8 UVR and host resistance to infections and tumours 
Host resistance studies in animals 
Evidence of the clinical significance of UVR induced immunosuppression has come from 
numerous studies assessing the host resistance against infections and tumours. Controlled 
studies have been conducted in animals (rats and mice) where an infection was induced or live 
vaccination given before or after UVR exposure (12,64,200). The infective dose, UVR exposure 
dose and other aspects of experimental design have varied widely between studies. Measures 
of host resistance have consisted of measures of microbial load, disease severity or an immune 
parameter such as DTH response to subsequent recall-antigen exposure. Table 2.4 
summarises the results of studies that have been conducted thus far. Overall, UVR exposure 
appears to decrease the host resistance to intracellular infections and response to 
immunisations that require integrity ofThl cell-mediated immune processes. Notably, host 
resistance is affected both locally (at the site of infection or UVR exposure) and systemically for 
non-cutaneous disease (e.g. murine leukaemia virus). 
Observational studies in humans 
Conducting host resistance studies in humans is considerably more ethically and logistically 
challenging than in animals, and therefore evidence of the influence of UVR exposure has 
largely been derived from non-controlled, observational studies. Surrogates of UVR exposure 
such as latitude (i.e. low latitude/tropical region vs. high latitude/temperate region) or season 
(i.e. winter vs. summer) have often been used, and the prevalence or incidence of an infection 
or disease has been used as a measure of host resistance. 
In a large Japanese study that assessed the role of various precipitants of recurrent Herpes 
simplex virus (HSV)-1 infection (responsible for oral 'cold sores'), sunlight exposure was the 
third most important precipitating factor after fatigue and upper respiratory tract infection 
(201). Incidence of varicella zoster virus (VZV) clinical infection (shingles) has also been shown 
to have a seasonal variation in two recent epidemiological studies - with lowest rates 
occurring in the winter (correlating with lowest ambient UVR) (202,203). There was also a 
report of higher recurrence rate of HSV and shingles in an immunosuppressed population 
(renal transplant recipients) (204). UVR is postulated to affect latent viral skin infections (e.g. 
HSV and VZV) in the following ways: i) indirectly, via impairment of critical virus-controlling 
cell-mediated immune processes, and ii) directly, via effects on the viral genome affecting 
latency within nerve endings (205). 
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Table 2.4: Host resistance studies in animal models with UVR exposure 
Microorganism Model Effect 
Mycobacterium bavis Mouse DTH:-1,/no effect; microbial load 1' 
Mycobacterium leprae Mouse -1,DTH; 1'microbial load; 1'symptoms 
Listeria monocytagenes Mouse -1, DTH response; microbial load 1' 
Candida albicans Mouse DTH:'1,/no effect; 1'mortality 
Murine leukaemia virus Mouse 1'1iver damage; 1'splenic pathology 
Rat cytomegalovirus Rat 1'viral load, inflammation and tissue necrosis 
Herpes simplex virus Mouse/ -1,DTH ; 1'severity of lesions; viral load 1' 
Rat 
Borrelia burgdorferi Mouse -1,DTH ; 1'symptoms 
Trichinella spiralis Rat 1'parasite load; -1, T-cell immunity to parasite; 
'1,lgE 
-
Leishmania major Mouse -1,DTH ; -!,symptoms 
Schistosoma monsoni Mouse No effect 
Plasmodium chabaudi Mouse 1' mortality 
Influenza Mouse 1'mortality; 1'1FN-y in lungs; 1'thymic atrophy 
Sources: (7,12,64,200,205) 
A number of studies have also examined the association between UVR exposure and efficacy 
of vaccination at a population level (see Table 2.5). These studies have varied by population 
(e.g. paediatric vs. genera l), geographic region, type of vaccine and time points for measuring 
immune end points (e.g. antibody response, disease incidence). Despite these differences in 
study design, again the overal l picture is one of lower vaccine efficacy in regions or seasons 
associated with high ambient UVR exposure (e.g. summer season, low latitude/tropical 
regions). 
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Taken in total, these studies indicate that populations potentially exposed to high ambient 
UVR levels are at risk of decreased vaccine effectiveness and increased incidence of certain 
infections. However, the influence of potentially important modifying or confounding factors -
such as demographic differences (e.g. gender and age profile), environmental conditions (e.g. 
temperature), socioeconomic variables (e.g. sanitation, poverty, malnutrition, overcrowding) 
and other prevailing infections - were not measured, and therefore firm conclusions are not 
possible. 
Table 2.5: Observational studies - the effect of latitude, season and UVR exposure on 
vaccination response 
Vaccine Effect of UV Radiation Reference Region/ Year of 
publication 
Poliovirus Antibody response higher in (206) Tropics (1972) 
temperate vs. tropica l area 
Poliovirus Antibody response higher if (207) Subtropics (1972) 
vaccinated in winter vs. summer 
Influenza virus lmmunogenicity higher if vaccinated (208) Russia (1987) 
in winter vs. summer 
Hepatitis B Initial antibody titre higher if (209) Netherlands (1999) 
vaccinated in winter vs. summer. No 
difference after final vaccination. 
Rubella virus Antibody response higher if (17) Israel (2009) 
vaccinated in winter vs. summer 
Bacillus Vaccine offered greater protection (210) Tropics/subtropics 
Calmette- against tuberculosis at higher (1994) 
Guerin latitudes 
Measles Immunity wanes with higher solar (211) India (2004) 
UVR exposure 
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2.3.9 Photoadaptation and photoprotection 
"Photoadaptation" refers to adaptive changes within the skin that follow repeated doses of 
UVR exposure, such that a given cutaneous response diminishes with subsequent equivalent 
UVR doses (212). An obvious example of this would be skin erythema - the skin adapts to 
repeated solar UVR exposure by tanning and this diminishes the erythemal response to 
subsequent equivalent doses of UVR. "Photoprotection" refers to photoadaptive processes 
allowing the skin to nullify a subsequent single high dose of UVR (8). 
The literature has recently been reviewed by various authors (8,93) to assess whether 
photoadaptation and photoprotection responses were also evident with regard to UVR-
induced down-regulation of immune function. They concluded that repeated (or cumulative) 
UVR exposure did not lead to significant photoadaptation or protection for the majority of 
immune parameters tested, with epidermal DNA damage and macrophage phagocytosis (in 
animal studies) the notable exceptions to this. 
2.3.10 Influence of skin colour on UVR-induced immunosuppression 
There has been conflicting evidence from studies regarding the effect of skin colour on UVR-
induced immunomodulation. An earlier study (213) demonstrated that in people with deeply 
pigmented skin (either via genetics or sun tanning), a single low dose of UVB radiation was 
able to deplete epidermal Langerhans cells. Additionally, CHS elicitation responses were 
reduced when DNCB hapten was applied to UVR exposed skin. The investigators concluded 
that melanisation did not protect against the immunosuppressive properties of UVB. 
By contrast, a study conducted with participants of Fitzpatrick skin phototypes I to IV (192), 
demonstrated that skin types 1/11 experienced more severe SS-UVR induced 
immunosuppression (as measured by CHS sensitisation response to DNCB exposure) compared 
with those with skin types Ill/IV (although all groups experienced some degree of CHS 
response reduction). 
Matsuoka et al (1999) administered whole body, low dose UVB irradiation to heavily and 
lightly pigmented participants, and evaluated peripherally circulating immune cells . NK cell 
activity was found to be significantly higher in the heavily compared with lightly pigmented 
group compared, whilst all other parameters were similar (214) . 
Given that skin pigmentation and photo-type are under polygenic control (76), it is likely that 
the susceptibility to UVR is also influenced by the prevalence of genes encoding for release of 
soluble mediators by the skin cells (i.e. IL-10, TNF- a) within different ethnic groups (192). 
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2.4 Vitamin D and immune function 
2.4.1 Introduction 
Despite the potential negative health consequences of solar UVR exposure, it performs a vital 
role in cata lysing endogenous vitamin D production. The biologically active form of vitamin D, 
calcitrio l {1,25{OHl,D)), is an essential steroid hormone required by the body for optimum 
bone and muscle function (through calcium regulation), photo-protection (reducing UVR-
induced cellular DNA damage) and possible immune system regulation (see Section 1.2). 
2.4.2 Mechanisms of vitamin D-associated immunomodulation 
The 'non-classical' immune modulating action of vitamin D is mediated through the vitamin D 
receptor (VDR) and results in altered gene expression. The VDR is a member of the nuclear 
receptor family of transcription factors and is produced by many immune ce lls (e.g. 
monocytes, activated macrophages, DC, NK cells, B- and T-cell lymphocytes) (3,104,120,121). 
Central to the influence of vitamin Don immune function is the capacity of extra-renal tissues 
(including keratinocytes, macrophages, T-cel l lymphocytes and dendritic cells) to up-regulate 
the la-hydroxylase gene (CYP2781), so that the complete pathway of vitamin D synthesis 
(from UVB-induced vitamin D precursors to calcitriol can be generated by keratinocytes within 
the skin in vivo (215). Although cutaneous production of calcitriol is unlikely to be a significant 
contributor to circulating levels of the active hormone, autocrine and paracrine effects may be 
of importance to immune function in the skin. 
2.4.3 Vitamin D and the innate immune system 
The innate immune response against Mycobacteria tuberculosis (M.tb) is a striking example of 
the influence of vitamin Don immunity. It has been recently shown that activation of certain 
pathogen recognition receptors for Gram-positive bacteria and M.tb (e.g. Toll like receptors 
(TLR2/1)) leads to up-regu lation of the VDR and CYP2781 genes in monocytes {216) . Increased 
local production of calcitriol acts in an autocrine fashion on the VDR, resulting in increased 
expression of the anti-microbial peptide, cathelicidin (LL37), which has activity against M.tb . 
Furthermore, the level of cathe licidin expression appears to be directly associated with the 
vitamin D status of the host- indicating that local conversion to calcitriol may be an important 
step (217,218). Many immune cells have now been shown to produce antimicrobial peptides 
(e.g. LL37, P-defensin 2) under the influence of calcitriol including monocytes, macrophages, 
neutrophils and epithelial ce lls (219) . There appear to be numerous other innate immune 
modulating effects of calcitriol including enhanced microbial killing via alteration of pathogen 
cell membranes, enhanced macrophage phagocytic activity, increased chemotaxis of 
inflammatory cells and down-regulation of pattern-recognition receptors (219,220). 
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2.4.4 Vitamin D and the adaptive immune system 
Calcitriol influences the adaptive immune system in numerous ways including effects on the 
proliferation and differentiation of the main constitutive cel ls (i.e. antigen presenting cells, T 
and B-cell lymphocytes) (12). As a general rule, evidence suggests that calcitriol exerts an 
overall inhibitory or regulatory action on the adaptive immune system (221). 
Experiments have shown that calcitriol inhibits the maturation of monocyte-derived dendritic 
cells, impairing their ability to process and present antigen (222,223). Calcitriol modulated 
dendritic cells also appear to induce Treg cells (CD25+ FoxP3+ IL-10 secreting) (224) and to 
down-regulate the production of co-st imulatory molecules (HLA-DR, CD40, CD80, CD86) that 
activate T cells (225). The results of these critical influences are to promote a tolerogenic or 
regulatory phenotypic role for dendritic cells (226). 
Calcitriol appears to have wide ranging effects on T-cell lymphocytes. Expression of VDR is 
increased upon T-cell antigenic activation . Calcitriol acts subsequently to reduce T-cell 
proliferation (via .J, IL-2) and influences the differentiation into effector T cell populations (via 
.J,IL-12) (220). The bulk of evidence suggests that calcitrio l preferentially suppresses Thl 
immune processes and promotes Th2 processes (227,228) . However, there is evidence 
suggesting that Th2 responses may also be suppressed (229). Additionally, development and 
proliferation of Thl 7 cells, important for neutrophil function and inflammation, are suppressed 
by calcitriol via reduced IL-23 and IL-6 production (221,230). As previously mentioned, Treg 
cells (that can secrete the immunosuppressive cytokine IL-10) are promoted by 1,25(OH l,D-
induced tolerogenic dendritic cells . In addition, ca lcitriol can also directly induce Treg 
differentiation (231). Finally, calcitriol appea rs to influence the migration ofT-cell 
lymphocytes, with increased homing to areas of inflammation in the skin (via up-regulation of 
chemokine receptors on keratinocytes (e.g. CCRlO)) (232) but decreased migration to lymph 
nodes (233). 
Further evidence suggests that ca lcitriol influences B-cell lymphocyte proliferation and activity, 
working in an autocrine or paracrine manner (107). Early work suggested that B cell function, 
including antibody production, may be indirectly influenced by T-cell mediated effects of 
calcitriol (i.e. T cell dependent antibody response) (234). More recently, Chen et al., (2007) 
found that there were direct ca lcitrio l effects on B-cell proliferation, differentiation (including 
inhibition of plasma cells and post-class switching memory cell production) and antibody 
production (235). 
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2.4.5 Epidemiological evidence of the immunomodulatory effect of vitamin D 
A number of immune system-mediated diseases have been epidemiologically linked to host 
vitamin D status - primarily to deficiency in circulating 25(OH)D. In particular, the 
demonstration of calcitriol-induced down-regulation of cell-mediated (Thl and Thl 7) immune 
processes gave weight to evidence suggesting a link between vitamin D deficiency and 
increasing incidence of so-called 'Thl- mediated' autoimmune diseases such as multiple 
sclerosis. The positive effect of calcitriol on the innate immune system (i.e . for antimicrobial 
peptide production), also suggests an association with reactivation of particular infections (e.g. 
M.tb) in the setting of vitamin D deficiency (3,106,236). 
Vitamin D status and Mycobacterium tuberculosis 
The beneficial effects of UVR for M.tb infection have been known for over a century (237). 
Numerous studies have shown that vitamin D deficiency is associated with reactivation of M.tb 
clinical disease (238). However, recent observations that calcitriol promotes M.tb-induced 
cathelicidin production (218) has prompted research into whether the relationship is causal 
and if vitamin D supplementation could reduce the ri sk of relapse or severity of infection (220) . 
One study has shown that vitamin D supplementation with standard therapy reduced the time 
for sputum clearance of organisms (239). However, a randomised, placebo- controlled study 
conducted in Africa did not show any benefit of vitamin D treatment a9ove that of standard 
therapy when assessing clinical end points, including mortality at 12 months. It sh ould be 
noted, however, that vitamin D status was not improved by supplementation (two high doses 
100,000IU over 8 months) in the intervention arm of this study (240) . 
Other clinical infections linked to reduced antimicrobial peptide production associated with 
vitamin D deficiency include Bordetel/a bronchiseptica, Pseudomonos aeruginosa and 
Helicobacter pylori (121). 
Vitamin D status and autoimmune disease 
An inverse association between occurrence of multiple sclerosis (MS) (an autoimmune 
demyelinating condition affecting the central nervous system) and latitude has been known for 
many decades (241-244) . However the potential link to host vitamin D status has only more 
recently been explored (245). Studies using an experimental model of MS in mice 
(experimental autoimmune encephalomyelitis) have shown that treatment with calcitriol 
(resulting in hypercalcaemia) suppressed the symptoms of disease (246,247) . Various studies 
have now shown that higher levels of circulating 25(OH)D are associated with a lower 
incidence of MS (245) and also a lower rate of clinical relapse or new lesions in existing cases 
(248). Recent and ongoing research has focussed on whether vitamin D supplementation can 
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alter the epidemiology and clinical course of MS, with conflicting provisional results 
(236,249,250) . 
The incidences of other autoimmune diseases that have also been shown to be inversely 
associated with vitamin D status include rheumatoid arthritis, inflammatory bowel disease 
and Type 1 diabetes (106,251-253). 
2.5 Summary 
The human immune system protects the host from infection and from proliferation of aberrant 
cells, and comprises innate (non-specific) and adaptive (antigen-specific) components. The 
skin acts as a crucial interface between the immune system and solar UVR exposure. UVR is 
absorbed by chromophores (i.e. DNA, urocanic acid and cellular membrane components) 
within epidermal cells that then initiate a complex cascade of immune processes. The overall 
effect is one of down-regulation of cell-mediated (Thl) processes and promotion of a 
regulatory environment within draining lymph nodes . Contact hypersensitivity and delayed 
hypersensitivity testing - in vivo assays of cell-mediated immunity - have shown that UVR 
exposure (at various doses, wavelength bands and anatomical sites) leads to antigen-specific 
local and systemic immunosuppression. The action spectrum for UVR-induced 
immunosuppression indicates that there are two immunosuppressive peaks for solar UVR-
centred around 300nm (UVB) and 370nm (UVA). Host resistance and observational studies 
indicate that UVR-associated immunosuppression may have clinical relevance, with UVR 
exposure leading to an increased burden of infectious diseases in animal and human models 
and decreased vaccine efficacy. 
Calcitriol (1,25(OH) 2D) has immunomodulatory properties that are mediated by the vitamin D 
receptor (VDR) found in the nucleus of many immune cells. Calcitriol can be derived from the 
systemic circulation or be produced locally by keratinocytes or by immune cells (e.g. 
macrophages, T-cell lymphocytes) . Calcitriol can have autocrine, paracrine or endocrine 
effects on immunological processes. Calcitriol can stimulate the production of anti-microbial 
peptides (e.g. cathelicidin), that are important components of the innate immune response. 
With regard to adaptive immune responses (and similar to the overall direct effect of UVR 
exposure), calcitriol acts to promote a tolerogenic / regulatory T-cell environment. Adding 
clinical weight to these findings, growing epidemiological evidence suggests an association 
between decreased 25(OH)D levels and the incidence or prevalence of so-called ''Thl -
mediated" autoimmune diseases (e.g. multiple sclerosis). 
51 
UVR exposure appears to modulate immune responses, either directly or indirectly via the 
action of calcitriol. However, much remains unknown, including the effect of solar UVR on 
immune function at doses relevant to activities of daily living. 
The following chapter will discuss the field of immunotoxicology, whose principles and 
methods are relevant for conducting studies aimi ng to assess the influence of environmental 
exposures (such as UVR) on immune function. 
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Chapter 3: lmmunotoxicology 
Synopsis 
The principles underpinning the field of immunotoxicology can inform an assessment of the 
effect of personal solar UVR exposure on human immune function. This chapter is divided into 
the following sections: i) overview and principles of immunotoxicology; ii) conducting an 
epidemiological study assessing the potential for UVR-mediated immunotoxicity; and iii) 
management of other immunomodulatory factors. 
3.1 An overview of immunotoxicology 
The field of immunotoxicology relates to the study of adverse influences of 'agents' on 
immune function and the resultant risks posed to health (20) . Agents can be chemica ls 
(including pharmaceuticals and pollutants), biological materials, medical devices or physical 
factors (e.g. UVR) (254,255). The adverse influences on immune function can manifest in 
diverse ways, from immunosuppression predisposing to infection and cancers, over-
stimulation leading to allergy or chronic inflammatory states, or impaired tolerance 
predisposing to the development of autoimmune disease (21). 
It is important to emphasise that robust homeostatic immune mechanisms are at play when 
the host immune system is challenged. The influence of putative immunotoxic agents may not 
necessarily result in " pathological deviation from a homeostatic norm for host res istance" 
(256) (pp. 363), as there are generous redundancies in immune processes and multiple 
immune pathways that ass ist return to homeostasis. Cha nges in immune function that lead to 
illness or disease result from more significant perturbations of an immune system unable to 
return to a homeostatic state, for example, following a more sustained or intense exposure to 
an immunotoxic agent or more minor changes in a susceptible host. Figure 3.1 illustrates the 
common pathways that maintain homeostasis and that can also lead to immune-mediated 
disease. 
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Figure 3.1: The possible pathways to toxin-mediated immunomodulation (Source: 256) 
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Table 3.1 lists examples of agents that have been implicated in immune-mediated 
manifestations. Historica lly, most research has focussed on immunosuppressive agents such as 
the halogenated aromatic hydrocarbon group (which includes dioxins and polychlorinated 
biphenyls (PCBs)) or agents causing contact allergy (e.g. latex) (254). More recently, research 
has diversified into developmental immunotoxicology, autoimmunity, ;ind refinement of 
molecular techniques to determine patterns of genetic susceptibility (257). 
Table 3.1: Examples of immunotoxic agents and their main immunomodulatory effect 
Immune outcome Examples of implicated immunotoxic agent 
lmmunosuppression Polyhalogenated aromatic hydrocarbons (i.e. polychlorinated 
biphenyls), pharmaceuticals (e.g. cyclosporine, anti-neoplastic 
agents), metals (e.g. lead, cadmium, mercury), radiation (e.g. 
UVR, ionizing), pesticides (e.g. chlordane, parathion) 
Allergy Metal salts (e.g. chromium, nicke l), anhydrides (e.g. phthal ic), 
proteins (e.g. latex), dyes (e.g. rifafix yellow), wood dusts (e.g. 
western red cedar), epoxy resin, mercaptobenzathiole 
Autoimmunity Organic solvents (e.g. polyvinyl chloride), antibiotics (e.g. 
pen icillins, sulphonamides), anti-convulsants (e.g. phenytoin) 
Chronic Beryllium, silicosis, organic dusts containing dairy or grain 
inflammation products 
Adapted from (254) 
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3.1.1 Approach to immunotoxicological studies 
lmmunotoxicity is a biological end-point analogous to other types of systemic toxicity 
considered in a standard toxicological assessment. In this context, a 'risk analysis' of the 
putative immunotoxic agent is commonly performed. This entails problem formulation (e.g. 
establishing goals and parameters of the study), ri sk assessment (see below), ri sk management 
(e.g. considering options, making and actioning decisions) and risk communication (i.e. to 
relevant stakeholders) (see Figure 3.2) (21). Risk assessment is the main component of the risk 
analysis, and comprises four steps: i) hazard identification (i.e. identifying the nature of the 
potential health risk); ii) hazard characterisation (i.e. determining biological pathways, dose-
effect relationships) ; iii) exposure assessment (i.e . determining how much exposure humans 
have to the putative toxin); and iv) risk characterisation (i.e. combining the findings of the 
previous steps to determine the actual risk to humans at varying levels of exposure) (258). 
Figure 3.2: Steps involved in undertaking an immunotoxicological risk analysis 
Risk analysis: the process of setting objectives, identifying hazards, 
assessing risks and management options, weighing these, and 
prioritizing, choosing and implementing risk management measures 
Problem definition: 
risk management questions 
l ----
Risk assessment 
l 
weighing and choice 
l 
Source (21) 
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Hazard identification and characterisation of ultraviolet radiation as an immunotoxic agent 
have been made via extensive studies in animals and humans as outlined in Chapter 2. This 
thesis is primarily concerned with the latter components of risk assessment - exposure 
assessment (i.e. what levels of UVR exposure are healthy adults routinely exposed to?) and risk 
characterisation (i .e. given the level of UVR exposure and known immunosuppressive 
pathways, what is the extent of immunosuppression in humans from routine UVR exposure?). 
3.1.2 Testing strategies in immunotoxicology 
Animal versus human data 
The vast majority of immunotoxicological studies performed thus far have been conducted 
using animal models, primarily rodents (259-261). Apart from the logistic, time and cost 
benefits of conducting laboratory animal rather than human research, the following 
advantages are afforded: i) control/ exclusion of potential confounding variables; ii) precise 
measurement of exposure variables; iii) opportunity to test a wide range of exposure doses; iv) 
use of genetically homogeneous animals; and v) opportunity to use an array of immune 
function tests, including invasive testing. The disadvantage of laboratory animal testing is that 
the animal immune model may not reliably or closely simulate the human immune response to 
a potential immunotoxic agent, and that testing in a controlled-laboratory (unstimulated) 
environment may be an insensitive test system for detecting immune dysfunction {21,262). 
Although animal-derived immunotoxicology data have been shown to be predictive for human 
immune outcomes in an increasing range of settings (26_3), primary human data are the 
preferred, relevant model where possib le {256) . However, for all the reasons that make 
laboratory animal testing easier, gathering robust data in humans poses significant challenges 
for study design, exposure measurement and immune parameter delineation . Humans differ 
by numerous intrinsic (e.g. age, genetics, gender) and extrinsic (e.g. diet, behaviour, 
medications) factors which can potentially confound or modify the association between the 
agent of interest and the immunomodulatory effect (see section 3.2.3) {256,264). 
Testing algorithms 
As the influence of immunotoxic agents may be su btle, intermittent, and affect various 
components of the immune system differentially, the choice of immune parameters to be 
tested in immunotoxicological studies is of paramount importance. The general aims of 
immunotoxicological testing are to: 
i) Choose sensitive tests that can detect subtle immunological changes 
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ii) Assess the specific component/s of the immune system most likely to be affected, based on 
current knowledge (i.e. innate vs. adaptive; humoral vs. cell-mediated) and at the most 
appropriate site (e.g. based on the site of exposure interface) 
iii) Use a combination of tests that can confirm a pattern of immunomodulation (i.e. changes in 
values of parameters in a single test may not reflect true immunomodulation) 
iv) Choose tests that can assess immune parameters at the appropriate time points for suspected 
immunomodulation (particularly if changes are transient) 
Tier testing 
In the 1980s, groups in the Netherlands and United States (in particular), performed much of 
the early work in establishing screening and functional assays in mice and rat studies involving 
chemical immunotoxicity (265,266). As part of the US National Toxicology Program (NTP), 
Luster et al (266) tested over 50 putative chemical immunotoxins and developed a 
comprehensive battery of tests that were divided into two 'tiers' (see Table 3.2) - Tier I tests 
acted as a screen to detect evidence of immunotoxicity resulting from an agent, and Tier II 
tests were more comprehensive tests designed to further define the immunotoxic effect. 
Whilst no individual test was found to be completely predictive for immunotoxicity, later 
validation studies demonstrated that combinations of two or three immune tests increased 
the sensitivity of predicting immunotoxicity of tested chemicals in mice to over 90% (and up to 
100% using specific combinations (267)). Quantification of the T cell dependent antibody 
response (i.e. to sheep red blood cell immunisation) (78% concordance) and/or quantification 
of lymphocytes by analysis of cell su rface markers (83% concordance) had very high predictive 
properties, whilst some Tier I screening tests (i.e. white cell count and organ weights) were 
quite insensitive. Further modelling studies examined the relationship between the above 
immune function tests and 'hard' functional end-points such as host-resistance tests (i.e. 
following exposure to an immunotoxic agent, the laboratory anima l was challenged with 
infection or tumour cell transplantation at a dose sufficient to cause morbidity in 20% of 
animals) (268). These studies showed a 'good' correlation between immune function assays 
and host resistance end-points, with high sensitivity for detecting diminished host resistance, 
but with low specificity. However, no individual assay or combination of assays was 
particularly predictive of diminished host resistance. 
The development of numerous national and International guidelines on immunotoxicology 
testing (21,264,269,270) has been informed by the semi nal work conducted by the NTP and 
others, and is reflected in recommendations wh ich have changed by iteration over the years 
(reviewed in: 20). 
57 
Table 3.2 Tiered approach to immunotoxicology testing in animals 
Tier Immune function tests 
Tier I (Screening) • lmmunopathology (e.g. spleen, lymph node &/or thymus 
histology) 
• Haematology (e.g. white cell count and differential) 
• Tota l body and organ weights (e.g. spleen, thymus, kidney) 
• Functiona l immune testing (e.g. quantification of lgM antibody 
plaque-forming cells following T-cell dependent antigen 
immunisation; lymphocyte proliferation assays using non-
specific mitogens; and NK cell activity) . 
Tier II • Quantification of splenic B & T lymphocytes (cell surface 
(Comprehensive) markers) 
• Cytotoxic T-lymphocyte assays 
• Quantification of lgG antibody response following T-cel l 
dependent immunisation -
• Host resistance challenge - testing host res istance to infection 
(e.g. bacterial, vira l, parasite) or tumour cell transplantation 
Source: (267) 
3.1.3 lmmunotoxicology testing in studies involving humans 
The tier approach to immunotoxicology testing can also be applied to human resea rch (264), 
however data validating its use are limited (271) and there are considerable logisti c and ethical 
issues with obtaining appropriate sa mples (e.g. t issue for histology or weight) or conducting 
host resistance testing. 
A comprehensive report resu lting from a World Health Organisation (WHO)-sponsored 
symposium (23) synthesised the views of International experts in the fie ld of clinical 
immunology, epidemiology and immunotoxicology and concluded that the "antibody response 
to a primary immunisation is recommended as the most convenient and comprehensive 
measure of immunocompetence" and the "primary immune response is also among the most 
predictive assays fo r immunotoxicity in laboratory stud ies" (pp. 141). Delayed-type 
hypersensitivity testing, NK cell assays and phenotypic analysis of lymphocyte surface markers 
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by flow cytometry have also been suggested by various authors (23,256,264) . The postulated 
or known mechanism of immunomodulation has a large influence on the types and range of 
immunology tests chosen. 
3.1.4 T-cell dependent antibody response 
Quantification of a primary antibody response to immunisation with a T-cell dependent (TD) 
antigen has been promoted as a sensitive tool for assessing immunotoxicity in epidemiological 
studies (22,23,272). In the literature, the immune response to immunisation with a TD antigen 
is commonly referred to as T-cell dependent antibody response or 'TDAR' . 
Protein antigens (e.g. sheep red blood cells, keyhole limpet haemocyanin, tetanus toxoid, 
diphtheria toxin, poliovirus, hepatitis B surface antigen) are examples of TD antigens (274-
276) . Antigens are presented to naive T-cells by APCs (e.g. Langerhans cells) in the form of a 
peptide:MHC class II complex. This interaction leads to the generation of antigen-specific T-
helper cells (CD4+) (See section 2.1.1). A humoral response from naive B cells cannot be 
generated against TD antigens without T-helper cell stimulation. Naive B cells detect TD 
antigen which binds to surface immunoglobulin and internalised, processed and re-displayed 
on the cell surface as a peptide:MHC class II complex which can be recognised by a primed T-
helper cell. The bound T-helper cell up-regulates the B-cell stimulatory molecule, CD40 ligand, 
leading to T cell production of cytokines (e.g. IL-4, IL-5, IL-6) that stimulate B cells to proliferate 
and differentiate into antibody secreting plasma cells and resting memory B cells (134). As 
described above, the generation of a primary TDAR requires all pathways of the adaptive 
immune system to be functioning and therefore an immunotoxic agent-induced deficit of any 
component will be reflected by reduced antigen specific antibody production (261). Primary 
immune responses to TD antigens are considered a more sensitive immunotoxicological tool 
compared with secondary responses, as the latter does not necessarily require operation of 
the full range of adaptive immune processes (264) . 
In animal immunotoxicity research, TDAR using sheep erythrocytes or keyhole-limpet 
haemocyanin (KLH) antigen has become the functional primary immune assay of choice 
(275,277,278). For human epidemiological immunotoxicology studies, opportunistic 
monitoring of the responses to routine childhood vaccinations (e.g. tetanus, diphtheria, 
pertussis) has been advocated (23,272). 
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Determining what is an ideal vaccine candidate for generating TDAR 
The properties for an ideal TD antigen vacc ine have been previously described (23,264,279). 
Ideally, such antigens should: 
i) Be a pure homogeneous substance available as a clinical grade product; 
ii) Be harmless in humans, if not beneficial, to the recipient (e.g. commercially available 
vaccination where protection from a commonly encountered infectious agent is 
conferred); 
iii) Be highly immunogenic for the whole population w ithout any genetic restriction; 
iv) Have no natural or cross-reacti ng antibody; 
v) Elicit predictable primary antibody responses and/or a delayed hypersensitivity response 
(without need for an adjuvant) following a single administration; 
vi) Produce a measurable antibody response which can differentiate subtle changes in 
immunomod ulation (i.e. have high sensitivity to detect change); 
vii) Have a quantifiable humoral response that can be measured using val idated tests (e.g. 
enzyme-linked immunosorbent assay) . 
Table 3.3 shows the commonly used TD antigen vacc ines in animal and.human research and 
how they fulfil the criteria listed above. Commercially available vaccines (e.g. hepatitis B, 
influenza, tetanus) have the advantages of already passing strict sa fety regulatory processes, 
providing a protective benefit for study participants and being avai labl e in a clinically 
appropriate form. The main disadvantages are that in a non-paediatric population, many 
participants wi ll have already been exposed to antigen from w ild-type infection or previous 
vaccination; and com mercial vaccines produce a very robust immune response thereby 
potentially overwhelming the assay's ability to detect subtle changes in immune response. As 
ment ioned, keyhole limpet haemocyanin is often used in animal immunotoxicological research 
and has many of the qualities of an ' ideal' vaccine cand idate (279) and wi ll be discussed in 
more detail in Chapter 4. 
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Table 3.3: Candidate thymus-dependent antigen vaccines for immunotoxicology studies 
TD-antigen Regulatory Provides Previous Natural or cross- Reliable antibody Antibody level Sensitive enough to Studies using vaccine in 
Vaccine safety protection exposure to reacting antibody response after cut-off detect human 
candidate testing in against antigen (wild- if previously single correlating with immunomodulation immunotoxicological 
humans infection? type infection naive? administration? clinical studies 
or protection? 
immunisation) 
Sheep No No No Yes N/A No 
erythrocytes 
Keyhole Yes No No Schistosomo Yes No Yes, depending on dose Yes (280-282) 
limpet mansoni # 
haemocyanin 
Measles Yes Yes Possible/ No No** Yes Yes (283) 
proba ble 
Influenza Yes Yes Possible Possible* Yes** No Yes (284,285) 
Hepatitis B Yes Yes Possible No No** Yes May overwhelm Yes (19,286) 
immune-modula tory 
signal 
Tetanus Yes Yes Possible No No** Yes Yes (287) 
* Antibodies to no n-vaccine st rains of pathogen # Reference (288) **Source: (289) 
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3.1.5 Use of TDAR in immunotoxicological epidemiology studies 
The next section gives examples of immunotoxicological studies in human populations where 
TD antigen immunisations have been used. 
Commercially available hepatitis B vaccine has been used in two recently reported (and 
related) studies assessing the effect of pesticide exposure on the vaccine response (286,290). 
In both studies, hepatitis B antibody was quantified approximately two weeks following the 
second vaccination. Neither study found a significant difference in hepatitis B antibody titres 
between exposed and non-exposed groups, which, when combined with the results of other 
immune parameter testing (e.g. total immunoglobulin, complement levels, lymphocyte 
subpopulations and natural killer ce ll levels), lent weight to the conclusion that pesticide 
exposure in these study settings did not influence immune function in a way that posed a 
health hazard. 
Weisglas-Kuperus et al (283) followed a Dutch cohort of 207 Caucasian mother-infant pairs 
from birth to 42 months and investigated whether the immunotoxic effects of prenatal 
exposure to polychlorinated bi phenyl (PCB) and dioxin persisted into infancy. As part of the 
Dutch immunisation program, infants received primary vaccination to measles, mumps and 
rubella at approximately 14 months of age. At 42 months, blood was assayed for antibodies 
against the vaccine constituents, and in a subgroup, lymphocyte subpopulations. The authors 
found that prenatal PCB exposure was associated with significantly lower antibody levels to 
mumps and measles at 42 months, as well as altered T-cell subsets. 
Two observational studies have used primary vaccination to assess the influence of season of 
vaccination on subsequent vaccine-induced antibody response. Season of vaccination was 
used as a surrogate of ambient UVR, the putative immunotoxic agent. In a recently reported 
Israeli study (17) rubella antibody titres were assayed three to four years after primary rubella 
vaccination in 203 infants of similar ethnicity and skin complexion attending kindergartens. 
The researchers found statistica lly higher rubella antibody titres in infants vaccinated in winter 
compared with summer months (mean geometric titre 73.0 IU vs. 47.6 IU; p<0.0S), and a 
similar trend with regard to proportions of infants adequately vaccinated (i.e. rubella titre >15 
IU). 
Similarly, a cohort of young Dutch adults vaccinated with hepatitis B vaccine had lower vaccine 
specific antibodies after the first and second vaccinations (administered at 0 and one month 
respectively) when these were given in summer compared to winter (209). However, soon 
after the third vaccination (at six months), the difference in antibody levels between groups 
was no longer apparent. 
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In the only reported controlled study aiming to assess the influence of UVR exposure on 
vaccination response, half of a group of 191 healthy young Dutch volunteers were randomised 
to receive five days of one (personal) MED of whole-body UVB, whilst the other half remained 
unexposed controls (19). Both groups were vaccinated with a commercial hepatitis B vaccine 
preparation (at 0, 1 and 6 months). At various time points post-vaccination, blood was taken 
for hepatitis B-specific antibody titres, lymphocyte proliferation assays and NK cel l assays. 
Although there was evidence of local immunosuppression at the site of UVB exposure 
(evidenced by reduced CHS responses), there were no differences in antibody levels or T-cell 
proliferation assays between exposure groups. This study will be discussed in more detail in 
Chapter 8. 
3.1.6 Delayed-type hypersensitivity response 
The DTH response is an in vivo assessment of cell-mediated immunity and has long been used 
as a measurement assay in immunotoxicological research . The NTP analysis of the predictive 
effectiveness of assays highlighted DTH testing as having high concordance with 
immunotoxicity particularly when used as a component of a multi-functional evaluation (267). 
In clinical practice the DTH response to purified protein derivative (PPD) has a long history of 
use for determining past exposure to M.tb (i.e. the tuberculin skin test or 'Mantoux test') 
(291). 
The DTH response (otherwise classically known as a Type IV hypersensitivity reaction) 
manifests as a smal l area of indurated (i.e. raised, oedematous, often erythematous) skin . It 
develops on re-inoculation of antigen into the dermal layer of skin when the host has been 
pre-sensitised to the antigen (i.e. had prior exposure naturally or via vaccination). DTH 
inducing antigens ca n be proteins, Mycobocterio, haptens or grafted tissue. The 0TH response 
classically takes 24- 72 hours to develop, although there is some variation depending on the 
antigen used (292). 
The immuno~athogenesis of DTH responses has largely been elucidated. The first step is 
antigen-specific priming (sensitization) of na·1ve T-helper cells, which can occur through natural 
exposure to antigen from infection or via immunisation (e.g. prior Bacillus Calmette-Guerin 
(BCG) vaccine in the case of tuberculin sk in testing). Antigen presenting cells display antigen in 
the form of antigen:MHC class II complexes and release IL-12 and IL-18, promoting 
differentiation of na'ive T helper cells to Thl lymphocytes (293). The 'e licitation' phase on re-
exposure to the antigen usually occurs in the dermal layer of the skin, where immune 
responses can be easily monitored. Following re-exposure to antigen, a number of cell types 
are recruited to the site of challenge including neutrophils, dendritic cells, macrophages and 
memory T-helper (particularly Thl) lymphocytes, which are present in differing concentrations 
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at varying time-points (293). Numerous cytokines and chemokines are released, promoting the 
inflammatory response and include: IL-8, monocyte chemoattractant protein-1, macrophage 
inflammatory protein 1-alpha, TNF-a and granulocyte-macrophage colony-stimulating factor 
(294). P- and L- selectins are also very important in attraction and formation of the 
multicellular infiltrate, and particularly for binding of memory Thl cells (295). Regulatory T 
cells can also influence the development of the DTH response (296,297). 
Essentially, the DTH response is a Thl-driven cell-mediated immune process which can be 
disrupted by problems with initial T-cell sensitisation, interference with cellular trafficking and 
chemotaxis to the site of re-exposure or regulatory T-cell influences (294). 
The DTH response is seen as a valuable functional in vivo test of cell-mediated immunity. There 
are a number of practical issues however. Although tuberculin skin testing has been 
standardised in terms of preparation of antigen, dosing, administration and interpretation of 
the result, the same is not true for other antigens (23) . Furthermore, even with long 
established tuberculin skin testing, subjectivity with reading of responses is a significant 
ongoing challenge (298). 
3.1.7 Use of DTH in immunotoxicological epidemiology studies 
There have been numerous studies that have used DTH testing to assess the influence of 
potential immunotoxins on the immune response. The recall antigen(s) in these studies have 
usually been either tuberculin antigen (in those previously immunised with BCG) or the 
'Multitest CMI' (a commercial preparation of seven commonly encountered antigens). The 
latter battery of antigens has been well validated and standardised in DTH testing (299). 
A Taiwanese investigation into the immunological effects of accidental PCB ingestion (300) 
demonstrated that DTH responses to tuberculin and a streptokinase/streptodornase 
combination were significantly lower in the exposed group compared with controls, even 
many years after exposure. The percentage of exposed participants demonstrating a DTH 
response, as well as the size ofthe response, reduced with increasing markers of initial PCB 
exposure. 
Several studies have assessed the immunotoxic properties of UVR by measuring the DTH 
response using either the Multitest CMI (16) or tuberculin antigen (183,185) (reviewed in 
Section 2.3.6). 
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3.1.8 Clinical significance of testing 
The purpose of conducting immunotoxicity testing is to establish changes in immune 
parameters (or 'biomarkers') that also reflect some real change in the susceptibility of the host 
to disease. Host resistance testing is one way to assess the predictive ability of changes in a 
given immune parameter - although this is more easi ly done in an experimental setting using 
animal models. Using various animal infectious disease and tumour models, immune tests 
were found to be very sensitive (though not specific) for detecting immunotoxic changes of 
clinical relevance (i.e. worsening infectious or tumour burden) (268) . To determine whether a 
threshold level of immunotoxicity existed, the same researchers studied the effects of 
increasing doses of cyclophosphamide (a potent immunosuppressant medication) on animals 
as a host-resistance model. They found an essentially linear relationship between change in 
the immune parameter and host-res istance (albeit acknowledging the results were derived 
from a limited data set). 
If the measured change in immune parameter is profoundly abnormal, such as very low 
lymphocyte counts in people with HIV infection (138) or primary immunoglobulin deficiency 
(302), individuals are at high risk of developing disease. In general though, using immune 
parameters as a surrogate for increased disease risk in the host is problematic, given the 
aforementioned functional immune reserve capacity (20). Therefore, a mild to moderate 
alteration to TDAR or DTH response in an individual following an exposure to an immunotoxin 
does not necessarily mean that an otherwise healthy individual is at risk of disease. 
As previously noted however, if there is a linear relationship between change in an immune 
parameter and disease outcome, then at a population level (which would include vu lnerable 
people - the aged, very young, ill), less profound impairment of specific immune processes 
occurring with high prevalence may manifest as an increased incidence of infection (e.g. 
influenza, otitis media or the common cold) (22) and reduced vaccine effectiveness (143) 
(Figure 3.3). Consistent with this view, Selgrade (303) stated that "it is reasonable in hazard 
identification to consider any statistically significant and consistent suppression on an immune 
function test as a potential risk to a population (pp.62)" 
65 
Figure 3.3: Changes in population susceptibility to disease as a result of immunotoxin 
exposure - a concept diagram 
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The proportion of a population susceptible to immune-mediated disease is represented by 
area 'A'. Exposure to an immunotoxic agent (e.g. ultraviolet radiation) is postulated to shift 
the population curve, such that a greater proportion of the population (Area 'A'+ 'B') is 
susceptible to immune-mediated disease. 
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3.2 Conducting an epidemiological study assessing immunotoxicity of 
ultraviolet radiation 
Apart from immunotoxicological parameters, careful consideration of numerous other factors 
is required when designing and conducting an epidemiological study in humans that aims to 
detect immunological influences due to an environmental agent, such as solar UVR. The 
aforementioned "Report of the Bilthoven Symposium" (23), canvassed many of the important 
issues relevant to conducting such research (and indeed, significantly inform ed the 
development of experimental research conducted for this thesis). These are summarised 
below. 
3.2.1 Study design 
Cross-sectional studies, where measurement of the exposure variable of interest, possible 
confounding factors and immune outcomes occurs at the same time, are logistically easier to 
conduct but are unable to distinguish the chronology of exposure-related effects. Prospective, 
longitudinal studies are preferred where participants are either randomized into different 
exposure groups (randomized control trial (RCT); gold standard) or followed as a cohort from 
the time of exposure to some defined time point. These studies are logistically challenging but 
allow more detailed information to be collected and a change in immune status to be noted in 
relation to the toxin exposure. 
3.2.2 Participant selection and sample size 
Based on previous research or pilot study data, calculations rega rding an adequate participant 
sa mple size should be determined. This calculation will be based on the expected difference 
between exposure groups (either absolute difference or effect size), study power and alpha 
level. Decisions regarding participant selection will depend on: i) demographic of interest (e.g. 
children versus adults); ii) potential recruitment population (i.e. from the general population 
versus some se lect sub-popula tion) ; iii) strategies to reduce confounding varia bles (e.g. well 
defined inclusion and exclusion criteria such as age or gender restriction); and iv) logistic and 
cost issues (e.g. research budget, research staff, time to completion). 
3.2.3 Measurement of exposures and potential confounders 
Using validated instruments to measure exposures and potential confounding variables is 
important. Direct measures are preferred for exposures rather than questionnaires or diary 
data which can be prone to recall error and/or bias. Environmental measures of exposure (i.e. 
ambient levels of UVR) or surrogates of UVR exposure (e.g. using latitude of residence) do not 
necessarily reflect an individual's exposure and risk false inferences about the exposure-
outcome relationship (the so-called "ecological fallacy") (304). Measurement/sat an 
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individual level are therefore preferred (305). Keeping in mind the aforementioned 
limitations, questionnaires and diaries are convenient, low cost and frequently used in 
epidemiological studies. Using validated questionnaires (i .e. that have had internal 
consistency checks and been tested in reference populations) is critical to maximise their 
reliability (23). They are most useful when recording contemporaneous information rather 
than retrospective data. Questionnaires are also reliable for obtaining demographic 
information and other 'set' information (e.g. family history, medications) and information 
difficult to measure (e .g. clothing worn, sunscreen use, other sun protection behaviour). 
3.2.4 Potential confounding variables and effect modifiers 
In a study of UVR and immune function, there are many potential confounding variables 
including age, gender, smoking status, nutrition, vitamin D status, ethnicity, psychological 
state, physical fitness, co-existing infections, medications and comorbid conditions. It is critical 
to also take validated, detailed measures of potential confounding variables and effect 
modifiers where poss ible (as important as measuring the exposure variable), otherwise 
important associations may be mis-estimated, and/or misinterpreted . Some confounding can 
be avoided in the way participants are chosen (i.e. only females, restricted age or ethnic group, 
or other definable characteristic) which is important pa rticularly in the non-RCT context. 
Section 3.3 will expand on the issues relevant to confounding variables. _ 
3.2.5 Participant burden 
A balance needs to be found where enough information i~ obtained from participants (i.e. 
from direct measurements, blood tests, questionnaires, diaries) to be able to assess 
associations between exposures and outcomes taking account of potential confounding 
factors, but without overburdening participants such that they do not accurately complete or 
fulfil study requests or attend study visits, or become distressed by their ongoing participation. 
The boundary between these outcomes is often not clear and maybe highly individualised; 
however this needs to be considered when designing and conducting the study. 
3.3 Potential confounding variables 
Numerous intrinsic and extrinsic conditions and exposures have the potential to influence the 
immune response to antigenic challenge. Those factors that also vary with UVR exposure could 
therefore be confounding variables. It is important to measure these variables, test them as 
possible confounders and adjust for them where necessary, in order to properly assess the 
effect of UVR exposure on immune function (306). This section will detail the evidence for 
relevant immunomodulatory variables and discuss in particular, how they may influence the 
response to immunisation . 
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3.3.1 Age 
At both extremes of life, the mammalian immune system operates sub-optimally (307) . During 
infancy, there is ongoing maturation of the immune system such that the immune response to 
polysaccharide antigen (in particular) is not robust until after the age of 2 years. In later life, 
the process of 'immunosenescence' or diminution of the immune system occurs with 
numerous elements of immune pathways being affected (See Table 3.4). lmmunosenescence 
is a gradual process - indeed some structural changes begin even in childhood (e.g. thymic 
involution) but the functional and clinical manifestations do not manifest until later in life 
(308,309). The main clinical implications of immunosenescence are decreased response to 
immunisations, increased incidence of autoimmune disease and increased morbidity from 
infections (310) . 
Numerous studies have shown that post-vaccination antibody titres are lower in the elderly (or 
'o lder' age groups), including for influenza (311), hepatitis B (312) and tetanus vaccines (313). 
For example, the proportion of antibody sero-conversion (to a level which corresponded with 
clinical protection) following hepatitis B vaccine was assessed in a group of adult Pakistan i 
health ca re workers (n=652) (314). The proportion of serological non-conversion increased 
with increasing age, such that the odds of non-co nversion in the >50 years group was 17.8 
times higher than the <25 years group (p<0.001). Hainz et al (315) measured anti-tetanus 
toxoid antibody and tick-borne encephalitis (TBE) antibodies in vaccinated Austrians aged 
between 18- 93 years. Post-vaccination antibody titres declined with age, in a linear manner 
throughout life for TBE antibodies, and from the age of 4Q years for tetanus. 
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Table 3.4 Immunological changes with aging 
Component of the Summary of changes occurring with aging 
Immune system 
T Lymphocytes 
- CD4+ T cells • -!, T-cell receptor (TCR) signalling intensity 
• -!, Expansion in response to TCR stim ulation 
• -!, Thl and Th2 effector differentiation 
• -!,Cognate helper function 
- CD8+ T ce lls • -!, TCR repertoire diversity 
• -!,Anti-tumour responses 
- Regulatory T cells • 1' Number 
• Retain/gain function with age 
• Down-regulation of an ti-tumour responses 
• May contribute to skewi ng towards Th17 respon se 
B Lymphocytes • -!,Diversity of B cell repertoire 
• -!,Expression of co-stimulatory molecules (CD27 CD40) 
• -!,Antibody affi nity 
• -!,Antibody class switching 
Innate immunity • Neutrophils: -J,,oxidative burst, phagocytic capacity, bactericidal activity 
• Macrophages: -!,oxidative burst, phagocytic capacity 
• Natural Killer cells: -!,Proliferative response to IL-2, cytotoxicity; 
• 1' Number of NK cells 
• Dendritic cells: -!,Capacity to stimulate T cells, lymph node homing 
• Cytokines & chemokines: 1'1L-6, IL-1~, TNFa serum level 
Source: (308,316,317) 
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3.3.2 Sex 
Human immune function is influenced by sex, largely due to differing levels of sex hormones 
but also due to behavioural, dietary and psychological differences. Oestrogens generally 
enhance immune function, particularly for humoral responses, whereas androgens (such as 
testosterone) are generally immunosuppressive to cell-mediated and humoral processes 
(318,319). In general, women have higher levels of circulating immunoglobulins and generate 
more vigorous humoral responses to exogenous antigens than males (320). Additionally, the 
prevalence of numerous autoimmune disease states is higher amongst females than in males. 
Examples include MS (321), Grave's disease (322) and autoimmune rheumatic disease (323). 
Green et al (324) assessed the antibody response to live attenuated measles vaccine in 223 
males and 66 females aged 18 -20 years in Israel. Females had higher geometric mean titres 
(~so% higher) at both 2 and 4 weeks post-vaccination compared with males. In the previously 
described study of Pakistani healthcare workers (314), young males demonstrated more than 
twice the rate of serological non-response to hepatitis B vaccination compared with young 
females (18% vs. 8%; p<0.001), consistent with the findings of other research (325). 
A recent systematic review (326) of studies specifically examining the differences by sex in the 
humoral response to vaccines, demonstrated higher antibody responses in adult females 
compared with males for influenza (elderly adults, young adults with ac1Jte stress and eccentric 
exercise), hepatitis A, hepatitis B, rubella, measles, tetanus and Bruce/la. Male adults had 
higher vaccine-associated antibody responses than females for pneumococcal polysaccharide 
(healthy and alcoholic adults), yellow fever and meningowccal A and C. Clinical vaccine 
effectiveness was consistent with the above findings (i.e. females had less clinical disease post-
vaccine than males for influenza, hepatitis A and B; males had less pneumococcal disease). All 
the studies assessed, regardless of vaccine type and mechanism for promoting immune 
response, showed differences in humoral response by sex . The author therefore concluded " it 
(be) mandatory that vaccine clinical trialists recruit a representative sample of females and 
males to be able to assess sex-differences which may have clinical implications" (pp. 3555). 
3.3.3 Genetics and ethnicity 
One of the most challenging issues in conducting non-experimental epidemiological studies is 
accounting for the heterogeneous genetic makeup of human participants, unlike the 
controlled, genetically homogeneous conditions of inbred animal research. Much of the 
important genetic variation pertaining to human immune function relates to genes (human 
leucocyte antigens (HLA)) encoding the MHC class I and II molecules that are critical for 
presenting antigen to T lymphocytes. There are over 400 alleles (variant HLA genes) encoding 
for MHC class I and II molecules (134). This variation or 'polymorphism' affects antigen 
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recognition by T cells by influencing peptide binding and the interaction between T-ce ll 
receptor and MHC molecule (134) . Variations in responses to influenza, measles and hepatitis 
B vaccines have been noted in individuals with certain HLA combinations (haplotypes) 
(Reviewed in 86). 
Non-HLA genetic polymorphisms have also been associated with vaccine responses. Sleijffers 
et al (328) found that participants in their hepatitis B randomised controlled study that were 
homozygous for a minor variant (polymorphism) of the IL-1~ gene, demonstrated significantly 
reduced antibody response following UVB exposure compared with non-irradiated 
homozygous counterparts. This research suggested that genetic determinants of critical 
immune mediators can modulate the effect of UVR exposure differentially. In another study, a 
number of single nucleotide polymorphisms (SNPs) within cytokine receptor genes (regulating 
Thl, Th2 and innate immune functions) were associated with variations in the humoral 
response to measles vaccination in a Somali population {329) . 
Ethnic variation in general immune parameters is also well known (330). For example, on 
average, compared with Caucasian populations, African Americans have serum lgG leve ls 10-
15% higher, neutrophil counts 10-15% lower and higher circulating B-lymphocyte counts (264). 
The clinical significance of these ethnic differences is not certain however. 
Taken together, these studies support the contention that individual genetic variation is 
important in the response to immunisation . 
3.3.4 Psychological state 
Researchers in the field of psychoneuroimmunology over the past four decades have 
demonstrated that an individual's psychological state can influence human immune function in 
diverse ways. A meta-a nalysis on thi s topic, which reviewed over 300 empirical studies (331), 
utilized a useful taxonomy for categorizing psychological stressors which distinguished 
between two important dimensions of stress - duration and course (continuous or discrete). 
Acute time-limited stressors (e.g. mental arithmetic or public speaking, lasting between 5 to 
100 minutes) increased immune parameters particularly associated with innate immunity (e.g. 
NK and neutrophil numbers in peripheral blood). Brief naturalistic stressors (short-term 
challenges such as academic examinations, spaceflight) tended to depress cell-mediated 
immunity (Thl) as evidenced by decreased Tcell proliferation, and elevation ofTh2-associated 
cytokines and antibodies to latent viruses (e.g. Epstein Barr virus (EBV)) (332,333). Chronic 
stressors (e.g. unemployment or living with a physical disability) were associated with 
deterioration of aspects of both innate and adaptive immunity. 
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The use of immunisation for examining the influence of various psychosocia l factors on 
immune function in vivo has been a common and informative research model (334-341). 
Immunisation with keyhole limpet haemocyanin (KLH) has been used to assess the effect of 
distress on the immune response in two studies involving medical students. In the first study 
(Smith, Vollmer-Conna, et al., 2004), 45 students were immunized with KLH during either an 
exam period (stressful environment) or an exam-free period (non-stressful environment). The 
Profile of Mood Scores (POMS) questionnaire was used to measure psychological distress at 
the time of immunisation. The authors found that the likelihood of developing an in vivo 
antigen-specific cell-mediated immune response (DTH response) was significantly reduced in 
the most distressed students. In a second study of 166 medical students immunised with KLH, 
distress levels at baseline, and increased levels of alcohol consumption at baseline and at 3-
week follow-up, were associated with reduced likelihood of development of an antigen-
specific DTH response (342). 
A recent meta-analysis (341) summarised the results of 13 clinical studies that exa mined the 
influence of psychological stress on the antibody response following influenza vaccination. In 
five studies, the psychological stress was related to providing care to ill persons (usually the 
elderly or children). In the remaining studies, data were collected rega rding self-reported 
stress related life events or perceived stress. The authors concluded th c1_t there was a 
significant negative association between psychological stress (of all types measured) and the 
antibody response to influenza vaccination (effects size correlation coefficient (ESR) -0.18; 
p<0.0001). The association was present both in older and younger aged persons, although the 
effect size was non-significantly higher in the older group (ESR -0.25 vs. -0.17; p=0.32). 
The psychological states that have been associated with altered immune respon se to 
vaccination include: distress (335,342}, stressful life events (343), chronic stress (344) and 
perceived stress (345). 
3.3.S Under-nutrition 
Under-nutrition is the commonest ca use of immune suppression world-wide and may result 
from inadequate intake of macro-nutrients (carbohydrates, protein, fat) and/or of 
micronutrients (essential vitamins, minerals) (346,347). Macro-nutrients provide the energy 
required to carry out daily activities and to build and repair tissues. Micronutrients are 
required for the optimal functioning of cellular processes and metabolic pathways. 
Macro-nutrient deficiency or "protein-energy malnutrition" (PEM) results in a generalized 
depression of immune function, particularly in young .children (348-350). Within the innate 
immune system, complement activation, phagocytosis and cytokine production are all 
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depressed (346,347,349,351,352). Lymphatic organs (spleen, thymus and lymph nodes) 
undergo atrophy (346,353). There is a reduction in both T-helper ce lls (CD4+) and cytotoxic T 
cells (CD8+), as well as a reduction in the CD4+:CD8+ ratio -thought to be an important 
correlate of susceptibility to infection (346). Function of the adaptive immune system, as 
evidenced by DTH sk in test responses, is impaired and antibody secretion and affinity to 
antigen is reduced (347). This has implications for the effectiveness of vaccinations (e.g. 
tetanus) (350). 
Micro-nutrient under-nutrition often accompanies PEM, but can occur as an isolated 
deficiency (i.e. of iron, vitamin A or zinc). The extent and nature of immune dysfunction 
depends on the specific micro-nutrient involved. A deficit of zinc, for example, is associated 
with lymphoid atrophy and decreased 0TH skin test responses and has been also associated 
with increased mortality and morbidity from infection in animal models (Enterovirus, coxsackie 
B, Listeria manocytagenes) (346). Of the micro-nutrients, deficiencies of vitam ins (A, C, E, B6), 
selenium, zinc, copper, iron and folic acid are associated with impaired immune function 
and/or increased rates of infection in humans (346,350). 
3.3.6 Physical activity 
There is a vast amount of literature which describes the effect of exercise and physical activity 
on innate and adaptive immunity (see comprehensive synthesis: (354)). -The current prevailing 
hypothesis is that there is an 'inverted J' association between exercise and immune function, 
such that little or extreme physical activity is detrimental to immune function, and moderate 
exercise is immune system enhancing (355). For example; moderate physical activity (i.e. 1 
hour of endurance exercise at 50% maximal oxygen intake) enhances immune function, 
whereas intense activity (i.e. 2 hours of concentric exercise at 65 - 75% maximal oxygen intake 
or shorter periods of more intense activity) diminishes immune function for between 2 and 24 
hours (356). Many components of the immune system are influenced by exercise as 
summarised in Table 3.5. Following an exercise session, acute changes in circulating leukocyte 
numbers and function typica lly return to pre-exercise values within 3-24 hours (357). 
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Table 3.5: Effects of exercise on human immune function 
Component of the Acute effects 
immune system 
Stress hormones 1' Adrenaline, cortisol, growth hormone, prolactin 
Cytokines 'l'IL-6, IL-10,IL-1 receptor antagonist; inhibition ofTNF-a 
NK cells 'l'numbers during exercise followed by -!,post-exercise for 2 
hours; normal by 24 hours; NK cell activity -!,post-exercise 
(transient) 
T-cell lymphocytes -!,proliferative response to mitogen; -!,numbers (strenuous 
exercise) 
B-cell lymphocytes -J,,immunoglobulin production (fol lowing prolonged, 
strenuous exercise) 
Neutrophils 'l'circulating neutrophils 
Antigen presenting cells -!,macrophage MHC-class II expression 
0TH response -!,after strenuous, prolonged exercise 
Source: (357) 
Severa l studies have assessed the effect of physical activity on the immune response to 
immunisation. Smith et al (358) assessed the influence of cardiovascular fitness and age on 
the humoral response to KLH immunisation . They recruited healthy men of specific age groups 
and physical activity status -younger (aged 20-35 years); older (aged 65-79 years), sedentary; 
and physically active categories. The sedentary men had performed no regular exercise for two 
years prior to study entry, and the physically active men had performed regular aerobic 
physical activity at least three times per week for two years. The researchers found that the 
physically active older group had significantly higher anti-KLH lgM, lgG, lgGl, and DTH skin 
responses, but not lgG2, three weeks post-immunisation, when compared with the sedentary 
older group. Antibody levels were generally higher in the physica lly active younger age group 
compared with sedentary individuals, but the difference was not statistically significant (albeit 
with low study numbers). 
Other studies have assessed the effect of short term activity on the immune response to 
immunisation. Edwards et al (359) recruited 160 healthy young adults and randomised them 
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into a control (no activity) group and three activity groups (who exercised at 60, 85 or 110% of 
a pre-determined concentric exercise maximum (e.g. bicep curl, lateral raise movement). All 
participants were vaccinated immediately with a reduced dose (50%) influenza vaccine. 
Compared with the controls, participants in the exercise groups demonstrated an enhanced 
antibody titre to the least immunogenic influenza strain (with lesser effects on the remaining 
strains). Exercise intensity was not related to rise in antibody titre. 
3.3.7 Cigarette Smoking 
The various components within cigarette smoke affect the immune system in diverse ways -
changes that are immunosuppressive and/or pro-inflammatory, local and/or syste mic, 
involving adaptive and/or innate immune processes and caused by active and/or passive 
smoking. An excellent recent review is provided by Stampfli & Anderson (360). Table 3.6 
summarises some of the more consistent research findings. 
Many studies have studied the effect of cigarette smoking on vaccine responsiveness, with 
conflicting results. Winter et al (361) vaccinated 115 health care workers with hepatitis B 
vaccine on either a rapid (0, 1, 2 and 12 month) or routine (0, 1 and 6 month) schedule. They 
found that smokers were significantly less likely to seroconvert at the end of the study 
regardless of vaccination schedule. Shaw et al (362) demonstrated that smoking status, 
increasing age and increasing skin-fold thickness were each related to a decreased likelihood of 
successfully seroconverting following hepatitis B vaccination if vaccination was administered to 
the buttock rather than the upper arm in healthy adults. 
Cruijff et al (285) assessed the effect of smoking on influenza vaccination efficacy (i.e. ability to 
protect against influenza) and the antibody response to vaccination in a large group of Dutch 
adults aged 60 years and older. They concluded that smoking was associated with higher post-
vaccination antibody titres against two of four vaccine-included strains, and there was no 
relation between smoking and the development of influenza post-vaccination (i.e. indicating 
no effect on vaccine efficacy compared with non-smokers). Another study showed no 
significant difference in post-influenza vaccination antibody titres between smokers and non-
smokers (363). However, older studies (284,364) demonstrated lower influenza specific 
antibodies post-vaccination after one year in smokers compared with non-smokers, a delayed 
time period not tested in more recent studies. 
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Table 3.6 lmmunomodulatory effects of different components of cigarette smoke 
Cigarette smoke Cellular target/s Immunological effect 
component 
Nicotine Endothelial and epithelial Suppression of effector function by 
cells, lymphocytes, macrophage skewing towards Th2 
macrophages response 
Hydrocarbons Endothelial and epithelial Gene regu lation mediated by basic 
cel ls, lymphocytes, loop-helix-loop proteins; adaptive up-
macrophages regulation of metabolic and bio-
transforming enzymes 
Carbon monoxide Epithelial cells, lymphocytes Suppression of effector function and 
and macrophages reduced proliferation 
Oxidants and Epithelial cells, lymphocytes, DNA damage, cell senescence, lipid 
reactive nitrogen NK cells, macrophages, peroxidation, chemical modification 
species endothelial cells of micro- of intracellular signalling 
vesse ls 
Acrolein Macrophages and T ce lls Suppression of effector function and 
reduced proliferation 
NKK (nitrosamine 4- Cytotoxic T cells, NK cells Suppression of killing 
(methyl-nitrosamino)-1-
(3-pyridyl)-1-butanone) 
Adapted from (360) 
3.3.8 Associations between UVR exposure and potential confounding variables 
To be classed as a confounder, a factor must fulfil three criteria : i) be correlated (within the 
study data-set) with the exposure variable (i.e. UVR exposure); ii) be an independent risk factor 
for the outcome (i.e . immune function parameter) and iii) not be an intermediate step 
between the exposure and outcome variables (365) . The preceding sections discussed the 
second criteria for the putative confounders (apart from vitamin D status; reviewed in Chapter 
2). Table 3.7 shows evidence demonstrating an association between potential confounding 
variab les and UVR exposure (or its surrogates, sun exposure, vitamin D status). 
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Table 3.7: Association between potential confounders and UVR exposure 
Potential Association with UVR / Sun exposure 
confounder 
Age • Annual personal UVR ambient (percentage of tota l annual ambient UVR) 
varies by age group (38) 
Sex • On average, males have substantially higher acute UVR exposure than 
females (40) 
• Males have higher cumulative sun exposure than females, based on 
measures of actinic sun damage (306,366) 
Psychologic . Low sun exposure and/or low vitamin D (2S(OH)D) status been associated 
al state with prevalence of seasonal affective disorder (367), depression (368) and 
schizophrenia (131). Note that the evidence for these associations is weak. 
Ethnicity . United States - ethnic differences in sun protection practices involving 
clothing and behaviour between Hispanics and non-Hispanics (369) 
. Low sun exposure amongst south Asian women living in New Zealand 
(370) 
Physical • High levels of sun exposure amongst cyclists and triathletes; sunburn in 
activity young adults undertaking physical activity (371-373) 
• Adult outdoor workers have higher personal UVR ambient exposures than 
indoor workers (~10% vs. ~3%; with wide variation) (38,40) 
• Higher grades of actinic skin damage in outdoor workers (374) 
Vitamin D • Incidences of a number of autoimmune conditions (e.g. MS, rheumatoid 
status arthritis) correlate positively with latitude of residence and/or inversely 
with vitamin D status (12) 
Whi lst cigarette smoking and nutritiona l status do not have good evidence for co-varying with 
an individua l's UVR exposure, they are important factors to measure as they could potentially 
act as confounders (or effect modifiers) in an epidemiologica l study. 
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3.4 Summary 
The field of immunotoxicology examines the influence of agents (e.g. UVR) on immune 
function and their health sequelae. An immunotoxicological assessment typically follows a 'risk 
analysis' structure. This thesis focuses mainly on the risk assessment component of a risk 
analysis, and specifically on exposure assessment and risk characterisation. 
Whilst animal testing affords logistic, cost and study design advantages over human 
immunotoxicological research, human-derived data are preferred where robust, valid methods 
are possible. The choice of immune function assays is critica l in an immunotoxicological study 
aiming to detect and quantify possible subtle and varied changes to immune processes. Based 
on extensive animal-based studies, a number of immune function assays have been found to 
be sensitive in detecting immunomodulation, particularly when performed in combination. In 
human epidemiological research, quantification of the response (humoral and cell-mediated) 
to primary vaccination with a T-cell dependent antigen has been advocated to assess the 
immunomodulatory effect of a putative immunotoxic agent. 
lmmunotoxin-mediated immunosuppression appears to have a linear dose-dependent 
relationship. At an individual level, it is only severe depression of immune competence that is 
likely to lead to disease (e.g. high risk of opportunistic infection in patients with advanced HIV 
infection) . There is evidence however, that low to moderate immunosuppression occurring at 
high prevalence at a population level can lead to increased rates of common infections and/or 
reduced vaccine effectiveness. 
Numerous factors need to be considered when planning an epidemiological study to detect 
possible immunotoxic effects of UVR, including: study type (e.g. cross-sectional, longitudinal), 
study length, participant se lection and sample size, measurement of UVR exposure and 
possible confounding factors, and participant burden. To avoid the ecological fallacy, 
measures of UVR exposure and other immune-modulatory measures taken at an individual 
level are preferred over aggregate data. 
Apart from UVR, other immunomodulatory factors (which might act as confound ing variab les 
of effect modifiers) include age, gender, ethnicity, physical activity, psychological state, 
nutritional state, smoking and vitamin D status. These need also to be carefully measured . 
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Chapter 4 Development of immunisation and immunoassay 
protocols 
Synopsis 
Primary immunisation with a protein antigen has been promoted as a valid and effective 
method to assess the influence of extrinsic (e.g. environmental exposure) or intrinsic (e .g. 
psychological distress) factors on the human immune system. Keyhole limpet haemocyanin 
(KLH) is such an immunogenic protein which is often used in animal immunotoxicological 
stud ies and has found numerous applications in the human context. This chapter discusses the 
relevant properties of KLH, its use in epidemiological and clinical studies and the development 
of appropriate assays to assess the immune response to vaccination. Finally, in the first 
experimental work conducted for this thesis, the development of a pilot study that assessed 
methods potentially usable in a larger study is discussed. 
4.1 Keyhole limpet haemocyanin 
4.1.1 Structure and properties 
Keyhole limpet haemocyanin (KLH) is derived from the haemolymph of the inedible marine 
mollusk, Megathura crenulata, native to the Pacific coastal waters of California and Mexico 
(375). Hemocyanins are cylindrical, copper-containing molecules that act as oxygen 
transporting proteins for many mollusk species (288). KLH is an extremely large molecule 
(>8,000kDa 2) comprising a variable number of sub-units (~LHl (390kDa) and KLH2 (350kDa)) 
(376,377) . The remarkable immuno-stimulatory properties of KLH result from high antigenicity 
derived from numerous carbohydrate and peptide epitopes (288,375). 
4.1.2 Biological uses for KLH 
The potent immunogenicity of KLH has been known for over 40 years (378-380) and in that 
time KLH has been used extensively in animal and human research to delineate cellular and 
humoral immune responses, as a carrier protein for cancer vaccines and as bladder ca ncer 
immunotherapy (278, 375, 382). KLH appears to have anti-proliferative action against certain 
tumour cel l lines, including breast, pancreatic and oesophageal ca ncer (383,384). KLH is 
currently listed in 29 US National Institutes of Health human clinical studies that are actively 
recruiting participants (www.clinicaltrials.gov; accessed 3 August 2012). 
As KLH exposure promotes a strong T-dependent antibody response (TDAR), and given that 
humans are na"ive to this antigen, KLH immunisa tion permits assessment of the complex 
2 kDa = kilo Daltons, unit measure of molecular weight 
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primary immune response involving antigen presentation, priming and collaboration ofT and B 
lymphocytes, antibody production and cytokine-dependent antibody class switching (278). In 
recent years, use of KLH immunisation for immunotoxicological investigations in animal 
models has been promoted (385). 
4.1.3 Previous studies using KLH as a test of immune function in humans 
KLH immunisation has been used to assess the influence of various exposures on immune 
function in a number of clinical studies. Exposures have included psychological stress 
(335,338,342,386), cardiovascular exercise (358,387), cancer and/or chemotherapy 
(279,380,388), immunodeficiency states (389,390) and atopy and asthma (391,392). Table 4.1 
details the human clinical trials conducted since 1970 where a trans-cutaneous KLH 
immunisation schedule has been used for the purpose of assessing immune function and 
where KLH-specific immune parameters are the primary immunological end-point. The studies 
have varied by the choice of KLH dose, formulation, mode of administration (route and site) 
and measured KLH-specific immune parameters. Of note, the two papers from Snyder et al 
(338,386), report results from different components of the same study (i.e. humeral and cell-
mediated primary immune responses). 
Dose 
Previous studies have used KLH doses ranging from lOµg to 5000µg, although the most 
common dose used in human clinical studies was lOOµg. All studies were able to show an 
antigen-specific response at doses given for that study, although Grant et al (387) failed to 
demonstrate a 0TH response at 3 weeks post-immunisation with 125µg KLH (with a 5µg intra-
dermal skin test). In the only published study to assess the effect of different doses of the 
same KLH formulation, Curtis et al (380) reported no significant difference in the kinetics or 
magnitude of the immune response amongst participants immunised with lOµg, lOOµg or 
5000µg of high molecular weight KLH. 
Formulation 
KLH for clinical use comes in two forms - high molecular weight (HMW) and sub-unit 
preparations (375). Both preparations are available in a clinical grade formulation that is 
sterile and endotoxin and pyrogen free. Sub-unit KLH (~400kDa) is often used as a vaccine 
carrier protein that is coupled to a carbohydrate or other non-immunogenic molecule to boost 
T-cell priming (e.g. novel anti-cancer vaccines (393)). HMW KLH (or "native" KLH) preserves 
the weight of the larger molecule, although manufacturers have found quality control issues to 
be more challenging (377). 
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HMW-KLH has greater immunogenicity compared with sub-unit KLH, as evidenced by the study 
conducted by Miller et al (388). Here, three forms of lO00µg KLH were administered to 
healthy participants: HMW KLH, sub-unit KLH or sub-unit KLH with mineral oil adjuvant 
(Montanide ISA-51). A similar and potent immune response was seen in participants 
immunised with the HMW-KLH and sub-unit KLH with adjuvant, but not in those immunised 
with sub-unit KLH alone. It was postulated that the lack of response was not due to a lack of 
important immunogenic epitopes in sub-unit-KLH but, instead, was due to an adjuvant 
property of HMW KLH that was successfully substituted by use of the mineral oil adjuvant. 
An adjuvant is simply an agent which enhances the immunogenicity of antigens (134). 
Common adjuvants, such as 'a lum' (aluminium phosphate and aluminium hydroxide) and oil-
water emulsions (e.g. Freund's adjuvant, mineral oil adjuva nt), work by sequestration and slow 
release of associated antigen to surrounding immune cells (394). 
Mode of administration (route and site) 
A measureable, robust antigen-specific immune response can be generated following 
administration of KLH by a number of routes - intra-dermal (380), sub-cutaneous (338), intra-
muscular (387) and inhalational (392). Studies which administered KLH intra-muscularly used 
the deltoid muscle. Site of sub-cutaneous administration was not stated in any study, whilst 
intra-dermal immunisation in one study was described as occurring in the 'upper arm' (389). In 
those studies assessing the DTH response, intra-dermal KLH was administered to the volar 
aspect of the forearm (342) or upper arm (279). 
4.1.4 Safety profile 
KLH appears to have an excellent sa fety profile which has been noted by several authors 
(342,382). In their comprehensive review, Harris & Marki (375) stated, "Importantly, KLH is 
considered to be an extremely safe substance for in vivo use in man, as a direct antigenic 
stimulus and immunotherapeutic agent" (pp. 614). KLH immunotherapy for bladder cancer 
has received European regulatory approval (377). There was no report of significan t adverse 
events related to the use of KLH in any human clinical study reviewed for this thesis. 
However, there are potential adverse effects associated with vaccine adjuvants. The use of 
alum for example, has been associated with local erythema, subcutaneous nodules, 
granulomas, and macrophagic myofasciitis (394). Oil-water adjuvants (e.g. Freund's complete 
and incomplete adjuvants) are potent immune-stimulants but have been associated with local 
skin necrosis and inflammation which has affected their tolerability in the human setting (394). 
Newer mineral oil adjuvants (e.g. MF59, Montanide ISA-51) have better safety profiles and 
have been used in vaccines in human trials (395). 
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4.1.5 Summary 
KLH is a potent immuno-stimulatory antigen that has been used in a number of human clinical 
research settings. A robust immune response can be attained from immunisation with a single 
dose of KLH via a number of routes and doses. Sub-unit KLH needs to be combined with an 
adjuvant to match the immunogenicity of HMW KLH. KLH itself has an excellent safety profile 
in humans, although the use of adjuvant agents has been associated with local adverse effects. 
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Table 4.1 Comparison of human clinical studies that have used primary KLH immunisation to assess immune function {1990 - 2010) 
Study and aim KLH formulation, dose, route Antibody assessment: ELISA type, target Cell-mediated immunity {Ex vivo and in 
& site of administration immunoglobulin{s), serum titre, sampling vivo testing) 
Spazierer (2009) (391) Sub-unit KLH Ind irect and sandwich ELI SA Ex vivo : Lymphocyte proliferation assays 
Establish immunisation protocol to lO0µg KLH with alum (dose Anti-KLH lgGl, lgG4, lgE, lgM In vivo: Not eva luated 
induce de novo Th2 response using not specified); Serum titre not speci fied; 
primary KLH vaccine IM; Ba se line, day 15, 29, 43 & 57 
site not specified; 
3 doses: baseline, d 15 & d 29 
Grant et al (2008) (387) HMW-KLH Indirect ELISA Ex vivo: Not eva luated 
Effect of aerobic exercise in sedentary 125µg Anti -KLH lgGl lgG2 lgM In vivo: 5µg KLH ID 3-weeks post-
older adults on primary KLH vaccine IM 1:64; immunisation; Date of reading not 
immune response Deltoid muscle Baseline, 2, 3 and 6 weeks post- specified 
immunisation 
Miller et al (2005) (388) 1. Sub-unit KLH 1000 µg SC Indirect & sa ndwich ELISA Ex vivo : Lymphocyte proliferation assays; 
Comparison of responses to KLH 2. HMW-KLH lO00µg SC anti-KLH lgGl lgG2 Enzyme-linked immunosorbent spot 
vaccines in healthy adults; 3. Sub-unit KLH lO00µg with 1:50, 1:100, 1:200, 1:400 & 1:800 (ELISPOT) assay for cellular responses to 
Immunisation response in Montanide-lSA-51 adjuvant Anti-KLH lgM KLH 
immunosuppressed patients (cancer & (0.6ml) 1:25000, 1:50000, 1: 10000; Baseline and 4 In vivo: Not eva luated 
bone marrow transplant) weeks post immunisation 
84 
Study and aim KLH formulation, dose, route Antibody assessment: ELISA type, target Cell-mediated immunity (ex vivo and in 
& site of administration immunoglobulin(s), serum titre, sampling vivo testing) 
Smith A et al (2004) (335) Sub-unit KLH lO0µg adsorbed Indirect ELISA; Ex vivo: Lymphocyte proli feration assays 
Effect of distress on primary KLH to 0.9mg alum Anti -KLH lgG In vivo : 1 µg ID 3 weeks post-
vaccine response in young adults IM 1:100, 1:1000 immunisation; Volar aspect of arm; Read 
Deltoid muscle Basel ine, 3 weeks post-immunisation at 48 hours 
Smith A et al (2004) (342) Sub-unit KLH l00µg adsorbed Not tested Ex vivo: Not eva luated 
Effect of distress on DTH response to 0.9mg alum In vivo: 1 µg ID 3 weeks post-
following primary KLH immunisation in IM immunisation; Volar aspect of arm; Read 
young adu lts Deltoid muscle at 48 hours 
Smith TP et al (2004) (358) Sub-unit KLH l00µg adsorbed Indirect ELISA Ex vivo: Not evaluated 
Effect of age and physica l activity on to 0.9mg alum Anti -KLH lgG, lgGl; lgG2 & lgM; In vivo: 1 µg ID 21 days post-
primary KLH vaccine immune response IM 1:100 (lgM); 1:200 (lgG); 1:2 (lgGl); 1:1 immunisation; Volar aspect of arm; Read 
Deltoid muscle (lgG2) 24, 48, 72, 96 & 120 hours 
Baseline, 1, 2, 3 & 4 weeks post-
immunisation 
Kondratenko (1997) (389) HMW KLH Indirect ELISA Ex vivo: Lymphocyte pro liferation assay 
Evaluate immune response to primary 200 µg ID Anti-K LH lgG, lgM In vivo : Not evaluated 
KLH immunisation in patients with Upper arm Serum dilutions not stated; 
immunodeficiency state Baseline, 2 & 4 weeks post-immunisation 
Snyder et al (1993)# (386) HMW KLH Not eva luated Ex vivo: Lymphocyte proliferation assays 
Effect of stressfu l events on primary KLH l00µg SC In vivo: Not evaluated 
vaccine cel l-mediated immune respon se Site not specified 
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Study and aim KLH formulation, dose, route Antibody assessment: ELISA type, target Cell-mediated immunity (Ex vivo and in 
& site of administration immunoglobulin{s), serum titre, sampling vivo testing) 
Amiot et al (1986) {279) HMW KLH Enzyme radio-immunoassay Ex vivo: Not evaluated 
Comparing primary immune response to 200µg lD Anti-KLH lgG, lgM In vivo: Three doses (0.1, 1 & lOµg) KLH ID 
KLH immunisation in hea lthy controls & Upper arm Serum titre: Starting at 1:20, final di lution 7 and 14 days post -immunisation; Same 
cyclosporine-treated bone marrow not stated . site as primary immunisation 
transplant patients Baseline, 1, 2 & 3 weeks post -immunisation Read at 24 and 48 hours post-skin test 
Curtis et al {1970) (380) HMW KLH S000µg SC over Haemagglutinin assays using sheep red Ex vivo: Lymphocyte pro liferation assays 
Primary immune response to KLH deltoid region or lO0µg ID* or blood cells. Serial dilution t itres - result In vivo : Variable testing (100µg+/-10µg+/-
immunisation in healthy adults & l0µg lD* reported as highest se ra dilution with lµg) KLH ID; Volar aspect of arm; Variable 
patients with solid tumours • site not specified haemagglutination; Baseline, 5, 7, 14, 21, day of skin test post-immunisation; Read 
28, 56, 84 & 112 days post-immunisa tion at 24 and 48 hours post skin test 
(not all subjects on all days) 
Legend: IM: Intra-muscular; SC: sub-cutaneous; ID : Intra-dermal HMW: High molecular weight DTH: Delayed type hypersensitivit y 
# Th ese studies report different components of t he sa me study sa mple 
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4.2 Immunological assays 
Reliable and sensitive immunologica l assays to measure changes in KLH-specific immune 
parameters following vaccination are essential for this research. Humeral immunity is 
commonly assessed by measurement of antibody titres, whi lst cell-mediated immunity can be 
assessed ex vivo using several varieties of lymphocyte assays or in vivo via CHS testing or DTH 
testing. The following sections will discuss these assays in more detail. 
4.2.1 Quantification of antigen-specific antibodies: ELISA 
Identification of antibody type and quantification of response has been made considerably 
easier with the development of assays which measure the direct binding of antibody to its 
antigen - enzyme linked immunosorbent assay (ELISA) being a prime example (396). 
There are several variations of ELISA assays (e.g. direct, indirect, 'sandwich') but the underlying 
principle is that an enzyme-label led antibody binds with a specific ligand (antigen or antibody 
of interest) which can be detected by addition of a substrate that causes a coloured reaction 
product (134). For detection of an unknown concentration of antibodies in sera, the indirect 
ELISA assay is preferred. The basic steps to detect anti-KLH antibodies in participant serum are 
outlined below (Figure 4.1). 
Figure 4.1 Steps performed in the indirect ELISA assay to detect anti-KLH antibody 
Step 1: Antigen coating of well 
00 00 00 
Step 3: Antibody binds to 
fixed antigen 
iiiiii 
Step 2: Addition of sera 
containing antibody of 
interest 
,l~,l~ 
00 00 00 
Step 4: En zyme-labelled 
secondary antibody added 
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Step 5: Secondary antibody 
binds to primary antibody 
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Step 7: Enzyme-dependent 
colour change 
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Step 6: Addition of enzyme 
substrate 
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Figure 4.1 illustrates the basic necessary steps in performing an indirect ELISA assay to 
detect anti-KLH antibody. Step 1: KLH antigen (e .g. in lyophilised (powdered) form) is 
passively adsorbed to the bottom of a well within a 96-well microtitre plate (causing 
antigen to become fixed) . Step 2: After washing (e.g. with mild detergent such as 
phosphate buffer solution (PBS)) and blocking (e.g. with skim milk) the well to prevent 
other antigens adsorbing, participant serum is added at various-dilutions. Step 3: Anti-
KLH antibodies within the sera bind specifically to KLH adsorbed to the well base. The 
wells are washed leaving only bound antibody. Step 4: An enzyme (e.g. biotin) -labelled 
secondary antibody is added to the well (also known as the 'detection antibody'); Step 
5: The secondary antibody binds to the KLH-specific fixed antibody. Further washing 
removes unbound secondary antibody. Step 6: A substrate (e.g. ABTS) specific for the 
enzyme attached to the secondary antibody is added; Step 7: The product of the 
reaction between enzyme and substrate produces a colour change which can be read 
by a spectrophotometer at a specific wavelength of light (reported as 'optical density'). 
The intensity of the colour change is proportional to the amount of specific antibody in 
the well (26,50). 
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Previous studies quantifying KLH-specific antibody response 
Most studies that have used KLH immunisation to assess an antigen-specific immune response 
have measured anti-KLH antibodies (9 of 10 studies in Table 4.1), with the more recent studies 
utilising indirect ELISA assays. The studies have differed by the timing of serum sampling, 
immunoglobulin sub-type targets (e.g. lgM, lgG and/or lgG sub-sets) and how the result was 
analysed and reported. There were also some differences in the reagents and protocols used 
for the assays. 
Table 4.2 summarises the timing of serum sampling from participants relative to KLH 
immunisation for the nine studies listed in Table 4.1. All studies collected serum at baseline, 
then at variable time-points following immunisation, with sampling at baseline, 2, 3 and 4 
weeks post-immunisation being most common . 
Table 4.2 Timing of serum sampling relative to KLH immunisation 
Timing of 0 1 2 3 4 6 8 12 16 
Sample (baseline) 
(weeks post-
immunisation) 
Number of 9 3 6 7 5 2 3 1 1 
studies (% of (100%) (33%) (67%) (78%) (56%) (22%) (33%) (11%) (11%) 
studies from 
Table 4.1} 
Anti-KLH lgG (or lgG sub-set) was assayed in 9 (100%) studies and anti -KLH lgM in 7 (78%) 
studies. Anti-KLH lgE was assayed in only one study (391), which aimed to investigate the 
pathogenesis of allergic disorders. 
The studies also differed by how anti-KLH antibody titre was read and presented . Two studies 
generated standard curves using sera with known concentrations of anti -KLH antibody, and 
from these interpolated the concentration of anti-KLH antibodies in subjects' samples 
{388,391). Three studies compared the optical density (measure of colour change/light 
absorbance in wells) of sample sera at defined dilutions with the positive and negative control 
sera on the same plate which also allowed adjustment for inter-plate variation in absorbance 
readings (335,358,387). The older studies gauged anti-KLH concentration by comparing the 
highest dilution of serum at which antibody was still detectable (279,338,380). 
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4.2.2 Cell-mediated immunity assays 
There is a diverse range of ex vivo I in vitro assays available for examining cell-mediated 
immune processes, largely aiming to identify and enumerate lymphocyte sub-populations 
and/or determine lymphocyte effector function . In this section, discussion is limited to assays 
involving peripheral blood lymphocytes, acknowledging that, whilst easiest to obtain, they are 
not necessarily representative of the lymphoid system at large or of lymphocytes involved at 
the site of antigen processing (134). Isolation of lymphocytes is most commonly achieved by 
allowing peripheral blood to separate by density centrifugation over a step-wise gradient 
consisting of the carbohydrate polymer, Fi coll, and an iodine-containing compound (e.g. 
metrizamide, diatrizoate), in a test tube. Differential migration of the varying cell types 
following centrifugation allows the layer of lower density peripheral blood mononuclear cells 
(PBMCs) - consisting of lymphocytes and monocytes - to be separated from the higher density 
granulocytes and erythrocytes (134,397). Isolated PBMCs can be used fresh following 
isolation, or after careful freezing and thawing, for further analysis. 
Flow cytometry, in combination with a fluorescence-activated cell so rter (FACS), allows 
detailed assessment of lymphocyte populations (398). PBMCs are first tagged with a 
fluorescent-dyed monoclonal antibody against specific cell surface markers (e.g. CD3, CD4) or 
intracellular cytokines (e.g. IL-4, IL-17, IFN-y) and passed in a droplet strea m of single cells 
through a laser beam. Sensors are able to detect the resultant scattered light which gives 
information on the granularity and size of cells. Additionally, the monoclonal antibodies 
fluoresce differentially upon excitation by the laser, further characterising the identity and 
functional role of lymphocytes (e .g. Thl vs. Th2 vs. 1h17) (134,399). Improving technology 
now allows for the assessment of multiple cell types from a single lymphocyte sample, as the 
number of fluorescent dyes that can be analysed simultaneously has increased (398). 
Other methods used to detect cytokine production by lymphocytes include ELISA, and its 
variation, the enzyme-linked immunosorbent spot (ELISPOT) assay (134). These assays employ 
cytokine-specific antibodies to bind to secreted extra-cellular cytokines following lymphocyte 
stimulation. The ELISPOT assay in particular is a very sensitive test, and can detect cytokine 
production at a single lymphocyte level. It is therefore useful for determining the frequency of 
cytokine-secreting cells within a population and requires approximately ten-fold less cel ls than 
flow cytometry methods (400). However, it does not provide information about the 
proportions of different sub-populations within a sample (134). 
An emerging technology, convenient for separating lymphocyte sub-populations and 
identifying the cytokines produced, makes use of antibody-coated magnetic beads. When 
these beads are mixed with a heterogeneous cell population of interest, they bind to their 
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specific ligand (e.g. cell surface marker or cytokine target). The magnetic bead-bound targets 
are held suspended when a magnetic field is applied, whilst the unbound fraction is washed 
away. In this fashion, and similar to the FACS method, multiple targets can be assessed 
simultaneously (134,401). 
Assessment of antigen-specific cellular immune responses is more problematic than for 
humoral immune responses (where quantification of antigen-specific antibody response is 
straightforward). There are multiple reasons for this, including the low frequency of circulating 
memory T-helper cells and that T-cell receptors require presentation of antigen by specific 
MHC-class molecules (134,402). Notwithstanding, antigen-specific T-cell responses have been 
achieved by incubating lymphocytes with the recall antigen-of-interest (e.g. KLH) or a 
'polyclonal mitogen' to which many or all lymphocytes of varying types and specificities will 
respond (e .g. phytohaemaglutinin, pokeweed mitogen), and then measuring a particular 
parameter (e.g. proportion of cytokine secreting cells by ELISPOT, sub-population identification 
and enumeration by FACS) . The ' lymphocyte proliferation assay' (LPA) involves incubating 
PBMCs in cell culture for a pre-defined time (usually several days) in the presence of polyclonal 
mitogen or recall antigen, followed by measurement of the incorporation of 3H-thymidine into 
DNA; this correlates with T-cell proliferation (403). LPA has been perhaps the most common 
assay for assessing post-vaccine T-cell response but does not elucidate the identity or function 
of the cell subpopulation involved (134) . 
Previous studies using cell-mediated immunity assays 
Several studies have assessed cell -mediated immu~ity ex vivo following KLH immunisation 
(335,380,386,388,389,391) (See Table 4.1) . The majority of these studies used conventional 
LPA, with the main difference between them being the PBMC incubation times with KLH, 
ranging from 4 days (386) to 7 days (388). 
Cytokine production by stimulated PBMCs following KLH immunisation was assessed in two 
more recent studies. lnterferon-y production was determined by ELISPOT assay after thawed 
PBMCs were incubated with KLH for 20 hours (388). Spazierer et al (391) incubated cells with 
KLH for 40 hours then tested the supernatant for IL-4, IL-5, IL-10, IL-13 and IFN-y using 
antibody-coated magnetic bead assays. 
For all the studies in Table 4.1, PBMC isolation was undertaken using Ficoll density 
centrifugation methods as outlined previously. 
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4.2.3 Delayed-type hypersensitivity responses 
As discussed in Section 3.2.2.4, delayed-type hypersensitivity (DTH) testing is a validated in 
vivo test of antigen-specific cell-mediated immunity. This section will discuss its use in previous 
studies, methods for administration and reading of the test. 
Previous studies utilising 0TH tests 
A number of human clinical studies have utilised DTH tests to assess in vivo KLH-specific cell-
mediated immunity (279,335,358,380,387). The studies have varied by the initial 
immunisation KLH dose, as well as formulation and subsequent skin test dose (see Table 4.1). 
There are conflicting data regarding the minimum skin test dose required to induce a reliable 
DTH response. Grant et al (387) were unable to elicit a DTH response after administration of a 
5µg intra-dermal skin test dose 3 weeks following immunisation with 125µg HMW-KLH 
administered intra-muscularly. Other researchers found that the DTH response was 
independent of initial sensitising immunisation dose (i.e. 5000µg / l00µg / lµg were 
equivalent). However, higher skin test dose yielded a higher proportion and magnitude of 
positive DTH responses in a dose dependent manner (i.e. lO0µg > lOµg > lµg) (380). Skin 
testing with simultaneous doses of 0.1, 1 and lOµg KLH at day 7 and day 14 post-immunisation 
(with 200µg HMW KLH) achieved a DTH response rate of 68% amongst healthy control patients 
(although the results at each skin test dose were not provided) (279) . 
The upper arm (where primary immunisation occurred) (279) and the volar aspect of the 
forearm (335,358) have been the only sites reported for KLH skin testing. 
Administering skin test and interpreting result 
The assessment of a DTH response secondary to tuberculin skin testing (TST or 'Mantoux 
testing') has long been used by clinicians to determine past exposure to Mycobacterium 
tuberculosis in humans (404). The TST method has been adopted for DTH testing using other 
antigens (294). The established method for administering the skin test is to inject antigen (to 
which the host has been pre-sensitised) intra-dermally such that a small raised area of skin 
('bleb') 5-8 mm in diameter becomes apparent (405). The subsequent DTH response takes a 
number of hours to develop, but in most studies the result is read at 48 to 72 hours post-skin 
test (183,291). The DTH reaction is manifest by raised (indurated) and erythematous skin over 
the site of the skin test. It is the indurated area that correlates with the cell-mediated immune 
response rather than the area of erythema. The 'palpation method' has been the traditional 
method for assessing the area of induration, although this requires considerable training and 
experience to ensure reliable readings (406). More recently, the 'pen method' has been 
shown to have greater sensitivity and reproducibility than the palpation method, whilst also 
92 
being easier to learn and administer (298,406-408) . Essentially, this technique involves using a 
ball point pen to run along the skin towards the area of induration until it meets resistance. 
The process is repeated on the opposite side and the distance between pen markings is 
measured to obtain a diameter of induration (in millimetres) (405). Some studies have 
averaged two readings taken at right angles (342,380). 
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4.3 Pilot study 
This section describes the initial experimental component of this thesis research . 
4.3.1 Background 
The objective of this pilot study is to develop protocols for the use of KLH immunisation to 
quantify the influence of solar ultraviolet radiation exposure on human immune function . As 
described in previous sections, KLH has attributes that make it an ideal candidate for testing 
the immune system. KLH is a potent immunogen resulting in measurable immune responses 
after only single administration, elicits a reliable in vivo cell-mediated DTH response, can be 
administered via various routes, and is safe and well tolerated . 
The dose, site and formulation of KLH used in this pilot study were determined based on the 
results of previous studies examined in the ea rly part of this Chapter. High molecular weight 
KLH was the formulation of choice for this study. However, due to commercial scarc ity, su b-
unit KLH with adjuvant (Montanide ISA-51) was used instead, though at a lower dose than that 
used by Miller et al (388). 
4.3.2 Aims 
The pilot study was a non-blinded randomised controlled study designed to assess the effect of 
sub-erythemal solar-simulated UVR on the humoral and cell-mediated immune responses to 
immunisation with the novel protein, KLH. 
This aims of the pilot study were to : 
i) Determine the feasib ility and appropriateness of using primary KLH immunisation as a 
tool to assess the influence of UVR exposure on immune responses 
ii ) Determine whether a 125µg KLH dose was appropriate for this purpose (i.e. stimulate 
responses in participants with enough variability to show an influence at different 
levels of UVR exposure) 
iii) Develop reliable antigen (KLH)-specific antibody assay protocols 
iv) Deve lop a protocol for in vivo testing of KLH-specific cell-mediated immune function 
(DTH test) 
4.3.3 Methods 
This study was conducted after approval by the Human Research Ethics Committee of the 
Australian National University. Informed written consent was obtained from all participan ts 
on enrolment into the study. This study was also registered with the Australian Therapeutic 
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Goods Administration under the Clinical Trial Notification scheme and the Australian and New 
Zealand Clinical Trials Registry (ACTRN 12609000380291). 
Study setting 
This study was conducted in the winter months (June and July) of 2009 at the Australian 
National University, Canberra, Australia. The average ambient clear-sky so lar noon UV Index in 
Canberra during these months ranges between 2 (low-intensity) and 3 (moderate-intensity) 
(Source: Bureau of Meteorology: www.bom.gov.a u). 
Recruitment 
Volunteers were recruited from advertisements placed in university departments, university 
email lists and by word-of-mouth. Participant inclusion criteria were: i) aged between 18 and 
40 years, inclusive; ii) self-reported as 'healthy', and iii) Fitzpatrick skin phototype 11-111 skin (i.e. 
"fair" complexion). This last criterion was to standardise the dose of solar-simulated UVR 
administered to all subjects without the need to determine a MED for each individual. 
Exclusion criteria were: i) known allergy to shellfish; ii) infection or immunisation within 30 
days of study entry; iii) pre-existing immunodeficiency state (including diabetes, HIV, chronic 
renal or liver disease, recurrent infections, solid organ transplantation); iv) use of immune-
suppressive agents within 30 days (systemic) or 7 days (topical) prior to study entry; and v) 
pregnancy or currently breastfeeding. 
Randomisation & UVR exposure 
Upon recruitment, subjects were randomly ass ign ed to a control group (i.e. no UVR exposure) 
or UVR-exposure group using a computer randomisation algorithm. Subjects were informed of 
their assigned group prior to the first visit . It was planned that thirty participants be enrolled, 
with fifteen randomised into each group. The study protocol is summarised in Figure 4.2. 
Control Group: The control group were instructed to take UVR-protective measures (e.g. when 
outside to wear long sleeve sh irts and trousers, UVA/UVB blocking sunscreen (provided) and 
sunglasses) from 5 days prior to immunisation. 
UVR-Exposure Group: Subjects in the UVR-exposure group were irradiated with a sub-
erythemal erythemally-weighted dose of solar-simulated UVR (via a calibrated UVR lamp). The 
spectral output of UVR by the lamp approximated solar UVR in the UVA range, but there was a 
lower proportion of lamp output in the shorter wavelength UVB range than would be expected 
in solar UVR (Figure 4.3) (although, given the high solar zenith angle present for much of the 
day in winter at mid-latitudes, the proportion of UVB in ambient UVR would be low). 
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Figure 4.2: Pilot study algorithm 
Randomisation 
Day 1 -5: No 
UVR exposure 
Day 1 - 5: daily sub-erythemal 
UVR to anterior thigh 
Day 6: Baseline blood test 
Vaccination: 125µg KLH subcutaneously 
Day 13: Blood test 
Day 27: Skin test (intradermal KLH 1µg) 
Blood test 
Day 28/29/30: 
Skin test reading 
Figure 4.3 Spectral output of UVR lamp compared with solar UVR spectrum 
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The UVR dose was delivered to a 5cm x 5cm area on the right lower thigh using a cardboard 
template (See Figure 4.4) . The position for irradiation was located by anatomical landmarks 
(lower margin of irradiation was 5cm above the superior margin of the patella when the knee 
was in an extended position). The pre-determined dose of UVB (~ 20mJ/ cm' , equivalent to 0.8 
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of an MED for Fitzpatrick Type 11-111 skin) was delivered by a UVR-emitting lamp exposing the 
skin over 4 minutes 51 seconds from a fixed distance of 50mm. Indelible ink marks were made 
at the template site to ensure accurate subsequent dosing of UVR. Participants attended for 5 
daily visits for UVR exposure, with examination prior to each UVR irradiation to ensure that no 
sunburn had resulted from previous dosing. 
The solar-simulated UVR was generated with a modified UVR lamp (Phillips Medical UVB TL11 
lamp). Prior to use, this instrument output was carefully calibrated to the US National Institute 
of Standards and Technology (NIST) UVR standard. Calibration was conducted by Professor 
Michael Kimlin at the AusSun Research Lab, Queensland University ofTechnology. The 
spectral output was assessed through an Acton 0.Sm focal length double monochromator 
spectroradiometer. Initial laboratory tests showed a high degree of reproducibility of the dose 
(within 3%) and emitted spectrum. Using a 1000W NIST FEL UVR lamp as a standard, doses 
were accurate to 3% of the world standard. Other researchers (409) have suggested that for 
controlled laboratory work, such a simulator was a valuable tool. 
Figure 4.4: Set-up of UVR lamp to deliver solar simulated UV radiation to participants 
Panel A demonstrates the UVR lamp set up with a participant positioned with leg extended 
and the UVR lamp covered with black cardboard apart from the dosing aperture. Participants 
were protected from UVR by a plywood board and other clothing. Panel B shows the 5 x 5cm 
template-restricted area of irradiation on the participant's lower right thigh. Indelible ink 
marks were made to enable accurate daily positioning of the template. 
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Immunisation 
On study day 6, all subjects underwent immunisation with 125µg sub-unit KLH (Stellar 
Biotechnologies, USA) emulsified with 0.6ml Montanide-51 mineral oil adjuvant (Seppic, 
France) as per the manufacturer's instructions. Immunisation was by the subcutaneous route 
at a standardised site on the right lower thigh (at the same site chosen for UVR exposure) . 
Blood sample collection 
Venous blood was collected at baseline (pre-immunisation), and at 7 days and 21 days post-
immunisation. At baseline, blood was tested for full blood count, kidney and liver function, (-
reactive protein and random blood glucose level (ACT Pathology laboratory, Canberra 
Hospital). At each visit, serum was separated from clotted blood by centrifugation and stored 
for later analysis in 1ml aliquots at -20°C. At the end of the study, serum 25(0H) D level was 
analysed at baseline by high performance liquid chromatography- tandem mass spectrometry 
(LC-MS/MS) performed at the Royal Melbourne Institute of Technology Drug Discovery 
Technologies laboratory (see Section 5.5.6) . 
Delayed type-hypersensitivity response 
At day 21 post-immunisation, to elicit a DTH response, lµg KLH (in lOµL sterile water) was 
injected intra-dermally via a 29-gauge insulin needle (BO Catalogue no. 591823) to the mid-
volar aspect (underside) of the forearm and also to the lower right thigh (at the site of 
immunisation+/· irradiation). At 24, 48 and 72 hours post KLH-challenge, the resultant skin 
induration was measured by the 'pen technique' (406). The diameter of induration was 
measured in millimetres in the horizontal and vertical planes by a single (non-blinded) 
observer. The measurement at 48 hours was undertaken by the study investigator, whereas 
measurements at 24 and 72 hours were taken by participants after instruction. Measurement 
of the DTH response by participants has previously been performed in other similar studies 
(342) although the reliability of self-reported measurement has been questioned (291). A 
positive DTH response was defined as a reaction to KLH skin test of 2mm or greater (140,342). 
Anti-KLH lgG response 
Anti-KLH lgG, lgGl and lgG2 concentrations were determined by indirect ELISA assay, the 
protocol for which was developed based on published studies, using standard methods 
(335,358,387). A summary of the assay protocol is provided here - a detailed explanation, 
including ELISA optimisation steps, is provided in Appendix A. To control for intra- and inter-
plate variation, sera were tested in duplicate for all three time-points of blood collection (i .e. 
baseline, day 7 and day 21 post-immunisation), along with a negative and positive control, on a 
single ELISA plate. 
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Ninety-six well ELISA plates (Nunc Maxisorb, Sigma-Aldrich) were coated with 1 µg/ml KLH 
(Sigma-Aldrich) in a carbonate coating buffer, then refrigerated overnight. The plates were 
washed with PBS-Tween 20 (Phosphate Buffered Saline with Tween 20, Sigma-Aldrich), 
blocked with 1% dry skim milk, incubated for 2 hours at room temperature (or for 45 minutes 
at 37°C), then washed again. Based on previous titration studies, participant serum (1 in 50 
concentration) was pipetted into wells diluted with 1% dry skim milk and made up to 100µ1 per 
well. Following further incubation and washing steps, an enzyme-labelled secondary antibody 
- lgGFc (full complement) (Monoclonal anti-human lgG Biotin Conjugate; Sigma-Aldrich), lgGl 
(Monoclonal anti-human lgGl Biotin Conjugate; Sigma-Aldrich) or lgG2 (Monoclonal anti-
human lgG2 Biotin Conjugate; Sigma-Aldrich) - was added at dilutions of 1/50,000, 1/2000 or 
1/25,000, respectively, in skim milk. Following further incubation and washing steps, 100µ1 of 
avidin peroxidise (Sigma-Aldrich) in skim milk was added. To each well, 100µ1 ABTS (3,3,5,5 
tetramethylbenzidine liquid substrate system, Sigma-Aldrich) solution was added to catalyse 
the colorim etric enzyme reaction . After 15 minutes, lM phosphoric acid in distilled water was 
added to stop the reaction. Colour change within the well was measured by an optical density 
reading performed by a microplate spectrophotometer (Thermo Labsystem Multiskan Ascent) 
at wavelength 450nm. 
Due to relatively high inter-plate coefficients of variation for positive control sera (lgG ~33%; 
lgGl ~ 15%; lgG2 ~ 22%), anti- KLH antibody values are presented-as "corrected" optical 
density (OD) by dividing raw absorbance by the standard positive control sa mple that was run 
on each plate in each assay (387) . The laboratory technician was blinded to the UVR exposure 
status of the participant. 
Statistical analysis 
The results were described using descriptive statistics (i.e. continuous data: mean/median, 
range; categorica l data: proportions). Comparisons involving continuous variables used 
parametric tests where the variab le was normally distributed or could be transformed into a 
normal distribution, and non-parametric tests otherwise. Comparison of proportions was 
performed using x' or Fisher's exact tests as appropriate . Two-tailed statistics were used 
throughout. 
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4.3.4 Results 
Participant characteristics 
Twenty one participants were recruited and randomised: intervention (n=9); control (n=12) 
over the winter months (June and July) of 2009. Participants attended all visits and completed 
all tasks. The groups were well matched at baseline in relation to gender, age, vitamin D 
(25(OH)D) level and body mass index (see Table 4.3) . Although the participant target sample 
size was set arbitrarily at thirty, further recruitment was suspended because a minority of 
participants (7 /21; 33%) experienced delayed and transient redness and discomfort at the site 
of injection. This was thought to be secondary to the vaccine's mineral oil adjuvant 
component. 
Table 4.3 Pilot study participant characteristics 
Control UVR Exposure p value 
(n = 12) (n = 9) 
Age (mean; range) 26.6 (22- 35) 28.0 (24 - 31) 0.80* 
Male (n; %) 7 (58%) 4(44%) 0.67# 
Baseline 2S{OH)D 67.8 55.4 0.14* 
level (nmol/L) 
BMI 25.4 24.4 0.62* 
* Unpaired I-test # Fi sher's Exact Test 
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Immune function assays 
The DTH responses and anti-KLH lgG, lgGl and lgG2 results for all participants are shown in 
Table 4.4. 
Table 4.4: Pilot study immune outcomes 
DTH response Antibody Results for anti-KLH lgGFc /lgGl / lgG2 s• 
at 48 hours (Baseline, Day 7, Day 21 post-immunisation) 
(mm) 
Study UVR Arm Thigh lgG,, lgG, lgG2 
No Exposure 
group 
1 Control 8.5 4.5 1.36 / 1.20 /1.20 0.45 I 0.47 I o.90 0.51 / 0.48 / 0.60 
2 Control 7 0 1.04 / 1.02 / 1.34 1.21 I 1.14 / 1.13 o.30 / 0.29 / 1.22 
3 Control 10 16 o.84 /0.88 I o.88 0.56 / 0.49 / 0.80 0.39 / o.34 I 0.41 
4 Control 3 9 o.84 I o.82 I o.88 0.43 / 0.28 / 0.58 o.50 I o.51 I 0.10 
5 Control 10 7.5 0.23 / 0.27 / 0.63 o.62 I o.79 I 1.11 o.35 / o.30 / o.s1 
6 Control 11.5 9.5 o.66 I 0.62 /0.11 o.5o I o.53 / o. 76 o.30 / 0.29 / 0.35 
7 Control 4.5 6.5 o.56 I o.64 I 1.04 o.57 I 0.61 / o.67 0.26 I 0.21 / o.74 
8 Control 9 11 0.83 / 0.77 / 0.13 o.59 I o.s7 / o.81 o.55 I o.53 / o. 72 
9 Control 5 0 1.09 / 1.01 I o.96 o.61 /Q.58 / o.86 0.49 I o.53 / o.92 
10 Control 9 9 o.67 I 1.04 I 2.41 o.59 I o.51 I o.96 0.42 I 0.42 I 0.64 
11 UVR 7.5 0 o. 79 I o.95 I 0.46 0.63 / 0.45 / 0.85 0.52 / 0.48 / o. 77 
exposed 
12 UVR 0 0 o.n I o.37 ( 0.56 0.46 I 0.60 I 1.27 0.40 I o.37 / 1.5 
exposed 
13 UVR 9 6 *I* I* o.57 I o.55 I 1.01 0.35 / 0.29 / 0.69 
exoosed 
14 UVR 6 5 o.82 I o.85 I 0.28 • I o.53 / o.73 * /0.62/0.66 
exposed 
15 Control 9 0 0.99 / 0.82 / 0.11 0.48 I 0.42 I 0.94 0.38 / 0.40 / 3.07 
16 Control 4 0 *I* I* o.55 I o.38 / o.65 o.37 / o.38 / 0.46 
17 UVR 8 8 o.o9 I 0.06 /0.08 0.60 I o.63 I o.68 0.36 / 0.38 / 0.59 
exposed 
18 UVR 9 0 0.48 I 0.47 /0.87 o.52 I 0.48 I 1.12 o.30 / o.29 / 0.35 
exoosed 
19 UVR 0 0 o.88 I o.88 I 1.02 o.67 I 0.32 / 1.66 0.35 / 0.28 / 0.36 
exoosed 
20 UVR 6.5 0 o.73 / 0.74 / o.84 o.30 /0.39 / 1.18 0.35 / o.30 / 0.48 
exposed 
21 UVR 4 5 o.63 / o.67 / o.56 0.46 I o.54 I o.95 0.48 I o.37 / o.52 
exoosed 
Corrected optical density - relative to the optical density reading of the positive plate control 
to adjust for plate-to-plate variation; lgGFc = lgG full complement (including all lgG subsets) 
• Missing result; 
# Results are reported for serum concentrations of 1:50 
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Delayed-Type Hypersensitivity Responses 
Table 4.5 shows data illustrating the DTH response rate by anatomical site. Overall, DTH 
responses above 2mm diameter were elicited from 31 of 42 sk in tests (73.8%) administered. 
However, 19 of 21 participants (90.5%) developed a DTH response at either the arm or the 
thigh suggesting that true anergy to the antigen was uncommon . There was a stati stica lly 
significantly higher number of DTH responses following forearm skin tests compared with tests 
at the thigh (90.5% vs. 57.1%; p=0.014). 
Table 4.5: Participants with positive DTH responses by anatomical site 
Site of skin test administration 
Thigh Forearm 
DTH response, n (%) 12 (57.1%) 19 (90.5%) 
DTH non-response, n (%) 9 (42.9%) 2 (9.5%) 
Total (n) 21 21 
The median magnitude of DTH response peaked at 24 hours at both the thigh and forearm, 
although a number of DTH responses were not taken by participants at the 24 hour and/or 72 
hour time-points (see Table 4.6). 
Table 4.6: Delayed type hypersensitivity reaction at various time points following skin test 
Skin test result (median*, range) (mm) 
Site 24 hours (n=17) 48 hours (n=21) 72 hours (n=12) 
Thigh (mm) 6.5 (0- 20) 5 (0-16) 0 (0-4.5) 
Forearm (mm) 8.5 (0-17.5) 7.5 (O- 11.5) 0 (0-9) 
* Average of two diameters taken at right angles 
Table 4.7 shows data comparing the magnitude of the DTH response according to exposure 
group and anatomical site. The UVR exposed group demonstra ted a reduced (but not 
statistically significant) median DTH response to KLH challenge compared with the control 
group, with the largest effect occurring at the site of irradiation (7 vs. 0 mm; p=0.10). 
Reduction in the median DTH response distal to the site of irradiation (forearm) was less 
pronounced (8 vs. 6.5 mm; p=0.41) . Two participants in the UVR group were non-responsive 
to KLH at either the arm or thigh (true anergy). 
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Table 4.7 Comparison of 0TH responses by UVR exposure group at different anatomical sites 
Groups (median*; range (mm)) 
Intra-dermal Control UVR exposed p value** 
skin test site (n=12) (n=9) 
Thigh 7 (0-16) 0 (0-8) 0.10 
Forearm 8 (0-11.5) 6.5 (0-9) 0.41 
*Average of two diameters taken at right angles, 48 hours post intra-dermal chal lenge 
** Statistical test : Wilcoxon-Mann-Whitney test for non-parametric data 
KLH-specific antibody titres 
Overall 
(n=21) 
5 (0-16) 
7.5 (0-11.5) 
Table 4.4 and Graphs 4.5 -4.7 show overall data for anti-KLH lgG, lgGl and lgG2 at the various 
time points relative to immunisation for all participants. The data demonstrate minimal lgG 
antibody detection at baseline and 1 week post immunisation, then a strong rise in antibody 
titre by week 3 post-immunisation . 
For participant 8, as there was no serum available for lgGl and lgG2 testing at baseline, the 
negative control value was substituted. 
Graphs 4.5, 4.6 & 4.7: Distribution of serum anti-KLH lgGFc, lgGl and lgG2 titres relative to 
positive plate control - Combined UVR exposure and control groups 
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Table 4.8 and Graphs 4.8 and 4.9 show data comparing anti-KLH lgGl and lgG2 at day 21 post-
immunisation by exposure group. There are no statistical differences demonstrated between 
the UVR exposure and control groups. 
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Table 4.8 Anti-KLH antibody results by UVR exposure group at day 21 post-immunisation 
Group (mean; range) 
KLH-specific antibody Control UVR exposure p value* Overall 
lgGFc 0.93 0.74 0.13 0.85 
(0.63 -1.34) (0.08 - 1.02) (0.08 -1.34) 
lgGl 0.85 1.05 0.10 0.94 
(0 .58-1.13) (0.68 - 1.66) (0.58 - 1.66) 
lgG2 0.86 0 .66 0.41 0.77 
(0.35 - 3.07) (0 .35- 1.50) (0 .35 - 3.07) 
* Unpaired t -test 
Graphs 4.8 and 4.9: Anti-KLH lgGl & lgG2 concentration at Day 21 post-immunisation, by 
UVR exposure group 
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4.3.5 Discussion 
This pilot study was successful in achieving a number of its stated aims. It showed that primary 
immunisation with KLH was a sensitive tool to assess the influence of UVR exposure on 
antigen-specific humoral and cell-mediated immune function. An antigen-specific immune 
response was generated in the majority of participants, which supported the dose and route of 
KLH administration and also the type and sensitivity of the immune assays performed. 
Although this small study was unable to disprove the null hypothesis (that solar UVR does not 
influence the antigen-specific immune response to primary immunisation), the findings were 
consistent with similar research in this area (See Section 2.3.6). 
Following sub-cutaneous immunisation with 125µg KLH, ~ 90% of participants developed a 
mea sureable DTH response in at least one anatomical site. The lower rate of DTH response at 
the thigh compared with the arm may be related to the anatomical site itself or a greater 
effect of UVR on the local immune response (185). Self-report of DTH response did not appear 
to be a reliable method of assessment. 
The ELISA protocols demonstrated an antigen-specific humoral response; however there were 
striking differences between the lgGFc, lgGl and lgG2 assays. Anti-KLH lgGl assays showed a 
clear rise in concentration by day 21-post immunisation for the majority of participants 
compared with baseline and day 7 sera. There was considerable background 'noise' for the 
lgGFc assay and minimal response above baseline for lgG2, making interpretation of these 
results difficult. Since lgGl is considered a Thl-associa ted an tibody and also makes up the 
majority of circulating lgG (134), in a future, larger ~tudy assessi ng the association between 
UVR and immunisation response, an antigen-specific lgGl assay would be a reasonable first 
approach. 
The formulation of KLH used in this study was problematic. One third of participants 
experienced a local adverse event related to immunisation, albeit minor and temporary, 
manifest as discomfort, erythema or 'bruising' at the site of immunisation and lasting days to 
weeks. This was attributed to the mineral oil adjuvant (Montanide ISA-51) used to promote 
the immunogenicity of sub-unit KLH and these adverse effects have been reported in other 
studies (although usually at higher doses of adjuvant +/- antigen) (410) ; Jeffrey Miller, 
University of Minnesota, Personal Communication). Given that immunisation is not otherwise 
beneficial for participants (i.e. not protective against infection), this side-effect profile is 
unacceptable for use in a larger epidemiological study where healthy participants are enrolled. 
There were a number of limitations to this study. The study sample was small with multiple 
inclusion and exclusion criteria designed to increase the internal validity of the study. The 
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spectral output of the UVR lamp approximated solar UVR in the UVA range but was limited in 
the solar UVB range. Also, the energy output of the lamp was designed to approximate 0.8 of 
an MED for participants with Fitzpatrick skin phototypes II & Ill, although this was by necessity 
a crude estimation. The lamp was calibrated initially against an accepted standard, however it 
was not rechecked following the initial calibration, leaving open the possibility for variation in 
spectral output through the study (183). 
4.4 Summary 
KLH is an ideal antigen for use in immunisation studies to assess influences on immune 
function. KLH immunisation produces a reliable and measureable immune response after 
single administration via the subcutaneous or intra-dermal route (particularly relevant to 
cutaneous UVR immunomodulation). Measurement of antibody and DTH responses at baseline 
and three weeks post-immunisation appears to be a relevant, convenient and common 
assessment time point. Testing for antibody level at one week post-immunisation does not 
appear to be useful for assessing change in lgG concentration, although it provides a useful 
check of baseline levels. 
Safety of immunisation is paramount. The combination of sub-u nit KLH with mineral oil or 
alum adjuvant confers an unacceptable risk of minor, local reactions. Therefore, for any future 
study, clinical grade HMW-KLH is the clear preference. 
In this pilot study, participants in the UVR exposure group were required to attend nine visits 
over a 31 day period which represented a high participation burden that would be difficult to 
maintain in a larger study. However, participants were comfortable with attending five visits 
over that time period with the attendant blood tests, immunisation and skin test. 
To advance this research, a larger well-designed study would need to be conducted that 
measured personal solar UVR exposure, assessed and adjusted for potential confounding 
factors and performed the array of ex vivo and in vivo immune function testing required. 
Chapter 5 will discuss the preparation and methods used for the larger Australian Ultraviolet 
Radiation and Immunity (AusUVI) study in more detail. 
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Chapter 5: AusUVI Study Methods 
Synopsis 
The Australian Ultraviolet Radiation and Immunity (AusUVI) Study aimed to determine the 
influence of solar UVR exposure, at doses relevant to day-to-day activity, on the immune 
response to primary immunisation in a healthy population of young adults. To conduct this 
type of epidemiological study, careful consideration needed to be given to obtaining an 
appropriate participant sample (i.e. demographics, location, sample size) and using validated, 
robust tools to measure UVR exposure (i.e. acute and cumulative individual exposure), 
potential confounding variables (e.g. age, gender, physical fitness, psychological state) and 
immune function outcomes (cell-mediated and humoral). The previous chapter discussed the 
development of the immunisation protocol and immune function assays in the context of the 
pilot study. In two sections, this chapter addresses the following issues - Section I: Rationale 
and evidence for the methods chosen for this research; and Section II : The AusUVI Study 
design, protocol and detailed methodology for the chosen measurements. 
SECTION I Rationale and evidence for the methods chosen for this 
research 
5.1 Measuring ultraviolet radiation exposure 
Chapter 2 discussed the current evidence supporting the immunomodulatory influences of 
UVR exposure in humans. It appears that both short-term and cumulative-UVR exposure may 
play a role, although more is known about the immtJnomodulatory mechanisms associated 
with the former where controlled experiments have been conducted (e.g. using CHS and DTH 
testing) . For the latter, there has been reliance on epidemiological data (e.g. comparing 
occurrence rates of immune-mediated diseases in different ambient UVR environments). 
For the AusUVI Study, where the immune response to immunisation (at an individual level) 
was the primary outcome of interest, emphasis was placed on obtaining detailed and accurate 
measurement of short-term personal UVR exposure in the periods (days) either side of KLH 
immunisation. As discussed in Section 3.2.3, direct measures of (UVR) exposure were 
preferred over data acquired by recall or by use of surrogate exposure markers (e.g. ambient 
UVR, latitude of residence). However, to obtain a complete data set looking at various aspects 
of UVR exposure (and sun protective behaviours), it was important to use a number of 
methods concurrently. 
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Measurement of cumulative UVR exposure was also undertaken, though acknowledging at the 
outset that this would be of lower resolution than for acute exposure data and would 
represent varying periods of past sun exposure. 
The advantages and disadvantages of different UVR measurement tools (See Table 5.1) will be 
discussed in the following sections. Reflectance spectrophotometry can be used for 
objectively assessing changes in skin pigmentation over time (i.e. UVR-induced tanning) and 
for constitutive pigmentation . This method is discussed separately in Section 5.2 .5. Similarly, 
changes in serum 25{OH)D level largely reflect recent UVR exposures (or changes in diet) - but 
will be discussed separately in Section 5.2.4. 
Apart from accuracy and reliability, cost-effectiveness and participant acceptability were other 
important considerations when deciding on appropriate methods for assessing UVR exposure. 
Table 5.1: Methods for measuring acute and cumulative UVR 
Possible measurement tools 
Short-term • Direct measurement - persona l UVR dosimeter 
(days to weeks) • Reflectance spectrophotometry- change in pigmentation of sun-
exposed skin over time 
• Sun exposure diary 
• Recent history of sunburn 
• Changes in vitamin D status over time (serum 25(OH)D level) 
• Ambient UVR monitoring - outdoor UVR monitor 
Cumulative • Microtopography- silicone skin casts 
(months, years, • Sun exposure questionnaires 
life-course) 
5.1.1 Measuring short term UVR exposure 
UVR personal dosimeters 
There are a number of UVR dosimeter types (i.e. chemical, biological, electronic), but the basic 
requirement is that their response function approximates the UVR action spectrum of the 
biological outcome of interest (e.g. erythema) (411). Studies using personal dosimeters began 
in the mid-1970s with the development of chemical dosimeters (412). These used chemical 
substrates (e.g. polysu\phone, ally\ diglycol carbonate, nalidixic acid, 8-methoxypsoralen) that 
underwent photo-transformation on exposure to bio logically-relevant UVR wavelengths (413). 
Most clinical studies have used the polymer polysulphone for which the spectral response to 
UVR closely approximates the erythema\ action spectrum {39,413). Polysulphone is usually 
mounted on a cardboard holder with a central aperture allowing direct UVR exposure. The 
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change in optical absorbance at 330nm is read after UVR exposure and compared with a 
standardised UVR curve generated by a spectroradiometer, to derive an erythemally weighted 
dose (i.e. SED) (43,414). Polysulphone badges are small, light and can be pinned to clothing or 
worn as a wrist band. The main disadvantages of chemical dosimeters are that they are dose 
saturable and therefore need changing regularly if undertaking a longer period of observation, 
indicate only a cumulative dose, and require a lengthy data extraction process (414). 
Biological dosimeters rely on UVR-induced DNA damage of a biofilm containing bacteria, 
spores or bacteriophages (415). Most interest has centred on the bacterium Bacillus subtilis, 
that has a spectral response in the UVB wavelengths that closely approximates the erythemal 
action spectrum (411) . A small number of published studies have utilised biological 
dosimeters, although a number of logistical issues limit their widespread use. 
Electronic dosimeters are the latest iteration of personal UVR dosimeters. They have several 
important advantages over chemical and biological dosimeters, namely a non-saturable 
response, short sampling intervals, 'time-stamped' data, re-usability and ease of data transfer 
(416). Disadvantages include potential for software and hardware malfunction, and expense. 
Electronic dosimeters are comprised of a sensor, amplifier, data logger and cell battery which 
are typically housed in a plastic casing that can be placed on a wrist band (i.e. worn as a watch) 
or worn as a badge (39,416,417). 
A recent well-designed study compared the accuracy of polysulphone dosimeters and 
electronic dosimeters against a reference spectroradiometer under natural daylight conditions 
(414). They found that polysulphone dosimeters ha_d an increased average and maximal 
deviation from reference data of 26% and 44%, compared with 15% and 33% for electronic 
dosimeters, respectively. They concluded that electronic dosimeters used in the study were 
more reliable than polysulphone versions. Table 5.2 summarises the advantages and 
disadvantages of the various dosimeter types. 
The wrist has been found to be a reliable site for personal UVR measurement and receives 
around 50% of the dose received at the top of the head (which is the best approximation of 
ambient UVR) (418,419) . Downs and Parisi (420) recently reported that the dorsum of the 
hands received a similar fraction of UVR even at varying solar zenith angles. 
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Table 5.2 Comparison of UVR dosimeters 
Type of Advantages Disadvantages Studies utilising 
dosimeter technology 
Chemical • Response function • Saturable response (43,44,421-424) 
(e.g. approximates the • Only cumulative dose 
polysulfone) erythemal action spectrum • Replaced frequent ly 
• Reliable • Laborious data 
• Experience with use extraction 
• Light, small 
• Ease of preparation, use, 
calibration 
• Thermal stability 
Biological • Response function • Complicated (418,425-428) 
(e .g. Bacillus approximates the preparation and 
subtilis) erythemal action spectrum analysis 
• Higher saturation ceiling • Saturable response 
compared with chemical 
dosi meters 
• Commercial dosimeters 
available (e.g. Viospor) 
Electronic • No upper SEO limit • Expensive & laborious (25,42,414,416,429-
• Monitor intra-daily doses to produce 432) 
• Re-usable for weeks • Issues with static, 
• Readings at programmable battery life, circuitry, 
intervals (e.g. 8 seconds, 1 uploading data 
minute) • Software issues 
• Instant read-outs 
• Long battery life 
• Small, light, portable 
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Sun diaries 
Sun diaries where participants are asked to log the time spent outdoors or "i n the sun" for a 
period of time, usually days to weeks, have been utilised by numerous researchers 
(25,42,423,433,434). For example, Glanz et al (423) asked lifeguards, parents and children to 
log their sun exposure in a diary for four consecutive days by marking each hour that they 
were outside. Correlation with polysulphone dosimeter data showed fair to good correlation 
with diary data on weekdays and weekends for children (r=0.18 and 0.34; p<0.05 and 
p<0.001), parents (r= 0.29 and 0.28, p<0.01) and lifeguards (r=0.38 and 0.57; p<0.001). Sun 
diary data are straightforward to analyse; however there is an increased participant burden 
which may be an issue over longer periods of observation. Using a similar study design, 
Chadick et al (42) also found significant correlation between recorded diary data of "time 
spent outdoors" and UVR dosimeter data. Notably, better correlation occurred at around 
noon compared with the extremes of the day. An additional benefit of sun diaries is that detail 
regarding concomitant use of clothing, sunscreen and other sun protection behaviours can be 
elicited. 
Assessments of recent sun exposure by self-report have also commonly asked about frequency 
of sunburn (i.e. over the previous 12 months) (435,436) and time spent outside on weekends 
and weekdays (423,437,438). Chadick et al (438) looked at the agreement between 
contemporaneously recorded diary data and subsequently recalled data of time spent 
outdoors on weekends and weekdays six months later in a group of American indoor workers. 
They concluded that recalled data for weekdays was more reliable than for weekends, possibly 
due to the lower number and less variation in spread of hours spent outdoors on weekdays. 
5.1.2 Measuring cumulative UVR exposure 
Sun exposure questionnaires 
Recall of past sun exposure has been commonly used in epidemiological studies assessing 
personal UVR exposure. There is no 'gold standard' approach to survey design and as such 
studies have varied by type of question asked, period of time (or age) recalled and by objective 
measures used to validate questionnaire responses (439) . Researchers commonly ask 
participants to recall the pattern of sun exposure from some previous defined time period (i.e . 
on vacation, during childhood, pregnancy) (440-442). This type of historical recall has shown 
reasonable correlation with objective measures of cumulative sun exposure such as silicone 
skin casts (440) . The advantages of using a questionnaire-based approach are convenience, 
participant acceptability, low cost, acquisition of data covering a wide range of other variables 
(e.g. sun protection strategies, demographic information, and dietary history) and time 
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periods, and utility within a large study population The obvious disadvantages of this method 
are that significant recall bias may be introduced particularly if participants have an inclination 
as to how sun exposure affects the outcome measure of interest (particularly relevant for 
case-control studies), poor reliability of data particularly when using data from a very remote 
period (i.e. early childhood) and low data resolution (i.e. can only obtain estimated averages of 
sun exposure over the period of interest). 
Using silicone casts to assess microtopography of skin 
Measuring actinic damage from chronic or cumulative solar UVR exposure with the use of skin 
casts (impressions) has been used in a number of studies since the 1980s. Photo-ageing is a 
pathological process distinct from chronological ageing, with characteristic macroscopic 
features (see Section 1.1.7). 
Beagley & Gibson (443) proposed a six-grade system to classify actinic damage based on skin 
surface characteristics of silicone rubber skin casts observed under low power light microscopy 
(microtopography). The Beagley-Gibson (BG) system uses deviations from features of non-
photo-aged skin in its grading descriptions (see Table 5.3). Undamaged skin (Grade 1) is 
described as having a series of diagonal and transverse primary lines which intersect to form 
quadrilaterals and triangles. Secondary lines are defined as smaller lines within primary line 
formations which form star like patterns at the points where they intersect (444) . At higher 
skin damage grades, there is progress ive flattening of secondary lines, loss of distinctive 
triangle formation, macroscopic deterioration in cast appearance, and deepening and 
increasing separation of primary lines. 
Table 5.3 Beagley-Gibson system of grading skin microtopography 
Grade Features 
1 Primary lines are all of the same depth . Secondary lines are all clearly visible, are 
nearly the same depth as the primaries, and often meet to form an apex of triangles 
('star formation') 
2 Some flattening and loss of clarity ofthe secondary lines. Star formations are still 
present, but often one or more of the secondary lines making up the configuration 
is/are unclear. 
3 Unevenness of the primary lines. Noticeable flattening of the secondary lines with 
little or no star formation. 
4 Macroscopic deterioration in texture. Coarse, deep primary lines. Distortion and loss 
of secondary lines. 
5 Noticeable flat skin between the primary lines. Few or no secondary lines. 
6 Large, deep and widely spaced primary lines 
Source: (444) 
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Uses and validation of the Beagley and Gibson classification system 
Numerous epidemiological studies have utilised silicone skin casts and the BG classification 
system to assess cumulative UVR exposure (25,366,440,444,445). Most studies have taken 
ski n casts from the dorsum of the hand as this represents a sun exposed area that is not likely 
to be covered by clothing and is easily accessible (420). 
The test characteristics of the BG system have also been assessed in several studies. Holman 
et al (444) graded the skin casts (dorsum of left hand, two independent graders) of 1216 
participants aged 16 to 86 years, and compared the results with questionnaire data on prior 
treatment for non-melanocytic skin cancer (NMSC) and a dermatological examination of su n 
exposed areas for solar ("actinic") keratoses. They found a significant increasing trend in age-
adjusted odds ratio between higher microtopographic grade and presence of solar keratosis 
(p<0.0001) or past treatment of NMSC (p=0.004) . There was 64% agreement of cast scores by 
graders, with a kappa statistic of 0.54 (moderate agreement). Battistutta et al (374) compared 
the microtopographic score of the dorsum of the left hand of 195 Australians (aged 18 - 79 
years) with the histological findings of a 2mm punch biopsy at the same site. Higher grade 
casts had 3.1 times greater odds (95% Cl 1.6 - 5.7) of demonstrating histological changes 
consistent with significant photo-ageing (e.g. dermal elastosis) than lower grade casts. This 
association persisted even after adjustment for other influential variables including age, sex, 
occupation, skin colour, tanning ability and smoking. Inter-rater agreement of cast scores was 
high - 88% of casts were given the same grade by both raters (weighted kappa statistic 0.86; 
very good agreement). Intra-rater agreement was also high (weighted kappa statistic> 0.80 
for both raters) . Lucas et al (440) compared the ski~ cast grades of 534 adults (aged 18 - 61 
years) with examination findings (e.g. skin complexion, solar keratosis, spectrophotometry 
findings), interview data regarding past sun exposure (including in childhood), and 
demographic information. Even after adjustment for age, sex and natural skin tone, the 
autho~s found that higher skin cast grades were significantly associated with higher lifetime 
cumulative UVR dose (adjusted OR 1.39; 95% Cl 1.11-1.75 per 1000 kJ/m 2), higher number 
(>10) of life-time sunburns compared with no sunburns (adjusted OR 2.86; 95% Cl 1.50-5.43) 
and history of solar keratosis (adjusted OR 1.55; 95%CI 1.03 - 2.32). 
Counter to the findings of these studies, Seddon et al (366) found the correlation between 
higher histological changes (elastotic degeneration) on skin biopsy (dorsum left hand) and 
higher skin cast grade did not persist after adjustment for age and other independent 
predictors (e.g. male gender, smoking, lighter skin complexion, lighter iris colour, lower 
education status, sunburn tendency) (r=0.18; p=0.13). The small numbers in this study (n=96) 
suggest the sample was insufficiently statistically powered to show a significant association 
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between the variables of interest, particularly with the number of covariates included in the 
regression model. 
5.2 Measuring potential confounders 
5.2.1 Physical activity 
Physical activity has been shown to modulate the immune response to immunisation (See 
Section 3.3.6). There are a multitude of questionnaires that are designed to measure physical 
activity, varying by target population, specific study aims, types of activity included and/or 
reference time periods (446). There is no gold standard method for assessing physical activity 
for clinical studies, although various instruments are available to verify the construct validity of 
questionnaires, including the doubly labelled water method (DLW), accelerometers, 
pedometers and actometers (447). Measures of physical fitness such as maximum oxygen 
uptake (VO, max) can also be useful, as fitness is related to physical activity (448). Each of 
these objective measu res of physical activity has limitations restricting their use in 
epidemiological studies, including the need for equipment and training, time commitment and 
expense. 
Amongst the questionnaire instruments for measuring physical activ ity, the International 
Physical Activity Questionnaire (IPAQ) has become the most widely used questionnaire for 
clinical studies where physical activity is measured (449), and was.also used in the AusUVI 
Study. 
International Physical Activity Questionnaire 
The IPAQ was designed by an International co llaboration to provide a questionnaire-based tool 
to obtain "comparable population estimates of health-enhancing physical activity" (450) (pp. 
753). There are two IPAQ versions - a long and short form . For the AusUVI Study, the short 
form (IPAQ-SF) was used. It asks participants to recall the frequency and duration of the 
following forms of activity over the previous seven days: vigorous intensity (e.g. aerobics, 
heavy lifting, digging), moderate intensity (e.g. carrying light loads, cycling at regular pace, 
playing doubles tennis), walking and sitting. The IPAQ-SF generates scores based on the 
'metabolic equivalent of task' (MET) that is attributed for different levels of activity intensity, 
and is expressed as MET-minutes per day or week. Scoring algorithms also allow for 
categorisation into low, moderate and high physical activity populations based on the 
frequency of physica l activity and/or MET-minutes per week (www.ipaq .ki.se). 
Validation studies have shown that the IPAQ-SF has good reliability (test-retest agreement) 
and initial assessment showed promising const~uct validity (451). However, more recent 
studies have cast doubt on the construct validity of the IPAQ-SF (446). 
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5.2.2 Psychological state 
Many studies have shown an association between psychological state and an individual's 
immune status (see Section 3.3.4). For the AusUVI Study, validated tools that reliably measure 
aspects of psychological state most likely to influence immune function were required (e.g. 
distress, stressful events, chronic stress). The questionnaire-based tools that were chosen 
were based on previous psychoneuroimmunological studies, and are described in more detail 
below. 
Measurement tools 
Mental Health Inventory 
The Mental Health Inventory (MHI) (www.rand .org) is a 38-item questionnaire developed to 
measure psychological well-being and distress over the previous 30 days in a non-psychiatric 
population. Participants choose from between five and six descriptive responses to questions 
that cover five domains: anxiety, depression, loss of behavioural and emotional control, 
positive affect and emotional ties (453). The MHI has been demonstrated to possess excellent 
internal consistency, test-retest reliability and construct validity after being validated in several 
large populations (452-454). The MHI has a complicated scoring system, though the final 
measurement outcomes are: One global higher-order score, the MHI score; two secondary 
higher-order global scores, the Distress Index and the Wellbeing Index; and five low-order 
scores covering the domains listed above. 
The MHI has been used in previous studies looking at the effect of psychological distress on 
the primary immune response to immunisation (wit:h KLH). Snyder et al (51) showed that 
participants with increased MHl-measured psychological distress had a decreased KLH 
antibody response, and those with increased MHl-measured wellbeing scores had increased 
KLH antibody response. In a subsequent study, the authors showed that increased MHl-
measured distress was associated with a decreased cellular response to primary KLH 
immunisation (386). 
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Profile of Mood States 
The Profile of Mood States (POMS) was developed to assess transient mood states. The 
original version conta ined 65 items and asked participants to describe their current mood (e.g. 
lively, forgetful, unhappy) on a five-point scale ranging from 'not at all' to 'extremely' (455) . 
Six sub-sca les are measured : tension-anxiety, depression-dejection, anger-hostility, fatigue-
inertia, vigour-activity and confusion-bewilderment (see Table 5.4). A shortened form of the 
POMS, 'POMS-SF', was later developed using on ly 37 items which reduced the time taken to 
complete the questionnaire significantly but maintained the psychometric properties of the 
longer version (456,457) . As with the long form, POMS-SF gives individual sub-sca le scores as 
well as an overall global index score, the so-cal led 'Total Mood Disturbance score' (sum of the 
individual sub-scales minus the score for the vigour sub-scale). 
The POMS-SF is considered an excellent tool where a brief measure of distress is required 
(457). The POMS questionnaire has been previously used in studies assessing the influence of 
distress (as measured by the POMS global index score) on the immune response to vaccination 
(335,342). 
Table 5.4 Profile of Mood Score - Short Form subscale items 
Sub-scale Items included Sub-scale 
total 
Depression Unhappy, sad, blue, hopeless, discouraged, miserable, 8 
helpless, worthless 
Vigour Live ly, active, energetic, cheerful, full of pep, vigorous 6 
Confusion Confused, unable to concentrate, bewi ldered, forgetful, 5 
uncertain about things 
Tension Tense, on edge, uneasy, restless, nervous, anxious 6 
Anger Angry, peeved, gravely, annoyed, resentfu l, bitter, 7 
furious 
Fatigue Worn-out, fatigued, exhausted, weary, bushed 5 
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5.2.3 Nutritional state 
Both macro- and micro-nutrient deficiency as well as obesity can influence human immune 
function (see Section 3.3.5). As nutrition encompasses a wide range of components (e.g. total 
energy intake, macro- or micro-nutrient intake), there is no universal measure of nutritional 
state. For the AusUVI Study - where under-nutrition in particular was not thought to play a 
large role given the inclusion and exclusion criteria - two relatively coarse measures of 
nutrition were used: body mass index and serum albumin . 
Body mass index 
The body mass index (BMI) is derived from the calculation: Weight (kg)/ (Height (metres)) 2• It 
is a simple, convenient and commonly utilised measure which correlates with body fat 
percentage (458). Various authorities have given guidance as to how to interpret BM! to 
delineate between underweight, normal weight and obese persons (www.cdc.gov/obesity) 
(See Table 5.5). 
Table 5.5 Body mass index classification 
Weight category Body mass index (kg/m2) 
Underweight <18.5 
Normal 18.5-24.9 
Overweight 25 .0 - 29 .9 
Obese >30 
Source: www.cdc.gov/obesity 
At the population-level, the distribution of BMI is a useful surrogate for population body fat 
levels (460,461). At the individual-level, BM! has been shown to correlate with objective 
measures of total body fat (e.g. dual-energy x-ray absorptiometry). However, as BM! cannot 
differentiate lean muscle mass from fat mass, there are numerous caveats that limit its 
applicability at an individual level (459). For example, for the same BM!, women generally 
have more body fat than men; older persons more body fat than younger persons; and 
muscular athletes less body fat than non-muscular individuals (460,461). There are differences 
in BM! between ethnic groups also that is related to genetic determinants of body composition 
(460). 
Serum albumin 
Protein malnutrition is very unlikely in the participants of this study due to the strict inclusion 
and exclusion criteria (see Table 5.6). Serum albumin reflects underlying protein stores which 
may be depleted during prolonged periods of poor oral intake (462,463). A low serum albumin 
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is not a specific test for chronic malnutrition as numerous conditions can lead to 
hypoalbuminaemia, such as inflammatory states, hepatic synthetic dysfunction (i.e. cirrhosis) 
or protein losing states (e.g. protein losing enteropathy, nephrotic syndrome) (464). 
5.2.4 Assessing vitamin D status 
As previously discussed, biologically active vitamin D (calcitriol) has immunomodulatory effects 
which may act in concert with, or independently of, direct UVR exposure. Assessment of 
vitamin D status is therefore important to include in explanatory models assessing the 
influence of UVR on the immune response to immunisation to delineate the relevant pathways 
of effect. As previously discussed, the usual method of assessing vitamin D stores in clinical 
studies is to quantify serum 2S(OH)D levels. 
Measuring 25(0H)D levels 
There are numerous commercial assays which measure 2S(OH)D serum levels, including 
competitive protein-binding assays, radioimmunoassays, enzyme immunoassays, 
chemiluminescence immunoassays, high performance liquid chromatography (HPLC), and 
liquid chromatography tandem mass spectrometry (LC-MS/MS) (Reviewed in 66). 
In recent years, inter- and intra-assay differences in 2S(OH)D level determination have been 
highlighted for many of the assays listed above (465,466). LC-MS/MS is now regarded by many 
as the "gold standard" assay (467) with very good key performance characteristics as well as 
the ability to differentiate and measure 2S(OH)D2 and 2S(OH)D 3 (468,469) . 
5.2.5 Skin pigmentation 
Skin pigmentation is an important factor modifying the effect of UVR exposu re on various 
biological sequelae, (e.g. skin erythema, epidermal cell damage, vitamin D synthesis) and 
potentially immune function (See Sections 1.1.6; 1.2.4). There are ethnic differences in 
constitutive skin pigmentation as well as wide variability within any specific ethnic group. The 
ability to measure and adjust for skin pigmentation is therefore an important consideration 
when assessing the potential associations between UVR exposure and immune function . 
Additionally, skin pigmentation changes following UVR exposure (i.e. tanning effect) and hence 
the difference in pigmentation between sun exposed and non-exposed skin ca n reflect 
personal UVR exposure. 
As briefly discussed in Section 1.2.5, the Fitzpatrick Skin Phototype scale provides a primarily 
qualitative tool for researchers to assess the association between UVR-related disease (e.g. 
skin cancer) and skin complexion/ sun reactivity. However, this scale relies on participants' 
answers to subjective questioning (e.g. "Do you.tan at the first average sun exposure?" (83)). 
Ethnicity also can influence (and bias) the categorisation of individuals into a particular skin 
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phototype category (where, for example, hair and eye colour are also included in the 
phototyping criteria) (470). 
Objective measures of skin pigmentation include fluorescence video, reflective colorimetry and 
melanin visualisation with a Wood's lamp (470) . Reflective spectrophotometry (RS) has 
emerged as a leading non-invasive method for assessing skin pigmentation . 
Reflectance spectrophotometry 
The method of RS is based on the differential attenuation of reflected light from skin of varying 
pigmentation. Most light in the visible spectrum (400 - 700nm) reaching the skin passes 
through the epidermis and follows a tortuous path either leading back out of the skin or to 
absorption by light chromophores - melanin, oxy-haemoglobin (oxy-Hb) or deoxy-
haemoglobin (deoxy-Hb) (note difference with UVR chromophores related to immune system 
mediation; see Section 2.3 .3) (471,472). Maximum visible light absorption for oxy-Hb occurs at 
412nm (with lesser peaks at 542nm and 577m); and for deoxy-Hb, maximum absorption occurs 
at 430nm (and a lesser peak at 555nm). Melanin exhibits no maximum absorption 'peak', but 
instead declines exponentially at longer wavelengths (473). Changes in blood circulation 
therefore (e.g. following application of a blood pressure cuff or changes to vasculature 
following sun exposure), can influence the absorption of light, dependent on the relative 
concentrations of melanin, oxy-Hb and deoxy-Hb (474). 
Spectrophotometers are hand-held instruments that emit light via a small aperture placed 
directly on the skin and analyse the wavelengths of light that are reflected back (473) . There 
are various algorithms for estimating melanin density from skin reflectance measurements, 
although the most robust algorithms take into account the relative absorption of light by the 
various chromophores (reviewed in 75). 
Dwyer et al (475) developed an algorithm to account for the visible light absorptive properties 
of cutaneous haemoglobin. They found that the difference in light reflectance at 400nm and 
420nm correlated well (r=0.68) with histopathological grading (via skin punch biopsies) of 
cutaneous melanin of the upper inner arm in a predominantly Caucasian study population. 
Furthermore, estimated cutaneous melanin density derived via this method was predictive of 
skin cancer occurrence, particularly amongst men in a Tasmanian study population (476). 
The anatomical sites for measurement using RS have varied by study, but the upper inner arm 
remains a common site for measurement of constitutive skin type in epidemiological research. 
Of note, a modest, but significant, seasonal variation in upper inner arm reflectance 
measurements has been demonstrated (likely due to some summer-time UVR exposure at this 
"protected site"). The buttock is another potential protected site for assessing constitutive 
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skin pigmentation, however can be practically difficult to access and can be influenced by body 
hair (477). 
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SECTION II: The AusUVI Study design, protocol and methods 
5.3 Study design and statistical considerations 
5.3.1 Research aim and hypotheses 
The AusUVI Study aimed to quantify the effect of personal UVR exposure on the primary 
immune response to immunisation in young healthy adults at UVR exposure levels relevant to 
daily activities; and to examine the moderating effect of other potentially relevant factors (e.g. 
sex, age, skin pigmentation, 25(0H)D level) on this association. 
Research Hypotheses 
The following hypotheses were generated based on the current photoimmunology literature: 
• Higher personal acute UVR exposure is associated with impaired cell-mediated and/ 
or humoral immune response to primary immunisation. 
• Higher cumulative personal UVR exposure does not lead to photoadaptation to the 
immunomodulatory effects of UVR. 
• Vitamin D status modulates the antigen-specific response to immunisation. 
5.3.2 Study design and setting 
In order to test these hypotheses, this study was required to: 
• Recruit healthy, young adult participants with a wide range of personal UVR 
exposures; 
• Assess personal UVR dose (acquired via usual daily activities) using validated 
instruments, including both short-term and cumulative UVR exposures; 
• Examine immune function by measuring the response to primary immunisation with a 
safe, reliable and novel T-cell dependent antigen; 
• Measure potential moderating effects of other factors using validated instruments; 
• Measure aspects of humoral and cell-mediated immunity using validated instruments 
and assays; 
• Undertake data collection across a full year to include coverage of all seasons; 
• Undertake all laboratory measurements of immune function in a standardized manner, 
in a si ngle laboratory, to minimize inter-laboratory variability. 
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5.3.3 Participant selection and recruitment strategy 
Participants in the AusUVI Study were volunteers, recruited through advertisement at 
universities, local hospitals, social and sporting clubs, local media and by word-of-mouth . A 
number of information sessions for the purposes of recruitment were held at the settings 
listed above. Volunteers were considered likely to have above-average motivation to complete 
study tasks and a volunteer sample allowed selective recruitment to ensure the broadest 
breadth of UVR doses. For example, if it became apparent during the study that indoor 
workers predominated, outdoor sporting groups or workers could be targeted for recruitment, 
to diversify the likely personal UVR exposure range. 
While participants randomly selected from the population might improve generalisability 
(external validity) of study results, the potentially low adherence and/or completion rate for a 
study requiring considerable commitment over several weeks would have negated this 
advantage, in addition to greatly increasing the recruitment workload. With regard to 
potential selection bias, there was no evidence (nor reasoned likelihood) to suggest that the 
relationship between immune response to immunisation and UVR exposure would differ by 
volunteer status. Importantly, potential confounders and effect modifiers would be measured 
and accounted for. 
Study promotions were professionally developed and included posters and brochures (see 
Appendix B). Study investigator contact details were provided on study promotional material 
for those wishing to express interest in participating. 
An information sheet was sent (e-mailed, mailed or _given directly- depending on individual 
preference) to interested parties following initial contact. A mutually convenient time was 
arranged for the first study visit, where, after appropriate counselling, written informed 
consent was obtained (see Appendix C). By way of compensation of a participant's time, effort 
and travel costs in attending study visits and completing study tasks, a $ASO gift voucher 
(redeemable at a chain of popular department stores) was provided to each volunteer at the 
last study visit, as well as feedback regarding examination findings and blood test results . 
Table 5.6 lists the inclusion and exclusion criteria for the AusUVI Study. 
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Table 5.6 Inclusion and exclusion criteria for study participants 
Inclusion criteria 
• Healthy adults (self-reported) 
• Aged 18 - 40 years 
• Willing and competent to sign informed consent 
Exclusion criteria 
• Allergy to shellfish 
• Any infection within 30 days of study entry 
• Known pre-existing immunosuppressed state (including diabetes, HIV, chronic renal 
or liver disease, recurrent infections, lgA deficiency, solid organ transplant recipient) 
• Use of immunosuppressive agents within 30 days (for systemic agents, including 
inhaled) or 7 days (for topical agents) of study entry 
• Immunisation within 30 days of study entry 
• Currently pregnant or breastfeeding 
• Unable to attend all study visits 
These criteria were chosen to maximise the internal validity of study findings. That is, we 
aimed to recruit a relatively homogeneous sample from which participants with non-
quantifiable potential confounding characteristics could be excluded. 
There is extensive literature demonstrating that older age (312,358), recent infection or 
immunisation (478), co-morbid medical conditions or immunosuppressive medications 
{388,479) can influence the subsequent immunisation response or immune testing, and 
therefore participants reporting any of these conditions were excluded (or had their entry into 
the study delayed until they no longer met any exclusion criteria). A list of immunosuppressive 
medications is provided in Appendix D). 
Although there have been no reports of anaphylaxis or other Type-1 hypersensitivity reaction 
with KLH administration, participants were excluded if they reported a shellfish allergy, in line 
with other comparable studies {358,387). As there had been no studies assessing the effect of 
KLH immunisation in pregnant or breastfeeding females, these potential participants were also 
excluded. 
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5.3.4 Study setting 
The AusUVI Study was conducted in two study cities - Canberra, Australian Capital Territory 
(35°15'5, 149°08'E) and Townsville, Queensland (19°15'5, 146°45'E) (see Figure 5.1) . These 
cities were chosen because they experience large seasonal differences in ambient UVR (see 
Table 5.7), are large regional centres with suitable populations from which to recruit, and have 
appropriate biomedical facilities that can support this level of research. 
Table 5.7 Average noon clear-sky UV Index by season for Canberra and Townsville 
Summer UVI Autumn UVI Winter UVI 
(Dec- Feb) (March - May) (June - Aug) 
Canberra 11- 12 5-6 2-3 
Townsville 13 10 7 
Source: Bureau of meteorology (www.bom.gov.au) Accessed : 7 April 2012 
Figure 5.1 Location of AusUVI Study cities 
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5.3.5 Statistical and data considerations 
Spring UVI 
(Sept - Nov) 
7-8 
12 
Descriptive statistics were used to summarise participant demographics, examination findings 
and blood test results. Comparison of proportions between groups was undertaken using x' 
statistic or Fisher's Exact Test, as appropriate. T-tests were used for comparison of groups 
with normally distributed data. Non-normally distributed continuous outcomes were 
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transformed as necessary. Where normal transformation could not be performed, non-
parametric analyses were undertaken as indicated (e.g. Wilcoxon rank-sum test). Sinusoidal 
functions in time-of-yea r were used to assess and adjust for seasonal variation for immune 
outcomes variables. Multiple linear regression and/ or ordinal logistic regression models 
examined associations between outcome and exposure variables, adjusting for other variables 
found to be confounders. Regression diagnostics were performed to confirm that regression 
assumptions had not been violated. Differences between groups were deemed sign ificant at p 
values< 0.05 . Where p values are reported, they are derived from two-tailed t -tests. 
Descriptive estimates (i.e. mean, standard deviation) and regression coefficients were 
reported to one decimal place. Where reporting to one decimal place did not reveal at least 
two significant figures, more decimal places were reported (i.e. the following exa mples would 
achieve the reporting standard: 12.0, 1.2, 0.12, 0.012). Data were analysed using the 
statistical softwa re package Stata, v12 (College Station, TX: StataCorp. LP) . 
Apart from the pilot study, there were no previous studies to guide an estimate of the likely 
magnitude of difference in KLH-specific antibody titres between those experiencing high 
versus low acute UVR exposure. An assumption was therefore made that titres would be 
reduced by at least 20%. Previous work suggests that mean KLH anti-lgGl co rrected optical 
density at 3 weeks post-immunisation would be approximately 0.55±0.1 in healthy young 
adults (358); we assumed this would fall to 0.45±0.1 in those expo2ed to high (above median) 
levels of UVR. The AusUVI Study was designed to have a minimum of 80% power (at a level of 
0.05) . Therefore this required 95 subjects above and 95 below median exposure, i.e. a total of 
190 between the two centres. Allowing for 10% attrition, this meant recruiting 212 subjects, or 
approximately 106 in each centre. 
The initial laboratory tests planned for ex vivo cell-mediated immunity were lymphocyte 
proliferation assays (LPA) with results reported as mean stimulation indices (MSI). However, 
soon after commencement of the study, a decision was made to change to more modern 
assays based on flow cytometry / FACS to give better information on T-helper subset 
populations. Therefore the original power calculations based on MSI are not reported. 
Seasonality of immune response was investigated using cosinor analysis. Assuming 190 
evaluable subjects accrued uniformly across 12 months, simulations show that this model has 
90% power to detect cycles of amplitude 0.4 standard deviations or more. Thus for humoral 
immunity, variations in titre of ±0.04 would be detectable corresponding to peak immunity 
27% above the annual minimum. 
Questionnaires were designed to be electronically entered ('teleformed') into a Microsoft 
Access (Redmond, WA USA) database. The database was checked for nonsensical, erroneous 
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or missing data by automated and manual methods and verified against paper copies of 
questionnaires. Outlier or influential points were identified using routine regression diagnostic 
techniques (e.g. Cook's D test). 
5.3.6 Ethics approval and regulatory considerations 
This study was conducted after approval by the Human Research Ethics Committees (HREC) of 
the Australian National University, Australian Capital Territory Health Department and James 
Cook University. Written informed consent was obtained from all participants on enrolment 
into the study. This study was also registered with the Therapeutic Goods Administration of 
Australia under the Clinical Trial Notification scheme (Trial No: 2010 / 0291) and the Australian 
and New Zealand Clinical Trials Registry (ACTRN12610000234011). 
High molecular weight KLH for immunisation was purchased from Biosyn Corporation 
(Carlsbad, USA) in a clinical grade form suitable for use in human clinical studies. Certification 
of Good Manufacturing Process standard was provided along with evidence of testing for 
endotoxin, metal ions and potential viral and bacterial infective agents (See Appendix E). KLH 
was imported to Australia for the purposes of this study under an Australian Quarantine and 
Inspection Service permit (IP0008186). 
Researchers independent of the AusUVI Study were appointed to a Safety Monitoring Board 
(SMB) to assess potential adverse events arising from use of the KU-I vaccine (or any other 
aspect of the AusUVI Study). The SMB was authorized to make recommendations to the 
relevant HRECs regarding change of protocol or cessation of study, where necessary. 
Funding for the AusUVI Study was primarily derived from a project grant from the National 
Health and Medical Research Council (NHMRC) (Grant No: 585489) which was obtained 
following a highly competitive, peer-reviewed process. 
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5.4 Study protocol 
There were two enrolment sites in Canberra (Australian National University city campus and 
the Canberra Hospital, located approximately lOkms south of the city centre) and one 
Townsville enrolment site, based at the Townsville Hospital. Participants were requested to 
attend five study visits over a 31 day period. There was an assigned study officer in each cit y 
whose responsibilities included recru iting participants, administrating questionnaires, 
completing examinations and keeping a detailed record of all activities. At the Canberra sites, 
the study office r (the author of this thes is and registered medical practitioner) also took 
participants' blood and administered immunisations. At the Townsvi lle site, a registered nurse 
was separately employed to take blood and administer immunisations. At both sites, qual ified 
laboratory scientists were employed to process and store blood samples fo r subsequent 
immune function testing. 
Figure 5.2 summarises the tasks undertaken at and between visits. At the outset, it was 
envisaged that two participants on average would be en ro lled per site per week for 52 weeks 
(to attain the target of 105 participants per site) . The remainder of this section summarises 
the study visits. A Manual of Procedures and Policies (MOPP) was developed for study officers 
at each site to ensure standardisation of methods of recruitment, measurement and 
laboratory issues. 
Figure 5.2 AusUVI Study protocol 
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5.4.1 Study visits 
V1s1r 1 Initial Assessment {Day 1) 
Questionnaires (See Appendix F) were administered relating to: 
• Demographic Information: age, sex, ethnicity of parents, place of birth, places of 
current residence (and duration), education, employment status, current occupation; 
• General Health: including chronic illness, menstrual patterns, smoking and alcohol 
intake, family history of immune related diseases; 
• Medications: including vitamin D supplements; 
• Previous immunisations: adverse events; 
• Allergies (including shellfish); 
• Physical activity: using the International Physical Activity Questionnaire . 
Sun exposure history: skin response to sun exposure at various times of year, frequency of 
sunburn, sun protection behaviours (amount of skin exposed, type of clothing worn, sunscreen 
usage), recent sun exposure (over previous month). 
A brief physical examination was undertaken, which included : 
• Eye and natural hair colour (by comparison to photographs to ensure standardization 
across centres); 
• Height and weight for calculation of body mass index; 
• Spectrophotometric measurement of skin colour at sun-protected (i.e. inner upper 
arm) site for natural skin colour and sun-exposed body site (i.e. cheek) to estimate 
tanning. 
Results were noted in a dedicated participant examination data record (see Appendix G) . 
Silicone skin casts were taken of a small area of the dorsal aspect of each hand (see Section 
5.5 .3) . 
Participants were asked to wear an elastic wrist band carrying an electronic UVR dosimeter for 
a ten-day period (day 3 to 12 inclusive), while continuing with their usual daily routine (see 
Figure 5.2). The dosimeter was programmed to collect UVR exposure data during the hours 
0700 to 2100 daily, at 8 second intervals (See Section 5.5.2). 
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Finally, participants were instructed on the use of the self-administered sun exposure diary, to 
be completed daily for the ten days concurrently with electronic dosimeter wearing. The diary 
asked for detailed recording of time in the sun, use of sun protection (type of clothing, 
sunscreen) and exercise patterns (See Appendix H). 
VISIT 2 Blood test and immunisation (Day 8) 
A questionnaire on psychological well-being was administered which comprised the Profile of 
Mood States (Short form) and Mental Health Inventory (See Appendix F). Participants were 
specifically asked about whether they had experienced sunburn in the previous week- details 
regarding frequency, site and severity were noted (See Appendix G). 
Repeat spectrophotometric measurement of skin at the inner upper left arm and left cheek 
was taken. 
A venous blood sample was taken for full blood examination, random blood glucose level, liver 
and renal function tests. Serum for 2S(OH)D level and KLH-specific antibody testing and whole 
blood for peripheral blood mononuclear cells (for cellular immune assays) were processed (See 
Appendix K) and stored for ana lysis at study completion. 
Participants were immunised subcutaneously with 125µg HMW KLH (0.125ml of lg/lml 
solution) (cGMP grade; Biosyn Corporation, USA) using a 29 gauge diabetic needle (BD 
catalogue no. 591823). The site of injection was strictly defined as one third of the straight-line 
distance from the insertion of the brachioradialis tendon at the elbow to the base of the radial 
styloid at the wrist, with the elbow resting on a flat surface and the wrist held in a neutral 
position (i.e. neither supinated nor pronated) (See Figure 5.4). This site was marked with a 
pen . This site was chosen for immunisation as it represented a sun exposed area (i.e. anterior 
aspect of forearm), had ample subcutaneous tissue for injection, and was accessible and easy 
to locate using the anatomical markers described. The wrist where the participant wore the 
electronic dosimeter was also the arm immunised . 
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Figure 5.4: Anatomical markers for KLH immunisation site 
The electronic dosimeter was collected and data downloaded to a personal computer via a 
Universal Serial Bus (USB) cable. The dosimeter memory was cleared and re-set to commence 
data recording as before. Participants were instructed to wear the dosimeter until day 13 had 
been completed (to complete the ten days of dosimeter wearing). 
The sun diary was also reviewed to ensure that it was being completed correctly. 
VISIT 3 Blood test and spectrophotometry reading (Day 15) 
Spectrophotometric skin measurements were again taken from the upper inner left arm and 
left cheek. 
A venous blood sample was taken: serum was subsequently aliquoted and stored for KLH-
specific antibody determination at study completion. 
The electronic dosimeter was collected and data were down loaded to a personal computer. 
The sun diary was also checked and collected. Specific enquiries regarding sunburn in the 
previous week and any adverse events associated with the immunisation were made. 
VISIT 4 Skin test and blood test (Day 29) 
Participants underwent intra-dermal injection with lOµg of KLH (0.01 ml of lg/lml KLH 
formulation) at the same point on the forearm as was immunised at Visit 2. This was also 
administered with a 29 gauge diabetic needle. 
A venous blood sample was taken: serum for KLH-specific antibody determination was 
aliquoted and stored and whole blood for peripheral blood mononuclear cells was processed. 
Details of sunburn episodes since the last visit were recorded . 
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VISIT 5 Reading of skin test and feedback (Day 31) 
DTH response was manifest by a rai sed area (indurated) of skin around the intra-dermal 
challenge site which was often (though not always) erythematous. The margins of the raised 
area were measured at 48 hours post skin test, by taking the mean of two diameters (mm) of 
induration perpendicular to each other. lnduration was detected by running a pen along the 
skin until it met resistance (see Figure 5.5). 
Figure 5.5 "Pen test": measuring induration secondary to 0TH challenge 
Participants were given a feedback form which recorded their blood pressure, BMI and 
screening blood test results (full blood count, liver and renal function , random blood sugar 
level) . The department store gift voucher was given to participant,at this time also. 
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5.5 Methods of specific tasks undertaken in the AusUVI Study 
The following section will provide technical detail regarding the various measurement tools 
used in the AusUVI Study protocol. The rationale for their use has been discussed in the first 
section of this chapter. Along with the MOPP, four face-to-face meetings and monthly 
teleconference meetings of study personnel were held for training purposes, standardisation 
of methods, testing and calibration of equipment and to discuss concerns. The face -to-face 
meetings occurred prior to recruitment and at three month intervals thereafter, either in 
Canberra (one meeting) or Townsville (three meetings). 
5.5.1 Sun diary and questionnaires 
Participants were given a Sun and Activity Diary ("sun diary") to complete for the ten days 
during which they also wore a UVR dosimeter on their wrist (See Figure 5.6 and 5.8; Appendix 
H) . The sun diary was to be completed each day to minimise recall error. The diary was divided 
into several parts: i) time spent outside in the sun for each hour of the day from Sam to 7pm 
(to the closest quarter hour); ii) clothing worn during each hour divided into headwear, upper 
body, lower body, footwear and gloves; iii) sunscreen use (timing, frequency and distribution) 
and iv) physical activity (indoors and outdoors) per hour. 
Finally, frequency of sunburn was asked for each season over the previous 12 months. For 
Visits 2 - 5, participants were asked by the research officer whether they had experienced an 
episode of sunbu rn since the last visit, and, if so, its site and severity (See Appendix G) . 
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Figure 5.6: Sun and Activity Diary example of daily sun exposure, clothing worn and physical 
activity 
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This is an example from the Sun and Activity Diary that participants were requ ested to complete at the 
end of each day. For each hour of the day (Sam to 7pm), participants indicated time spent outdoors, if 
they applied sunscreen, what type of clothing was worn on different regio_ns of the body and the type 
and duration of physical activity. Also, the distribution of sunscreen application was also required . 
5.5.2 Use of electronic dosimeters 
Electronic dosimetry was the preferred method for measuring an individual's ambient UVR 
exposure for the AusUVI Study. Electron ic dosimeters, manufactured in New Zealand, had 
been tested and validated in various settings, including with skiers and workers at a ski resort, 
school children, outdoor workers and an older adu lt popu lation (25, 416). 
The dosimeter utilises a ternary semiconductor system with a photodiode (Genicom) that 
exhibits a spectral response that mimics the CIE erythemal action spectrum (particu larly at 
wavelengths 325 - 400nm) (See Figure 5.7). On exposure to UVR, the photodiode sensor 
produces a minute current (1 - l0nA) which is amplified to a measurable voltage (0 - 2.4V), 
then sampled at pre-determined time intervals (i.e. 8 seconds in the AusUVI Study) by a 
microcontroller. The data are stored in non-volatile memory (416). 
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Figure 5.7: Spectral response of electronic dosimeters compared with the CIE erythemal 
action spectrum 
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(Source: Martin Allen, University of Canterbury, New Zealand (Unpublished)) 
The dosimeter is round with a diameter of 35mm and thickness of 10mm and each unit weighs 
approximately 20 grams. The housing is made of a water-resistant plastic white casing and the 
badge is secured to the participant's wrist by an elastic wristband. The dosimeters are 
programmed with customised software via a USB cable attached to_ a personal computer. In 
the AusUVI Study, dosimeters were programmed to commence collecting data at Visits 1 and 2 
for each participant, with downloading of UVR exposure data at the following visits (i.e. Visits 2 
and 3, respectively) . Dosimeters were programmed to commence data co llection at 0700 
hours and cease at 2100 hours, and to sample UVR exposure at eight second interva ls. 
Participants were asked to wear the badge on the outside of clothing (e.g. jacket) or to roll 
their sleeves up to expose the dosimeter's sensor to sunlight. Participants were requested to 
wear the dosimeter on the same wrist each day. If engaged in outdoor activity where the 
dosimeter could not be worn (e.g. swimming, competitive sport), the dosimeter was to be 
placed or.i a surface in the open (e.g. beach towel) to approximate the participant's exposure 
(and this variation noted in sun diary) . Batteries (3V lithium cells) were changed monthly to 
ensure data were not lost or compromised due to low voltages. 
UVR exposure was measured in standard erythemal doses (SED) . Calibration of electronic 
dosimeters was undertaken against a Yankee Environmental Systems spectroradiometer at the 
National Institute for Water and Atmospheric (NIWA) Resea rch (Lauder, Otago, New Zealand) 
before and after the badges were deployed to Australia. Raw UVR exposure data from the 
digital dosimeters were downloaded to a personal computer and stored as digital files 
(Microsoft Notepad, Redmond, USA) . On completion of recruitment, all data files underwent 
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extensive checking for errors, repeat segments, wavering baseline and " noise", by staff at 
NIWA (see Appendix I). 
Interpolation of electronic dosimeter missing data 
For missing or clearly erroneous electronic dosimeter data, an "i nterpolation" of estimated 
UVR personal exposure was calculated using corresponding diary and maximum cloud-
adjusted UVR data (sourced from ground-based UVR monitors (Solar Light Co, Biometer Model 
501) situated at the ANU campus and Townsville Hospital, managed by the AusSun Laboratory, 
Queensland University of Technology). The algorithms that generated the interpolated values 
were developed by NIWA researchers experienced with handling electronic dosimeter, 
ambient UVR and diary data (Liley & Liley, unpublished manuscript). Detailed explanations of 
the mathematical algorithms used are given in Appendix J. 
Personal UVR exposure - Adjustment for clothing 
The sun diary required participants to detail the types of clothing worn for each hour (between 
0500 and 1900) of the ten days that the electronic dosimeter was worn . Participants chose the 
relevant item from a set of pictures illustrating the most common types of clothing for each 
body region (see Figure 5.8). 
Based on the work of Lee et al (482) where detailed analysis of the body surface coverage of 
many common clothing types (including of feet, hand and head coverings) was undertaken, a 
body surface area coverage (BSAC) adjustment coefficient was assigned for each clothing item 
shown in Figure 5.8. These are presented in Table 5.8. 
136 
Figure 5.8: Clothing options for Sun and Activity Diary 
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Table 5.8: Assigned body surface area covered coefficients for individual clothing types* 
0 1 2 3 4 5 6 
Upper No Bikini Swimsuit Crop top Singlet Short- Long 
body clothing top top 0.128 top sleeved sleeved 0 0.041 0.354 0.207 top 
top 0.358 
0.254 
Lower No Speedos Shorts or Medium Long Medium Long 
body clothing / briefs short skirt shorts or trousers/ skirt skirt 
0 0.070 0.200 3/4 pants jeans 0.304 0.431 
0.294 0.423 
Headwear No Beanie Cap Legionnaire' Bucket Wide- Veil/ 
headwear 0.049 0.049 s cap hat brimm ed burkha 
0 0.061 0.054 hat 0.065 
0.071 
Footwear No Thongs / Semi - Enclosed Workboo Long socks 
footwear open enclosed shoes ts 0.154 
0 sanda ls shoes 0.077 0.111 
0.032 0.056 
Gloves No gloves Gloves 
0 0.049 
* Adapted from (482) 
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To determine a participant's daily personal UVR exposure adjusted for the body surface area 
covered by clothing for each day where the electronic dosimeter was worn, the following 
formula was employed: 
u 
Daily personal UVR exposure = I (1 - BSACi) UVRi 
i =l 
where i indexes the hours of the day, from 0700 to 1900 (these were the common hours of 
data collection between the electronic dosimeter and sun diary) 
B5AC;: proportion of body surface area covered by clothing for the houri; determined by 
summation of all clothing BSAC coefficients for different body regions for that hour (i.e. upper 
body+ lower body+ footwear+ headwear + gloves) (Theoretic range 0 - 1) 
UVR;: UVR measurement from electronic dosimeter (with interpolated values) for the houri 
5.5.3 Silicone cast impressions for microtopography 
Silicone skin casts were taken during Visit 1 for each participant. Choosing an appropriate site 
for making a skin impression was important. Macroscopically 'normal' appearing skin on the 
dorsum of the left and right hand was required, free of scars, veins or other blemishes. 
Participants were seated comfortably with their hands resting on a flat surface (i.e. desk or 
table). Participants loosely held a plastic cylinder (diameter ~ 4cm)Jn each of their hands with 
palms facing down, ensuring that the skin surface on the back of the hand was flat and the 
hand was held still. A cartridge containing Affinis Fast Body silicone cast material (Coltene, 
Altstatten, Switzerland) was loaded into the supplied. applicator gun. The applicator nozzle 
could optionally be attached to the applicator gun. Silicone material (comprising two 
reagents) was squeezed onto a mixing tray and thoroughly mixed with a metal spatula, with 
care to avoid bubbles. Using the spatula, mixed silicone material was applied to the dorsum of 
both hands to cover the area of a 50 cent coin (~2.s x 2.5cm). If the area contained many hairs, 
then an increased thickness of silicone was applied . The timer was set for eight minutes and 
the participant instructed not to move their hands from the table . Following setting of the 
impressions, they were peeled from the skin and examined. If there was evidence of bubbles 
or smudging, the procedure was repeated. The casts were placed in a clear plastic pocket and 
labeled on the opposite side of the impression with the date, study number and whether the 
cast was from the left or right hand. 
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5.5.4 Reflectance spectrophotometry 
An estimate of cutaneous melanin density was obtained by reflectance spectrophotometry. 
Two skin sites were chosen - a non-sun exposed area (left upper inner arm) and a sun exposed 
area (left cheek) - as they were easy to access, were relatively flat surfaces and had been used 
in previously published studies (440,483,484) . 
Skin reflectance was measured at study Visit 1, 2 and 3 using a hand-held spectrophotometer 
(Konica Minolta; Model: M-2500d, Japan). Skin reflectance measurements were undertaken 
before blood pressure assessment or venepuncture, as these procedures could affect local 
blood flow and hence complexion. Facial cosmetic make-up was removed where poss ible, and 
those having applied recent tanning products were excluded from reflectance measurements. 
The spectrophotometer was calibrated prior to each session . Identification of the appropriate 
site for reflectance measurements was critical and therefore much emphasis was placed on 
correct positioning of the participant and identification of anatomical landmarks. 
For the inner arm measurement, the participant was seated with their left arm resting on a 
white pillow with the elbow at approximately the height of the heart. A pen mark was made 
just above the halfway point of a straight line between the mid-point of the axilla and the 
medial epicondyle of the humerus (See Figure 5.9). 
Figure 5.9: Skin reflectance measurement: Left upper inner arm representing 
non-sun exposed skin 
The reading from the left cheek was taken at approximately 2.5 cm lateral to the inferior 
aspect of the left nostril. 
Three reflectance readings were taken at each site. After each measurement the reading was 
checked and the spectrophotometer re-positioned . Reflectance results were deemed 
acceptable if all three readings were within a 1% range. If outside this range, further set/s of 
three readings would be taken until the required consistency was attained . Skin reflectance 
measurements at 400nm and 420nm wavelengths at each anatomical site were recorded on 
the data collection sheet. 
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5.5.5 Vaccine-related issues 
The high molecular weight (HMW) KLH vaccine (Biosyn Corporation, Carlsbad, USA) was 
custom manufactured for the AusUVI Study. Vaccine was packaged in borosilicate glass vials 
with butyl -rubber stopper closures and flip-top aluminium seals (see Figure 5.10) . Each vial 
contained G00µg HMW-KLH in phosphate buffer solution at concentration lmg/ml. The initial 
expiration/ retest date was set at 12 months with stability and sterility testing performed at 3 
monthly intervals following this to ensure ongoing suitability for use. The vials were stored 
within the recommended range of 2 - 8°C in refrigerators at the Canberra Hospital and 
Townsville Hospital pathology laboratories that had generator back-up systems. At regular 
intervals, the temperature logs for both fridges were checked to ensure that there had been 
no fluctuation of temperature outside of the recommended storage range. 
Figure 5.10: Customised HMW-KLH in glass vial with rubber stopper 
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As each vial contained 600µg KLH, an individual vial could be used more than once to obtain 
KLH for immunisation (125µg per dose) or DTH testing (l0µg per dose), although a maximum 
limit of three "accesses" per vial within a maximum period of four hours of first use, was set. A 
new, sterile diabetic needle was used for each vial access and the rubber stopper 
decontaminated with an alcohol wipe prior to each dosing. The vials were kept refrigerated 
between uses. When participants were seen at the ANU study site, vaccine vials were collected 
from the Canberra Hospital just prior to use and transported in an insulated transport 
container (e.g. Esky™) with ice (following National Vaccine Storage Guidelines) to maintain 
cold-chain integrity. Importantly also, the KLH solution was gently mixed by swirling prior to 
each dosing to ensure an even distribution of antigen. 
5.5.6 Blood samples for biochemistry, haematology and 25(0H)D analysis 
For the AusUVI Study, blood was collected by venesection from participants at Visit 2 (study 
day 8), Visit 3 (day 15) and Visit 4 (study day 29) : Blood collected in serum separator tubes 
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(SSTII; BD Catalogue no. 367782) was centrifugally spun at 1000g for 10 minutes within four 
hours of collection. Biochemistry (electrolytes, urea and creatinine; liver function tests; 
random blood glucose; (-reactive protein) was determined by automated chromatography 
assay at the clinical pathology laboratories at Canberra Hospital and Townsville Hospital. In 
addition, a full blood count was determined by an automated cell counter from whole blood 
collected in an EDTA tube (BD catalogue no. 366437). 
Serum was also transferred in 1 to 1.5 ml aliquots to three labelled vials (Nunc CryoTubes® 
Cat. No 347627) and stored in designated freezer boxes at -20°C. On completion of 
recruitment at both study sites, one vial of stored serum for each participant at Visits 2 and 4 
was transported on dry ice in one batch to Royal Melbourne Institute ofTechnology (RMIT) 
Drug Discovery Technologies for 25(OH)D analysis by LC-MS/ MS. Thirty duplicate serum 
samples (with re-coded labels) were also included for quality control testing. The remaining 
frozen serum was stored for later anti-KLH antibody assays. 
At Visit 2 and Visit 4, blood was also collected in acid citrate dextrose (ACD) tubes (BD 
Catalogue no 455055) for isolation of peripheral blood mononuclear cells (PBMCs) . A 
maximum time limit of 16 hours was set from collection of blood to PBMC isolation, although 
in the vast majority of cases, this was performed within 4 - 6 hours of collection. Isolation of 
PBMCs was by Ficoll centrifugation over a step gradient as per standard protocols (See 
Appendix K). Separated PBMCs were then carefully frozen in cryovials in a -80°C freezer, then 
transferred for liquid nitrogen storage until further analysis. 
5.5.7 lmmunoassays used for the AusUVI Study 
Assessment of KLH-specific humoral response was by indirect ELISA against lgGl. The decision 
to proceed with this lgG subset alone was based on the results of the Pilot Study where this 
assay demonstrated the lowest background noise and gave the clearest signal. However, 
serum has been stored for later analysis of other lgG classes as required . The ELISA protocol is 
otherwise as described in Section 4.4.3 and Appendix A. Anti- KLH lgGl values are prese nted 
as a "corrected" optical density (OD) by dividing th e raw absorbance by the result for the 
standard positive control sample that was also run on each plate (387). The assay's 
"background noise" was subtracted from the day 7 and day 21 post-immunisation readings. 
Background noise was defined as the difference in optical density reading between the 
negative control and a participant's baseline serum . 
Assessment of cell-mediated immunity ex vivo was undertaken using flow cytometry / FACS 
and intracellular staining of cytokines to quantify the proportion ofThl, Th2, Th17 and 
regulatory T cells (FoxP3+ CD127lo) in PBMC samples isolated at baseline and day 21-post-
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immunisation (also See Table 5.8). Due to logistic and time constraints, this assay was limited 
to a subset of AusUVI participants with extremes of personal UVR exposure. Of note, the 
assays were conducted using ce lls proliferated with polyclonal mitogens only (Concanavalin A / 
phytoha emagglutinin). Incubation with KLH alone did not generate enough stimulated 
lymphocytes to enable further analysis (although work in this area is ongoing). Appendix K 
contains the protocol detai ls for the cellular assays conducted. 
Table 5.8: Cellular targets for FACS analysis of PBMCs from AusUVI Study participants 
T-helper subset Cell surface markers Intracellular Transcription 
cytokine factor 
Thl CD3+ CD4+ IFN y 
Th2 CD3+ CD4+ IL-4 
Th17 CD3+ CD4+ IL-17 
Regulatory T cell CD3+ CD4+ IL-10 Foxp3 
CD25 h; CD127'0 
5.6 Summary 
The AusUVI Study was designed as a prospective longitudinal study aiming to assess the 
relationship between personal UVR exposure, at doses relevant to day-to-day living, on the 
immune response to primary immunisation with a T-cell dependent antigen . 
Reliable and accurate measurements of short-term and cumulative personal UVR exposure 
were critical for the AusUVI Study. Personal UVR dosimetry allows for highly detailed 
measurements within the periods adjacent to immune challenge with immunisation, whilst 
sun diaries additionally collate corollary information such as clothing and sunscreen . 
Assessment of cumulative sun exposure was achieved by questionnaires and measurement of 
UVR-induced skin damage by cutaneous microtopography. 
Measurement of factors potentially confounding the association between UVR exposure and 
the immunisation response were achieved via a combination of examination techniques (e.g. 
BMI, reflectance spectrophotometry), questionnaires (e.g. assessing physical activity or 
psychological state) or blood testing (e.g. vitamin D status). As with measurement of UVR 
exposure, choice of assessment tool was a balance between accuracy, reliability, cost-
effectiveness and participant acceptability. 
142 
The AusUVI Study was conducted in two cities - Canberra and Townsville - that had 
appropriate biomedical facilities and a wide ambient UVR differential. Based on sample size 
calculations, 105 participants from each site were to be recruited over 52 weeks. Inclusion 
criteria were designed to optimise the study's internal validity by identifying a healthy, young 
volunteer cohort of adults without characteristics that could affect immune status (i.e. 
medications or co-morbid conditions). KLH was obtained in a clinical grade form appropriate 
for immunisation. Participants were seen at five visits over 31 days. Baseline information was 
collected detailing participant characteristics, 25(0H)D level, skin pigmentation and cumulative 
UVR exposure. Detailed personal UVR measurements (via electronic UVR dosimetry and sun 
diary) were planned for five days either side of subcutaneous KLH immunisation to the 
forearm. An interpolation function for missing or erroneous dosimeter data was developed. 
Subsequent visits assessed changes in skin reflectance (tanning), serum 25(0H)D level and 
changes in immune parameters compared with baseline (KLH-specific antibodies, DTH 
response and cellular assays). 
Subsequent chapters will detail the results from the AusUVI Study. 
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Chapter 6: AusUVI Study Results: Participant characteristics and 
UVR exposure data 
Synopsis 
This chapter describes results of the AusUVI Study in three sections: i) participant enrolment 
and demographic characteristics, ii) potential immunomodulatory factors, and iii) personal 
UVR exposure data . Chapter 7 will describe the results of the immune assays and associations 
with UVR exposure and other variables . 
6.1 Demographic data and participant characteristics 
6.1.1 Participant recruitment 
Two-hundred and twenty two participants completed the AusUVI Study, 110 recruited from 
Canberra and 112 from Townsville. Recruitment commenced in mid-July 2010 and fini shed in 
mid-July 2011 in Canberra and early-August 2011 in Townsville. Graph 6.1 illustrates the 
cumulative total and monthly rate of enrolment at both sites over the study period. 
Townsville recruitment was temporarily suspended in September 2010 due to technical issues 
with the electronic UVR dosimeters and associated software. Due to this unavoidable delay, 
Canberra recruited more participants in spring 2010 compared with Townsville, with the latter 
'catching up' with recruitment by the following winter (2011) (see T.able 6.1). Recruitment was 
suspended in December 2010 for the Christmas-New Year holiday period, and re-commenced 
in January 2011. 
Graph 6.1: AusUVI Study recruitment - Monthly and cumulative totals by study site 
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Table 6.1: Participant recruitment: By season 
Period Canberra Townsville Overall 
n(¾) n(¾) n(¾) 
Winter (July -Aug 2010 & June - Aug 2011) 27 (24.6) 49 (43.8) 76 (34.2) 
Spring (Sept - Nov 2010) 34 (30.9) 18 (16.1) 52 (23.4) 
Summer (Dec 2010 - Feb 2011) 20 (18.2) 20 (17.9) 40 (18.0) 
Autumn (March - May 2011) 29 (26.4) 25 (22.3) 54 (24.3) 
Total 110 (100) 112 (100) 222 (100) 
Participants were seen at either of two sites in Canberra depending on participant preference. 
Fifty-one participants (46%) were seen at the Australian National University campus (in central 
Canberra) and the remainder at the Clinical Trials Unit at Canberra Hospital (south Canberra). 
All Townsville participants were seen at the James Cook University's Skin Cancer Research Unit 
located at the Townsville Hospital, Queensland. 
In Canberra, two participants withdrew after commencing the study, one because of interstate 
employment relocation and the other after learning of pregnancy (before KLH immunisation 
was given). In Townsville, seven participants commenced the study and subsequently 
withdrew - three due to employment relocation from Townsville, three due to busy schedules 
and one for unknown reasons. Participants who withdrew from the study were not counted in 
the 222 completed study participants and were excluded from analysis. 
6.1.2 Participant characteristics 
Table 6.2 summarises age and sex characteristics of participants overall and by study site. A 
higher proportion of females (63.5%) were recru ited, and this was consistent across sites. The 
age distribution was positively skewed (median age 27.3 years; mean 27.9 years). Canberra 
recruits were on average 2.6 years older than their Townsville counterparts, although there 
was a similar age range. Female participants in Townsville were younger than females 
recruited in Canberra (25.7 vs. 29.4yrs; p<0.001), but there were no significant differences in 
age amongst males between si tes (29.2 vs. 28.2yrs; p=0.49). 
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Table 6.2: Participant characteristics - Age and Sex 
Participant characteristic Canberra Townsville Overall 
Number, n (%) 110 (49.5%) 112 (S0.5%) 222 
Female, n (%) 71 (64.S%) 70 (62.S%) 141 (63.S%) 
Age (years), mean (SD) 29.2 (5.8) 26.6 (6.5)** 27.9 (6.3) 
(Range) {18.3 - 40.9) (18 .2 -40.6) (18.2 -40.9) 
* *Significant at p<0.01 using t-test after log transformation of positively 
skewed age distributions 
6.1.3 Ethnicity 
There was a wide ethnic diversity amongst AusUVI participants, with 34 different countries of 
birth. Table 6.3 displays data showing region of birth . The majority of participants were born 
in Australia (71.6%), followed by south-east Asia (6.3%) and northern Europe (5.9%) . Similar 
proportions were seen at both sites. 
Table 6.3: Participant's country of birth grouped by geographic regions 
Region of Birth Canberra Townsville Overall 
Australia 77 (70.0%) 82 (73.2%) 159 (71.6%) 
New Zealand 3 (2 .7%) 3 (2 .7%) 6 (2.7%) 
Northern Europe (including UK) S (4.S%) 8 (7.1%) 13 (5 .9%) 
Central or Southern Europe 1 (0.91%) 2 {1.8%) 3 (1.3%) 
South Asia 4 (3.6%) 3 (2.7%) 7 (3.1%) 
South East Asia 11 (10.0%) 3 (2.7%) 14 (6.3%) 
East Asia 3 (2.7%) 1 (0.91%) 4(1.8%) 
Middle East 1 (0.91%) 2 (1.8%) 3 (1.3%) 
Africa 1 (0.91%) 1 (0.91%) 2 (0.91%) 
North America 3 (2.7%) 5 (4.5%) 8 (3.6%) 
Central / South America 0(0%) 2 (1.8%) 2 (0.91%) 
Pacific 1 (0.91%) 0 (0%) 1 (0.45%) 
The ethnicity of participants based on nomination of their parent's ethnic background was also 
diverse. Table 6.4 shows the maternal and paternal ethnic groups based on the question -
"What is your parent's ethnic origin (that is, the place where most of their ancestors came 
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from)?" Townsville participants had a statistically higher proportion of mothers with northern 
European ethnicity. 
Table 6.4: Ethnic Group of Participant's Mother and Father 
Mother Father 
Ethnic group Overall Canberra Townsville Overall Canberra Townsville 
n (%) n (%) n(%} n (%) n (%} n (%) 
Northern European 168 (75.7) 77 (70.0) 91 (81.3)* 164 (73.9) 78 (70.9) 86 (76.8) 
Central/Southern European 10 (4.5) 5 (4 .6) 5 (4.5) 18 (18. 1) 6 (5.5) 12 (10.7) 
Pacific Islander/ATS!# 5 (2.3) 0 (0) 5 (4.5) 3 (1.4) 0 (0) 3 (2.7) 
South Asian 13 (5.9) 9 (8.2) 4 (3.6) 12 (5.4) 8 (7.3) 4 (3.6) 
South East Asian 12 (5.4) 9 (8.2) 3 (2.7) 10 (4.5) 8 (7.3) 2 (1.8) 
East Asian 12 (5.4) 9 (8.2) 3 (2.7) 12 (5.4) 9 (8.2) 3 (2.7) 
Middle Eastern 2 (0.91) 1 (0.91) 1 (0.91) 2 (0 .9) 1 (0.9 1) 1 (0.91) 
African 0 (0) 0 (0) 0 (0) 1 (0.45) 0 (0) 1 (0.91) 
#ATSI -Aboriginal or Torres Strait Islander *Signifi ca nt at p <0.05 using x' t est 
For data analysis where the ethnicity of participants was exa mined, it was useful to ca tego rise 
participants into ethnic groups w here both parents shared the sa me ethnicit y. Overall , 198 
participants (89.2% of all participants) had common parental ethnicity (Table 6.5) . Only the 
proportion of participants w ith south-ea st Asian parents was significantly different betwee n 
sites. The majority of parti cipants had both parents wi th northern Europe ancestry (156/222 = 
70. 3%). 
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Table 6.5: Participants with common parental ethnicity 
Ethnic group Canberra Townsville Overall 
n{%) n{%) n{%) 
Northern European 73 (73 .7) 83 (83.4) 156 (78.9) 
Central /Southern European 3 (3.0) 4 (4.0) 7 (3.5) 
Pacific Islander or ATSI# 0 (0) 2 (2.0) 2 (1.0) 
South Asian 8 (8.1) 4 (4.0) 12 (6.1) 
South-east Asian 8 (8.1) 2 {2.0)* 10 (5 .1) 
East Asian 7 (7.1) 3 (3.0) 10 (5.1) 
Middle Eastern 0 (0.0) 1 (1.0) 1 (0.5) 
Total 99 (100) 99 (100) 198 (100) 
#ATSI -Aboriginal or Torres Strait Islander 
*Significant at p <0.05 using Fisher's exact test 
6.1.4 Education and Employment 
Canberra participants were significantly more likely to have a Bachelor degree or post-
graduate qualification compared with Town svi lle participants (82% vs. 39%; p<0.001) (Table 
6.6) . Almost half ofTownsville's participants had the Higher School Certificate as their highest 
educational qualification. 
Table 6.6: Highest educational qualification attained 
Highest Educational Qualification Canberra Townsville Overall 
attained n(%) n(%) n(%) 
High school (not including Year 12) 1 (0.91) 2 (1.8) 3 (1.4) 
Higher school certificate (Year 12) 12 {10.9) 54 {48.7)*** 66 {29.9) 
Trade/ Apprenticeship 1 (0.91) 3 (2 .7) 4 (1.8) 
Certificate or Diploma 6 (5.5) 8 (7 .2) 14 (6.3) 
Bachelor's Degree 54 (49.1) 27 (24.3)*** 81 (36.7) 
Postgraduate degree 36 (32.7) 17 (15.3)** 53 {24.0) 
** Significant at p < 0.01 *** Significant at p < 0.001 using x' 
Table 6.7 displays the occupations of participants, with students and professionals constitu ting 
the majority. There were significantly more professionals enrolled at the Canberra sites and 
students at the Townsville site. 
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Table 6. 7: Occupation held for longest period 
Occupation Canberra Townsville Overall 
n(%) n(%) n(%) 
Student 49 (44.6) 70 (62.5)** 119(53.6) 
Manager or administrator 9 (8.2) 4 (3.6) 13 (5 .9) 
Professional (e.g. engineer, doctor, teacher) 46 (41.8) 22 (19.6)*** 68 (30.6) 
Tradesperson (e.g. Carpenter, electrician) 1 (0.9) 5 (4.5) 6 (2.7) 
Clerk (e.g. typist, receptionist, data processor) 3 (2.7) 5 (4.5) 8 (3.6) 
Salesperson or personal service worker 0 (0) 3 (2.7) 3 (1.4) 
Member of defence force 2 (1.8) 1 (0.9) 3 (1.4) 
Other 0 (O) 2 (1.8) 2 (0.9) 
** Significant at p < 0.01 *** Signifi ca nt at p < 0.001 using x2 
Table 6.8 shows the employment status of participants on enrolment into the study. The 
majority of participants were either working full-time or enrolled in studies, with differences 
between sites consistent with previous data . 
Table 6.8: Current employment status 
Current employment status Canberra Townsville Overall 
n(%) n(%) n(%) 
Unemployed 0 (0) 4 (3.6) 4 (1.8) 
Home duties 0 (0) 1 (0.9) 1 (0.S) 
Part-time work 13 (11.8) 23 (20.5) 36 (16.2) 
Full-time work 68 (61.8) 35 (31.3)*** 103 (46.4) 
Student 29 (26.4) 47 (42.0)* 76 (34.2 ) 
Other 0 (0) 2 (1.8) 2 (0.9) 
* Significant at p <0.05 ** * Significant at p < 0.001 using x2 
Table 6.9 shows the proportion of participants ' occupations described as being mainly indoors, 
outdoors or half-indoors/ half outdoors vocations. The vast majority of participants described 
their occupation as being 'mainly indoors'; however, there were some significant differences 
between study sites. Townsville participants had a greater proportion of occupations 
described as "half indoors/ half outdoors", and lower proportion of occupations that were 
"mainly indoors" compared with Canberra participants. 
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Table 6.9: Indoor - outdoor occupation status 
Indoor - outdoor status of current occupation Canberra Townsville Overall 
n(%) n(%) n(%) 
Mainly indoors (e.g. office worker) 104 (94.6) 93 (83.0)** 197 (88.7) 
Half indoors and half outdoors (e.g. Physical ed. teacher) 5 (4.6) 16 (14.3)* 21 (9.5) 
Mainly outdoors 1 (0.9) 3 (2.7) 4 (1.8) 
* Significant at p<0.05 ** Significant at p< 0.01 using x' test 
6.1.5 Income level 
Table 6.10 shows the average personal income (before tax) from all sources. Consistent with 
the above data, Canberra participants reported significantly higher incomes than Townsville 
participants, reflecting the differences in education levels and occupations. 
Table 6.10: Personal income before tax• 
Personal annual income Canberra Townsville Overall 
before tax n(%) n(%) n(%) 
low (<$30K) 30 (28.3%) 68 (61.2%)*** 98 (45.2%) 
Middle ($30K - $70k) 34 (32 .1%) 26 (23.4%) 60 (27.6%) 
High ($>70K) 42 (39.6%) 14 (12.6%)*** 56 (25 .8) 
# Based on 214 responses; ***Significant at p< 0.001 using x' test 
6.1.6 Suitability for enrolment 
Enrolment for the AusUVI Study was conditional on meeting the inclusion and exclusion 
criteria. Inclusion criteria were based on age (18 -40 years inclusive) and self-report of good 
health. Section 6.1.1 shows data confirming all participants met the age criteria. Table 6.11 
shows data of participants' self-rating of "general health over the past month" . All participants 
reported fair to excellent recent health, and this was consistent across sites. 
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Table 6.11: Participant self-report of general health over previous month 
General health over past Canberra Townsville Overall 
month n(%) n(%) n(%) 
Excellent 32 (29.4) 29 (26.1) 61 (27.7) 
Very good 52 (47.7) so (45.1) 102 (46.4) 
Good 21 (19.3) 28 (25.2) 49 (22.3) 
Fair 3 (3 .7) 4 (3.6) 8 (3.6) 
Poor or Very poor 0 (O) 0 (O) 0 (O) 
There were a number of exclusion criteria for this study (See Table 5.6). At enrolment, no 
participants met exclusion criteria (although a small number were required to delay their entry 
into the study because of recent infection or medication). 
Although participants reported having had no infection over the past 30 days prior to 
enrolment, a number did report infections in the previous three months (Table 6.12) . 
Table 6.12: Reported infections over the past three months prior to entry into the study 
Infection site (number of responses) Canberra Townsville Overall 
n(%) n(%) n(%) 
Upper respiratory tract (n=217) 41 (38.3) 47 (42.7) 88 (40.6) 
Gastrointestinal (n=214) 10 (9.5) 10 (9.2) 20 (9.4) 
Skin or nail (n=214) 10 (9 .5) 12 (11.0) 22 (11 .2) 
Urinary or genitourinary (n=213) 1 (1) 9 (8.2) 10 (4.7) 
Other 2 (2.4) 6 (S.9) 8 (4.3) 
No participants reported suffering from any chronic heart, kidney or liver condition. Seven 
participants reported 'chronic respiratory illness' whose aetiology was not specified, though in 
most this represented asthma that did not require inhaled or oral steroids at the time of, or in 
the lead up to, the study. Three participants reported a diagnosis of coeliac disease . 
To support the self-report of "good health" at time of enrolment, a number of screening blood 
tests were performed at Visit 2 (the day of immunisation), that aimed to detect inflammatory 
states (indicative of active infection or inflammation), diabetes and chronic kidney or liver 
disease. 
In this study, the markers used to detect clinically significant inflammation were (-reactive 
protein (CRP) and white cell count (and differenti?I). Local laboratories were used at the two 
study sites -ACT Pathology at Canberra Hospital and Queensland Pathology Service at 
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Townsville Hospital. This led to the potential for variation in test results due to differences in 
methodology, reagents and equipment. However, both laboratories were accredited under 
the National Association of Testing Authorities {www.nata .com.au) and were mandated to 
undertake quality control testing. As the reference ranges reported by these labs were similar 
for these tests, the results between sites were compared directly for the purposes of screening 
participants for eligibility. The results are summarised in Table 6.13. 
Table 6.13: C-reactive protein, white cell count, lymphocytes and neutrophils 
Laboratory Test N Mean Median SD Range Number of 
(Reference range) participants 
above 
reference 
range 
(-reactive protein (<10 mg/LI 220 2.7 1 6.2 0.2-77.0 10 
White cell count 222 6.4 6.1 1.6 3.4-12.9 3 
(4.0-11.0xlO'/L) 
For participants with CRP levels above the reference range {n=lO), the mean and median were 
22 .lmg/L and 12.Smg/L respectively. Graph 6.2 plots CRP against WBC to identify participants 
where both inflammatory marker tests were raised . 
Graph 6.2: Scatterplot of C-reactive protein vs. white cell count 
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One participant (Study ID 543) had both (-reactive protein and white cell count above the 
reference range. This participant, a female non-smoker on the oral contraceptive pill, rated 
her health over the past one month as "very good" and reported no infections in the previous 
three months and no history of chronic illness. Symptoms of inflammation or infection were 
not reported at subsequent visits. Participant 180 had a markedly elevated (-reactive protein 
(77mg/L). This was attributed to an accident several days prior to the blood test where an 
injured ankle was sustained. Again there was no evidence of recent infection on history, or 
evident at subsequent visits. 
Previous studies have shown an association between increased BMI and raised inflammatory 
markers, supporting evidence that obesity con fers a state of low grade inflammation (485). 
There is a moderate positive association between (-reactive protein and BMI in the AusUVI 
Study population also (r=0.33; p<0.001). Notably, participants 543 and 180 both recorded BMI 
readings in the obese range. 
Analysis of random blood glucose level (BGL) readings for all participants did not show any 
individual with overt hyperglycaemia that would warrant additional testing for diabetes 
mellitus (i.e. with random BGL > 7.8mmol/L). One participant had an elevated serum 
creatinine level (114 µmol/L) . However, this was explained by this participant's high muscle 
mass (he was a rugby player, weighing 95kg). Additionally, he had a non-elevated se rum urea 
level (7.8mmol/L), another marker of renal function. 
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6.1.7 Summary 
Two hundred and twenty two participants were recruited into the AusUVI Study over a 13 
month period. Approximately two thirds of vo lunteers were women. The Townsville 
participants differed from their Canberra counterparts in the following ways - they were 
generally younger, had attained lower educational qualifications, were on lower incomes, and 
comprised a higher proportion of students and workers involved with non-indoors 
employment. Over three-quarters of participants were of northern European heritage, whilst 
the others were of very varied ethnic backgrounds. All participants self-reported as being 
healthy, however a small proportion had blood tests at baseline suggesting underlying 
inflammatory activity, the aetio logy of which was uncertain in most cases but may be related 
to obesity. 
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6.2 Potential confounding factors and biologically relevant variables 
6.2.1 Measures of nutrition 
There were no participants with evidence of moderate or severe hypoalbuminaemia which 
may indicate protein-energy malnutrition or an inflammatory state (mean 43.4 g/L; range 35 -
52 g/L)) (486). Participants' body mass index (BMI) values were similar across sites (see Table 
6.14). Canberra had a higher proportion of participants in the overweight category than 
Townsville, based on BMI measurements. 
Table 6.14: Measures of nutrition 
Measure of Canberra Townsville Overall 
nutrition 
Mean 24.0 24.3 24.2 
Body Mass Median 23 .6 22.8 23 .3 
Index 
Range 17.8-33.6 17.0-53.4 17.0-53.4 
(kg m·2) Standard deviation 3.3 5.3 4.4 
Underweight (<18.S) 3 (2.7%) 1 (0.9%) 4 (1.8%) 
BMI by Normal weight (18.5 -24.9) 66 (60.0%) 75 (67 .0%) 141 (63.5%) 
category Overweight 12s -29.9) 3S (31.8%) 22 (19.6%)* 57 (25.7%) 
Obese (>30) 6 (5.5%) 14 (12.5%) 20 (9.0%) 
* Significant at p < 0.05 using x' test ** * Significant at p < 0.001 using t-test 
6.2.2 Smoking 
Data regarding smoking habits of participants are shown in Table 6.15. A higher proportion of 
males than females were "current smokers" although this was not stati stically significant (10% 
VS. 3.5%, p=0.07). 
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Table 6.15: Proportion of participants who were active or past smokers 
Category of smoker Canberra, n (%) Townsville, n (%) Overall n (%) 
Have ever been a regular 15 (13.6%) 20 (18.0%) 35 (15.8%) 
smoker (221 responses) 
Current regular smoker 5 (4.5%) 8 (7.1%) 13 (5.8%) 
(222 responses) 
6.2.3 Exercise and physical activity 
Physica l activity status of participants was assessed by the International Physical Activity 
Questionnaire - Short Form (IPAQ-SF) (see Section 5.2.1.2). The IPAQ-SF assessed activity in 
three domains: walking, moderate-intensity and vigorous-intensity activities. Based on recall 
of activities during the previous week, a continuous score was derived for each domain based 
on that activity's " metabolic equivalent" (measure of intensity), number of active sessions per 
week and number of minutes spent per session. An overal l activity categorica l score - low, 
moderate or high - was also obtained, based on the continuous score and/or number and type 
of activities engaged in. Table 6.16 shows the categorical data for the AusUVI Study 
participants with comparisons made between relevant groups. "High activity" constituted the 
greatest proportion of participants in each comparator group. There were significantly more 
participants in the low activity group from Canberra compared with Jownsville. There was no 
stat istical association between age and activity score (data not shown). 
Table 6.16: IPAQ-SF Categorical scores: comparison by site, sex and body mass index 
Site Sex BMI 
Activity category Overall Canberra Townsville Male Female <25 ~25 
Low 14 (6.3) 12 (10.9) 2 (1.8)** 5 (6.3 ) 9 (6.4) 6 (4.2) 8 (10.3) 
Moderate 72 (32.6) 38 (34.6) 34 (30.6) 22 (27.5) 50 (35 .7) 48 (33 .3) 24 (31.2) 
High 135 (61.0) 60 (54.6) 75 (67.6) 53 (66.3) 81 (57.9) 90 (62.5 ) 45 (58.4) 
•• Significant at p <0.01 using Fisher's exact test 
156 
6.2.4 Psychological state 
Aspects of psychological states were assessed by validated questionnaires - Profile of Mood 
States and Mental Health Inventory. 
Profile of Mood States 
Table 6.17 shows data for the different domains measured by the Profile of Mood States 
(POMS) questionnaire, as wel l as the overall global index score 'Total Mood Disturbance' 
(TMD). There was no statistical difference evident between study sites, or according to gender 
or age groups (compa ring younger with older participants) with regard to the TMD score (using 
t-tests) . 
Table 6.17: Profile of Mood States: Sub-scores and global indices 
Site Gender Age 
M ean score (SD) Mean score (SD) Mean score (SD) 
POMS scale Overall Canberra Townsville Male Female <Median 2:Median 
(n=219) (n=108) (n=lll) (n=79) (n=139) age age 
(27.3yrs) (27.3yrs) 
(n=llO) (n=l09) 
Subscale scores 
Tension-anxiety 2.8 (3.3) 3.0 (3.6) 2.4 (3.0) 2. 70 (3.2) 2.9 (3.4) 3.2 (3.9) 2.4 (2.5) 
Oepression•dejection 1.5 (2.5) 1.4 (2.5) 1.5 (2.5) 1.24 (2.1) 1.6 (2.7) 1.3 (2.13) 1.6 (2 .8) 
Anger-hostility 0.9 (1. 9) 1.01 (1.9) 0.86 (1.9) 0.91 (1.8) 0.9 (2.0) 0.88 (2.0) 0.98 (1.8) 
Fatigue-inertia 4.3 (3.9) 4.4 (4.3) 4.2 (3.6) 4.41 (3.9) 4.2 (4.0) 4.2 (3.9) 4.3 (4.0) 
Vigour-activity 10.5(5.0) 10.5 (5.2) 10.5 (5.2) 11.3 (4.6) 10.1 (5.1) 11.2 (5.0) 9.9 (4.8) 
Confusion- 2.5 (2.5) 2.4 (2.4) 2.7 (2.5) 2.49 (2.5) 2.6 (2.5) 2.8 (2.7) 2.3 (2.2) 
bewilderment 
Total Mood 1.5 (13.4) 1.3 (13.0) 1.7 (13.8) 0.49 (11.7) 2.1 (14.3) 1.2 (14.1) 1.8 (12. 7) 
Disturbance • 
* NB: Range of scores: -20 to 56; Median -1 
Mental Health Inventory 
Table 6.18 displays data from the Menta l Hea lth Inventory (MHI) questionnaire . There are six 
sub-scale scores (higher scores indicating more of the construct described by the sub-sca le 
name), two global sca les indicating the degree of psychological distress (higher sco res 
indicating greater distress) or psychologica l well being (higher scores indicating greater 
wellbeing), and a globa l mental health index score with higher scores indicating greater 
psychological wel lbeing and relatively less psychological distress. 
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Statistically different global scores were noted according to gender, with females scoring 
higher overall distress, lower overa ll we llbeing and lower overa ll index score compared with 
males. There was no statistical difference in global indices between younger and older 
participants, or by study site. 
Table 6.18: Mental Health Inventory: Sub-scores and global indices 
Site Sex Age 
Mean score (SD) Mean score {SD) Mean score (SD) 
MHI sub-scales Overall Canberra Townsville Male Female <Median ~Median 
and global (n=219) (n=108} (n=lll) (n=79) (n=l39) age age 
indices (27.3yrs) {27.3yrs) {n=ll0) (n=109) 
Sub-scale scores 
Anxiety 20.0 (5.7) 20.1 (5.2) 19.9 (6.2) 18.4 (5.0) 21.0 (5.9) 20.2 (5.8) 19.8 (5.7) 
Depression 8.1 (2.5) 8.2 (2 .6) 8.0 (2 .5) 7.5 (2.1) 8.4 (2.7) 7.9 (2.4) 8. 3 (2.6) 
Loss of behavioural 
and Emotional control 15.7 (4.7) 15.9 (5.0) 15.5 (4.5) 14.1 (3.5) 16.6 (5.1) 15.7 (4.3) 15.8 (5 .2) 
General Positive 40.9 (7.1) 40.7 (6.8) 41.1 (7 .5) 42.2 (6.4) 40.l (7.4) 41.8 (6.8) 40.0 (7.4) 
affect 
Emotional ties 9.0 (2.4) 9.2 (2.4) 8.8 (2 .4) 9.1 (2.5) 9.0 (2.3) 9.0 (2.3) 9 .1 (2.5) 
Life satisfaction 4.3 (1.0) 4.2 (1.0) 4.4 (1.0) 4.4 (0.92) 4.2 (1.0) 4.4 (1.0) 4.2 (1.0) 
Global indices 
Overall Distress 49.2 49.5 49.0 45.0 51.6*** 49.2 49.3 
(12.8) (12.5) (13 .1) (10.5) (13.5) (12.2) (13.5) 
Overall-Wellbeing 58.3 58.2 58.4 60.0 57.3* 59.4 57.2 
(10.0) (9.6) (10.4) (9.0) {10.4) (9.4) (11.0) 
Global mental 167.8 166.8 168.7 172.0 165.3*** 169.4 166.1 
health score (23.1) (25.0) (21.2) (25.8) (21.2) (19.5) (26.2) 
Statistical testing for global scores only and assessed by t-test: * p<0.05 * * * p<0.001 
Consistency of questionnaires in measuring similar psychological constructs 
To check agreement between the POMS and MHI questionnaires for the various sub-scale and 
global measures of similar psychologica l constructs, a correlation matrix was constructed . It 
showed a strong correlation between the MHI global mental health score and POMS TMD 
(r=-0.60; p<0.0001); moderate correlation between MH I overall wellbeing score and POMS 
vigour-activity subscale (r=0.44; p<0.0001); and moderate to strong correlation between MHI 
overall distress score and all POMS sub-scales (excluding vigour-activity) (all r>0.40; p<0.0001). 
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6.2.5 Skin phototype and spectrophotometry measurements 
Skin Phototype 
Table 6.19 details the Fitzpatrick skin phototype for AusUVI Study participants based on 
questionnaire responses and observation of skin, eye and hair characteristics. Using an ordinal 
logistic regression model, there was a statistical difference in the proportion of skin 
phototypes amongst participants between study sites (p=0.033). 
Table 6.19: Fitzpatrick phototype classification 
Fitzpatrick Description Canberra Townsville Overall 
Skin 
Phototype 
I White skin, burns easily, never 3 (2.7%) 4 (3.6%) 7 (3.2%) 
tans, red/blonde hair 
II Fair, burns easily, tans minimally 35 (31.8%) 45 (40.2%) 80 (36.0%) 
with difficulty 
Ill Burns moderately, tans 42 (38.2%) 48 (42.9%) 90 (40.5%) 
moderately and uniformly 
IV "Mediterranean Complexion" 20 (18.2%) 9 (8.0%) 29 (13.1%) 
Burns minimally, tans moderately 
and easily 
V Rarely burns, tans profusely, 10 (9.1%) 6 (5.4%) 16 (7.2%) 
South Asian complexion 
VI Black skin, never burns, tans 0 0 0 
profusely 
Spectrophotometry readings 
Skin reflectance readings were taken of the left upper inner arm (to represent non-sun 
exposed skin) and left upper cheek (to represent sun exposed skin). Previous work (see 
Section 5.5.4) has shown that the difference in measured reflectance at 400 and 420nm 
wavelengths correlates with cutaneous melanin density (a technique validated in participants 
of northern European descent) (476) . 
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Estimate of cutaneous melanin density was derived using the following equation: 
Melanin density (MD}400 = 100 x (0.035307 + 0.009974 (R420 - R400 ) 
Where: MD400 = estimate of the percentage of epidermis containing melanin 
R = reflectance at the specified wavelength 
Calibration and error checking of spectrophotometry readings 
Skin reflectance readings were taken by a single researcher at each study site using a 
spectrophotometer of the same model type. Three readings were taken at each anatomic site 
and averaged (or repeated if the readings differed by more than 1% in skin reflectance). Inter-
rater reliability testing was undertaken in two ways. At three of the four study investigator 
meetings (November 2010, March and July 2011), both spectrophotometers were tested on a 
set of coloured 'swatch' fabrics (black, pink, "fair" skin colour, off-white, white) to assess 
consistency of results. Calibration readings were also taken on 'test ' individuals using both 
spectrophotometers. 
Graph 6.3a shows the difference in reflectance measurements (420nm -400nm) between 
spectrophotometers (Canberra meter - Townsville meter) against the average of reflectance 
measurements for each of the swatch colours. The difference between meters was relatively 
small in proportion to the average meter reading. The bias towards higher Canberra meter 
readings for pink, skin colour and white swatches were considered not clinically significant, and 
hence no correction was made for later participant re;idings. 
Graph 6.3a: Level of agreement between spectrophotometers - coloured fabric 
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Graph 6.3b and 6.3c show the difference in reflectance measurements (420nm - 400nm) 
between spectrophotometers (Canberra meter- Townsville meter) against the average of the 
reflectance measurements for 12 volunteers, for the inner arm and left cheek, respectively. 
The central red line represents the average difference between spectrophotometers and the 
two outer lines represent 95% confidence limits. The graphs show that mean difference 
between meters was close to zero at both anatomical sites, and there was no bias in the 
distribution of data points above or below zero (i.e. point of no difference) . This calibration 
study (albeit with limited numbers) supported the use of the spectrophotometers at each site, 
with no correction of raw measurements required. 
Graph 6.3b: level of agreement between spectrophotometers - volunteers' inner arms 
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Graph 6.3c: level of agreement between spectrophQtometers - volunteers' cheeks 
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Reflectance measurements were assessed for potential errors. If variation between 
reflectance measurements at a particular anatomical site (i.e. cheek or inner arm) for an 
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individual over the three study visits was high (defined as a standard deviation of >1% 
reflectance), data for that participant were reviewed - and removed if a particular reading was 
clearly erroneous (based on the other arm and cheek readings) . Using this method, 8 (1.5%) of 
readings were deleted from the cheek data (Visit 1: participant 166, 506; Visit 2: 111, 135, 509, 
571, 574; Visit 3: 208). For the inner arm, only two data points (<0.4%) were removed -Visit 1: 
participant 146; and Visit 2: 151. 
Skin reflectance results for AusUVI Study participants 
Table 6.20 displays the calculated melanin density data from spectrophotometer readings for 
all participants for each study visit by anatomical site. The data were normally distributed and 
there was no significant difference in readings between visits taken at a given site. As 
expected, the estimated cutaneous melanin density was higher at the cheek compared with 
the inner arm (p<0.0001 for all visits). As Visit 2 had the most data points, Visit 2 was used for 
all subsequent analyses. 
Table 6.20: Estimated cutaneous melanin density from spectrophotometer readings by study 
visit and anatomical site 
Site of Estimated melanin Visit 1 Visit 2 Visit 3 
measurement concentration 
n 216 220 215 
Left upper inner Mean (SD)% 3.30 (1.27) 3.30 (1.29) 3.29 (1.26) 
arm 
Range(%) -0.44- 5.6 -0.54- 5.4 -0.02- 5.6 
n 215 216 212 
Left cheek Mean (SD)% 3.88 (0.78) 4.01 (0.78) 3.92 (0.78) 
Range(%) 1.06-6.32 1.07-5.83 1.06-6.56 
As cutaneous melanin density is related to environmental and genetic factors, the next section 
assesses cutaneous melanin density in relation to ethnicity and environment. Graph 6.3 shows 
the distribution of estimated melanin density by ethnic group (where participants have 
common parental ethnicity). 
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Graph 6.3: Estimated melanin density distribution by common parental ethnicity 
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Graph 6.4 shows the strong relationship between constitutive skin pigmentation as measured 
by estimated melanin density (from skin reflectance) at the inner arm and Fitzpatrick skin 
phototypes. 
Graph 6.4: Estimated cutaneous melanin density by Fitzpatrick skin phototype -
measurements taken from left upper inner arm 
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6.2.6 Vitamin D status 
Vitamin D supplementation 
Although the majority of vitamin Dis derived from UVR-induced cutaneous synthesis, oral 
supplementation also contributes (see Section 1.2.5). Table 6.21 shows the number of AusUVI 
participants who reported taking vitamin D supplementation at the time of study enrolment. 
Table 6.21: Participant report of vitamin D (cholecalciferol) supplementation 
Type of supplementation Average vitamin D Number of Participants 
content (%) 
No supplementation - 159 (71.6%) 
Vitamin D supplements(+/- Calcium) 400- lO00IU 8 (3.6%) 
Multivitamins 200- 400IU 52 (23.4%) 
Cod liver oil 130IU* 3 {1.4%) 
* http ://www. vitamin herbu n iversity.com/topic.asp ?categoryid=3&topicid=l 108 
There was no sex difference in the proportion taking vitamin D supplementation (males 29 .6% 
vs. females 27.7%; p=0.83). There was no seasonal variation in vitamin D supplementation 
(winter 31.6%; spring 2S .0%; summer 30.0%; autumn 25.9%; p=0.83). 
Serum 25-hydroxyvitamin D levels 
Quality control 
Serum 25-hydroxyvitamin D (25(OH)D) levels were obtained from blood taken at study Visits 2 
and 4 (i.e. 21 days apart). 
Quality control (QC) samples analysed with AusUVI Study samples passed internal laboratory 
benchmarks- i) the coefficient of variance for each QC level for 2S(OH)D3 did not exceed 6.9%; 
and ii) the mean QC determinations for each QC level fell within the upper and lower limits of 
the RDDT historical database for the corresponding QC lot numbers. 
In addition, 30 duplicate samples were included with participant samples, coded such that 
laboratory staff were blinded to their purpose. To assess the " repeatability of the assay", the 
methodology advocated by Bland and Altman (1986) was used. Essentially, the differences 
between assay readings for two duplicate samples (which should be at or close to zero, with 
no variation across the range of measurements) were plotted against the mean of the 
duplicate 25(OH)D results . For a test to be regarded as having adequate " repeatability", 95% 
of measurements should fall within two standard deviations of the average difference in 
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duplicate samples. Graph 6.5 shows these data plotted . As only one duplicate (out of 30) fell 
outside the 95% confidence interval, the assay was deemed to have acceptable repeatability. 
Graph 6.5: Difference in ZS(OH)D level between duplicate tests plotted against mean of the 
duplicate tests. 
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AusUVI Study participants' results 
Graphs 6.6 and 6.7 show the serum 25(OH)D result (at Visit 2) for each participant by day of 
their enrolment, where July 14, 2010 was day 1, and day 385 was the last day of enrolment 
which occurred in August 2011. The level of serum 25(OH)D 'sufficiency' is indicated on the 
graphs at 50nmol/L. Table 6.22 shows the serum 25(OH)D data by season and site for Visit 2 
(Day 8) and Visit 4 (Day 29). 
There was a sinusoidal seasonal variation in 25(OH)D levels across both sites of enrolment 
(summer> autumn> spring > winter). The amplitude of the seasonal change in 25(OH)D levels 
from winter to summer was most pronounced for Canberra participants. The difference in 
25(OH)D levels over the 21 days between Visit 4 and Visit 2 was most pronounced in spring 
(~+3 nmol/L) and autumn (~-4 nmol/L) seasons reflecting the direction of ambient UVR 
changes occurring during these periods. 
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Graph 6.6: 25(0H)D level at Visit 2 by day of enrolment for Canberra participants 
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Graph 6.7: 25(0H)D level at Visit 2 by day of enrolment for Townsville participants 
Townsville: Serum 25(0H)D level 
By season 
• ~ ~ I 
• 
• ~ • • • • .: • • 0 • • • .. • E o • I • • • • • ,So • • 
- ·•- • - ~ • Q) . > 
'· 
., . 2 • • • 9.. • • • • • • • 25 0 • • • • .. :. • ~ ID . 
ID 
I 
• N • 
Winter Spring Summer Au tumn Winter 
0 -l,-
0 100 200 300 400 
Day of enrolmen t 
Locally weighted smoothing function 
166 
Table 6.22: Serum 25(OH)D level (nmol/L) by season and study visit (mean, SD, range) 
Canberra Townsville Overall 
Season Visit 2 Visit4 Visit 2 Visit4 Visit2 Visit4 
Winter 39.7 (20.1 ) 39.3 (18.6) 80.0 (20.9) 81.4 (20.5) 65.7 (28.3) 66.6 (28.2) 
8.7 - 83.1 6.0 - 75 .8 36.5 - 120.6 38.4 - 116.9 8.7 - 120.6 6.0 - 116.9 
Spring 63.7 (20.7) 66.3 (19.1) 92.8 (25.2) 95.0 (23. 1) 73.8 (26.1) 76.5 (24.6) 
23.5 - 94.5 29.8 - 93.3 48.0 - 137.6 45.9 - 134.5 23.5 - 137.6 29.8 - 134.5 
Summer 82.1 (19.8) 81.6 (19.7) 97.9 (24.9) 98.1 (24.0) 90.0 (23.6) 89.4 (23.1) 
41.8 - 119.8 45.5 - 119.0 58.4 - 163.2 65.3 - 164.6 41.8 - 163.2 45.5 - 164.6 
Autumn 76.2 (32.6) 71 .4 (31.7) 93.7 (26.9) 89.7 (26.3) 84.1 (31.1) 79.9 (30.5) 
30.7 -195.8 26.9 - 184.6 54.2 - 149.9 43.5 - 150.7 30.7 - 195.8 26.9 - 184.6 
Table 6.23 shows the proportions of participants by vitamin D status (categorised according to 
recent guidelines). Over 95% of Townville participants were categorised in the vitamin D 
'sufficient' or 'optimal ' range, compa red w ith 69% from Canberra (p<0.0001). Of note, 56% 
(19/34) of Canberra participants with vitamin D deficient/mildly deficient status (i .e. 25(OH)D 
<50nmol/L) were enrolled in the win ter months. 
Table 6.23: Vitamin D status by category* 
Vitamin D status Canberra Townsville Overall 
(Range of 25(OH)D levels**; nmol/L) 
Deficient(< 25) 6 (5 .5) 0 (O) 12 
Mildly deficient (~ 25 - SO) 28 (25.5) 5 (4.5) 33 
Sufficient (~50 - 75) 39 (35.5) 31 (27.7) 70 
Optimal (~ 75) 37 (33.6) 76 (67.9) 113 
*Source for definition of categories for vitamin D status: (488); ** Mean of 25(OH)D level from 
Visit 2 and 4. 
There were also marked differences in 25(OH)D levels between participants of different ethnic 
backgrounds which may be related to sk in pigmentation, and/or dietary and behavioura l 
factors. Participants with common northern European parental ethnicity had a serum 25(OH)D 
level 17.2nmol/L higher t han those with non-northern European parents (p<0.001) (adjusted 
fo r season and site). 
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6.2.7 Summary 
This section examined participant characteristics that may also affect the immune response to 
immunisation. Approximately two-thirds of participants were in the " normal" weight range as 
defined by BMI, with one-third categorised as overweight or obese. A small proportion of 
participants were current cigarette smokers . The majority of participants were classed as 
being in the moderate to high physical activity categories. The Mental Health Inventory 
demonstrated gender differences in global indices of distress, well-being and overall mental 
health, with females scoring higher in the distress constructs of the various scales. Assessment 
of Fitzpatrick skin phototypes showed the majority of participants were of "Caucasian" skin 
type (Phototype 1-111). There were a higher proportion of Canberra participants with skin 
phototypes IV and V compared with Townsville participants. Higher cutaneous melanin 
density (as estimated by skin reflectance measurements) was demonstrated: i) at the cheek 
compared with the inner arm for those of European ethnicity, ii) in participants of non-
European parentage compared with European parentage; and iii) in participants with higher 
skin phototypes. Finally, serum 2S(OH) levels showed marked seasonal variation, particularly 
amongst Canberra participants. Differences in serum 25(0H)D levels were also demonstrated 
according to ethnic group. 
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6.3 UVR exposure 
Participants' level of UVR exposure during the study was measured in several ways. Short-
term UVR exposure was measured using i) electronic dosimeter badges worn on the wrist; ii) 
sun diary data; and iii) ambient UVR levels (measured by an outdoor monitor). Cumulative 
UVR exposure over the life-course was measured by taking si licone impression casts of the 
dorsum of the hand to assess degree of actinic damage. 
6.3.1 Electronic dosimeter UVR measurements 
Short-term personal UVR exposure was measured by electronic dosimeters worn on the wrist 
for ten days (with KLH immunisation occurring on the sixth day) with UVR readings taken every 
eight seconds. 
Assessing the performance characteristics of interpolant UVR data 
As described in Section 5.5.2, an interpolation function was used to generate UVR data to 
replace raw data that were missing (e.g. dosimeter not worn or low battery error) or removed 
because of repeats, oscillations or clearly erroneous data. Th e average hourly dosimeter 
measured UVR value was 0.026 SEO. The average hourly interpolant value, where measured 
values were available, was 0.022 SEO. The average daily difference between measured totals 
and interpolated totals on corresponding days was 0.050 SEO, a sma[I difference when 
compared with the average daily measured total of0.38 SEO. 
Graph 6.8 directly compares dosimeter measured data against the interpolation function 
derived value. The graph shows a wide range of interpolated va lues at the lower end of 
measured values (tending to overestimate the measured value); whilst at the higher end, 
interpolated va lues tended to underestimate measured varues. However, there was 
reasonable correlation across the range of intermediate values. 
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Graph 6.8: Direct comparison of measured data and corresponding interpolated values 
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Graph 6.9 shows the frequency distribution of dosimeter measured and interpolated va lues 
(note the logarithmic y-axis scale). Measured and interpolated va lues were clustered in the 
lower UVR range. There were more interpolated than measured values in the lower UVR 
measurement range, whilst there were comparatively more measured values than 
interpolated values in the higher UVR measurement range. 
Graph 6.9: Distribution of interpolated and measured values 
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Graph 6.10 is an example of a participant's dosimeter measured UVR over the ten days of 
measurement (in hours) compared with the corresponding interpolated values . Again, this 
shows the typical overestimation of the interpolant when the measured values were zero or 
very low, and the underestimation in 'spike' areas (high UVR values) of measured data. 
Graph 6.10: Comparison of measured and interpolated UVR values for a typical 
participant 
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Use of interpolated values for AusUVI Study participants 
Interpolated values were used to replace missing or removed measured UVR data only when 
there was less than 20 minutes of measured data for any given hour. Overall, a minority of 
missing measured values were replaced by an interpolated va lue in the final UVR data set 
(Canberra 9.1%; Townsville 5.8%). 
The interpolation algorithm was not able to replace all missing values where there was 
incomplete UVR dosimeter badge data, diary data or insufficient data to be able to generate an 
interpolant using the methods outlined in Section 5.5.2 .1. A straightforward 'imputation' 
method was thus developed to replace additional missing values where there were at least 
eight days (out of ten) of daily UVR data available for each individual. The mean of the 
available data for an individual was simply used to replace the missing daily total , with 
weekdays data averaged for a missing weekday data value, and weekend data for missing 
weekend data value. In this way, 56 participants (25.2% of overa ll participants) had one daily 
UVR exposure imputed and 17 (7.7%) had two daily totals imputed . These imputed values 
were used only when aggregated daily totals were to be analysed (e.g. days 1 to 10) (See also 
Section 7.1.2). Where individual days were analysed, on ly measured plus interpolant data 
were used, cognisant that filling in with further non-directly measured data could adversely 
affect data precision. Figure 6.1 illustrates the algorithm used for generating the personal UVR 
exposure dataset. 
Figure 6.1 Algorithm for determining participant's personal UVR measurements 
Step 1: Interpolated values Step 3: Adjustment for 
generated using diary data clothing based on body 
and clear-skv UVR data surface area covered 
1 1 Direct UVR Final daily 
dosimeter personal UVR 
measurements exposure data 
Step 2: Imputation of remaining missing 
daily values based on average exposure 
on days where complete data available 
(used for aggregated data on ly) 
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AusUVI Study electronic badge measurements 
Graphs 6.11 and 6.12 demonstrate the electronic badge 10-day cumulative UVR exposure 
(measured plus interpolated plus imputed) for Canberra and Townsville participants over the 
N13 month study course. 
Graph 6.11: Electronic UVR badge output with interpolated values: Canberra 
0 
Electron ic badge UVR measurements - Canberra 
10 days cumulative total for each participant 
• 
!;i? I Winter I Spring I Summer I Autumn I W inter 
0 
(") 
~~ ' i:.L • • • I : 
o J I 
• 
-.. -' 
0 
-i • • • • 1• - - • I r' 
0 1 00 200 300 400 
Day from beginning of study 
• Electronic badge measurement over 10 days --- Locally weighted smoothing functi on 
Graph 6.12: Electronic UVR badge output with interpolated values: Townsville 
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Table 6.24 shows the range of cumulative UVR readings by season and site. UVR exposure, as 
directly measured by the electronic badge, varied by season in Canberra and Townsville 
participants. Townsville participants had significantly higher UVR measurements compared 
with Canberra partic ipants in the winter months (5.6 vs. 1.7 SED; p<0.0001), but were not 
significantly different at other times of year. The amplitude of seasonal variation was more 
marked fo r Canberra than Townsvil le participants. Badge measured UVR exposure in Canberra 
participants was significantly lower in winter relative to other seasons (p<0.001). There was no 
statistical difference in badge-measured UVR exposure between seasons for Townsville 
participants. Personal UVR exposure on weekdays was significant ly lower than that 
experienced on weekends (0.16 vs. 0.32 SED per day; p<0.0001). This phenomenon was seen 
at both sites. 
Table 6.24: Seasonal distribution of 10-day cumulative UVR exposure measured by electronic 
badge, adjusted for clothing and by site 
SED (mean, range) 
Season UVR 
Canberra Townsville 
Measure* 
Winter EB 1.7 (0.27 - 6.8) 5.6 (0.48 - 23.6) 
(J une-Aug) 
CA 0.32 (0.04 -1.4) 2.3 (0.13 - 8.5) 
Spring EB 7.4 (0.35 -43 .7) 10.6 (1.3 - 65.9) 
(Sept - Nov) 
CA 2.5 (0.11- 13.6) 3. 7 (0.-58 - 16.8) 
Summer EB 8.4 (2.8 -18.3) 9.3 (0.88 - 29.4) 
(Dec- Feb) 
CA 3.1 (1.5 - 10.1) 2. 7 (0.37 - 8.2) 
Autumn EB 5.3 (0.22 - 21.4) 4.7 (1.2 -12.5) 
(Mar -May) 
CA 1.5 (0.05 - 7.2) 1.8 (0.26 - 5.0) 
Overall EB 5.6 (0.22 - 43. 7) 6.9 (0.48 - 65 .9) 
CA 1.8 (0.04 -13.6) 2.5 (0.13 - 16.8) 
• EB;electronic badge measurement; CA; clothing adjusted measurement 
# t-test of log-transformed distributions 
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p value# 
<0.0001 
<0.0001 
0.87 
0.44 
0.45 
0.26 
0.98 
0.20 
0.15 
0.003 
Overall 
4.2 (0.27 - 23.6) 
1.6 (0.04 - 8.5) 
8.5 (0.35 - 65 .9) 
2.9 (0.11-16.8) 
8.9 (0 .88 - 29.4) 
2.9 (0.37 -10.1) 
5.1 (0.22 - 21.4) 
1.7 (0.05 - 7.2) 
6.2 (0.22 - 65 .9) 
2.1 (0.04 -16.8) 
Graph 5.13 shows the distribution of daily personal UVR exposure for a typical day (in this 
case, the fourth day of wearing the dosimeter) for Canberra and Townsville participants. The 
majority of readings were concentrated around zero (i.e. no UVR exposure); however there 
was a spread of measures, with Townsville participants having a greater range than their 
Canberra counterparts. 
Graph 6.13: Distribution of daily electronic badge measured UVR exposures for a typical day 
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As described in Section 5.5.1, daily personal UVR exposure was derived by multiplying the 
electronic badge UVR data for a given hour by the proportion of the body surface area not 
covered by clothing for that same hour, and summing the total for that day. 
Graphs 6.14 and 6.15 show the seasonal change in clothing-adjusted UVR exposure (over ten 
days) compared with electronic badge measured data for Canberra and Townsville. Table 6.24 
also shows these data by season and by site. On average, clothing-adjusted UVR exposure was 
approximately 1/3 the total electronic-badge measurement, although this ratio changed by 
season and site. Overall, participants from Townsville had a higher clothing-adjusted UVR 
exposure over 10 days compared with Canberra participants (2 .5 vs. 1.8 SED; p=0.003). The 
largest difference between sites occurred in the winter season (Townsville 2.3 vs. Canberra 
0.32 SED; p<0.0001). 
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Graph 6.14: Dosimeter UVR measurement vs. clothing-adjusted UVR dose: Canberra 
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Graph 6.15: Dosimeter UVR measurement vs. clothing-adjusted UVR dose: Townsville 
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6.3.2 Association between UVR exposure and other immunomodulatory variables 
Table 6.25 demonstrates the simple associations between various potential 
immunomodulatory variables and cumulative ten-day clothing-adjusted personal UVR 
exposure adjusted for season of enrolment. Participants with both parents of northern 
European ethnicity had, on average, 86% higher UVR exposure than participants with one or 
both parents of non-northern European ethnicity (p<0.001). Outdoor workers had significantly 
higher ten day UVR exposure than indoor workers. Participants reporting the highest level of 
physical activity in the week prior to wearing the electronic dosimeter had significantly higher 
UVR exposure than those reporting moderate activity (and non-significantly higher than those 
in the lowest activity category). 
The table also shows some inconsistent results in relation to psychological function (as 
measured by the POMS globa l index) and personal UVR exposure. Despite the appearance of 
an association between quartiles of the globa l index scale and UVR exposure, there is no 
consistent pattern across quartiles to suggest a true linear (i.e. dose-response) or non-linear 
association and therefore a statistical Type-I error remains a plausible explanation. 
Vitamin D status was strongly linearly associated with clothing-adjusted UVR exposure. Each 
one unit SED increase in UVR exposure was associated with a rise in serum 25(OH)D of 
3.9nmol/L (95% Cl 2.4 - 5.5; p<0.001) at baseline, and 4.lnmol/L (95% Cl 2.7 - 5.6; p<0.001) at 
21 days-post immunisation, respectively. 
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Table 6.25 : Association between clothing-adjusted UVR exposure and other potential 
immune-modulator variables 
Potential immune Sub-group (n) Mean SED SED Range p value* 
modulators (SD) 
Overall (216) 2.1 (2.4) 0.043 -16.8 
Sex Male (79) 2.2 (2.4) 0.051 - 2.4 0.85 
Female (137) 2.1 (2.4) 0.043 -16.8 
Site Canberra (108) 1.8 (2.2) 0.043 - 13.6 <0.001 
Townsville (108) 2.5 (2.6) 0.13-2.6 
Age (years) 18-24 (83) 2.1 (2.1) 0.051 -11.1 Reference 
25-29 (67) 1.9 (1.9) 0.043 -9.5 0.47 
30 - 34 (31) 2.5 (3.4) 0.074- 16.8 0.83 
35-40 (41) 2.3 (2.9) 0.094-13.6 0.75 
Parental ethnic Northern European (152) 2.5 (2.6) 0.043 -16.8 <0.001 
background Non-Northern European (64) 1.3 (1.6) 0.051 - 10.1 
Indoors/ Outdoors Indoors worker (193) 2.1 (2.4) 0.043- 16.8 Reference 
Worker status Half indoors/ half outdoors (19) 2.3 (1.3) 0.11 -5.10 0.14 
Outdoors worker (4) 5.3 (3. 8) 1.6-9.6 0.038 
Smoking Non-smoker (204) 2.1 (1.5) 0.043 -16.8 0.29 
Current smoker (13) 3.0 (2. 7) 0.31- 6.6 
Body mass index Underweight (3) 1.1 (1.3) 0.13 - 2.6 0.37 
Normal weight (138) 2.2 (2.4) 
- 0.051-16.8 Reference 
Overweight (56) 2.0 (2.3) 0.043 - 9.5 0.37 
Obese (19) 2.1 (2.9) 0.068 -11. 1 0.33 
Psychological Below first quartile score (54) 2.8 (3.0) 0.11-13.6 Reference 
profile: Between 1" & 2°• quartile (62) 1.5 (1.6) 0.043 - 9.5 0.008 
POMS (TMD) Between 2°• & 3•• quartile (SO) 2.3 (2.3) 0.084 -9.6 0.69 
Above fourth quartile (SO) 2.7 (2.6) 0.051- 16.8 0.084 
Psychological Below first quartile score (58) 1.9 (2.7) 0.043 -16.8 Reference 
profile : Between 1" & 2°• quartile (55) 1.9 (2.3) 0.051-11.1 0.71 
MHI (Global score) Between 2"' & 3'' quartile (SO) 2.5 (2.0) 0.084-9.5 0.052 
Above fourth quartile (50) 2.3 (2.7) 0.11-13.6 0.35 
Physical activity Low activity (14) 1.9 (2.8) 0.094 - 10.1 0.24 
I PAQ category Moderate activity (72) 1.5 (1.3) 0.043 -1.3 0.038 
High activity (129) 2.5 (2.8) 0.051- 16.8 Reference 
Vitamin D status <25 (6) 0.23 (0.30) 0.043 - 0.81 <0.001 
(Baseline blood test) 25 - 49.9 (33) 0.74 (0.64) 0.068- 2.5 <0.001 
(nmol / L) so - 74.9 (69) 1.9 (1.8) 0.051-11.1 0.018 
> 75 (108) 2.8 (2.9) 0.11- 16.8 Reference 
linear regression models using log-transformed UVR exposure distributions and adjusted for season 
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6.3.3 Cumulative UVR exposure with silicone skin casts 
Skin cast quality control 
Silicone skin casts were taken from the dorsum of the left and right hand (i.e. su n exposed 
area) for all participants. The casts were graded according to the previously described Beagley 
and Gibson criteria by two independent scorers (AS & VM) who were blinded to the 
participant's enrolment and study details (see Section 5.5.3). Results that differed by more 
than two grades (44 casts (9.9% of total)) were re-graded by both scorers. The degree of cast 
grade agreement between scorers was determined by a linear-weighted kappa statistic (given 
the categorical nature of skin grading), where a conservative weighting matrix was applied as 
follows: 
i 1 0.66 0 0 0 0 l 
I o.66 1 0.66 0 0 0 I 
I 0 0.66 1 0.66 0 0 I 
I 0 0 0.66 1 0.66 0 I 
I 0 0 0 0.66 1 0.66 I 
L 0 0 0 0 0.66 1 J 
The kappa (K) statistic as a measure of level of agreement can be interpreted as follows (489): 
0 - 0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, good; 0.81-1.00, very good. 
Table 6.25 and Graph 6.16 show the grading of casts by each scorer. -Scorer 2 graded, on 
average, half a grade higher than Scorer 1 for both hands, although there was 'moderate' 
agreement between scorers according to the weighted kappa sta tistic. On average, both 
scorers had graded the right hand casts higher than the left. 
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Table 6.25: Grading of skin casts by two independent scorers. 
Scorer 1: Scorer 2: Weighted Kappa statistic 
Mean (SD) Mean (SD) 
Left cast (n=214) 3.5 (l.0) 4.0 (0.94) 0.55 Moderate agreement 
Right cast (n=213) 3.7 (l.0) 4.1 (0.97) 0.59 Moderate agreement 
Graph 6.16 Histograms of left and right hand graded skin casts - comparing scorers 
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As a quality control measure to assess intra-rater grade reproducibility, both scorers re-graded 
60 randomly selected skin casts . Scores for these duplicate casts were compared with the 
original grad ing using the same weighted kappa statistic as described above (Table 6.26) . Both 
scorers demonstrated "good agreement" between original and re-graded scores. 
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Table 6.26: Regrading of duplicate casts to assess intra-rater agreement 
Original grading Re-grading Level of 
agreement* 
Scorer 1 Mean (SD) 3.62 (1.19) 3.63 (1.02) 0.66 Good 
25th / 75 th percentile 3/4.5 3/4 agreement 
Scorer 2 Mean (SD) 4.08 (1.00) 3.82 (1.07) 0.65 Good 
25 th / 75th percentile 3/5 3/4 agreement 
* Weighted kappa statistic 
Distribution of skin cast grades 
As there was moderate agreement between scorers (and good intra-rater agreement), the 
average of the two scorers grades have been used for subsequent analyses involving the skin 
cast grade. This has led to an increase to 12 scoring gradations because of the generation of 
half marks. 
Graph 6.17 demonstrates the relatively normal distribution of combined grades for left hand 
skin casts. The left hand was chosen for analysis as previous studies have also shown that the 
right or "driving hand" in Australia is subject to higher UVR exposure and may not reflect 
overall cumulative sun exposure (440). 
Graph 6.17: Frequency distribution of left hand skin cast grades 
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Cumulative sun exposure was also related to age. The box plots (Graph 6.18) shows a positive 
relationship between age and left hand skin cast grade. An ordinal regression model revealed 
that for each 1 year increase in age, odds of an increased skin cast grade (1/2 grade increment) 
increased by 0.11 (95% Cl: 0.07-0.15); p <0.0001). 
Graph 6.18: Left hand skin cast grade vs. age category 
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Table 6.27 shows the left hand skin cast grade by study· site, sex and ethnicity. When included 
in an ordinal regression model, an increased odds of higher skin cast grade was strongly 
associated with age, male sex, northern European parentage and Townsville residence. 
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Table 6.27: Association between left hand skin cast and skin, ethnicity and study site 
Sex Study site Ethnicity 
Male Female Canberra Townsville Northern Non-Nth. 
European European 
parents parents 
Number 78 136 108 106 160 31 
Mean (SD} 4.1 (0.94) 3.6 (0.91) 3.6 (0.91) 3.9 (0.95) 3.9 (0.93) 3.1 (0.65) 
Median 4 3.5 3.5 3.5 3.5 3 
25th/ 75th 3.5 / 4.5 3 / 4.5 3 / 4 3 / 4.5 3.5 / 4.5 2.5 I 3.5 
percentile 
Odds ratio# Females Townsville Nth European parents 
(9S% Cl}: odds 0.36 (0.21- 0.61) 2.3 (1.4 - 3.7) 3.3 (1.9 - 5.8) 
of higher skin p < 0.001 * p=0.001 ** p < 0.001 *** 
cast grade 
# Ordinal logistic regression 
* Adjusted for age, study site, ethnicity * * Adjusted for age, sex, ethnicity*** Adjusted for 
age, sex, study site 
6.3.4 Summary 
Short-term personal UVR exposure was measured by electronic wrist dosimeters. An 
interpolation function was used in a small proportion of cases to 'fil l in' for missing or 
erroneous measured data. The interpolated values were similar to the measured values but 
tended to overestimate values near zero and under~stimate high measured (or 'spike') UVR 
values. For remaining missing daily UVR values, a simple imputed value was generated by 
averaging the remaining days for that individual (differentiated by weekday or weekday). This 
imputed value was only used where aggregated daily data (i.e. more than one day of daily 
data) were required . 
Canberra participants had lower cumulative electronic-badge measured UVR exposure over 
ten days compared with Townsville participants in the winter season, but this was not 
statistically different for other seasons. When adjusted for clothing, Townsville participants 
had significantly higher UVR exposure over ten days compa red with Canberra participants 
overa ll , and in the winter season. In Canberra, participants enrolled in winter had the lowest 
UVR exposu res over ten days compared with other seasons. Clothing adjusted UVR exposure 
was approximately one-third of the corresponding electronic badge measurement, although 
this also varied with season and site of enrolment. 
Cumulative UVR exposure over the life course was assessed by quantifying the degree of 
actinic damage observed in sil icone skin casts taken of the dorsum of hands. In this study, 
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agreement between independent scorers of skin casts was moderate and intra-observer 
agreement was good. Factors associated with increased skin cast grade (and hence cumulative 
UVR exposure) were: right hand, increasing age, male sex, northern European heritage and 
Townsville residence . 
The next chapter describes the results from the immune assays and regression models which 
aim to determine associations with UVR exposure and other potential immunomodulatory 
factors. 
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Chapter 7: Associations between UVR exposure and immune response 
Synopsis 
This chapter discusses the relationship between personal UVR exposure and primary immune 
responses to KLH immunisation. Figure 7.1 illustrates the postulated relationships between 
UVR exposure variables, immune outcome measures and potential confounding and/or effect 
modifying factors. Linear regression models were developed to fully examine these 
associations. 
This chapter is divided into two sections: i) immune responses (sub-divided into humoral and 
cell-mediated immune response); and ii) vaccine-related safety issues. The first section details 
the distribution of immune responses, their (univariate) association with potential 
immunomodulatory factors and UVR exposure(s), respectively, and finally, the results of 
multiple linear regression modelling. 
Figure 7.1: Postulated relationship between UVR exposure variables, vaccine-associated 
immune outcomes and potential immunomodulatory factors 
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7.1 Immune responses 
7.1.1 Exclusion of participants with high baseline inflammatory markers 
Participants with screening test results ((-reactive protein (CRP) and white cell count (WCC)) 
that suggested an inflammatory state at the time of KLH immunisation were excluded from 
further analysis. The threshold level for exclusion was set at three times the standard 
deviation above the study population mean for each screening test. The threshold for CRP was 
20.7mg/L which led to exclusion of four participants, and for WCC was 11.3 x 109/ L, excluding 
two participants. As one participant had both a CRP and WCC above these thresholds, a total 
of five participants were excluded from analysis leaving 217 evaluable participants. Of note, 
the average BMI of excluded participants was significantly higher than the remaining 
population (37.7 vs. 23.8; p=0.03), but they were similar in other characteristics. 
7.1.2 Humoral immune response 
Distribution of anti-KLH /gGl response 
KLH-specific lgGl antibody responses were assessed at baseline, 7 and 21-days post-KLH 
immunisation, by ELISA. The coefficient of variation of the anti-KLH lgGl positive control 
concentration on each plate (at concentration 1:50) was 11.8%. Anti -KLH lgGl levels are 
presented as a "corrected" optical density by dividing the raw absorbance value by that of the 
positive control sample that was run on each plate in each assay. 
Table 7.1 and Graph 7.1 show the anti-KLH lgGl concentration relative to the positive control 
titre for the three time points. The data show a significant increase in lgGl co ncentration with 
each visit; the spread of data is most evident for sera collected at day 21 post-immunisation. 
Table 7.1: Anti-KLH lgGl concentration at time-points relative to KLH-immunisation 
Time relative to N* Mean (SD) Median Range 
KLH-immunisation 
Baseline 217 0.17 (0.06) 0.16 0.04, 0.35 
Day7 216 0.30 (0.18) 0.26 0.00, 1.31 
Day 21 216 0.65 (0.30) 0.67 -0.04, 1.40 ** 
*Excluding participants with high inflammatory markers at baseline 
•• Readings below zero were due to subtraction of " background noise" from the day 7 and day 
21 post-immunisation readings. Background noise was defined as the difference in optical 
density_reading between the negative control and a participant's baseline serum. 
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Graph 7.1: Frequency distributions of anti-KLH lgGl at baseline, 7 and 21 days post-
immunisation 
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Association between anti-KLH lgGl and potential immunomodulatory variables 
Table 7.2 shows the relationship between anti-KLH lgGl response at day 21 post-immunisation 
and potential immunomodulatory variables. Females demonstrated a 20% higher anti-KLH 
lgGl response than males (p=0.006). Additionally, a negative linear association between age 
and antibody response was demonstrated (See Graph 7.2). The youngest age group (18- 24 
years) had a 39% higher antibody response compared with the oldest age group (35 - 40 
years) (p<0.001). 
Graph 7 .2: Scatterplot of anti-KLH lgGl vs. age of AusUVI participant 
Anti-KLH lgG1 at day 21 post-vaccination 
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Table 7.2: Anti-KLH lgGl at day 21 post-immunisation vs. potential immune modulators 
Potential Sub-group (n) lgGl titre Range p value 
immune mean (SD}* 
modulators 
Overall (216) 0.65 (0.30) -0.040, 1.40 
Sex Male (79) 0.58 (0.29) -0.040, 1.26 0.006 
Female (137) 0.70 (0.30) -0.010, 1.40 
Site Canberra (107) 0.62 (0.29) -0.040, 1.40 0.065 
Townsville (109) 0.69 (0.30) 0.15, 1.37 
Season Winter (76) 0.64 (0.32) 0.17, 1.37 Reference 
Spring (49) 0.67 (0.31) -0.040, 1.40 0.58 
Summer (38) 0.66 (0.26) -0.010, 1.17 0.68 
Autumn (53) 0.65 (0.29) 0.024, 1.26 0.79 
Age (years) 18-24 (81) 0.75 (0.28) 0.19, 1.40 Reference 
25-29 (67) 0.62 (0 .27) -0.010, 1.17 0.005 
30-34 (30) 0.61 (0.32) -0.040, 1.26 0.022 
35-40 (38) 0.54 (0.32) 0.024, 1.36 <0.001 
Parental ethnic Northern European (both parents) (150) 0.68 (0.29) -0 .040, 1.40 0.32 
background Other (66) 0.64 (0.024) -0.010, 1.37 
Melanin density Quartile 1 (54) 0.60 (0.31) -0.010, 1.40 Reference 
Left inner arm Quartile 2 (54) 0.67 (0.30) -0 .040, 1.36 0.18 
(Lightest to Quartile 3 (SO) 0.68 (0.28) 0.18, 1.17 0.18 
darkest ski n) Quartile 4 (56) 0.66 (0.31) 0.024, 1.37 0.24 
Melanin Density Quartile 1 (54) 0.65 (0 .33) -0.040, 1.40 Reference 
Left upper cheek Quartile 2 (51) 0.67 (0.28) 0.14, 1.13 0.62 
(Lightest to Quartile 3 (51) 0.64 (0.29) 0.15, 1.26 0.98 
darkest skin) Quartile 4 (54) 0.65 (0.31) 0.024, 1.36 0.89 
Smoking Current non-smoker (204) 0.66 (0.30) -0.040, 1.40 0.76 
Current smoker (12) 0.62 (0.35) 0.16, 1.36 
Body mass index Underweight (4) 0.73 (0.55) 0.024,1.37 0.73 
Category Normal weight (141) 0.67 (0.29) -0.039, 1.40 Reference 
Overweight (56) 0.58 (0.30) 0.14, 1.22 0.038 
Obese (15) 0.72 (0.30) 0.29, 1.36 0.61 
Psychological Quartile 1 (58) 0.66 (0.32) -0.040, 1.26 Reference 
profile: Quartile 2 (58) 0.67 (0.28) 0.14, 1.40 0.91 
POMS (:fMD) Quartile 3 (44) 0.63 (0.30) 0.16, 1.22 0.61 
Lowest to highest Quartile 4 (54) 0.65 (0.30) -0.010, 1.37 0.87 
mood disturbance 
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Psychological Quartile 1 (58) 0.62 (0.31) -0.010, 1.37 Reference 
profile: Quartile 2 (55) 0.69 (0.27) 0.20, 1.40 0.23 
MHl (Global) Quartile 3 (50) 0.67 (0.30) 0.14, 1.36 0.38 
Lowest to highest Quartile 4 (51) 0.64 (0.66) -0.040, 1.19 0.68 
well-being 
Physical activity Low activity (13) 0.63 (0.34) 0.20, 1.22 0.68 
lPAQ category Moderate activity (71) 0.62 (0.31) -0.040, 1.40 0.28 
High activity (131) 0.67 (0.29) 0.024, 1.37 Reference 
2S(OH)D level <25 (6) 0.56 (0.32) 0.19, 1.03 0.39 
(nmol /L) 25 - 49.9 (32) 0.57 (0.34) -0.040, 1.40 0.08 
(at baseline) so - 74.9 (68) 0.68 (0.29) 0.14, 1.37 0.91 
>75 (110) 0.67 (0.29) -0.010, 1.36 Reference 
* Corrected OD relative to positive control titre 
The data in Table 7.2 suggests a relationship between serum 2S(OH)D and anti-KLH lgGl when 
the former is considered as a dichotomous variable with a cut-off set at SOnmol/L. Indeed, a 
significantly higher mean anti-KLH lgGl titre was seen in participants with serum 2S(OH)D ~ 
SOnmol/L compared with those with <SOnmol/L (0 .67 vs. 0.57; p=0.049). 
Associations between personal UVR exposure and anti-KLH lgGl response 
Acute UVR exposure 
Personal acute UVR exposure, as measured by electronic UVR dosimeters with interpolated 
data and adjusted for body surface area covered by clothing, was compared with anti-KLH lgGl 
response at day 21 post-immunisation. 
Due to the uncertainty regarding which days were most critical for UVR-induced 
immunomodulation, an exploratory approach was undertaken. Data were analysed for each 
individual day that the dosimeter was worn and by combinations of days (by summing the 
individual daily UVR exposures) as per the matrix shown in Table 7.3. Particular scrutiny was 
placed on the days adjacent to immunisation day, as this period was deemed o priori to have 
the maximum potential for UVR-associated immunomodulation. Only days with complete UVR 
data (i.e. no missing data) were used to generate the aggregated combinations of days. To 
assist with making this aggregated-day dataset as complete as possible, missing daily totals 
that remained after the interpolation process were replaced by a simplified imputation 
method (based on the average of the remaining days that had complete data, differentiated by 
weekda.y and weekend) (see Section 6.3). This most complete data set comprised ten days of 
daily UVR exposure totals for 216 participants (97.3% of the total sample). 
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Table 7.3 Combinations of UVR exposure daily totals used for regression models 
Days electronic dosimeter worn 
1 2 3 4 5 6* 7 8 9 10 
A 1 2 3 4 5 6 7 8 9 10 
Day B 2 3 4 5 6 7 8 9 
combinations C 3 4 5 6 7 8 
to be D 4 5 6 7 
analysed# E 5 6 
F 5 6 7 
G 5 6 7 8 
H 5 6 7 8 9 
I 4 5 
J 3 4 5 
K 2 3 4 5 
L 1 2 3 4 5 
M 6 7 
N 6 7 8 
0 6 7 8 9 
p 6 7 8 9 10 
* Day of immunisation # Sum of daily UVR exposure totals (measured+ interpolated+ 
imputed) 
Natural logarithm-transformed data were used for individual days and combinations of days to 
normalise the highly positively skewed UVR exposure data (see Figure 6.13). Table 7.4 shows 
the simple association between log-transformed personal UVR exposure and anti-KLH lgGl 
response at day 21 post-immunisation . The data show no significant simple linear relationship 
with any measure of acute UVR exposure. 
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Table 7.4: Clothing-adjusted personal UVR exposure vs. anti-KLH lgGl response at day 21 
post immunisation: Simple linear analyses 
Adjusted UVR Number of Regression 9S% Confidence p value 
exposure (log observations coefficient interval 
transformed; (SEO) {xlO00) (x 1000) 
Individual days 
Day 1 204 113 -164, 391 0.42 
Day2 205 165 -41, 372 0.12 
Day3 196 1.4 -119, 147 0.83 
Day4 190 -0.72 -152, 150 0.99 
Day 5 197 3.9 -169, 248 0.71 
Day6* 211 -6.8 -308, 171 0.57 
Day7 203 7.8 
-157, 314 0.51 
Days 200 112 -5.5, 280 0.19 
Day9 192 1.0 -179, 200 0.92 
Day 10 185 3.2 -111, 175 0.66 
Combinations of 
days** 
A: Days 1-10 200 3.5 -3.5, 105 0.33 
B: Days 2-9 200 3.3 -42, 108 0.38 
C: Days 3-8 200 3.0 -51, 112 0.46 
D: Days 4-7 200 6.5 -9 .6, 109 0.90 
E: Days 5 - 6 200 -12 
-170, 146 0.88 
F: Days 5 - 7 200 7.4 -122, 137 0.91 
G Days 5-8 200 3.4 
-7 .3, 140 0.53 
H: Days 5- 9 200 2.4 -7.2, 119 0.63 
I: Days 4- 5 200 2.1 -101, 143 0.73 
J: Days 3- 5 200 3.1 -6.2, 125 0.51 
K: Days 2- 5 200 4.5 
-4.4, 135 0.32 
L: Days 1- 5 200 4.7 
-4.1, 134 0.30 
M: Days 6-7 200 
-1.8 
-184, 147 0.83 
N: Days 6-8 200 2.6 -9.4, 145 0.68 
0: Days 6-9 200 1.4 
-8.9, 117 0.79 
P: Days 6-10 200 1.9 -7.0, 108 0.68 
* Day of immuni sat ion;** Using imputed UVR data for missing days 
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Cumulative UVR exposure 
Table 7.5 demonstrates anti-KLH lgGl response at day 21 post-immunisa tion by cumulative 
UVR exposures as quantified by skin cast grade. There was no statistical difference between 
participants with the lowest skin cast grades (~3.5) and those with the highest (~4) (0.67 vs. 
0.64; p=0.47). In a multiple regression model using skin cast grade as an ordinal explanatory 
variable (and adjusting for age, sex, site and ethnicity) , a moderate but non-s ignificant 
association between increasing skin cast grade and increasing anti-KLH lgGl titre was seen (i.e . 
for every half-step increase in skin cast grade, there was an increase by 0.047 in lgGl titre; 95% 
Cl : -0.0035, 0.098; p=0.068). 
Table 7.5: Skin cast grade versus anti-KLH lgGl at day 21 post immunisation 
Skin cast grade* N lgGl titre 95% Cl Range 
mean (SD)** 
2 4 0.68 (0.14) 0.48, 0.81 
2.5 26 0.66 (0.28) 0.17, 1.26 
3 30 0.68 (0.27) 0.25, 1.11 
3.5 59 0.66 (0.30) -0.010, 1.40 
4 25 0.59 (0.33) 0.19, 1.36 
4.5 30 0.67 (0.32) 0,!4, 1.37 
5 20 0.69 (0.34) -0.040, 1.19 
5.5 6 0.44 (0.24) 0.20, 0.78 
6 8 0.70 (0.32) - 0.42, 1.22 
* Average score of two independent assessors;* * Relative to posi tive control titre 
Multiple linear regression analysis of UVR exposure and anti-KLH lgGl response 
The main goal in developing an explanatory model was to determine the association between 
the exposures of interest (i.e. acute and cumulative UVR exposure) and the outcome of 
interest (i.e. anti-KLH lgGl response at day 21 post-immunisation) . All potential 
immunomodulatory variables were included where there was a priori evidence &/or univariate 
evidence of an association with anti -KLH lgGl. As acute and cumulative personal UVR 
exposures were hypothesised to independently influence cell -mediated immune response, 
both were included in the regression model. As vitamin D status may lie on the causal UVR 
immunomodulatory pathway (particularly for cumulative UVR exposure), models with and 
without 25(OH)D levels at baseline were assessed. 
Table 7.'6 shows the results of the multiple regress ion models for different UVR exposures. 
The following variables were modelled as continuous measures: age (years), BMI, 25(OH)D 
level (at visit 2), skin reflectance at the left inner arm and cheek, and psychological profiles 
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(POMS-TMD and MHl-global index). Physical activity was modelled as a continuous variable 
using MET-minutes per week as recorded in the IPAQ (See Section 5.2.1.2). This variable was 
square-root transformed to normalise the initial positively-skewed distribution. Skin cast 
grade was modelled as an ordinal explanatory variable. The effect of season was accounted for 
by fitting a sine-cosine function across the study enrolment period. Separate seasonal terms 
were fitted for Canberra and Townsville given their distinct climates. 
While no statistical association was found between anti-KLH lgGl response and personal UVR 
exposure (either acute or cumulative), other covariates did demonstrate a significant 
association with immune response. 
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Table 7.6 Clothing-adjusted UVR exposures vs. anti-KLH lgGl response at day 21 post-
immunisation: Multiple linear regression analyses 
Adjusted UVR Number of Regression 95% Confidence p value 
exposure (log observations coefficient interval 
transformed; (SED) (xl000) (xl000) 
Individual days 
Day 1 188 - 53 - 384, 278 0.75 
Day2 187 197 - 33,426 0.093 
Day3 178 42 -104, 188 0.57 
Day4 173 - 46 - 211, 119 0.58 
Day 5 180 -11 - 249, 226 0.93 
Day 6* 193 - 145 - 413, 122 0.29 
Day 7 185 94 - 158, 347 0.46 
Day8 182 36 - 146, 219 0.70 
Day 9 177 6.9 - 205, 219 0.95 
Day 10 168 38 - 110,186 0.61 
Day combinations** 
A: Days 1-10 182 16 - 75, 107 0.72 
B: Days 2-9 182 -19 - 77, 115 0.70 
C: Days 3-8 182 8. 7 - 93, 111 0.87 
D: Days 4- 7 182 - 22 -147, 102 0.72 
E: Days 5-6 182 - 61 - 249, 127 0.52 
F: Days 5-7 182 - 12 - 170, 146 0.88 
G: Days 5-8 182 0.35 - 130,130 1.0 
H:Days5-9 182 -1.4 
- 119, 116 0.98 
I: Days4-5 182 0.088 -139, 139 1.0 
J: Days 3 - 5 182 27 - 82, 136 0.63 
K: Days 2 -5 182 48 - 59, 154 0.38 
L: Days 1- 5 182 38 - 70, 145 0.49 
M:Days6-7 182 -39 - 232, 155 0.69 
N: Days 6- 8 182 
- 19 - 160, 122 0.79 
0: Days 6-9 182 - 17 -140, 107 0.79 
P: Days 6-10 182 - 6.2 
- 111, 98 0.91 
* Day of immunisation;** Using imputed UVR data for missing days; Adjusted for age, sex, study site, 
season, BMI, physical activity (MET-minutes/week), psychological state (MHl-global index, POMS-TMD), 
skin reflectance at the inner arm and left cheek, smoking status, 25(0H)D level (on day of 
immunisation), cumulative sun exposure (l eft hand skin cast grade), parental ethnicity (both parents 
northern European vs. other) 
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Table 7.7 shows the results of the multiple regression model with acute UVR exposure 
combination K (Days 2 to 5) which had the best 'fit' for the data based on the model's R' value 
(and where all models contained the same number of participants; n=182) . Female sex 
remained strongly associated with humora l immunisation response with a 14.6% higher anti-
KLH lgGl response than in males (p=0.004) at 21 days post-immunisation. Age was strongly 
linearly associated with anti-KLH lgGl response, with antibody response declining by 1.6% 
(95% Cl 0.63% - 2.5%; p=0.001) for every increased year of participant's age. Notably, serum 
25(OH)D level (including when modelled as a dichotomous variable using a 50nmol/L cut-off) 
or cumulative UVR exposure was not significantly associated with anti-KLH lgGl response. 
Table 7.7: Association between covariates and anti-KLH lgGl response at 21 days: A multiple 
linear regression analysis using the best fitting regression model" 
Variable Regression 95% confidence p value 
coefficient interval 
(x 1000) (x 1000) 
UVR Days 2 - 5 (Model K) 47 -58, 154 0.38 
Skin cast grade (ordinal½ step) 51 -9.5, 112 0.097 
Age (years) -16 -25, -6.3 0.001 
Sex: Female 146 47, 24_5 0.004 
Parental ethnicity: Northern -88 -21, 35 0.16 
European {both parents) 
BMJ* 3.3 -9.2, 16 0.61 
Melanin density* Inner arm 25 -22, 73 0.30 
Melanin density* Left cheek -24 
-91, 42 0.47 
Physical activity• 0.28 -1.7, 2.3 0.79 
IPAQ (MET minutes / week) 
Psychological profile* 1.0 -2.8, 4.9 0.22 
POMS-TMD 
Psychological profile* 1.7 -0.99, 4.4 0.21 
MHI - global score 
Vitamin D (25(OH)D)* 
-1.2 
-3 .1, 0.74 0.22 
Current smoker 132 -86, 35 0.23 
# N= 182 • Modelled as a continuous variable 
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Checking regression assumptions 
This section outlines the tests used to verify that the assumptions underpinning the use of 
linear regression modelling were met. As the best model in Table 7.6 with the best fit for the 
data, the aggregated personal UVR exposure over days 2 to 5 (combination 'K' from Table 7.5; 
n=182) is used to demonstrate robustness of regress ion assumptions. 
Influential data points: Data points with high residual (deviation from the regression line) or 
'leverage' can potentially influence regression coefficients. The most influential data points 
were checked for accuracy and transcription errors. When regression models were run with 
and without these data points, little change to the regression coefficients of the UVR exposure 
variable was found. Therefore all data points were retained. 
Normality of residuals: The Shapiro-Wilk W test demonstrated that there was no evidence to 
reject the hypothesis that the residuals were normally distributed (p=0 .96) 
Homascedasticity of residuals: The White's test and Breusch-Pagan test demonstrated no 
evidence to reject the hypothesis that there was no pattern of the residuals when plotted 
against fitted va lues (p=0.30 and p=0.57, respectively). 
Multi-collinearity: Variance inflation factors applied to the explanatory variables did not show 
evidence of co llinea rity between variab les in the model. 
Summary 
Following KLH immunisation, there was a rise in anti-KLH lgGl titres at 7 and 21 days post-
immunisation. The latter response demonstrated the greatest variation and was used as the 
end-point for further analyses. 
Simple linear analysis demonstrated that higher anti -KLH lgGl at 21 days post-immunisation 
was significantly associated with younger age, female sex and serum 2S(OH)D levels greater 
than S0nmol/ L. On multiple regression analyses, only the statistica l associations with sex and 
age persis_ted. Measures of clothing-adjusted acute and cumulative personal UVR exposure 
were not found to be significant explanatory variab les. 
Diagnostic testing supported the underlying regression model assumptions. 
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7.1.3 /n vivo cell-mediated immune response: DTH response 
Delayed type hypersensitivity (DTH) responses to KLH were used as the in vivo measure of 
antigen-specific cell-mediated immunity. Twenty-one days following KLH immunisation to the 
forearm, intra-dermal injection of KLH was given at the same site and the subsequent DTH 
response was read 48 hours later. 
Intra-rater and inter-rater agreement for DTH testing 
At the Canberra study sites, a single observer (AS) measured all DTH responses. In Townsville, 
the majority of responses were measured by a single observer (KP) . However, when KP was 
unavailable, a second study officer was required to measure responses (CvB). 
For the purpose of assessing inter-rater agreement, sets of DTH responses were read by the 
three raters over three calibration visits . Each rater was blinded to the others' measures (and 
pen markings were removed between readings). DTH responses were derived from: i) multiple 
intra-dermal KLH injections (varying doses: 5 - 20 µg) administered to the thighs of a pre-
sensitised volunteer' (see Figure 7.2); and, ii) a sample of AusUVI participants. The former 
strategy occurred on two occasions at calibration sessions when all assessors were present at 
the same site, and the latter strategy was opportunistic, using participants who were attending 
for their study visit at the time of the calibration visit. 
Figure 7 .2: Assessing inter-rater agreement in reading DTH responses 
Use of the 'pen method' proved challenging for assessing the repeatability of DTH 
measurement. There was noticeably increased erythema and local swell ing around the DTH 
response following pen marking of the skin. Nevertheless, 22 DTH responses were assessed by 
all three raters, and the two-way mixed-method intra-class correlation coefficient was 0.63 
{95% Cl: 0.38 - 0.80), indicating moderate to strong agreement between scorers. 
3 The volunteer was a study investigator (AS) 
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DTH responses amongst AusUVI participants 
For the AusUVI Study, 211 DTH responses were recorded (98% of evaluable participants) - six 
participants were unable to attend for ski n test reading at the prescribed time. 
Graph 7.3 demonstrates the distribution of DTH responses. The mean response was 7.4mm 
(SD 4.3mm) and median response 6.5mm with a range of O - 29.5mm. Twelve participants 
(5.7%) did not have a measureable DTH response (i.e. 0mm). Given the positively-skewed 
distribution, square-root transformation was required to allow for parametric testing and 
robust linear regression models. 
Graph 7 .3: Distribution of DTH responses 
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Participant 186 had the most extreme measured DTH response (29 .5mm), above the 99 th 
centile for the distribution and 55% higher than the next measured response (19mm) . It was 
not clear from the corresponding photograph whether the measurement was of the erythema 
associated with the DTH response rather than the area of induration. In view of the lack of 
confidence in the accuracy of this measurement, the models presented in this section were 
generated with this value excluded given its propensity to be influential on regression 
coefficients (see also Section 7.1.3). 
Table 7.8 shows the relationship between the DTH response and potential immunomodulatory 
variables. Females had a significantly higher DTH response than males (17%; p=0.03) . Other 
putative immunomodulatory factors were not significantly associated with DTH response. 
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Table 7.8: Association between potential immunomodulatory factors and DTH response 
Potential immune Sub-group (n) Mean {SD) Range (mm) p value* 
modulators (mm) 
Overall (210) 7.0 (4.0) 0-19 
Sex Male (79) 6.5 (4.2) 0-19 0.038 
Female (131) 7.4 (3.8) 0-19 
Site Canberra (102) 7.2 (4.2) 0-19 0.86 
Townsville (108) 6.9 (3.7) 0 -19 
Season Winter (75) 7.3 (4.4) 0-19 Reference 
Spring (47) 6.8 (3.7) 0 -16 0.61 
Summer (37) 7.6 (4 .0) 0- 19 0.65 
Autumn (51) 6.4 (3.5) 0-17 0.33 
Age (years) 18- 24 (79) 6.7 (3.9) 0 -19 Reference 
25-29 (66) 7.3 (3.8) 0-16 0.39 
30-34 (29) 7.1 (4.3) 0-19 0.69 
35-40 (36) 7.3 (4.3) 0-17 0.61 
Parental ethnic Northern European (both parents) (146) 7.2 (3.9) 0-17 0.62 
background Other (64) 7.0(4 .0) 0-19 
Melanin density Quartile 1 (52) 7. 5 (4.1) 0-17.5 Reference 
Left inner arm Quartile 2 (51) 6.2 (3.6) 0-19 0.16 
(Lightest to darkest Quartile 3 (SO) 7. 1 (4.0) 0-19 0.71 
Quartile 4 (55) 7.3 (4.2) 0-17 0.74 
skin) 
Melanin density Quartile 1 (54) 6.5(33) 0-13.5 Reference 
Left upper cheek Quartile 2 (56) 7.4 (3.9) 2 - 17.5 0.29 
(Lightest to darkest Quartile 3 (44) 6.4 (4.5) 0-17 0.59 
Quartile 4 (53) 8.0 (4.2) 0-19 0. 11 
skin) 
Smoking Non-smoker (199) 7.0 (4.0) 0-19 0.74 
Current smoker (11) 7. 1 (2.9) 2 -13 
Body mass index Underweight (4) 6.5 (1.9) 4 -8.5 0.87 
Categories Normal weight (136) 7.2 (3.9) 0-19 Reference 
Overweight (55) 6.4 (4.4) 0-17.5 0.69 
Obese (15) 7.9 (3.0) 3.5 -14 0.58 
Psychological Quartile 1 (54) 7.0 (4.1) 0-19 Reference 
profile: Quartile 2 (56) 7.5 (4.1) 0 -17.5 0.46 
POMS (TMD) Quartile 3 (44) 6.8 (4.5) 0-19 0.67 
Lowest to highest Quartile 4 (53) 6.6 (3.3) 0-17 0.81 
mood disturbance 
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Psychological Quartile 1 (57) 6.5 (3.8) 0-19 Reference 
profile: Quartile 2 (53) 7.9 (4.3) 0-17.5 0.083 
Quartile 3 (47) 6.9 (4.0) 0-16 0.65 MHI (Global score) 
Quartile 4 (SO) 6.6 (3.9) 0-19 0.86 
Lowest to highest 
well -being 
Physical activity Low activity (12) 6.1 (4.8) 0-14 0.26 
IPAQ category Moderate activity (70) 7.3 (4.2) 0 -19 0.79 
High activity (128)# 7.0 (3.8) 0-19 Reference 
2S(OH)D level <25 nmol /L (6) 7.2 (7.8) 0 - 14 0.99 
(nmol /L) 25 - 49.9 nmol /L (31) 7.4 (4.6) 0-19 0.71 
50 - 74.9 nmol/L (65) 7.4 (4.4) 0-19 0.56 (at baseline) 
> 75 nmol /L (108) 6.7 (3.5) 0- 17 Reference 
*Parametric testing or regression performed using square-root transformed distribution of DTH 
responses 
There was no association with DTH response when serum 2S(OH)D level was analysed as a 
dichotomous variable with cut-off set at 75nmol/L (7.3mm vs. 6.8mm; p=0.58). 
Associations between personal UVR exposure and 0TH response 
Acute UVR exposure 
Table 7.9 shows the simple linear association between clothing-adjusted personal UVR 
exposure and DTH response. 
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Table 7.9: Adjusted personal UVR exposure vs. DTH response: Simple linear analyses 
Adjusted UVR 
95% Confidence exposure (log Number of Regression 
transformed; (SED) observations coefficient interval p value 
Individual days (x 100) (x 100) 
Day 1 198 -3 .7 - 108, 32 0.29 
Day 2 200 0.79 - 51, 53 0.98 
Day3 191 9.7 - 23, 43 0.56 
Day4 185 3.3 - 33, 40 0.86 
Day 5 192 -60 -110,-9.8 0.019 
Day 6* 206 25 - 34, 85 0.40 
Day 7 198 -40 - 97, 17 0.17 
Days 195 - 26 - 68, 16 0.22 
Day 9 187 - 31 - 78, 17 0.21 
Dayl0 181 7.4 - 31, 45 0.70 
Day combinations** 
A: Days 1-10 195 - 8.3 
- 26, 0.88 0.34 
B: Days 2 - 9 195 - 9.3 - 27, 8.9 0.31 
C: Days 3-8 195 - 7.5 - 27, 12 0.45 
D: Days4-7 195 -13 - 38; 12 0.30 
E: Days 5- 6 195 - 21 
- 59, 17 0.27 
F: Days 5-7 195 - 23 
- 55, 8.3 0.15 
G: Days5-8 195 - 22 -47, 4.1 0.100 
H: Days 5 - 9 195 - 22 · 45, 1.0 0.060 
I: Days4-5 195 -16 
- 46, 13 0.27 
J: Days 3- 5 195 -4.9 
- 28, 18 0.67 
K: Days 2-5 195 - 6.2 
- 28, 16 0.58 
L: Days 1- 5 195 - 9.6 - 31, 12 0.38 
M: Days6-7 195 - 11 
- 51, 30 0.60 
N: Days6-8 195 -17 - 46, 122 0.26 
0: Days 6-9 195 - 18 
- 43, 6.6 0.15 
P: Days 6-10 195 -9.9 
- 32, 12 0.38 
* Day of immunisation;** Using imputed UVR data for missing days 
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Clothing-adjusted personal UVR exposure on Day 5 (i.e. the day prior to immunisation) was 
significantly associated with a decreased DTH response (p=0.019). Graph 7.4 illustrates this 
association. Additionally, UVR exposure over the Days 5 to 8 (i.e. the day before immunisation 
to day three fo llowing immunisation) and Days 5 to 9, showed low-moderate evidence of a 
simple linear association with decreased DTH response (p$0.10). 
Graph 7.4: DTH response vs. clothing-adjusted personal UVR exposure on Day 5 
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Table 7.10 compares the DTH response according to cumulative UVR exposure as quantified by 
skin cast grade. Participants with above-median grade skin casts (2'.4) had a lower average DTH 
response compared with those with below-median($3.S) skin cast grades, however this did not 
reach statistical significance (6.6mm vs. 7.5mm; p=0.20) (See Graph 7.5). Adjustment for age, 
sex, site and ethnicity in a multiple regression model did not change the significance of this 
association. 
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Table 7.10: Skin cast grade vs. DTH response 
Skin cast grade* N Measurement 
(mean, SD (mm)) 
2 4 7.3 (2.6) 
2.5 24 6.5 (2 .7) 
3 29 8.1 (4.1) 
3.5 58 7.3 (4.4) 
4 26 5.8 (3.6) 
4.5 29 7.1 (4.8) 
5 19 7.2 (4.4) 
5.5 5 6.7 (1.8) 
6 8 6.0 (2.1) 
* Average score of two independent assessors 
Graph 7.5: DTH response by skin cast grade 
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Multiple linear regression analysis of UVR exposure and DTH response 
Table 7.11 displays the output of multiple regression models assessing the association 
between acute UVR exposure and DTH response, adjusted for various postulated 
immunomodulatory variables. Again, all variables in Table 7.7 were included in the multiple 
regression models as was the skin cast measure of cumulative UVR exposure. 
Clothing-adjusted personal UVR exposure on Day 5 was significantly associated with a reduced 
DTH response (p=0.015). Additionally, aggregated UVR exposure over Days 5 to 8 and 5 to 9 
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were also significantly associated with a reduced DTH response 21 days later. Notably, the 
regression coefficients for all other aggregated acute UVR exposure variables, pre- and post-
immunisation, demonstrated a negative (albeit non-significant) association with DTH response, 
providing some additional support of a suppressive UVR effect. 
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Table 7.11: UVR exposure vs. DTH response: Multiple linear regression analyses 
Clothing-adjusted UVR Number of Regression 95% Confidence p value 
exposure {5ED) {log observations coefficient*• interval 
transformed) (x 100) (x 100) 
Individual days 
Day 1 183 -59 - 150, 32 0.20 
Day2 182 6.1 - 57, 69 0.85 
Day3 174 25 - 14, 65 0.21 
Day4 168 17 - 26, 59 0.45 
Day 5 175 -78 - 140, - 15 0.015 
Day 6* 188 so - 23, 123 0.18 
Day 7 180 - 47 -115, 22 0.18 
Day8 177 -45 - 95, 4.3 0.073 
Day 9 172 - 34 
- 93, 25 0.26 
Day 10 164 21 - 24, 65 0.37 
Day combinations 
A: Days 1-10 177 -10 - 35, 14 0.41 
B: Days 2-9 177 - 11 - 37, 14 0.38 
C: Days 3-8 177 - 7.6 - 35, 19 0.58 
D: Days 4- 7 177 - 15 - 48, 18 0.38 
E: Days 5- 6 177 - 28 - 78, 21 0.26 
F: Days 5 - 7 177 -34 _ - 75, 7.7 0.11 
G: Days 5 - 8 177 - 36 -70,-1.7 0.039 
H:Days5-9 177 -35 - 66, -4.4 0.025 
I: Days4-5 177 - 15 - 52, 21 0.41 
J: Days3 - 5 177 1.2 - 28, 30 0.93 
K: Days 2-5 177 - 1.1 
- 29, 27 0.94 
L: Days 1- 5 177 - 7.7 - 36, 21 0.60 
M:Days6-7 177 - 11 - 63, 40 0 .66 
N: Days 6-8 177 
- 26 - 63, 11 0.16 
0: Days 6-9 177 - 27 
-59, 5.4 0.10 
P: Days 6-10 177 - 12 
-40, 17 0.42 
* Day of immunisation 
** Adju sted for age, sex, study site, season, BMI, physical activity (MET-minutes/week), psychological 
state (MHl-global index, POMS-TMD), skin refl ectance at the inner arm and left cheek, smoking statu s, 
2S(OH)D level (on day of immunisation), cumulative sun exposure (left hand skin cast grade), paren ta l 
ethnicity (both parents northern Europea n vs. other) 
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Table 7.12 shows the results of a multiple linear regre ss ion model using acute UVR exposure 
on Day 5 which had the strongest association with DTH response. No other putative 
immunomodulatory factor (including sex, cumulative UVR exposure or serum 25(OH)D level) 
showed a significant association with DTH response. 
Further exploratory analysis with interaction terms involving acute UVR exposure, cumulative 
UVR exposure, age and sex was conducted, but did not reveal any other significant 
associations. 
Table 7.12: Association between covariates and anti-KLH DTH response at 21 days: A 
multiple linear regression analysis using acute clothing-adjusted UVR exposure on Day 5 
Variable Regression 95% confidence p value 
coefficient (x 100) interval (x 100) 
UVR exposure Day 5 -78 -140, -15 0.015 
Skin cast grade (ordinal ½ step) -12 -29, 4.3 0.15 
Age (years) 1.0 -1.4, 3.6 0.38 
Sex: Female 22 -4.0, 49 0.096 
Parental ethnicity: Northern -7 .2 -39, 25 0.66 
European (both parents) 
BMI* -0.17 -3.5, 3.1 0.92 
Melanin density* Inner arm -4.8 
-17, 7.1 0.43 
Melanin density* Left cheek 2.9 -16, 21 0.76 
Physical activity* 0.38 -0.19, 0.94 0.20 
IPAQ (MET minutes / week) 
Psychological profile* -0.0010 -1.0, 1.0 1.0 
POMS-TMD 
Psychological profile* 0.32 -0.43, 1.0 0.39 
MHI - global score 
Vitamin D (25(OH)D)* nmol/L -0.11 -16, 21 0.66 
Current smoker 16 -41, 73 0.58 
* Modelled as continuous variable 
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Checking regression assumptions 
As personal UVR exposure on Day 5 showed evidence of a significant inverse association with 
DTH response, this model was used as a typical example of the regression models in Table 
7.11. 
Influential data points: All 'influential' points were assessed in the data set and checked to 
ascertain validity of measurement (i.e. by reviewing primary data collection documents or 
photographs of DTH skin tests) and accuracy of data entry. As previously mentioned, the most 
influential data point related to the largest DTH response (29.5mm) that was recorded in 
participant 186. Inclusion of this data point in regression models confirmed that it had a 
highest residual, and measure of influence (Cook's D test). As there was concern regarding the 
val idity of this particular skin test measurement, it was excluded from further analysis. 
Normality of residuals: The Shapiro-Wilk W test demonstrated that there was no evidence to 
reject the hypothesis that the residuals were normally distributed (p=0.34). 
Homoscedasticity of residuals: The White's test and Breusch-Pagan test demonstrated no 
evidence to reject the hypothesis that there was no pattern of the residuals when plotted 
against fitted values (p=0.45 and p=0.076, respectively). 
Multi-collinearity: Variance inflation factors applied to the explanatory variables did not show 
evidence of collinearity between va riables in the model. 
Summary 
There was moderate to strong agreement between assessors of DTH responses across the two 
study sites. The DTH distribution was positively skewed and required sq uare-root 
transformation to allow use of parametric statistical models. On simple linear analysis, 
females demonstrated significantly higher DTH responses than males. Increased clothing-
adjusted personal UVR exposure on Day 5 had a strong linear association with reduced DTH 
response. Multiple linear regression models confirmed this association, and also an association 
with aggregated UVR exposure over Days 5 to 8, and 5 to 9 (i.e. spa nning the period just before 
and after immunisation), after adjusting for all other potential immunomodulatory factors. 
Cumulative UVR exposure, serum 2S(OH)D levels and other potential immunomodulatory 
variables (including sex) were not associated with DTH response in these models. 
Diagnostic testing supported the underlying regression model assumptions. 
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7.1.4 Comparing in vivo cell-mediated immune response with humoral responses 
As KLH immunisation promoted a T-dependent antibody response that relied on Thl cell-
mediated processes, it was expected that the KLH-specific DTH response would correlate with 
the KLH-specific lgGl response. Graph 7.6 shows this to be the case with a positively 
correlated association (r=0.22; p=0.001). 
Graph 7.6 Comparing DTH responses with corresponding KLH lgGl response at 21 days post-
immunisation 
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r=0.22; 
p=0.001 
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7.1.5 Ex vivo cell-mediated immune response 
Lymphocytes from a selected subgroup (55/ 222 ~ 25%) of the overall AusUVI Study cohort 
were analysed to assess whether an association existed between personal UVR exposure and 
circulating T-helper cell subsets. To maximise the chance of detecting a UVR-associated 
immunomodulatory effect in this initial analysis, the samples chosen for testing represented 
the extremes of measured personal UVR exposure (clothing-adjusted aggregated data over ten 
days) . Participants were thus categorised into 'high ' or ' low' UVR exposure groups. 
Importantly, it was assumed that the level of UVR exposure over the ten days (centred on the 
day of immunisation) would be representative of personal UVR exposure throughout a 
participant's enrolment period, although this was not confirmed . The characteri stics of the 
UVR groups are shown in Table 7.13. Apart from the significant difference in UVR exposures, 
the low UVR group had a higher proportion of participants from Canberra than from 
Townsville. 
Table 7.13: Participant characteristics for lymphocyte assays 
Low UVR High UVR Overall 
exposure exposure 
Number(% total) 28 (55%) 27 (45%) 55 (100%) 
-Personal UVR exposure 
over 10 days (SED) 0.36 (0.32) / 0.26 5.3 (4.0) / 4.5 ••• 2.9 (3 .8) / 1.4 
mean (SD)/ median 
Age (years) 30.0 (6.0) 28.6 (6.3) 29.3 (6.0) 
(Mean, SD) 
Female(%) 15 (54%) 15 (56%) 30 (55%) 
Site: Canberra (%) 25 (89%) 18 (67%)* 43 (78%) 
*Significar.it at p <0.05 by x' test 
•• • Significant at p <0 .0001 by Wilcoxon rank sum test 
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Cell sorting strategy 
As described in Section 4.2.2, ex vivo assessment of cell-mediated immunity was undertaken 
using fluorescent labelled antibodies to identify surface cell markers and intracellular 
cytokines, fol lowed by flow cytometry to quantify the proportion of Thl, Th 2, Thl 7 and 
regulatory T cells in PBMC samples isolated at baseline and day 21 post-immunisation. These 
were not antigen-specific assays. Figures 7.3 and 7.4 illustrate the flow cytometer output and 
the strategies used for enumerating the T-helper cell su bsets . 
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subsets. Panel 1: Side scatter vs. forward scatter plot to identify and remove debris/ 
non-cellular elements; Panel 2: Gated to select lymphocytes. Panel 3: Gated to select 
CD3+ and CD4+ cell surface markers on lymphocytes (i.e. T-helper cells). Panel 4: 
Gated to antibodies against intra-cellular cytokines of interest, in this case IL-17 and 
IFN-gamma. Ql represents IL-17 staining T-helper cells only, Q2 represents both IL-17 
and IFN-gamma staining cells, Q3 represents IFN-gamma staining cells only, and Q4 
represents T-helper cells not staining for IL-17 or IFN-gamma. The percentages in each 
quadrant reflect the proportion of cells compared with the total number ofT-helper 
lymphocytes. The final number of lymphocytes was determined by subtracting the 
proportion of cells seen in unstimulated from stimulated samples. A similar strategy 
was used for enumerating IL-4 and IL-10 staining T-helper cells. Note that each point 
in the panels represents an individual cell, with colour representing cell density. 
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Results of lymphocyte assays 
Table 7.14 shows the percentage ofT-helper cell subsets at baseline (pre-immunisation) and 
21 days post-KLH immunisation. 
Table 7.14: Effector T-helper cell subsets pre- and 21-days post-immunisation* 
T-helper Cell surface markers/ Intra- Pre- 21-days Post p value" 
lymphocyte cellular cytokine or immunisation* immunisation* 
subset transcription factor 
Mean (SD) (%) Mean (SD) (%) 
n = 55 n = 50 
Thl CD3+ CD4+ / IFN-y 7.2 (5.4) 6.8 (5.2) 
Th2 CD3+ CD4+ / IL-4 0.49 (0.44) 0.46 (0.73) 
Th17 CD3+ CD4+ / IL-17 0.82 (0.80) 0.81 (0.77) 
T reg CD3+ CD4+ / IL-10 0.26 (0.39) 0.23 (0.50) 
T reg CD3+ CD4+ CD25h; 0.055 (0.18) 0.056 (0.19) 
CD127'0 / Foxp3 + 
* Expressed as percentage of total T-helper cells (CD3+ CD4+); # Paired t-test of log-t ransform ed 
distributions 
0.23 
0.60 
0.82 
0.55 
0.26 
There was no statistical difference in the percentage of helper T-cell subsets when comparing 
levels pre-vaccine with 21-days post-immunisation (where paired results were available). 
Table 7.15 shows data for each of the T-helper subsets pre- and post- KLH immunisation by 
UVR group. Pre-immunisation Th17 cell percentage was higher in the low UVR group 
compared with the higher UVR group, approaching statistical significance (1.0% vs. 0.61%; 
p=0.076). 
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Table 7.15 : T-helper cell subsets{%) pre- and post-immunisation by UVR exposure group 
Pre-vaccine Post-vaccine 
T-helper Mean {SD) %cells (SD) 
subset Low UVR High UVR p Low UVR High UVR p 
(n=27) (n=28) value* (n=24) (n=26) value* 
Thl 7.2 7.2 0.99 5 .8 7.8 0.17 
(6.0) (5.6) (4 .8) (5 .5) 
Th2 0.40 0.57 0.15 0.50 0.43 0.76 
(0 .38) (0.49) (0 .96) (0.43) 
Th17 1.0 0.61 0.076 0.71 0.90 0.39 
(1.0) (0.47) (0 .68) (0.84) 
Treg {IL-10 0. 27 0.25 0.88 0.31 0.16 0.30 
staining) (0.40) (0 .38 ) (0 .69) (0.23) 
Treg* 0.060' 0 .052b 0.10 0.057' o.o55d 0.70 
(Foxp3+) (0 .019) (0 .016) (0 .019) (0 .019) 
a: n;:;26; b: n:;;28; c: n=23; d: n=26; * using t-tests of log-transfo rmed distributions to assess significance 
NB: T-helper subsets expressed as percentage of tota l T-hel per cells (CD3+ CD4+) 
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Following on from the previous data, Graphs 7.12 A➔ E, illustrate the difference in the 
percentage ofT-helper cell subsets pre- and post-vaccine (i.e. using individuals with paired 
data, pre-vaccine percentage was subtracted from day-21 post-immunisation percentage) 
comparing low and high UVR exposure groups. 
Graph 7.12: Change in proportion of T-helper lymphocytes: by UVR exposure group 
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The Thl 7 subsets demonstrated the most significant difference in percentage pre- and post-
immunisation time points when comparing low with high UVR exposure (-0.39% vs. 0.31%; 
p=0.004).(Graph 7.12c). The contributions to this difference can again be seen in the data 
presented in Table 7.15 - in participants with low UVR exposure, the percentage ofTh17 ce lls 
was significantly higher in the pre-vaccine compared with post-vaccine group (1.0% vs. 0.71%; 
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p=0.033; paired t-test of log transformed data). Conversely, in the high UVR exposure group, 
Th17 cell percentage was higher in the post-vaccine group than pre-vaccine, (0.90% vs. 0.61%; 
p=0.075). 
Given that there were no significant differences in Th17 cell percentage between time-points 
when UVR exposu re was not considered, this indicates a possible interaction involving 
immunisation and UVR exposure influencing Th17 expression . 
Summary 
Ex vivo testing of cell-mediated immune response was undertaken on lymphocytes using flow 
cytometry methods to enumerate effector T-helper cell subsets by identifying their ce ll surface 
markers and intracellular cytoki ne profile. KLH specific testing was not undertaken for this 
component of the study. 
Lymphocytes analysed for this component of the study were taken from participants who had 
experienced extremes of UVR exposure. The significant findings involved Th17 subsets . 
Participants with low UVR exposure pre-immunisation had a higher Th17 cel l percentage than 
those with high UVR exposure, w hich approached statist ical significance. There was a 
significant difference in the change in Th17 cell percentage pre- and post- immunisation when 
compared by UVR exposure group. 
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7.2 Vaccine-related safety issues 
KLH immunisation and skin testing were very well tolerated . Table 7.16 shows the number of 
adverse events documented amongst AusUVI Study participants . The most common adverse 
events were transient erythema or pruritus at the site of KLH immunisation . 
Table 7.16: Vaccine-associated adverse events 
Site 
Adverse event classification* 
Canberra Townsville Total 
Serious Adverse events: 0 0 0 
Unexpected adverse events: 0 1 1 
Adverse Events: 4 1 5 
* Definitions: 
Adverse event: Any untoward medical occurrence in a clinica l investigation subject administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with this 
t reatm ent. 
Unexpected adverse drug reaction : An adverse reaction, the nature an d severity of which are not 
consistent with past clinica l experience with the adm inistered agent. 
Serious adverse reaction : A serious adverse event (experience) or react ion is any untoward medica l 
occurrence that at any dose results in death or is life threatening. The term "life threaten ing" refers to an 
event in which the patient was at risk of death at the t ime of the event; it does not refer to an event which 
hypothetical ly might have caused death if it were more severe. 
An unexpected adve rse event occurred in a 20-year old female participant who developed 
num erous skin lesions (macular, 2-3mm in diameter) bilaterally on the hands and forearm s, 
ten days following immunisation. The lesions resolved after several days with no specific 
treatment. Her general practitioner performed a skin biopsy which revealed non-specific 
spongiform dermatitis. This reaction had not previously been noted following KLH 
administration. The Safety Monitoring Board (5MB) and the Therapeutic Goods 
Administration were notified of this event. The SMB concluded that a causal relationship 
between KLH immunisation and the skin reaction remained a possibility in the absence of 
another explanation, but did not recommend any changes to study protocol. The full details of 
this adverse event are presented in Appendix L. 
There we.re no serious adverse events experienced by AusUVI participants related to 
immunisation. 
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7.3 Chapter summary 
Linear regression models were used to determine the association between UVR exposure 
(both acute and cumulative), other potential immunomodulatory variables and measures of 
immune function (both antigen and non-antigen specific). Data from participants with high 
inflammatory markers were excluded from further ana lyses as inflammation at the time of 
immunisation may have influenced other baseline and subsequent immune outcome 
measures. 
On multiple regression analyses, higher anti-KLH lgGl response was only significantly 
associated with younger age and female sex. There was no association noted between the 
humoral immune response and cumulative UVR exposure or acute UVR exposure on any day 
or combination of days before or after immunisation . The simple linear association between 
higher serum 2S(OH)D level (~S0nmol/L) and higher anti-KLH lgGl titres, did not persist after 
inclusion of other immunomodulatory variab les. 
KLH-specific DTH responses were significantly reduced in association with higher personal 
clothing-adjusted UVR exposure on the day prior to immunisation (Day 5), as well as Days 5 - 8 
and Days 5 - 9, which spanned the day prior to immunisation to three to four days fo llowing. 
KLH-specific assays (DTH and anti-KLH lgGl at 21 days post-immunisation) were positively 
correlated, consistent with the assumption that both reflected Thl ce1I-mediated processes. 
A preliminary study using non-antigen specific ex vivo assays to enumerate sub-populations of 
T-helper cells showed evidence of a possible interaction between UVR exposure, 
immunisation and Th17 cells . 
HMW-KLH was very well tolera ted as both a subcutaneous immunisation and an intra-dermal 
skin test. No severe adverse events were reported, and only minor, transient reactions were 
noted. 
The following chapter wi ll discuss the significance of the findings from this study and how they 
relate to the overall literature. 
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Chapter 8: Discussion and Conclusions 
Synopsis 
This chapter discusses the results of the AusUVI Study in light of the current literature, and the 
study's contributions to the overall understanding of UVR-induced immunomodulation . 
Limitations of the study are discussed and plan s for future work outlined. 
8.1 Summary of study 
The AusUVI Study is the largest study to date to have assessed the immunomodulatory 
influence of UVR on immune function in humans. The longitudinal observational study design 
was carefully planned and conducted, reflecting recommendations of relevant 
immunotoxicology guidelines and literature (22,23). Unique amongst studies in this field, 
much effort was made to characterise the participant cohort in terms of demographic, 
behavioural, physical and physiological attributes. This allowed adjustment for potential 
immunomodulatory variables apart from UVR exposure that might confound or modify the 
association of primary interest. Contemporaneous measurement of serum 2S(OH)D levels 
allowed for assessment of an independent immunomodulatory effect of UVR exposure. 
Immunisation with the novel protein antigen KLH allowed for a safe, reliable and controlled 
immune challenge. A range of humoral and cell-mediated immune responses was measured 
with validated and sensitive assays. Importantly, immunisation was delivered subcutaneously, 
adjacent to the dermis and epidermis that constitute the relevant biological interface for UVR 
exposure. Prior immunisation studies in this field have·used an intra-muscular route (19,209) 
and at a high antigen load, thus producing a strong systemic immune response potentially 
masking the immunomodulatory influence of UVR exposure. 
Personal solar UVR exposure was directly measured with electronic dosimeters during usual 
activities of daily living, an important advance on previous studies that either used surrogates 
of UVR exposure (e.g. season of vaccination), high UVR doses and/or irradiation with a non-
solar UVR spectrum. Additionally, recruitment of participants across all seasons, at sites 
situated over a large latitudinal gradient and of outdoor workers, allowed for a wide range of 
measured personal UVR exposures. The narrow participant inclusion and exclusion criteria 
maximised the potential to detect the immunomodulatory signal of UVR exposure, thereby 
improving the study's internal validity. 
The AusUVI Study successfully recruited the target number of participants in the required 
time-frame. There was a low rate of participant drop-out after initial enrolment, and this was 
offset by increased overall recruitment. Immunisation with KLH was well tolerated . 
218 
Storage of serum and PBMC samples will enable future genotyping studies (e.g. for cytokine 
single nucleotide polymorphisms) and immune assays. 
8.2 Key findings 
8.2.1 Pilot study 
A group of young, healthy and fair-skinned adult volunteers were randomised to a UVR-
exposure group or control group. Five days of sub-erythemal solar-simulated UVR at the site of 
subsequent sub-cutaneous KLH immunisation resulted in a relative reduction of KLH-specific 
DTH response of 56% (p=0.10) compared with the non-irradiated control group. Whilst not a 
statistically significant finding in this small pilot sample (n=21), the result was consistent with 
previous work that had used solar-simulated UVR protocols and DTH response outcome 
measures (albeit with different antigens and testing regimes) (15,185) . There were no 
significant differences in anti-KLH antibody responses between UVR-exposed and control 
group at 21 days post immunisation . The most differentiating humoral assay was the anti-KLH 
lgGl sub-class ELISA. The mineral oil adjuvant used to enhance the immune response to sub-
unit KLH was associated with a moderate incidence of local, transient adverse skin reactions 
and was therefore not used in later studies. Conducting this pilot study allowed trialling and 
refinement of recruitment strategies, study protocols, immunisation and immune function 
testing procedures which informed the planning of the larger AusUVI Study. 
8.2.2 AusUVI Study 
Demographic information 
The AusUVI Study recruited 222 healthy adult volunteers, aged between 18 and 40 years, over 
the period July 2010 to August 2011 from study sites in widely spaced latitudinal locations 
(Canberra (35°15'5) and Townsville (19°15'5)). The participants were predominantly indoor 
workers recruited from university ca mpuses and hospital staff. Approximately two thirds of 
participants were female and three-quarters were of northern European ethnicity. Over 90% 
of participants reported undertaking moderate to high levels of physical activity in the week 
prior to enrolment. Just over one-third of participants were classified as overweight or obese 
according to their BMI. A minority of participants were current smokers. 
Vitamin D status 
Participants' serum 25(OH)D levels showed a marked seasonal variation over the year, with 
participants enrolled in winter and spring having significantly lower levels than those enrolled 
in summer or autumn. Canberra participants and those with non-northern European common 
parental ethnicity, had a significantly lower seasonally-adjusted 25(OH)D level than their 
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Townsville and northern European counterparts, respectively. These results are in keeping 
with previous Australian research that found latitude and season explained a significant 
proportion of 25(OH)D level variation in study populations of non-elderly adults (490). The 
addition of a crude categorisation of ethnicity to our regression models increased the 
explanation of variat ion in 25(OH)D levels to~ 37%. It is likely that cultural, gender and age 
differences in diet, clothing and sun exposure behaviour and protection between participants 
also contributed significantly to the variation in 25(OH)D levels. This is the subject of ongoing 
research stemming from this dataset. 
Personal UVR exposure 
In an innovative measure of personal UVR exposure in immunotoxicological research, 
participants wore electronic UVR dosimeters on their wrist for ten days and completed 
comprehensive diaries describing time spent outdoors and clothing items worn over the same 
period. After identifying and cleaning erroneous data, interpolating missing data (based on 
corresponding diary data and ambient UVR measurements) and adjusting for body surface 
area covered by clothing, a daily quantification of personal UVR exposure was obtained. These 
data again showed seasonal variation in personal UVR exposure at both study sites that was 
more pronounced amongst Canberra participants. Townsville participants had significantly 
higher clothing-adjusted personal UVR exposures in the winter month_s compared with 
Canberra participants; though at other times of the year, UVR exposures were not statistically 
different between sites. Participants enrolled in winter in Canberra had significantly lower 
average adjusted UVR exposures than at other times of the year at this site. Average personal 
UVR per day was significant ly higher on weekends compared with weekdays, reflecting 
increased recreational time on weekends and consistent with previous research (437). 
Participants of northern European heritage had significantly higher leve ls of personal UVR 
exposure compared with those of non-northern European heritage, after adjustment for 
season of enrolment. A recently published study (491) showed that south Asian women (aged 
20 - 55 years) living in the United Kingdom had markedly low serum levels of 25(OH)D 
throughout the year (~95% with levels< 50nmol/L), with a main contributory factor being low 
UVB exposure as measured by polysulphone badges (compared with Caucasian controls). 
Again, this may reflect cultural differences in outdoor behaviours and physical activity and 
reluctance for tanning in non-white populations (492). As would be expected, outdoor 
workers had significantly higher personal UVR exposures compared with indoor workers 
consistent with previous Australian research (421). Similarly, those categorised in the highest 
physical activity group by the International Physical Activity Questionnaire, had significantly 
higher personal UVR exposure than those in the moderate category (and non-significantly 
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higher than the low activity group). This association between increased physical activity and 
UVR exposure has been highlighted in many studies (371-373) . 
UVR exposure over the life course (i.e. cumulative exposure) was measured by analysing the 
microtopography of skin from the dorsum of the hands obtained by silicone cast impressions. 
As found in other Australian studies (374,440,493), higher skin cast grades were associated 
with increasing age, male sex, European heritage and casts taken from the right hand. A 
significantly increased skin cast score was found in participants from Townsville compared with 
Canberra likely related to higher year-round ambient UVR exposure. This observation was not 
found in the only other comparable large multi-centre Australian study (440) that examined 
skin casts, which may be attributable to older age groups being included in that research (49% 
over the age of 40 years) with changing regions of residence over the life-course tempering the 
association. No association between increased skin cast score and cigarette smoking (either 
current or past smoking) was evident, although this may be due to the low smoking rate and 
younger participant cohort compared with other comparable studies (374,494) . 
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8.2.3 UVR exposure and immune responses 
Humoral response 
Anti-KLH lgGl antibodies were assayed at baseline (day of immunisation), 7 and 21 days post-
immunisation. Baseline titres were not significantly different from non-immunised control 
serum and day 7 post-immunisation titres were minimally raised (consistent with the expected 
two to three week lag in the generation of an lgG antibody response (134)). Therefore, to 
determine associations with putative immunomodulatory factors, the antibody responses at 
day 21 post-immunisation were examined. 
Multiple linear regression ana lysis including al l relevant immunomodulatory variables showed 
that only age and sex were significantly associated with anti-KLH lgGl response. Age was 
negatively correlated with antibody response (adjusted regression coefficient: -0.016; 
p=0.001). A meta-analysis of studies assessing the effect of age on immune response to 
recombinant DNA hepatitis B vaccination found that 'older age' was significantly associated 
with a higher rate of serological non-response at least one month following the last dose of 
vaccination (312). This effect was seen also in included studies where 'older age' was defined 
as> 30 years of age. In previous studies using KLH vaccine, only Smith et al (358) reported age-
stratified humoral responses following immunisation. They found that younger participants 
(aged 20 -35 years) had higher anti -KLH total lgG and lgM antibody tit'.es compared with older 
participants (aged 65 - 79 years) up to four weeks post-immunisation . Notably, physical 
activity status interacted with age for anti-KLH lgGl titres (i.e. decreasing titres in the following 
order: physically active older participants> physical active younger participants > sedentary 
younger participants> older sedentary participants). There was no such interaction between 
age and physical activity for antibody responses in the present study. 
Female AusUVI Study participants demonstrated significantly higher anti-KLH lgGl titres than 
males (15% increased titre; p<0.001). Previous vaccination studies have shown differences in 
serologica l response by sex, varying by vaccine antigen used and population assessed (326). In 
previous KLH vaccine studies there has been no reporting of the differences in anti-KLH 
humoral responses by sex (noting that for several studies, only participants of one sex were 
recruited (e.g. 11,13)). 
UVR exposure and anti-KLH lgGl response 
No association was found on simple or multiple regression analysis between measures of acute 
personal UVR exposure and anti-KLH lgGl response at 21 days post-immunisation . This was in 
keeping with the only other comparable controlled human immunisation study by Sleifjjers et 
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al (19) which had used hepatitis B vaccination to assess the humeral and cell-mediated 
immunomodulatory effects of UVB irradiation. 
In that Dutch study conducted over two consecutive winter seasons, 191 participants (age 
range 19 - 52 years, median 21 years) were randomised to either a control group or UVB 
irradiation group. The irradiated group received 1 personal MED of whole body UVB exposure 
daily for five days. Both groups were vaccinated intramuscularly with a commercially available 
recombinant DNA hepatitis B (HBsAg) vaccine to the upper arm. The vaccine contained an 
aluminium hydroxide adjuvant (known to promote a Th2-mediated humeral response). 
Vaccination in the irradiated group commenced three days after the last UVB dose. 
Participants were vaccinated at baseline, one month and six months. Vaccine-specific (anti -
HBsAg) lgG antibodies were assayed at seven time points - at baseline, and at various times 
following the first and second vaccinations (up to 60 days post initial vaccination). There was 
no statistically significant difference in anti-HBsAg lgG responses between UVB exposure 
groups at any time points following the first and second vaccinations, although there was a 
non-significant trend towards a higher antibody response in the irradiated group at the later 
time points. 
A follow-up study which stratified participants according to cytokine polymorphism status 
found that irradiated participants who were homozygous for the min~r allelic variant of IL-1~ 
(n=S) had significantly suppressed anti-HBsAg lgG levels compared with non-irradiated 
homozygous controls (n=4) (328). This polymorphism variant is known to be associated with 
an approximately four-fold increase in IL-1~ production.; stimulation by UVB exposure could 
result in an immunosuppressive cascade (IL-1~ ➔ prostaglandins, IL-4 and IL-10), ultimately 
leading to suppression of antibody response (7). Notably, participants homozygous for the 
minor allelic variant of IL-1~ also demonstrated higher personal MED values compared with 
those homozygous for the wild-type variant or with heterozygous profiles. These data 
suggested that the minimal immunosuppressive dose for UVB was not directly associated with 
the personal MED for UVB (19). 
There have been no controlled clinical studies in humans where antibody responses have been 
correlated with UVR exposure following immunisation . However, Wang and colleagues (178) 
studied the effect of UVR exposure post-immunisation in mice using various T-cell dependent 
(TD) antigens (e.g. ovalbumin) and T-cell independent (Tl) antigens (e .g. trinitrophenol (TNP)-
LPS). Mice were exposed to a single dose of UVB seven days following immunisation, whereas 
control a~imals were not irradiated. Antibody response to TD antigen-immunisation was 
significantly suppressed in UVR-exposed animals compared with controls but immunisation 
responses to Tl antigens were not affected. Further experimentation involving adoptive 
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transfer of CD4+ T cells from irradiated immunised animals to controls demonstrated that 
regulatory T cells (IL-10 producing; Foxp3-) were responsible for a reduction in antigen-specific 
antibody response. Caution is needed in extrapolating from such animal studies, but these 
striking results warrant further examination in human studies. 
Delayed-type hypersensitivity response 
In the tradition of many other photoimmunology studies, DTH testing was used to assess the 
influence of UVR on the in vivo cell-mediated (Thl) immune response. Here, 21 days following 
immunisation (sensitisation) with KLH antigen, an intra-dermal dose of antigen was injected at 
the same site and subsequent wheal reaction observed 48 hours later. After adjustment for 
postulated immunomodulatory variables, only UVR exposure at various time-points relative to 
immunisation was significantly associated with the DTH response. Female sex was associated 
with a higher DTH response compared with males on simple linear testing but not after 
multiple linear regression adjustment. Previous studies have shown an association between 
psychological distress and the DTH response to KLH vaccine (335,342), but this was not seen 
here, despite si milarities in study population and design. The volunteer basis for recruitment 
in the present study may have affected the prevalence of participants with certain 
psychological characteristics (i.e. distressed individuals may have been less likely to volunteer 
for the AusUVI Study). 
UVR exposure and DTH response 
On multiple linear regress ion modelling, clothing adjusted-UVR exposure on Day 5 of electronic 
badge monitoring (i.e. the day prior to immunisation) demonstrated a strong association with 
subsequent DTH response, as did aggregated UVR exposure over Days 5 to 8 and Days 5 to 9. 
At these times, higher personal UVR exposure was correlated with reduced DTH response, 
which supports the hypothesis (and previous research) that solar UVR exposure suppresses the 
antigen-specific cell-mediated immune response to antigen sensitisation. 
Several studies have shown evidence that UVR exposure in the days prior to antigen 
sensitisation is critical in modifying subsequent measures of in vivo cell -mediated immunity 
(191,193,198). For example, in the study by Kelly et al (198), healthy Caucasian participants 
aged 18 - 35 years of varying skin phototypes (I to IV) received a single solar-simulated UVR 
(55-UVR) exposure of varying dose (0 to 3 MED) to a 5 x 5cm area on the buttock. At 24 hours 
post UVR exposure, participants underwent sensitization with the contact allergen 2,4-
dinitrochlorobenzene (DNCB) at the site of irradiation and elicitation of a subsequent contact 
hypersensitivity (CHS) response occurred 21 days later. The study found that : i) UVR exposure 
was associated with reduced CHS responses in a dose-dependent manner; ii) skin phototypes 
1/11 were more sensitive to UVR exposure than phototypes Ill/ IV; iii) sub-erythemal doses of 55-
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UVR exposure (including down to 0.25 MED) were associated with significant 
immunosuppression in Type 1/11 phototype skin; and iv) there was (unexplained) seasonal 
variation in CHS responses (with summer> winter responses). Notably, the AusUVI Study did 
not show evidence of varying sensitivity to immunosuppression of DTH response by season or 
by skin phototype. 
Research by Damian et al (190) showed that the effect of UVR exposure on subsequent CHS 
response varied by timing of exposure and UVR spectrum. Groups of healthy adult volunteers 
(predominantly female) of varying skin phototypes (1-V) and with confirmed nickel allergy were 
exposed to one, two, three, four or five days of sub-erythemal SS-UVR and UVA to separate 
areas of the back. Nickel patches were placed on the irradiated skin and adjacent non-
irradiated sk in, immediately after the last UVR dose for groups exposed to three, four or five 
days radiation, and 24 hours after the last UVR dose for groups exposed to one or two days 
radiation. The degree of immunosuppression was assessed by comparing reflectance meter 
measurement of allergic erythemal respo nses from irradiated skin with non-irradiated skin. 
The investigators found a significant reduction in erythemal response in irradiated skin after 
just one day of SS-UVR, reaching maximal levels by two days and sustained suppression with 
up to five days exposure. In contrast, UVA-associated immunosuppression peaked at three 
days irradiation and subsided with further exposures. 
Most other studies that have used an in vivo model for assess ing UVR-modulated cell-
mediated immune response have used a longer protocol for UVR exposure (i.e. over a number 
of days or weeks), making it difficult t o tease out which _are the most critical days of UVR 
exposure prior to sensitisation. Indeed there is no consensus in the literature for the duration 
or intensity of UVR exposure prior to immune function testing, and consequently many 
different study designs have been used (183,184). 
The interpretation of the finding that UVR exposure spanning the day before sensitisation to 
two or three days following (Days 5-8; 5-9, respectively) was associated with reduced DTH 
response requires consideration. This result could indicate a persistent suppressive effect of 
the UVR exposure prior to sensitisation, or alternatively, that there was an augmentation of 
the immunosuppressive effect by post-immunisation UVR exposure (presumably via ongoing 
impairment of antigen presentation and promotion of a regulatory T-cell environment within 
the draining lymph node). The lack of a statistically significant association between UVR 
exposure on Days 6-8 or 6-9 and DTH response lends support to the former, rather than latter, 
explanation. There is minimal previous research to assist in the interpretation of these results 
and no relevant human data. In a series of murine experiments (495,496), Nghiem and 
colleagues found that UVA and SS-UVR exposure seven to nine days following sensitisation 
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with Candida a/bicans led to maximal reduction in elicitation of a subsequent antigen-specific 
DTH response. Toda et al (181) showed that mice immunised with a tumour-associated T-
dependent antigen (ovalbumin) then irradiated (with predominantly UVB) seven days post-
immunisation, had significantly reduced anti-tumour immune response compared to non-
irradiated controls when subsequently re-challenge with ovalbumin. The authors ascribed this 
result to post-sensitisation UVR suppression of antigen-specific cytotoxic T cell response, 
mediated by IL-10 producing regulatory T cells. 
UVR exposure and T-helper cell subsets 
Enumeration of helper T lymphocyte populations (Thl, Th2, Th17 and Treg) was undertaken by 
staining for their signature intracellular cytokines (interferon-y, IL-4, IL-17 and IL-10, 
respectively) with subsequent fluorescent antibody cell sorting (FACS) by flow cytometry. A 
further assay to enumerate regulatory T cells (Foxp3+ CD25 h; CD12i0 ) was also conducted. 
These non-antigen specific assays were performed on peripheral blood mononuclear cells 
(PBMCs) sampled at baseline (pre-immunisation) and 21 days post-immunisation. Due to the 
time-consuming nature of these assays, samples from only a subset (n = 55) of the total 
AusUVI participant group were analysed, selected to represent extremes of personal UVR 
exposure. 
No association was found between personal UVR exposure and the proportions of Thl, Th2 or 
Treg cells isolated pre- or post-immunisation. Prior research suggests that the effect of UVR 
exposure on immune responses is an antigen-specific one, so that the findings from the 
present study are not inconsistent with the bulk of existing literature. However, an interesting 
recent study (497) suggests that chronic, but not acute, UVR exposure can affect the 
proportions of T helper cell populations in a non-antigen specific manner. Here, investigators 
exposed mice to either acute UVR (four consecutive days of 0.5 MED) or chronic UVR (20 days 
of 0.25 MED), then examined for evidence of local and systemic immunomodulation. The UVR 
emission spectrum ranged from 280-370 nm (peak 302nm) and included 20-30% UVA. For 
both UVR groups, there was evidence of local skin changes, with epidermal hyperplasia and 
reduced epidermal T-cell density. Systemical ly, acute UVR exposure led to an increase in 
inguinal lymph node (ILN) T-cell responsiveness to a non-specific T-cell mitogen (ConA), 
whereas chronic UVR led to a suppressed response. Furthermore, chronic UVR exposure was 
associated with changes in IL-4, IL-10 and IFN-y production in ILN and splenic T-cells. 
Notable findings in the AusUVI Study, however, were the apparent associations between Th17 
cells, UVR-exposure and immunisation status. Pre-immunisation, participants with low UVR 
exposure had a higher Thl 7 cell percentage than participants with high UVR exposure, 
approaching statistical significance (p=0.076). Though speculative, this finding would be 
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consistent with experimental findings showing high UVR exposure suppressed the 
development ofTh17-mediated processes such as experimental autoimmune 
encephalomyelitis (EAE) (a demyelinating condition of the central nervous system) in mice 
(498). 
Additionally, there was a significant difference in Thl 7 cell percentage between pre- and post-
immunisation when comparing low with high UVR exposure (-0.39% vs. 0.31%; p=0.004). The 
main contributor to this was a fall in Thl 7 cell percentage post-immunisation in the low UVR 
group (1.0% vs. 0.71%; p=0.033); however, there was also a similar magnitude but non-
significant rise in Th17 cell percentage post-vaccine in the high UVR group (0.61% vs. 0.90%; 
p=0.075). Given that there were no significant differences in Th17 cell percentage between 
time-points when UVR exposure was not considered, an interaction involving immunisation 
and UVR exposure is possible. 
The reason for the apparent down-regulation ofTh17 cells post-immunisation in the low UVR 
group and the up-regulation ofTh17 cells in the high UVR group is not clear. One potential 
explanation of the latter phenomenon involves the interaction of UVR-induced breakdown 
products, the aryl hydrocarbon receptor (AHR) - an important ubiquitous transcription factor, 
and antigen stimulation. UVR exposure leads to the breakdown of tryptophan (a keratinocyte 
chromophore), forming intracellular 6-formylindolol[3,2-b]carbazole (FICZ) that acts as a high 
affinity ligand for the AHR (499). The AHR is a ligand-activated transcription factor expressed 
in the cytoplasm of many cell types and has been implicated in an increasing number of 
immunomodulatory functions (500) . It has been recentJy shown that FICZ-mediated AHR 
activation is an important UVB-induced stress response in epidermal keratinocytes, leading to 
the expression of numerous genes (499). In mouse and human models, Th17 cells have 
recently been shown to exhibit high levels of AHR; stimulation by FICZ leads to proliferation of 
Th17 cells and increased expression of cytokines IL-17 (A and F) and IL-22 (501,502). Th17 cells 
have been recently implicated in the pathogenesis of an increasing number of autoimmune 
diseases (503-505). In a landmark paper, Veldhoen et al (504) demonstrated that EAE could 
be induced experimentally in mice by immunising with myelin oligodendrocyte peptide 35-55 
(MOG3s.s5). In mice also injected with FICZ at the time of MOG35.55 immunisation, not only 
were the numbers of IL-17 staining T-helper cells in spinal cord tissue higher than in control 
mice (e.g. AHR deficient mice or mice not given FICZ), but progression to disease onset was 
also significantly faster. This study supports the findings of the AusUVI Study, suggesting that 
UVR-induced formation of AHR ligands (e.g. FICZ) in the setting of antigen processing (i.e. 
immunisation) promotes IL-17 production by T helper cells. 
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The above mechanisms are speculative and cannot be confirmed by the data presented in this 
thesis. A research design that would better ascertain whether there is an interaction between 
UVR exposure and immunisation in promoting Th17 cell expression would involve 
unimmunised and immunised groups exposed to differential levels of UVR (over the duration 
of the study). In this way, a 2x2 table could be generated, where only those immunised and 
exposed to UVR would be expected to have a change of IL-17 expression over time (see Table 
8.1) 
Table 8.1: 2 x 2 Table resulting from an experimental design that demonstrated the 
interaction between UVR exposure and immunisation on Th17 lymphocyte populations 
NoUVR UVR 
Not Immunised No change over time No change over time 
Immunised No change over time Change over time 
8.2.4 Vitamin D status and vaccine-associated immune responses 
Previous research has demonstrated that calcitriol has a significant immunomodulatory role 
(largely regulatory) within the adaptive immune system. Low vitamin D status has also been 
epidemiologically linked to increased rates of various Thl-mediated autoimmune disorders 
(See Section 2.4). An important research question for the present study, therefore, was to 
assess how 25(OH)D status related to vacci ne-associated immune responses . On simple linear 
testing, participants with serum 2S(OH)D levels ~50nmol/L had a significantly higher anti-KLH 
lgGl titre than participants with 2S(OH)D levels <50nmol/L (0.67 vs. 0.57; p=0.049). However, 
the association did not persist when this variable was included (either as a continuous or 
dichotomous measure) in a multiple regression model. No association was found between 
serum 25(OH)D level and anti-KLH DTH response . 
Studies assessing the relationship between vitamin D status and vaccine-associated an tibody 
response have shown mixed results. In a recent study evaluating responses to T-cell 
dependent vaccines in post-splenectomy patients, 25(OH)D levels did not differ between 
'responders' and 'hypo-responders' to pneumococcal and meningococcal conjugate vaccines 
(506). However, there was a weak (but significant) negative correlation between 25(OH)D 
level and Haemophilus influenzae Type B antibody titres post- immunisation. Other studies 
have mainly examined immunosuppressed populations where low 25(OH)D levels have been 
associated with poor vaccine-specific antibody responses. These include hepatitis B vaccine 
response in patients with chronic renal failure (507) and influenza vaccine responses in 
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patients with prostate cancer (508). Low 25(OH)D levels in these groups may also reflect co-
existing poor nutrition, physical condition and psychological state which may also lead to 
suboptimal vaccine response. 
The use of serum 25(OH)D levels as a surrogate for the activity of calcitriol in peripheral tissues 
may have contributed to the inconsistent findings of laboratory, clinical and epidemiological 
studies in this area. Clinical and epidemiological studies use serum 25(OH)D levels - a stable 
measure of vitamin D stores (509). However, given the short circulating half-life (6-8 hours) 
and tight regulation of calcitriol production (by parathyroid hormone, phosphate levels and 
other molecules independent of 25(OH)D), a linear relationship between serum 25(OH)D and 
calcitriol levels does not occur (2). Furthermore, extra-renal synthesis of calcitriol by immune 
cells is likely to play a significant role in immunomodulation via paracrine and autocrine 
mechanisms (107). Therefore, serum 25(OH)D levels are unlikely to be useful as a calcitriol 
surrogate where the immunomodulatory effect on vaccine response is postulated to occur 
cutaneously or within the draining lymph node. 
Relatedly, research has been performed assessing the local effect of exogenous calcitriol on 
immune responses. Animal studies have demonstrated that co-administration of calcitriol 
with various vaccines (including herpes simplex virus, hepatitis B surface antigen, tetanus 
toxoid and influenza virus) enhanced the mucosal +/- systemic antibody response to 
immunisation (510-513). However, a randomised, double-blind clinical trial in humans that 
evaluated the efficacy of calcitriol co-administered with influenza vaccine, did not reveal 
similar evidence of local calcitriol-induced immunom9dulatory activity (514). 
Finally, despite the initial (and ongoing) enthusiasm for vitamin D supplementation for 
prevention of autoimmune disorders such as multiple sclerosis, the evidence thus far of its 
effectiveness is weak and conflicting (236). This raises the question of whether low serum 
25(OH)D levels simply reflect low UVR exposure, and that it is this latter factor which is most 
contributory to the development of immune-mediated disease (236). Given that for the 
majority of the population, vitamin D stores depend on UVR exposure, it is methodologically 
challenging to identify the independence of effects in epidemiological studies (although it has 
been attempted (515)). 
The results of the AusUVI Study support the hypothesis of a direct UVR suppressive effect on in 
vivo antigen-specific cell-mediated response independent of serum 25(OH)D levels . 
8.2.5 Evidence for photoadaptation or photoprotection 
As discussed in Section 2.3.9, there is minimal evidence in the literature to suggest that photo-
sensitive immune parameters "photo-adapt" (or "photo-protect") with repeated UVR exposure 
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of skin (reviewed in (8)). Most of the studies reviewed however, made their conclusions based 
on just several weeks (or months) of repeated UVR exposures, delivered to small areas of skin 
and/or using non-solar UVR spectrum. 
The AusUVI Study offered a unique opportunity to assess whether photoadaptation occurred 
using measures of acute and cumulative UVR exposure in relation to both DTH and humoral 
responses. Table 8.2 shows the theoretical changes expected in the setting of no 
photoadaptation (DTH responses: "A") or photoadaptation (DTH responses: "B"). 
Table 8.2: Postulated changes in DTH response in the setting of photoadaptation 
Acute UVR 
exposure 
Cumulative UVR 
Exposure 
low 
High 
Low 
A: Normal/ B: Normal 
A: Decreased/ B: Normal 
Key- A: No photoadaptation; B: Photoadaptation apparent 
High 
A: Decreased / B: Decreased 
A: Decreased/ B: Normal 
In the AusUVI Study, skin casts were used as a measure of cumulative UVR exposure over the 
life course. Participants with higher skin cast scores (~Grade 4) demonstrated lower DTH 
responses than lower grade skin grades (:S3.5), however, this was not statistically significant 
(6.6mm vs. 7.5mm; p=0.20). When adjusted for skin cast grade in the multiple variable 
analysis, the association between acute UVR exposure (i.e. on Day S) and DTH response 
remained significant suggesting that cumulative UVR exposure did not modify the 
immunomodulatory influence of acute UVR. There was no association between cumulative 
UVR exposure and anti-KLH lgGl response. Taken together, the data presented do not support 
the hypothesis that immune processes of the skin 'photo-adapt' to the immunosuppressive 
properties of UVR. 
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8.3 Clinical implications of the AusUVI Study 
KLH fulfilled many of the attributes of an ideal vaccine antigen for use in an 
immunotoxicological study (see Section 3.2.2.3.2). However, unlike the antibody response to a 
commercial vaccine (e.g. hepatitis B, measles, rubella) where a known minimum titre 
(threshold) corresponds to likely clinical protection from disease based on longitudinal 
research (289), there is no level of anti -KLH vaccine response that corresponds with clinical 
outcome. This is sim ilar for anti-KLH DTH response, in comparison to the established 'cut-offs' 
for the Mantoux test for example, that gives information regarding prior exposure to 
tuberculosis (or BCG vaccination) (291). In the AusUVI Study, therefore, anti -KLH humoral and 
DTH responses were analysed as continuous variables with no attempt to classify as " high" or 
" low", "protected" or "not-protected", or some other arbitrary grouping. 
The influence of UVR on anti-KLH responses following immunisation can be viewed as 
representative of the effect of UVR on any T-dependent antigen that the skin may encounter. 
In this way, response to KLH immunisation acts as a 'sentinel' marker of potential 
immunomodulation by an environmental exposure. Thus the finding of reduced KLH-specific 
DTH response associated with higher natural so lar UVR exposure on the day prior to 
immunisation, could also indicate reduced host immune response to skin infection where cell-
mediated (T-helper ce ll) processes are important (e.g. secondary to Candida sp. (516), herpes 
simplex virus (517)) . Reduced DTH responses in other settings have been shown to be 
associated with adverse clinical outcomes. In one large study, surgical trauma an d intensive-
care patients who exhibited anergic (absent or small) _DTH responses to ubiquitous antigens 
pre-operatively (e.g. Trychophyton, tuberculin, Candida) , had significantly higher sepsis- related 
mortality following surgery (141). This evidence could be interpreted as showing impaired 
immune processes (i.e. reduced DTH responses to ubiquitous antigens} increase the 
susceptibi lity of the host to subsequent infective complications. 
8.4 Epidemiological research and study design considerations 
The potential for adverse effects of UVR exposure on the response to vacc ines has obvious 
public health implications (143). As outlined in Section 2.3.8, a number of observationa l 
stud ies have suggested that populations vaccinated in high ambient UVR environments (i.e. 
either living at low latitudes or vaccinated in the summer months) have lower vaccine-related 
antibody leve ls compared with those in low ambient UVR environments (7) . Whilst suggestive 
of an immunosuppressive role for UVR, these types of studies succumb to the ecological fallacy 
as personal UVR exposures were not taken into account. Similarly, the contributions of other 
potential confounding factors (e .g. age, sex, nutrition, etc.} were not considered, thereby 
possibly skewing the association between UVR exposure and immune response. Controlled 
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clinical studies, such as that conducted by Sleijffers et al (19) where participants were 
randomised to a UVR exposure group and monitored prospectively for hepatitis B-specific 
antibody responses, were a significant advance on the afore-mentioned observational studies. 
Randomisation of study participants nullified the influence of potential confounding factors, 
although the success of randomisation was uncertain as stratification by immunomodulatory 
variables was not reported. 
The AusUVI Study design represented an improvement on previous studies for a number of 
reasons summarised in Table 8.2. The conduct of this study should inform future research in 
this area, particularly in relation to vaccine antigen choice and mode of administration, 
prospective longitudinal design, direct measurement of personal UVR exposure and 
comprehensive measurement of potential immunomodulatory variables. The potential for 
drawing incorrect inferences when confounding factors are not considered was illustrated by 
the significant simple association noted between serum 2S(OH)D level (as a dichotomous 
variable) and anti-KLH lgGl vaccine response -the association was no longer apparent when 
other relevant factors were adjusted for. 
The limitations of the AusUVI Study are set out in the next section . 
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Table 8.3: lmmunotoxicological study design issues: The AusUVI Study compared with previous research where vaccines were used 
Design issue Previous research Disadvantage AusUVI Study Advantage 
Measuring individual • Surrogate markers of . Ecological fallacy - can't assume all individuals • Direct UVR measures via • Quantify personal UVR exposure, with day-to-
UVR exposure UVR exposure (e.g. living in a high or low ambient UVR environment electronic dosimeters & day variation, adjusted for clothing 
66,67) experience high or low personal exposure diaries • Can assess seasonal change 
• Skin casts - cumulative UVR • Life-time UVR measurement with skin casts 
• Missing data replaced w ith interpo lated values 
Using biologically • Artificial UVR sources . Non-sola r UVR spectrum or only an • Solar UVR exposure • M easurement of biologically relevant, solar UVR 
relevant UVR (i.e. UV lamps) (19) approximation of solar UVR • At levels relevant to day-to-day living 
spectrum and dose • Low ambient UVR . UVR doses may not be relevant to day-to-day • Wide range of person al UVR doses 
environment (209) living 
. +/· Only sma ll areas of skin exposed 
. Low range of personal UVR doses 
Immunisation dose, • Commercial vacc ines . Large dose (high antigen load) - aims to • KLH antigen • TD antigen 
route and type (e.g. Hepatitis B) generate a very large antibody response • Reliable immune response to single dose 
(209,518) . Use of adjuvant (e.g. alum) which can skew • Low dose - doesn't "swamp" the immune 
• Childhood vaccinat ions immune response to Th2 processes (19) system with antigen 
(e.g. measles, polio, . Multiple vaccinations (equired (e.g. hepatitis B) • No adjuvant required 
rubella) (17,207,519,520) . Non-cutaneous route of administrat ion (e.g. IM) • Skin administration - at site of UVR interaction 
. May not be primary immunisation or TD antigen 
Accounting for • Minimal or no attempt to . Any associat ion found between UVR exposure • Careful measurement of • Allows for adjustment for other 
potential measure potential and immune outcome may be misleading due to potential immunomodulatory variables 
confounding confounding or effect non-consideration of other var iables immunomodulatory • j accuracy of the estimate of association 
variables modifying variables variables between UVR & immune outcome 
Measurement of • Non-comprehensive . Narrow set of immune tests limits analysis of the • Measurement of a range of • Able to quantify humera l and cell-mediated 
immune outcome evaluat ion of immune association between UVR and immune respon se humeral and cell-mediated immune response to immunisation 
outcome measures (e.g. immune responses • Ex vivo and in vivo testing, including functional 
66) assays (i.e. DTH) 
TD= T-cell dependent 
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8.5 Limitations 
Despite the robustness of study design, and improvements on previous human research in the 
area of UVR-induced immunotoxicology, there were a number of limitations identified . 
A strength but also limitation of the AusUVI Study was the set of strict inclusion and exclusion 
criteria for participant recruitment. They were designed to increase the internal validity of the 
study (i.e. the chance of detecting the signal of UVR-induced immunomodulation) but at the 
possible expense of generalisability to the wider population . Indeed, excluded individuals may 
have been more susceptible to UVR-induced immunomodulation. These groups might include 
children, elderly, malnourished and immunosuppressed individuals (e .g. organ transplant 
recipients appear to be highly sensitive to UVR exposure with documented increased rates of 
skin cancers and mucocutaneous infections) . 
Some tools used for measuring potential immunomodulatory variables were likely not reliable 
enough to accurately and discriminately measure the variable of interest. The International 
Physical Activity Questionnaire (IPAQ-SF) has been used extensively as a measure of physical 
activity in epidemio logical studies, but a recent systematic review concluded that the IPAQ-SF 
tended to overestimate physical activity and/or not correlate with objective measures of 
physical activity (e.g. pedometer, accelerometer) to an acceptable standard (446). The use of a 
pedometer may have been a better choice for the AusUVI Study. 
Body mass index (BMI) and albumin were used as crude measures of nutritional status of 
participants. Though convenient to measure and widely used, BMI does not discriminate 
between mass derived from lean muscle compared w i°th fat. There are also caveats related to 
gender and leptin levels (521). However, other anthropometric measures such as waist-to-hip 
ratio and skinfold thickness also have limitations and more sophisticated measures (e.g. 
electrical bio- impedance, DXA scans) have cost and/or logistic implications. Additionally, 
although most measures of body fat quantify total body fat percentage, it may be the 
distribution of fat which is more important for abnormal physiological processes and disease 
(522). 
Immune responses were measured out to 21 days from immunisation, but this length of 
follow-up may not have demonstrated the full extent of UVR-induced immunomodulation. 
However, longer periods of observation would have been logistically challenging with higher 
number of study visits and blood testing potentially leading to reduced numbers of volunteers 
or more participants dropping out of the study. Furthermore, personal UVR exposure was 
measured directly (by electronic dosimeter) only for five days either side of KLH immunisation; 
thus the study of UVR-induced immunomodulation was restricted to the antigen se nsiti sation 
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phase of the immune response. Comment therefore cannot be made on the influence of UVR 
exposure on the elicitation phase of the DTH response, for example. Nevertheless, extending 
the duration of wearing of the electronic dosimeter and/or completing of the sun diary would 
have been an additional participant burden with the likely consequence being a fall-off in the 
reliability of data recording. 
Although sunscreen worn during the days of direct UVR monitoring was recorded on the sun 
and physical activity diaries, this information has yet to be integrated into the personal UVR 
dataset. Inclusion of this additional information would clearly influence participants' personal 
received UVR dose and possibly the association with immune outcomes. However, adjusting 
for the UVR protection afforded by sunscreen is problematic. Sunscreen protection varies by 
thickness and distribution of application, sun protection factor and decay in effectiveness over 
time (e.g. towelling after swimming) (30) . There is current ly no validated method for 
correcting UVR exposure for sunscreen use based on questionnaire-derived data. 
Personal UVR exposure, as measured by the electronic UVR badge, was adjusted for the body 
surface area covered by clothing based on information obtained in the sun and activity diary. 
This adjustment was crude at best as it assumed that all clothing types provided complete UVR 
protection regardless of fabric type, weave, thickness and colour - variables known to affect 
the UVR protective effectiveness of clothing (62) . It also depended on accurate completion of 
the diary- unreliable details regarding clothing worn could lead to significant inaccuracies in 
personal UVR dose determinations. 
The clothing-adjusted personal UVR dose also did not take into account the different planes at 
which UVR arrives at the skin surface. The UVR electronic dosimeter was calibrated in a 
horizontal position, whereas anatomic regions positioned in a vertical plane (e.g. the wrist, 
trunk) can receive higher levels of radiation (523). Again, the personal UVR dose measured by 
the dosimeter and adjusted for clothing should be taken only as an approximation of the 
actual dose. However, as all participants wore the badge in the same position, there should 
not be any bias in the way the measurements were undertaken. 
To maximise the chance of detecting an immunomodulatory influence from UVR exposure, it 
was important to immunise at an anatomic site that was reliably exposed to sunlight. To this 
end, the anterior aspect of the forearm was chosen with the additional benefits of ease of 
access and ample subcutaneous tissue suitable for injection. However, this site was often 
covered by long-sleeved clothes particularly in the colder months. Therefore, for a (likely 
sizable) proportion of the participant cohort, the immunomodulatory effect of UVR was 
secondary to a systemic rather than a local effect (i.e. UVR delivered remote to the site of 
immunisation). Given that the local UVR-induced immunomodulatory effects are stronger 
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than systemic effects, the likely consequence for this study is an underestimation of the effects 
of UVR exposure on vaccine response. 
Overcoming this limitation in future studies could be achieved by insisting that clothing not 
cover the vaccinated area for a designated period before and after immunisation (challenging 
for the forearm) or instead, choosing a different site for immunisation. Possible sun-exposed 
immunisation sites include the dorsum of the hand or at the wrist - however, minimal 
subcutaneous tissue at these sites and density of important structures (e.g. nerves) would 
make injection difficult. 
Due to limitations in resources, a full array of immune outcome measures was not possible in 
time for reporting in this thesis. Anti-KLH lgGl was chosen as the antibody to be first assayed 
as it showed the greatest response in the pilot study (additionally noting that lgGl is the 
predominant lgG sub-class and the primary antibody product ofThl cell-mediated processes in 
humans. However, antigen-specific assays of lgGfc (full complement of sub-lgG sub-classes) 
and lgG2 would be additionally informative particularly in relation to UVR-induced promotion 
of Th2 processes. 
Antigen-specific ex vivo lymphocyte assays were not conducted for this study but would 
complement the DTH response assays. Nevertheless, antigen-specific cellular assays are 
problematic due to the very small frequencies of circulating memory_T-cells and also the lack 
of MHC-complexes to present antigen to T cells in the ex vivo setting. 
As part of the study protocol, paracetamol was recommended for participants to take if they 
experienced fever or discomfort post-immunisation or skin test. Paracetamol administration 
has been associated with reduced antibody response post-immunisation in children (524) . 
Information regarding paracetamol ingestion during the study was not collected . However, 
there was no reason to suspect that paracetamol ingestion was more prevalent in any 
particular UVR exposure group or associated with another immunomodulatory variable. 
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8.6 Future research 
Planned or underway 
In response to some of the limitations noted above, a method for integrating the detailed 
records of participant's sunscreen coverage during the period of UVR exposure measurement 
with the clothing-adjusted electronic dosimeter data will be developed . In addition, further 
laboratory work is planned using stored serum and lymphocyte samples. Antigen-specific 
antibody testing (anti-KLH lgGfc and lgG2) will be performed. To build on the preliminary 
results of the lymphocyte assays already performed, preparatory work has commenced on 
developing antigen-specific cellular assays (i.e. incubating PBMCs with KLH for various periods 
of time, and then quantifying the ratios of the various CD3+ CD4+ T lymphocyte populations 
present). 
Previous work has shown that the immunomodulatory effects of UVR exposure are greater in 
the presence of specific cytokine gene polymorphisms. This will be explored further within the 
AusUVI Study, using a commercial gene array kit or chip and residual PBMCs as the source of 
participant DNA. Along the lines of the work by Sleiffjers et al (328), a re-analysis of the 
relationship between personal UVR exposure and the immune response to immunisation, 
stratified by specific genotypic sub-populations, will then be undertaken. 
A study is currently underway using the AusUVI Study database to better understand the 
variability of serum 25(OH)D amongst different ethnic populations. The database offers a 
unique opportunity to assess this important question as it includes informat ion on physical 
activity, clothing coverage, skin complexion, sun protection and vitamin D supplementation as 
well as personal UVR exposure. 
Potential 
Given the results of the lymphocyte assays performed for this study where changes in Thl 7 
cell populations have been observed related to UVR exposure and immunisation, further work 
is warranted to confirm and extend these findings. A study design to assess this question has 
already been outlined in Section 8.3.3.5 where the same or a different vaccine (e.g. influenza) 
could be used. 
UVR-induced immunomodulation is likely to be most influential to the immune cells and 
processes of the epidermis and dermis. This may be relevant for Nanopatch ™ technology, a 
promising vaccine delivery system under development that uses micro-projection arrays 
(>20,ooq/cm') to topically deliver vaccine antigen and adjuvant to the skin's immune system 
(525). Determining the extent to which UVR modulates the Nanopatch™ response would be of 
considerable interest. 
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Conducting studies involving potentially susceptible populations (e.g. elderly, infants, 
immunosuppressed) that may be more sensitive to UVR-induced immunomodulation may 
provide valuable information. For example, research into the effect of UVR on the immune 
response to routine childhood immunisation (e.g. measles, BCG) in a high ambient UVR 
environment (e .g. indigenous communities of northern Australia; peri-equatorial regions of the 
developing world) should be given strong consideration . Given that vaccination programs are 
already established in most parts of the developing world and reliance on vaccine 
effectiveness is paramount, particularly in these less affluent settings, this constitutes an 
excellent opportunity to extend UVR-immunotoxicology research in a context where the 
results are clinically translatable. 
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8.7 Conclusions 
Since Kripke's landmark experiments in the 1970s, the emerging field of photoimmunology has 
demonstrated that UVR exposure is an important environmental immunotoxin to animal and 
human immune systems. However, much of the experimental and observational research 
conducted in this area has not allowed for extension of conclusions to the broader population 
under "real world" conditions due to limitations in the spectrum or dose of UVR studied; 
measurement and/ or control of relevant immunomodulatory variables; and/ or immune 
function tests used. The AusUVI Study was carefu lly designed and conducted using 
immunotoxicology research principles to avoid or minimise these potential pitfalls. 
Ultimately, the AusUVI Study set out to answer the following question - " Does solar UVR 
exposure, at levels relevant to normal daily activity, influence the immune response to primary 
immunisation in humans?" At the completion of the study, the following conclusions are 
made: 
• Acute solar UVR exposure at levels relevant to day-to-day activity suppresses in vivo measures 
of cell-mediated immune response to immunisation with a T-cell dependent antigen, w ith 
UVR exposure on the day prior to immunisation most important. 
• Acute solar UVR exposure, in conjunction with immunisation, modulates the expression ofT-
helper lymphocytes expressing IL-17, a cytokine known to be important in the development of 
inflammation and autoimmune diseases. 
• Acute so lar UVR exposure at the time of immunisation does not affect the production of 
vaccine-specific lgGl antibody. 
• UVR exposure over the life course does not influence vaccine-specific cell-mediated or 
humoral immune responses. There was no evidence to support the contention that long-term 
UVR exposure leads to photo-adaptation to the immunomodulatory effects of acute UVR 
exposure. 
• There was no evidence that vitamin D status influenced antigen-specific cell-mediated or 
humoral immune responses. 
The clinical significance of the observed processes is unclear, although any degree of UVR-
induced immunomodulation could be expected to alter the susceptibility of a population to 
common infections, cancers and/or to the pathogenesis of autoimmune disease. This research 
cont ributes to our understanding of the optima l range of UVR exposure that individuals and 
populations should have to balance the positive and negative health outcomes of sun 
exposure. 
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Further analyses will be conducted on the data thus far obtained in the AusUVI Study, and 
experimental work is planned to strengthen or extend the findings discussed. This study adds 
to the growing literature in this important area and, hopefully, lessons learnt from this 
research will be applied to future photoimmunology studies. 
Seeking to better understand the influence of ubiquitous environmental exposures on human 
physiological functions should remain an important scientific research priority. This is already 
apparent for populations subject to extremes of exposure, but will take on increased import in 
the context of global climate and environmental change . 
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Appendix A: Anti-KLH lgG ELISA optimisation and protocol 
ELISA optimisation strategies 
The protocol for the ELISA assay described below was developed after consideration of 
published protocols that had successfully quantified the anti-lgG response to KLH 
immunisation in humans (342, 387). Much effort was undertaken by laboratory researchers 
following the pilot study (Canberra laboratory) and the main AusUVI Study (Townsville 
laboratory) to optimise the assay output. Differences in assay output (e.g. reduced labelled-
antibody signal or increased background 'noise') were noted between laboratories that may 
reflect varying reagents, characteristics of antibodies, technique and equipment. 
The protocol described was finalised following much experimentation including varying the 
concentration of initial serum concentration (e.g. 1/10 to 1/100) (Step 7.ii), varying 
concentration of biotin-labelled secondary antibody (Step 10), changing the time to reading 
well absorbance (e.g. 15 - 30 minutes) (Step 18), and/or use of stopping agent (Step 19). The 
main difference between the pilot study and AusUVI Study assays was that a stopping agent 
was not used in the latter protocol. 
Anti-KLH lgG ELISA protocol 
Stage One - Coat with KLH 
1. 96 well NUNC plates coated with lug of KLH (Hemocyanin from Keyhole Limpets, Sigma 
No. H 7017) per lO0ul carbonate coating buffer 
i. pipette lO0ul using 200tips 
2. Refrigerate overnight in cold room (should always leave overnight) 
Stage Two - Block 
3. Wash plates x4 with PBS-Tween 20 (Phosphate Buffered Saline with Tween 20, Sigma No. 
P3563) 
4. Block with 200ul of 1% skim milk 
5. Incubate at room temp 2 hours or 45 mins in 37°C 
Stage Three - Serum (Primary Antibody) 
6. Wash plates x4 with PBS-Tween 20 
7. Undertake a half log dilution 
i. Pipette lO0ul 1% skim milk into all wells 
ii. Pipette 2ul of serum into the first row of wells (i.e. concentration 1/50) 
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iii. Mix and Transfer 46.2ul of solution from 1st row to 2"d row 
iv. Discard pipette tips 
V. Mix and Transfer 46.2ul of solution from 2"d row to 3'd row etc. 
8 . Incubate at 37°C for 45mins or leave at room temperature for 2 hours or incubate 
overnight (preferred) 
Stage Four - Secondary Biotin-labelled Antibody 
9. Wash plates x4 with PBS-Tween 20 
10. lgGFc (Sigma, Monoclonal Anti-human lgGFc Biotin Conjugate, No. B3773), Dilution 
1/50,000 in skim milk; lgGl (Sigma, Monoclonal Anti-human lgGl Biotin Conjugate, No. 
B6775), Dilution 1/2000 in skim milk; lgG2 (Sigma, Monoclonal Anti -human lgG2 Biotin 
Conjugate, No. B3398), Dilution 1/25,000 in skim milk 
11. Pipette 100µ1 of diluted antibody in each well 
12. Incubate at 37°C for 45mins or leave at room temp for 2 hours 
Stage Five - lmmuno-enzyme to bind to Biotin-labelled antibody 
13. Wash plates x4 with PBS-Tween 20 
14. Add lO0ul of 200:1 skim milk:Avidin Peroxidise (Sigma, No.A3151,- Reconstituted with 
l000ul PBS) 
15. Incubate at 37°C for 45mins or leave at room temp~rature 2 hours 
Stage Six - Detecting labelled antibody and Reading Results 
16. Wash plates x4 with PBS-Tween 20 
17. Add lO0ul ABTS (3,3,5,5 Tetramethylbenzidine Liquid substrate system, Sigma No. A3219) 
solution to each well 
18. Leave for 15 minutes 
19. Add lO0ul lM phosphoric acid in distilled water to each well * 
20. Read on spectrophotometer plate reader (at wavelength 450nm) 
* This step was performed in the Canberra laboratory for the pilot study assays but not for the 
main AusUVI Study assays conducted in Townsville (see below) 
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Appendix B: AusUVI Study Promotions 
Poster 
THE AUSTRALIAN ULTRAVIOLET 
RADIATION Et: IMMUNITY STUDY 
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Does sun exposure affect your immune system· 
Do you get too much sun? Or not enough? 
What are ultraviolet rays doing to your skin? 
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IN FORMATION SHEE.T 
TITLE: The Australian Ultraviolet R.adiatron and) fmmunrty Study 
INVESTIGATORS: DrAsll,win Swaminathan 
Dr R. obyn Lucas 
Dr Simone Harrison 
A/Prof Natkunam Ketheesan 
A/Prof MatthewCook 
ProfessorM'ichae l Kimfin 
ProfessorTony M:cMichael 
You are invited to take part in a research study. The following information is provided to 
help you make a decision about whether or not you would like to participate in the study. 
This consent form may contain words that you d.o not understand. Please read:the 
information carefully and ask the study officer to explain anything you do not understand 
You may take home a copy of this consentformto think aboutortalk about with family or 
friends before makingyour dedsion. 
This is a research study and.you do not have to be involved. 
Once you understand:whatthe study is about and if you agree to take part, you will be asked 
to sign the Consent Form. Signing the Cons ent Form indicates that you understand the 
io.l.rurMIJ.Qn andlhatyou give your consentto participate in the research study. 
1. Background and Purpose of this Study 
Scientificstudies showthatsun exposure may suppress human immune function. This 
could: affect how we fight infection, respondto vaccination and defend, againstskin cancer, 
amongst otherthings. 
The purpose of our research is to find outwhether exposureto ultraviolet (UV) radiation 
receivedvia sunlight and in doses relevant to activities of normal d'aily living, is sufficient to 
suppress the human immune system We do not Im ow the answer to this question currently, 
but it is clearly important in helping to und.erstandthe effects of sun exposure on human 
health. This is particularly relevantfor people living in very sunny countries such as 
Australia. 
For this study, we will measure personal UV exposure through use -of special UV absorb-en! 
badges attached to a wrist bandthatis worn dailyfor 1 O days. We will also measuresun 
exposure with the use of activity diaries. We will use vaccination with a harmless protein 
(KLH) as a way of generating an immune response that can be accurately and reliably 
measured: 
2. Study Procedures 
We aim to recruit healthy adult participants. At the time of recruitment, yo u will be asked 
some simplescreening questions to ensure that you do not have any conditions or are 
taking any medications that would: make you unsuttable for this study. 
The fol.lowing table details the procedures arid requirements of each visit. 
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STUDYTlMELINE 
Pra-<Study After you have expressed interest in participating in the study; a convenienttimewill 
be organisedforyouto attend for thefir.;tvis~. 
Day1 ,, Questionnaires: On general health, medications, sun exposure history and 
physical fitness 
. Brief Physical exam: Height, Weight; Skin, Eye and Hair Colour 
. Skin cast: a silicone ru.bber impression of a small part of the back of your 
hand to estimate chronic sun damage 
I Assessment of degreeoflanning 
.,, Instruction on use of UV sensing digital badge and sun diary 
I Time:Appmx50-60 m ins 
DayJ- 7 I Wear UV sensing badge on wrist band daily 
,, UseSu:n Diary to document sun exposure a.nduse of sun protection 
DayB ,, Blood lest: !hi.swill besentfor immunefunctiontests , Vitamin D level, full 
bloodcou.ntand blood glilmse level. 
•· Vaccination - a .sub--cutan eous injection of KLH to the forearm 
I Questionnaire: 0 n g ener:al psychological wel ~being I as it also can affect 
immunefunction) 
,, Time: 40 m inutes 
DayB-12 I Continue to wear wrist band daily ; and fill in Sun Diary 
Day15 , BloodTest: for immunefunciiontesting 
, Ti me: 5 m inutes 
Day29 I Bloodtesl - for immunefunctiontesting 
,, Skin test - invotve.s an injection of KLH with a very fine needle just under 
the skin oflheforearm; May requires having of a small .area of skin 
, Time: 1:5mi:nutes 
Day31 I Read result ofSkintests 
I Feed back ofinierim results 
I Thank-you, gift 
,, Time 1i0 minutes 
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Although you will not receive any direct medical benefitfrom participating in this study, there 
are a number of other potential indirect benefits. We will feed!b,ack information regarding 
your blood pressure, resting: h.eart rate , random bloodi glu:cose feve l and useful 
information about your natural sk.in pigmentation,. 
We can also tell you the results of your blood tests {including full blood count, liver and 
kidney function}. At the end of the overall study, we can inform you of yourv itamin, D level 
and skin cast result (which reflects the cumulative level of solar skin damage). 
A study doctor can counsel you with regardto the interpretation of these results . 
The information collected from this study will also help researchers understand the effect of 
UVR on the human immune system, andtherefore assist in the development of approprtate 
·sun smart' public health messages for our commun ity. 
4. Risks and Discomforts 
Vaccination with the protein "Keyhole Limpet Haemocyanin" (KLH ) is very safe . There have 
been no reports of severe reactiontotll.e use of KLH in h.umans , despite extens ive use 
in research for over 40 years. 
Studies have shown thatthe side effects that can occur with KLH are: transient and local ised 
discomfort and/or redness and/or swelling atthe site of injection and/ortransientfever. 
Rarely have more severe reactions been reportedsu ch as skin breakdown or nodules at the 
site of vaccination , although these havetendedto occur with much higher closes of KLH than 
we are using in this study. 
You will be observed for30 minutes for any sid.e effects foll owing vaccination as an added 
safety measure. 
You will also be having blood tests which may cause so.me mild discomfort and/or bruising. 
You will be offered a local anaesthetic ointment prior to blood!tests to reduce the level of 
dis comfort. 
We also request completion of a brief questionnaire asking about recent stressful events as 
this can also impact on immune function. 
5. Privacy,Conf1d'entia llty and Use of Information 
Any identifying information about you which is collected as a result of your participating in 
this study will remain confidential andwill only be usedforthe purpose of this research 
study. Your information will only be disclosed with your permission, or as required! by law. 
Blood taken forthis studywill also be tested for specifi c genes that are associatediwith 
immune function. The results of these genetictests will not be released'to any th ird parties. 
The results of this stud,y may be published: in mecicaljournals or presented! at scientific 
meetings. In any informationwhich is presented, you will not be identified1• 
If you choose to withdraw from the study you may elect to have your personal d1ata 
destroyed or kept by the rese.archers for use in their analys is. 
A::acn.m=-... m 1 
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285 
= JA.\! ESCOOK 
'":-' l';\'."J\.ER.'>ITY 
AU ST.A;ti. U ,l\ 
6. Physical Inj ury Resulting from Participation 
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You should report any discomfort, problems, or research relatedinjuries to the stud;y doctor. 
If you are injure di as a direct result of your participation in this study, appropriate medical 
care will be provid:ed' at no cost to you . 
7. Costs an.di Reimbursements 
Any reason ab.le travel cost that has been borne b,yyou in participating in this stuclywill be 
reimbursed'. 
In addition , atthe endofthe study you will receive a $50 gift voucher in appreciation of 
providing your valuabletime. 
8 . Ethical Review 
The ethical aspects of this research study have been considered by the Human Research 
Ethics Committees of the Australian National University, James Coo l< Un iversity and ACT 
Health. 
This study will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2 007) prod:uced by the National Health and, Medical Research Council of 
Australia (NHMRC). This document has been clevelopedto protect the people who agree to 
participate in human researchstud·ies. 
The investigators do not have any finandal conflicts of interest in conducting this study. 
This study is funded by a National Health and Medical Research Council grant (Project No: 
585489). 
P..1i.5.i::lUlF·J"ll 
lnb'TTEil!~n & lnfanBi Cons-s-n: =c·:m, [Version 2; 20 June-101(]] 
Al.JU Hil~:'.: F:mo::012!10~ 1 ~28'-.,&Jl tlREC Pro1oco l tfo: C5; .ACT tleal1h: 3.10.2.10 
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Appendix D: List of medications and medical conditions that preclude AusUVI Study 
enrolment 
lmmunosuppressive Medications 
Medication Trade Name Class of Agent Minimum 
exclusion 
period 
Aclomethasone Topical steroids 7 
dipropionate 
Aspirin Astrix Anti-pyretic 3 
Azathioprine lmuran Systemic 30 
immunosuppressant 
Beclomethasone Becotide Qvar Inhaled corticosteroid 30 
Di propionate 
Betamethasone Diprosone Topical Steroids 7 
Budenoside Symbicort Inhaled corticosteroid 30 
Pulmicort 
Cyclophosphamide Cyc/ob/astin, Systemic 30 
Endoxan immunosuppressant 
Cyclosporin Neora/, Ciciora/, Systemic 30 
Sandimmun immunosuppressant 
Fluticasone Flixotide seretide Inhaled corticosteroid 30 
Hydrocortisone (Acetate) Topical Steroids 7 
Ibuprofen Brufen Nurofen Anti-inflammatory 3 
(NSAID) 
lndomethaci n lndocid Anti-inflammatory 3 
(NSAID) 
Interferon Systemic 30 
immunosuppressant 
Ketorolac Anti-inflammatory 3 
(NSAID) 
Leflunamide Arova Systemic 30 
immunosuppressant 
Methotrexate Methob/astin Systemic 30 
immunosuppressant 
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Methylprednisolone Topical Steroids 7 
Mometasone Furoate Elocon Topical Steroids 7 
Mycophenolate Cellcept Systemic 30 
immunosuppressant 
Naprosyn Neurofen Anti-inflammatory 3 
(NSAID) 
Prednisolone Salone, Corticosteroid 30 
Panafcortelone, 
Predsone 
Sulphasalazine Salazopyrine Systemic 30 
immunosuppressant / 
anti-inflammatory 
Tacrolimus Progrof Systemic 30 
immunosuppressant 
Participants with the following conditions were excluded from the study: 
• Cancer (not in remission) 
• Cardiac failure 
• Chronic liver disease 
• Chronic renal (kidney) disease 
• Diabetes 
• HIV/ AIDS 
• Inflammatory bowel disease (i.e . Crohn's disease, ulcerative col itis) (NB -
irritable bowel disease not excluded) 
• lgA deficiency 
• Lupus (Systemic lupus erythematosis (SLE) 
• Lymphoma or Leukaemia 
• Renal impairment or failure 
• Splenectomy (no spleen) 
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Appendix E: Certificate of Analysis for Biosyn Keyhole limpet Haemocyanin 
I 
t ' 
-~ of Aaalysis 
D■lth No,: 0IS!IOJ.A 
N<, • CA-Kl.$9210-01 
EffcliN dole 04 .0l.lOIO Is 
biosyn 
Oat~ Bf •••td:actwrr. lt.14.2011 
QC-ID-No.: 12ll2 
F.n•la■tlM / Metllod 
G~■rnl l'ropcnla 
l,xtnc11ble volum,: I 
Ph. Eur. 2. 9.17 
appeanrnc,, of llOlution / 
viJUal lal 
pH-,,,,luc / 
Ph. Eur. U .l 
=nol&lity I 
l'b. F.ur. 2.2.35 
amolLIIC: dcmity I 
electronic-...- of lbe 
durwrion or OICIILloon 
ldndly 
Sped flea lion 
~0.timl 
Slighlly blulslt liquid 
7.0-H 
◄00 . SO() mOsmollk& 
1.0000 • I.I 000 flan' 
Raoll 
0.7ml 
Slig)ltly blui,h liquid 
7.2 
04m0m,ol/kg 
1.0140 g/an1 
distribution of molccular weialW mention lime °' hanocyanin rclmtion !)me or bcmocyaoin 
MPLC-SEC 30.0 • -40.0 111111 32.S min 
identity KLH / characccrialjc b■nd pllllml wilh cballlCUrislic b■nd poaau with 
SOS PAOE typical band - 370 kDa ryp;,,.I b■nd-)70kDa 
copper/ clear signal • 324.1 nm_ clear signal 11 32-U Drll 
AAS 
UV~/ e_ (345 • >49 am) E._(34S nm) 
pho~ E.. (2n. 211 mn) f-.(279nm) 
!'Drily 
purily ICU{ / > 98.0% 100.0% 
MPLC-SF,C 
nucleic ■cida I 
clc:clrOpbo,c:tic 
DNA < 300 Will DNA < 300 pt.Ip! 
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u 
of Analysis 
Date of manufacture: 30.04.2010 QC-ID-No.: 12232 
Examination / Metb.od 
Content 
protein content / 
photometric / 280 run 
BiologiC11I Safety 
bacterial endotoxins / 
Ph. Eur. 2.6.14, E 
sterility/ 
Ph. Eur. 2.6. l 
Specification 
No.: CA-KL699210-0I 
Effective date: 04 .05.2010 
Result 
0.9-1.1 mg/ml l.0mg/ml 
5 11.71.U./mg < 0.21.U./mg 
sterile sterile 
ls 
biosyn 
Additional testing on active ingredient bulk solution (Batch No.: 015503) 
abnormal toxicity / 
Ph. Eur. 2.6.9 
Viruses/ 
PCR 
no abnormal toxicity no abnormal toxicity 
HAV HAV 
no genome of HA V detectable no genome of HA V detectable 
HBV HBV 
no genome ofHBV detectable no genome ofHBV detectable 
HCV HCV 
no genome ofHCV detectable no genome ofHCV detectable 
Enteroviruses 
no genomes of enteroviruses 
detectable 
Noroviruses 
no genomes ofNor<iviruses 
detectable 
Rota viruses 
no genomes of Rota viruses 
detectable detectable 
Enteroviruses 
no genomes of enteroviruses 
detectable 
Noroviruses 
no genomes ofNoroviruses 
detectable 
Rotaviruses 
no genomes of Rotaviruses 
detectable detectable 
Page2orJ blosvn Anneimi1iffl (';mhH . Sr_hnmrinrfPr StNilt• It? . 1rr1u ~uh.,..., . n-........ ,,. .. ,. T .. , .. , .... ,.., , , ., -.r .... ,... .. . .. ..... - -- -- - -
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Appendix F: Questionnaires used in the AusUVI Study 
Questionnaire A: General health and demographic information 
-~ ■ 27232 
THE AUSTRALIAN ULTRAVIOLET RADIATION & IMMUNITY STUDY 
■ 
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Part A: 
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-:" UNIVERSITY 
AUSl R:ALIA 
General Health & 
Information 
Questionnaire 
Thank you for agreeing to take part in the AusUVI study. We are 
conducting this study to assess how sunlight-derived ultraviolet radiation 
(WR) exposure affects the human immune system. 
Toe AusUVI study relies on the willingness of participants to share 
information about their lives and their experiences. This will assist 
researchers in understanding the positive and negatives impacts of sun 
exposure on our health. 
Participation is completely voluntary and you may withdraw from the 
study at any time. · 
Study Participant Code: DJ:J 
Today's Date: [D / [D / I I I I I 
There are no right or wrong answers to these questions. It is very important 
that you answer ALL of the questions relevant to you. To help us read your 
answers, please write as clearly as possible using a BlACK or BLUE pen. 
Please put a ti ck or cross in the small box beside each answer that is right 
for you, or write in the big box or on the line as appropriate. 
All of the information you provide to us will 
remain st rictly confidential 
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I . What gender are you? (Please cross the- appropriate box) □ Male □ Female 
l . What is your date of birth? [I] t[I]t l I I I I 
:l. In what country were you 00ml 
la. If you were NOT born in Australia, in what year <fid you come to live in AustraliaJ I l I I ] 
lb. In wtlat state/territory do you live? (Please cross one box} 
D Queensland □ Tasmania □ ACT 
D New South Wales □ South Australia □ Northern Terr-itory 
□ Victoria D Western Australia 
le. For how mil.fly years have you been living in this state/territory? [D years 
4. What is your PARENT'S ETHNIC ORIG IN (that is. the place where most of their ancestors came 
from) and the COUNTRY THEY WERE BORN IN . 
Parent Country of birth: Ethnic Origin (Plea:se. a-os.s the ONE th.it best describes youT mother) 
Mother 
I I 
□ Australian □ English □ Irish 
□ ATSI □ Vietnamese □ Croatian 
D Chinese □ ltalian □ Greek 
D Scottish D German □ Lebane! e 
D Dutch D Maltese □ Polish 
D Filipino D Indian □ Other, ple-ase describe: 
D Don't know □ Prefer not to answer 11 I 
Parent Country of birth: Ethnic O rigin (PiNSe- cross the ONE th;it best describes y<MJr D.ther) 
Father I I 
D Australian □ Engl~h □ rri:sh 
□ ATSI D Vietnames.e D Croatian 
□ Chinese □ Italian □ Greek 
□ Scottish □ German □ Lebanese 
□ Dutch □ Maltese □ Pol~h 
□ Filipino □ Indian D Other. please describe; 
D Don't know D Prerer not to answer 71 I 
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S. What is the highest technical. professional or academic: qualification that you have completed? 
(Ple:ase cross one of the boxes De/ow) 
□ Did not complete primary school □ Trade/Apprenticeship 
D Primary school □ Certificate or Diploma 
□ Some high school (Year 11 or under) □ Bachelor's degree 
□ Year 11 Senior Certificate (or HSC) □ Po,tgraduate degree 
Sa. Which of the following best describes the occupation you had for the longest per iod? 
(Plei.5.e cross one of the. boxes below) 
□ Student 
□ Ma11ager or administrator 
D Professional (e.g. engineer. doctor. teacher. nurse. police. technka.l officer) 
D Trades.person (e.g. c.arpenter. electrician. plumber. mechanic, etq 
□ Clerk (e.g. typist receptionist. data processor. etc.) 
□ Salesoerson or oersonal service worker le.~. sales ren. teller. insurance reo, etc.) 
D Plant or mac.hine ooerator or driver te.v. taxi dri ve r, bus driver) 
D Farmer 
D Labour er or related work.er fe.-o- . trade ilSSistant. factorv hand. ae:rie:ultural labourer. construction, minim!) 
□ Member of defence force:s (army. navy, air forces) 
□ Other (please state) 
Sb. Which of the following best describes you r current employment status? 
(Please crnss one of the- boxes below) 
D Unemployed 
□ Home duties 
□ Part-time work - emoloved/self-emoloved 
□ Full-time work - employed/self-emoloved 
□ Student 
□ Sole oarent oension 
D Di:sabilitv nens ion 
D Reti red 
□ Other (please state) 
Sc, Which of the following best describes your current, maJn occupation? 
Ple:;ase cr oss one of the- boxes be/owl 
D Ma.inly indoors (e.g. office worker) 
□ Half indoors and half outdoors (e.g. physical education teacher) 
□ Ma_inly outdoors (e.g. gardener) 
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The following questions refer to smoking and akohol consumption. 
6, Were you ever a regular smoker of cigarette:S or cigars or pipes? (A regular smoker is one 
who smoked daily. or at least 7 times per week,. for at least 3 months.) 
□ Yes (Please go to Question 7a) 
□ No (Please go to Question 8) 
7a. Are you currently a regular smoker of cigarettes or cigars or pipes? 
7b . Over the pa.st month. on average. how many cigarettes and/or 
cigars and/or pipes did you smoke each day? 
□ Yes 
□ No 
rn Perday 
7c.. Over the past month. which brand and type have you smoked most often? 
Brand (eg. Hor izon/Craven A/Winfield) 
TYJl" (eg. Plain/Super Mild 8/Extra mild (Blue)) 
Did they have a filter? □ Yes 
□ No 
These next questions ask about your smoking history. 
7 d. How o ld were you when you first became a regular smoker? 
7e, If you are no longer a smoker, at what age did you stop? 
□ I did not stop 
7f. If you ha,,.e stopped being a regular smoker in the past. and then 
started being one again (perhaps doing this several t imes) for how long 
in total have you stopped being a r egular smoker ~ 
0 I did not start and stop 
7g, On aver age. during the years that you smoked. how many cigarettes. 
cigars or pipes did you smoke each day? 
rn Years of age 
[TI Years of age 
rn Years 
rn Perday 
8. About how many alcoholic drinks do you have each week? 
rn number of standard alcohollc drinks each week (on.e standard dr ink = a gta:ss of wine. middy of beer, or nip of spirits) Please put •on if you do not drink. or have le:s:s than one drink each week. 
9. On how many days ead1 week do you usually drink alcohol~ D Days each w eek 
■ 
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The following questions refer to your general health and to prescription medications 
(medications prescribed by your doctor) and any over-the-counter vitamin/ mineral 
supplements that you take. 
I O. Overall. how would you rate your general health over the PAST MONTH? (please cross one box) 
D Excellent 
□ Very good 
□ Good 
D Fair 
D Poor 
D Very Poor 
I I. In the past l months. ha.ve you suffered from an infection/s~ (Pfease tick the appropriate boxes below, if you 
haven't exper-i@.tced ;my infections, ple;ise select O for each.) 
frequency 
0 I 1 J+ 
Cold or u:ppec respintory tnct infection D D D D 
Gastrointestinal infection D D D D 
Sim Of" n.iil infection D D D D 
Urinary or genitourinary infection D D D D 
Other infection (please specify) D D D D 
12. Do YOU suffer frnm any chronic illnesses! (Please tick the appropriate boxes below. if you do not suffer 
from ;my chronic ilrnesses. please select No for each.) 
Liver di.sease □ Yes □ No 
Kidney disease □ Yes □ No 
Heart disease □ Yes □ No 
Skin condition □ Yes □ No 
Respiratory / lung disease □ Yes □ No 
Immune system disorder: Please specrfy 
□ Yes □ No 
Other: Please specify 
□ Yes □ No 
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13. Does :a.nyone in your family have a history ohn immune system reh.ted il.lness or "autoimmun.e" 
disorder? (Please tick the appropriate boxes for each item be-low.) 
Rheumatoid arthritis 
Lupus or SLE 
Thyroid diseas-e 
Type I diabetes 
Scleroderma 
Multiple sclerosis 
Other: Please specify 
14. Do you take any regub.r med.icatioM? (including prescription medicines 
from your doctor and •over--the--c·ounter• medidn,e,s). 
K Yes. please specify the medications below. 
□ Yes 
□ Yes 
□ Yes 
□ Yes 
□ Yes 
□ Yes 
□ Yes 
□ Yes 
□ No 
Medication I _________________ _ 
Mediation 2 _________________ _ 
Medication 3 _________________ _ 
Me<lication ◄ _________________ _ 
Medication 5 _________________ _ 
15. Do you Wee ;u,y medic.a.tions or supplements which mily contain Vita.min D? 
Vitam in D s.upplement a.Jone □ Yes 
Vi'tlmin D s.upplement with calcium □ Yes 
Multivitamin tablet □ Yes 
Cod nver oil / tablets □ Yes 
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□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
□ No 
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This section relates to vaccinations you have had and any problems you m ight have 
had with them. Also this section will inform us whether there ,.,-e any issues with you 
taking part in our vaccination study. 
I 6. H:a.ve you suffered any side effects from vaccinationl 
□ No 
□ Yes Vaccine 
Please list 
17. Are you a.llergic to shellfish? 
□ No 
□ Yes T ype of Shellfish 
Please list 
Year 
I I I 
I I I 
I I I 
Year 
I I I 
I I I 
I I I 
Please d escr ibe the r eaction 
I I 
I I 
I I 
Please desc.ribe the reaction 
I I 
I I 
I I 
18. Have you ever had an "Anaphylactic react ion" to shellfish or a m edication? That is have you 
ever suffered from breathing problems. swelling of lips or throat or required immediate medica l 
attention after consuming shellfish or a medication? 
□ No 
□ Yes Shellfish / M ed ication Year Please describe the reaction 
Please list I I I I I 
I I I I I 
The fo ll owing two questions are to be answered by women on ly. They ,.,-e to identify 
women who could be or ,.,-e pregnant or are breastfeeding, as they will be excluded 
from the study. 
I 9 . Is there :a.ny possibility th.tt )'Ol.l could be p regna.nd 
□ No 
□ Yes 
20. Are you c-urrently b reastfeedin g an infan t ? 
□ No 
□ Yes 
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22. What is your usual PE RSONAL income before tax. from all sources! {Please include benefits., 
pensions. superannuation, etc,) (Please t ick one box only) 
D less t han $5-000 per year D $50,000 - $69,000 per year 
D $5,000 - S9,999 per year D $70,000 - S89.999 per year 
□ S I0.000 - Sl9.999 per ym D $90,000 - $ 109,999 per yea.-
D S20,000 - $29,999 per year D $ 110,000 o r more per yen 
D $30.000 - $49,000 per yea.r D I would prefer not answer 
You have now completed Part A of the AusUVI study questionnaire! 
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SUN &SKIN 
QUESTIONNAIRE 
Thank you for agreeing to take part in the AusUVI study. We are 
conducting this study to assess how sunlight-derived ultraviolet radiation 
(WR) exposure affects the human immune system. 
The AusUVI study relies on the willingness of participants to share 
information about their lives and their experiences. This will assist 
researchers in understanding the positive and negatives impacts of sun 
exposure on our health. 
Participation is completely voluntary and you may withdraw from the 
study at any time. 
Study Participant Code: I I I I 
Today's Date: [I] / [I] / I I I I I 
There are no right or wrong answers to these questions. It is very important 
., that you answer ALL of the questions relevant to you. To help us read your 
answers, please write as clearly as possible using a BLACK or BLUE pen. 
Please put a tick or cross in the small box beside each answer that is right 
for you, or write in the bib box or on the line as appropriate 
All of the information you provide to us will 
remain strictly confidential 
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The following questions ask about your skin and how it reacts: to the sun . 
I 
I. How does your skin react when you sit in the sun in your current ar e·a of residence. in the middle of 
the day. for the first time in summer, without sunsc.re.en? (please crnss. .llile. box) 
D Never Burn 
□ Burn after more than 2 hours sun exposure 
□ Burn after l -2 hours 
D Burn alter I fl- I hour 
□ Burn within half an hour 
2. At the end of summer or after a two week holiday in the sun, what kind of tan would you have? 
(please cross :Q.D.e. box) 
□ A dark tan 
D A medium tan 
□ Light tan 
□ Practicalty no tan 
:la, How does your skin react w hen you go out in th~ sun in your current area. of r esidence. for one 
hour in the middle of the day, for the first time in summer, without sunscreen/ (please cross .wie. box) 
□ Burn then peel 
□ Burn then tan 
□ Tan only 
lb. How fre,quendy did yotJ get sunburnt a, the last 12 months~ 
Please indicate the freqtJency as a numbe, in the boxes provided 
Summer Autumn 
(Dec• Feb) (Mar• May) 
Frequenc·y DJ DJ 
Winter 
(June • Aug) 
DJ 
'l e. W hen was the last time you got sunburnt? Please complete the following sbte-ment 
The last time I was sunburnt was □ 0 Da:,-5 
300 
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The following questions ask about your skin and how it rea.cts to the sun. 
I 
I . How does your skin react when you sit in the sun in your current ar ea of residence. in the middle of 
the day. for the first time in summer. without sunscreen~ (ple3se cross .c.n.e. box) 
□ Never Bum 
D Burn after more than 2 hours sun exposure 
D Burn after l -2 hours 
D Burn after I 12-1 hour 
D Burn within half a.n hour 
1. At the end of summer or after a two week holiday in the sun, what kind of tan would you have? 
(pleJ:se cr-os:s J2D.e. box) 
□ A dark tan 
□ A medium tan 
□ Light tan 
□ Practically no tan 
la. How does your skin react when you go out in th: sun in your current area of r esidence. for one 
hour in the middle of the day, for the fi rst time in su mmer, without sunscreen/ (plea~e- cross .wie,box) 
□ Burn then peel 
D Burn then tan 
□ Tan only 
lb. How frequently did :,ot.1 get sunburnt in the last 12 months? 
Ple.se indka.te the frequency ;a,s a number in the boxes provided 
Summer Autumn W i nter Spring 
(Dec• Feb) (Mar• May) (June• Aug) (Sept• Nov) 
Frequency DJ DJ DJ DJ 
le. W hen w..s the last time you got sunburnt? Please complete the following nateme.nt 
The last time I wa;s: sunburnt was □ 0 D,y, 0 Weeks 0 Mond\s ago. 
301 
■ 
■ 
• ~ 11_,4,_~L_u :::: rM,! ESCOOK 
"'!"' UNtVERSilY 
1'11 f-"IJSlitML,<._r-i li'/.TW~"'L\l t.-t.'fH51~ AUSTl.'.A.LlA 
The following questions. ask about your indoor and outdoor activities and your sun exposure. 
4. Have you worked a night shift at lea.st once in the past month! 
□ Yes 
□ No /Please go to question 5) 
4a.. Please te ll u.s approximately how many night shifu you have worked in the past month? 
(Pl,e;ise cross one box) 
□ I Night Shifts □ 8- IO Night Shifts 
□ 2 Night Shilt, □ 11- 13 Night Shifts 
□ 3 Night Shifts □ 14- 16 N(!ht Shifts 
□ 4 Night Shilt, □ 17- 19 N(!ht Shifts 
□ 5-7 Night Shilt, □ 20+ N ight Shifts 
5 . Thinking about the PAST MONTH, we would like to know the TIMES OF DAY as w e-lJ Js the USUAL 
LENGTH OF T IME that yo u spend OUTSIDE bet>Neen sunr-H.e and sunset on: 
Sa, A typical MONDAY in the PAST MONTH (Cross one response for EACH time period) 
Lengd, of time spent outside 
Never <I S minutes 15-30 minutes 30-45 mi~ute.s 45-60 minutes 
Morning (am) 
S-6 □ □ □ □ □ 
6-7 □ □ □ □ □ 
7-8 □ □ □ □ □ 
8-9 □ □ □ □ □ 
9-10 □ □ □ □ □ 
10-11 □ □ □ □ □ 
11-12 □ □ □ □ □ 
Afterno.on (pm) 
12-1 □ □ □ □ □ 
1-2 □ □ □ □ □ 
2-3. □ □ □ □ □ 
l-1 □ □ □ □ □ 
-1-5 □ □ □ □ □ 
5-6 □ □ □ □ □ 
6-7 □ □ □ □ □ 
■ 
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Sb. A typical TUESDAY in the PAST MONTH (Cross one response for EACH time period) 
Length of time spent outside 
■ 
Never <15 minutes 15-30 minutes 30-45 minutes 45-60 minutes 
Morning (am) 
5~ □ □ □ □ □ 
6-7 □ □ □ □ □ 
7-8 □ □ □ □ □ 
8-9 □ □ □ □ □ 
9-10 □ □ □ □ □ 
10- 11 □ □ □ □ □ 
11- 1'.2 □ □ □ □ □ 
Afternoon (pm) 
12-1 □ □ □ □ □ 
1-2 □ □ □ □ □ 
1-J □ □ □ □ □ 
3-4 □ □ □ □ □ 
4-5 □ □ □ □ □ 
5-6 □ □ □ □ □ 
------- ----- -
n 
6-7 □ □ □ □ □ 
Sc A typical WEDNESDAY in tile PAST MONTH (Cross one response for EACH time 
Length of time spent outside 
Never <1 5 minutes 15-30 minutes 30-45 minutes 45-60 minutes 
Morning (am) 
5-6 □ □ □ □ Q 
6-7 □ □ □ □ □ 
7-8 □ □ □ □ □ 
8-9 □ □ □ □ □ 
9-10 □ □ □ □ □ 
10- 11 □ □ □ □ □ 
11 -12 □ □ □ □ □ 
Afternoon (pm) 
11- 1 □ □ □ □ □ 
1-2 □ □ □ □ □ 
1-J □ ., □ □ □ □ 
3-4 □ □ □ □ □ 
4-5 □ □ □ □ □ 
5-6 □ □ □ □ □ 
6-7 □ □ □ □ □ 
■ ■ 
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6. fs the PATTERN of sun exposure that you have described FOR THE PAST MONTH. similar to your 
exposure over the previous months! 
□ Yes Go to Question 7 
□ No 
6a. Do you usually spe.nd:: 
D MORE time in the sun~ 
□ LESS time in the sun~ 
6b. Please ten us WHY your patter-nor sun exposure has been DIFFERENT over the PAST MONT H ~ 
Were you im □ Yes If yes. what was the duration of your illness ? 
□ No 
Were you on holidays? D Yes lf ye.s. was your sun exposure while on holidays: 
□ No □ More than usual 
D Less than usual 
Did you change jobs and are now working: 
More outdoors D 
Less outdoors □ 
More shift work 0 
less shift work. □ 
Other. please describe: I I 
■ 
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The following questions ask about how you protect yourse-lf fr-om the. sun . 
7. We are interested in the CLOTHING AND SUN PROTECTION that you have worn in the PAST 
MONTH. During the pa.st month. when outside. did you_ ... 
Never/Rarely Less thm ha.If the: 
time 
7a. W ear a 
broad-brimmed hatl □ 
7b. Wear a cap? □ 
7c. Wear any other □ head co,,.eringl 
7d. Wear a shirt with □ 
long sleeves? 
7e. Wear long trousers 
or e:lothing that covers all □ 
or most of your lefsl 
7f. Wear sunglasses? □ 
8. Have you used sunscr een in the PAST MONTH? 
□ Yes 
□ No G-0 to Queslion 9 
□ 
□ 
□ 
□ 
□ 
□ 
M'oret:lan Alw.i)"lalmost 
h;olf the time ,a]wa.ys 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
Ba_, What is the sun-protection factor (SPF) of the sunscreen that you have used most often? (eg. SPF30+) 
Consider any product you may use that have an SPF. including daily moisturiser or make-up products_ 
Sunscreen SPF CD 
Daily Moisturiser SPF CD 
Make-up SPF CD 
8b. Over the PAST MONTH. how often on average have you used any of the: products described in 8ad 
□ Everyday 
□ 5-7 days a week 
D 3-4 days a week 
D 1-2 days a week 
□ Less than once a week 
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8c. On days that you have used sunscreen in the PAST MONTH. how often did you apply it~ 
[D Times per day 
8d. Ptease look at this diagram and tell us over the PAST MONTH. when you used sunscreen. WHERE 
did you usua1ty apply it? (Remember to inc.lude any products you included in Ba.) 
FRONT BACK 
..,L J 
■ 
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The foHowing questions are- about the amount of exercise that you do as part of your 
everday life, 
The questions will ask you about the time you spent b€ing physically active in the rast 7 days. Please 
answer each question even if you do not consider yourself to be an active person. Please tll.ink about tlle 
activities you do at work. itS p;irt of your hous.e and yard work. to get from place to place. and in your 
spare time for recreation. exercise or sport. Driving does not count as physic.al acti'l'ity. 
9a. Think. about all the vigorous activities that you did in the last 7 da.ys. Vigorous physical activities refer 
to activities that take h.ird physical effort and make you breathe much harder than normal. Think only about 
those physical activities that you did for at least 10 minutes at a time. 
■ 
During the last 7 days on how many days did you do vigorous physical activities like heavy lifting. 
digging. aerobics. rnnning. swimming. or fast bicycling! 
D days per week □ Don't .know/Not sure 
□ No vigorous physical activities. {Go to Q9b) 
How much time did you usually spend doing ,,.igorous physical activities on one of those days? 
[D:[Dperdayin>i<l.e. [D:[D perdayll..!Jll.i<k 
9b. Think about all the moderat e activities that you did in the last 7 days. Moderate activities refer to 
activities that take moderate physical effort and make you breathe s.ornewhat harder than nonnal Think 
only about those physical activities that you did for at least 10 minutes at a ti.me. 
During the last 7 days on how many days did you do moderate physical activities like carrying light 
loads, bicycling at a regular pace. slow jogging. or dot1bles tennis? Do not incJude walking. 
D days per week □ Don"t know/NOt sure 
□ No moderate phsyical activity. (Oo to Q9c) 
How muc.h time did you usually spend doing moderate physical activities on one of those days~ 
·[D: [D per day inside [D: [D per day outside 
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tc. Think about all the time you spend walking in the last 7 days. This includes at work and at home. 
waJldng to travel from place to place. and walking that you mi,ght do solely for recreation. sport. exercise, 
or leisure. 
During the last 7 days on how many days did you walk for at feast IO minutes at a time? 
D days p-er week D Don't know/Not sure 
□ No w>lking. (Go to Q9d) 
How much time did you u:s.ually spend walking on one of those days? 
[D: [D per day instde [IJ:[D perdayoutside 
9d. The last question is about the time you spent sitting on weekdays during the last 7 days. Include 
time spent at work. at home.. while doing course work and during leisure time. This may include time 
spent sitting at a desk. visiting friends, reading, or sitting, or lying down to watch tele-vis.ion. 
During the last 7 days. how much time did you spend sitting on a week day? 
[D: [Dper day inside 
□ Don't know/Not sure 
[I]: [D per day outside 
IOa. Is the PATTERN of physical a.cfuiity that you des.c'J'ibed above for the past 7 days. typical of your-
physica.l activity over the past month? 
□ Yes (GotoQI I ) 
□ No 
I Ob. Do you usually spend: D MORE time being physic.ally acrNe? 
□ LESS time being physially >ctive' 
I Oc. Pleilse te ll us WHY your pattern of physical actl'lity has been D IFFER.ENT over the past 7 days. 
compared with the pa.st month~ 
Were you ill? □ Yes lf yes. what was the duration of your illness? 
□ No 
Were you on holidays~ □ Yes If yes, was your sun exposure while· on holidays: 
□ No □ More tllan usual 
□ Less th an usual 
Did you change jobs and are now w orking: D In a more physic-ally a.ctive occupation 
□ In a less physically active occupation 
Other. please decribe.: I I 
■ 
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Hormonal changes occurring through the menstrual cycle are kn own to affect immune function. These 
questions rel.ate to the timing of menstruation. 
11 a. W ith regard to your menstrua~ cycle. do you currently: 
Have regular periodsl 
Have irregular periods~ 
□ Go to Quesion 11 b 
□ Go to Quesion 11 b 
Not have menstrual periods? □ 
11 b. W hen was the first day of your most recent menstrual period? 
DJ Daysago 
You have now completed Part B of the AustJVI Questionnaire! 
Thank you for your time and assistance. 
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PSYCHOLOGICAL 
PROFILE 
QUESTIONNAIRE 
Thank you for agreeing to take part in the AuslNI study. We are 
conducting this study to assess how sunlight-derived ultraviolet radiation 
(lNR) exposure affects the human immune system. 
The AusUVI study relies on the willingness of participants to share 
information about their lives and their experiences. TI1is wi ll assist 
researchers in understanding the positive and negatives impacts of sun 
exposure on our health. 
Participation is completely voluntary and you may withdraw from the 
study at any time. 
Study Participant Code: OJ] 
Today's Date: [D / [D / I I I I I 
There are no right or wrong answers to these questions. It is very important 
that you answer ALL of the questions relevant to you. To help us read your 
answers, please write as clearly as possible using a BLACK or BLUE pen. 
Please fill in the circle beside each answer that is right for you. 
All of the information you provide to us will 
remain strictly confidential 
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We know that our psychological state can affect how our immune system functions. The foUowing surveys 
wirl ask strnctured questions assessing your current psychofogical s.tate and moods. It is impoitant that you 
be as honest as possible with your answers. 
Directions: Describe HOW YOU FEEL RIGHT NOW by filling in t he correct circle 
after each of the words fisted below. 
FEELING Not at all A little Moderately QJitea bit Extren1ely 
Livelv 0 0 0 0 0 
Foraetful 0 0 0 0 0 
Unhannu 0 0 0 0 0 
Active 0 0 0 0 0 
Confused 0 0 0 0 0 
Tense 0 0 0 0 0 
Annrv 0 0 0 0 0 
Worn-out 0 0 0 0 0 
Sad 0 0 0 0 0 
Unable to concentrate 0 0 0 0 0 
Restless 0 0 0 0 0 
Annoved 0 0 0 0 0 
Exhausted 0 o· 0 0 0 
Blue 0 0 0 0 0 
Cheerful 0 0 0 0 0 
Bewildered 0 0 0 0 0 
Nervous 0 0 0 0 0 
Gravelv 0 0 0 0 0 
Wearv 0 0 0 0 0 
Discouraqed 0 0 0 0 0 
Full of oe1> 0 0 0 0 0 
Uncertain about thinos 0 0 0 0 0 
Anxious 0 0 0 0 0 
Resentful 0 0 0 0 0 
Bushed 0 0 0 0 0 
Helpless 0 0 0 0 0 
Bitter 0 0 0 0 0 
Vinorous 0 0 0 0 0 
Worthless 0 0 0 0 0 
Furious 0 0 0 0 0 
Falioued 0 0 0 0 0 
Miserable 0 0 0 0 0 
Peeved 0 0 0 0 0 
Eneraetic 0 0 0 0 0 
Onedqe 0 0 0 0 0 
Uneasv 0 0 0 0 0 
Hooeless 0 0 0 0 0 
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This section assesses the number and severity of recent stressors you may have encountered. 
Directions: Please completely fill in the circle next to one or more statements which describes an 
experience that has happened to YOU in the last 6 MONTHS. 
Health 
An il lness or inj ury that kept you in bed for more t han a week or sent 0 vou to the hos oi tal 
An illness or inlurv that wa.s less se1i ous t han above 0 
Maior den tal work 0 
Maior chanae in eatina habi ts 0 
Maier channe in slee □ i na habits 0 
Maior channe in vou r us ua l tvne and/ or amount of recreation 0 
Work 
Chanoe to a new tv □e of work 0 
Channe in vour work hours or co ndit ions 0 
More work resoonsi bili ties 0 
Fewer wo rk resoonsi bil ities 0 
A oromobon 0 
A demotion 0 
A tra nsfer 0 
Trouble with vo u r boss 0 
Trouble wit h vou r co-wo rkers 0 
Trouble with those vo u s uoervise 0 
Other work troubles 0 
Maio r busi ness readiustmen t 0 
Re ti rement 0 
Laid off 0 
Fired 0 
Took a cou rse to heto vour work 0 
Home and familv 
Move within same citv or town 0 
Move to d ifferent town citv. o r state 0 
Maior cha nne in livinn condit ions 0 
Channe in fa milv net -tonethers 0 
Maioi· cha nae in health or behavior of a. familv mem ber 0 
Maniaoe 0 
Preanancv 0 
M[sca1Tiaae or abortio n 0 
Bi1th of a ch ild 0 
Adoptio n of a child 0 
Rela tive moves in with vou 0 
Soouse bea in.s o r stoos wo rk 0 
Ch ild leaves ho me to a ttend colleae or for marriaoe 0 
Ch ild leaves ho me for other reasons 0 
Chanoe in arauments with soouse 0 
Problems with rela tives or in-la ws 0 
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Directions : Please completely fill in the circle next to one or more statements which desc,i bes an 
expetience that has happened to YOU in the la5t 6 MONTHS. 
Parents divorce 0 
A oarent remarTies 0 
Seoaration from soouse due to wo rk 0 
Senaratio n from snouse due to marita l difficulties 0 
Divorce 0 
Birth of a randchi ld 0 
Death of s□ o use 0 
Death of child 0 
Death of oarent 0 
Death of a brother or sister 0 
Personal and socia l 
Chanoe in oersonal ha bits 0 
8eainni na or endino school 0 
Cha nne of school or coHene 0 
Chanoe in oolit fcal beliefs 0 
Cha nae in relfaious beliefs 0 
Chanae in social activities 0 
Vacat ion 0 
New close oersonal retationshio 0 
Enoaoement t o manv 0 
Girlfriend or bov friend nro blems 0 
Sex ual difficulties 0 
An accident 0 
"FaHina out" of a close oe rso:nal relationshio 0 
Minor violation of t he !aw 0 
BeinQ he ld in iail 0 
Maior deci.s:ion a bout immediate fu t ure 0 
Maior oersona l achievement 0 
Death of a close nersonal friend 0 
Financial 
Maier loss of incom e 0 
Maio,· increase in income 0 
Investme nt and/or credit diffi cu lties 0 
Loss/damaae to oersona l orooertv 0 
Maior ourchase 0 
Moderate nurchase 0 
Foreclosure on mo rtoaae or loan 0 
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These next questions are a bout how you have felt over. the past month. 
Directions: P{ease read each question and fill in the circle by the one statement that best describes how 
things have been for you during the past month. There are no right or wrong answers. 
1. How happy, satisfied, or pleased have you been with your personal life during the p-ast month? 
0 Extremely happy, could not have been more satisfied or pleased 
0 Very happy most of the time 
0 Generally, satisfied, pleased 
0 Somtimes fairly satisfied, sometimes fairly unhappy 
0 Generally dissatisfied, unhappy 
0 Very dissatisfied, unha ppy most of the time 
2. How much of the time have you felt lonely during the past month? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
3. How often did you become nervous or jumpy whe-.n faced with excitement or unexpected 
situat ions, during the past month? 
OAlways 
0 Very often 
0 Fairiy often 
OSometimes 
0 Almost never 
0 Never 
4. During the past month., how rnuch of the time have you felt that the future looks hopeful 
and promising? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the ttme 
0 A little of the time 
0 None of the time 
5. How much of the time, during the past month, has your daily life been full of things that 
were i.nteresti ng to you? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
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These next questions are about how you have felt over the past month. 
Directions: Please read each question and fill in t he circle by the one statement that best describes how 
things have been for you during the past month. There are no right or wrong answers. 
1. How happy, satisfied, or pleased have you been with your pe.rsonal life during the past month? 
0 Extremely happy r could not have been more satisfied or pleased 
0 Very happy most of the time 
0 Generally, satisfied, pleased 
0 Somtimes faidy satisfied, sometimes fa a·ly unhappy 
0 Generally dissatisfied, unhappy 
0 Very dissatisfied, unhappy most of the time 
2. How much of the time have you felt lonely during the past month? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the! time 
3. How often did you become nervous or jumpy whe:n faced with excitement or unexpected 
situations during the past month? 
OAlways 
0 Very often 
Ofairly often 
OSometimes 
0 Almost never 
ONever 
4. During the past month, how much of the time have you felt that the futu re looks hopeful 
and promising? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
5. How much of the time, during the past month, has your daily life been full of things that 
were interesting to you? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
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6. How much of the time, during the past month, did you feel relaxed and free from tension? 
0 All of the time 
0 Most of the time 
0 A good btt of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
7. During the past month, how much of the time have you generally enjoyed the things you do? 
0 All of the time 
0 Most of the time 
0 A good btt of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
8. During the past month, have you had· any reason to wonder if you were losing your mind, or 
losing control over the way you act1 talk, t hink, feel or of your memory? 
0 No, not at all 
0 Maybe a little 
0 Yes, but not enough to be concemed or worried about 
0 Yes, and I have been a little COl)Cemed 
0 Yes, and I am qurte concerned 
0 Yes, and I am very much concerned about it 
9 . Did you feel depressed during the past month? 
0 Yes, to the point that I did not care a bout anything for days at a time 
0 Y.es, VeiY depressed almost every day 
0 Yes, quite depressed several times 
0 Yes, a little depressed now and then 
0 No, never felt depressed at all 
10. During the past month, how much of the time have you felt loved a.nd wanted? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
11. How much of the time, during the past month, have you been a very nervous person? 
0 All of the time 
0 Most of the time 
0 A good btt of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
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12. When you have got up in the morni:ng, this past month1 about how often did you expect to have 
an interesting day? 
0 Always 
0 Very often 
0 Fairly often 
OSometimeS 
0 Almost never 
ONever 
13. During the past month, how much of the time have you felt tense or "hig:hl'y strung"? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
14. During the past month, have you been in firm control of your behaviour, thoughts, emotions 
and feelings? 
0 Yes, vety definitely 
0 Yesr for the most part 
0 Yes, I guess so 
0 No, not too well 
0 No, and I am somewhat disturbed 
0 No, and I am very disturbed 
15. During the past month, how often did your han<is shake when you tried to do something? 
OAlways 
0 Ve1yoften 
0 Fairly often 
OSome-times 
0 Almost never 
ONever 
16. During the past month1 how often did you feel that you had nothing to look forward to'? 
0 Always 
0 Very often 
0 fa;rly often 
OSometimes 
0 Almost never 
ONever 
17. How muc:h of the time, during the past month1 did you feel calm and peacefu1? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
18. How muc:h of the time1 during the p-ast month, have you felt emotionally stable? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
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19. How much of the time, during the last month, have you felt downhearted and blue? 
OAlways 
0 Very often 
0 Fairly often 
◊Sometimes 
0 Almost never 
ONever 
20. How often have you felt like crying, during the past month? 
OAlways 
0 Very often 
0 Fairiy often 
OSome.times 
0 Almost never 
0 Never 
21. During the past month, how often have you felt th.at others would be better off if you were 
dead? 
0 Always O Sometimes 
0 Very often 
0 Fairly often 
0 Almost never 
ONe1,1er 
22. How much of the time, during the past month, ,were you able to relax without difficulty? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
23. How much of the time, during the past month, did you feel t:hat your love relationships, 
both loving and being loved, were full and complete? 
0 Always 
0 Very often 
0 Fairly often 
0 Sometimes 
0 Almost never 
0 Never 
24. How often, during the past month, d'id you feel that nothing turned out for you the way you 
wanted it to? 
0 Always 
0 Very often 
0 Fairly often 
OSometimes 
0 AJmost never 
ONever 
25. How much have you be-en bothered by nervousness, or your 'nerves' during the past month? 
0 Extremely oo, to the point where I could not 
take care of things 
0 Very much bothered 
0 Bothered quite a bit by naves 
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0 Bothered sometimes, enough to notice 
0 Bothered just a little by naves 
0 Not bothe,·ed at all by this 
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26. During the past month, how much of the time has living been a wonde-.rful adventure for you? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
27. How often, during tbe past month, have you felt so down in the dumps that nothing could ch,eer 
you up? 
0 Always O Sometimes 
0 Very often 
0 f airly often 
0 Almost never 
0 Never 
28. During the past month, did you think about taking your own life? 
0 Yes, vety often 
0 Yes, fairly often 
0 Yes, a coopfe of times 
0 Yes, at one time 
0 No, never 
29. During the past month, how nmc.h of the time have you felt restless, fidgety or impatient? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
30. During the .past month, how much of the t ime h.ave you been moody Oli brooded about 
t hings? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
31. How much of the time, during the past month, have you felt cheerfulr light hearted? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
32. During the past month, how often did you get rattled, upset or flustered? 
OAlways 
0 Very often 
0 Fairly often 
OSorne.times 
0 AJmost never 
0 Never 
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33. During the past month, have you been anxious or worried? 
0 Yes, extremefy to the point of being sick or almost sick 
0 Yes, vel'y much so 
0 Yes, quite a bit 
0 Yes, some, enough to bother me 
0 Yes, a little bit 
0 No, not at all 
34. During the past month, how much of the time w e.re you a happy person? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the time 
0 A little of the time 
0 None of the time 
AUST l.:A. Ll.11 
35. How often during the past month did you find yourself trying to calm down? 
0 Always 
0 Very often 
0 faidy often 
OSometimes 
0 Almost never 
ONever 
3 6. During the past month, how much of t h.e time have you been low or in very low spirits? 
0 All of the time 
0 Most of the time 
0 A good bit of the time 
0 Some of the. time 
0 A little of the time 
0 None of the time 
37. How often, du ring the past month, have you been waking up feeling fresh and rested? 
0 Alway~, every day 
0 Almost every day 
0 Most days 
0 Some days, but usually not 
0 Hardly ever _ 
0 Never wake up feeling rested 
38. During the past month, have you been under or felt you were under any strain, stress or 
pressure? 
0 Yesr .almost more than I could stand or bear 
0 Yesr quite a bit of pre--~re 
0 Yesr some - more than usual 
0 Yes, some, b ut about normal 
OYes, a little bit 
0 No1 not at all 
You have now completed Pait C of the AusUYI Questionnaire! 
Thank you for your time and assistance. 
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AusUVI Data Collection Sheet 
I LRO Initials: [D Participant ID: I I I I ] 
VISIT 1 
Date: DJ / [D / I I I I I 
Natural Hair Colour at 18 
years: □ Black □ Brown □ Blonde □ Red 
Eye colour: D Brown □ Hazel □ Blue or Grey □ Green 
Recent use of tanning products: 
Have you used any tanning products in the past month that may have 
affected the colour of your skin? 
1. Left inner upper arm 
2. Your face 
Skin Reflectance: 
Left Inner 
Upper Am l 
Left Cheek 
Flash Number 
[IIJ 
[IIJ 
[IIJ 
[IIJ 
[IIJ 
[IIJ 
YES 
□ 
□ 
NO 
□ 
□ 
400nm 
[I].DJ 
[IJ.[D 
[IJ.D] 
'420nm 
[IJ.DJ 
[[].[D 
[D.D] 
Expects<I ,..,.. 11.0 • 33.6% 
[I].[[] 
[IJ.[IJ 
[IJ.[D 
[[].[D 
[D.DJ 
[D.DJ 
Expect£& v.Wes 6.0 • 26.4% 
Blood Pressure: I I I I Systolic I I I I Diastolic 
Weight: I I I 1-1] kg Height: 1 1 1 1-0 Clll 
Body Mass Index: 
Weight (kgs) / (height (m)) ' DJ.□ 
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VISIT 2: 
Date: [D / [D / I I I I I 
LRO Initials: [D Participant ID: I I I I 
Recent use of tanning products: 
Have you used any tanning products in the past month that may have 
affected the colour of your skin? 
1. Left inner upper arm 
2. Your face 
Ski II Reflectance: 
Left Inn.er 
Uppe ,.. Ar-n1 
Left Cheek 
Flash Number 
[[]] 
[IIJ 
[[]] 
[IIJ 
[[]] 
[[]] 
YES 
□ 
□ 
400.nm 
NO 
□ 
□ 
[I].OJ 
·[IJ.[IJ 
OJ.OJ 
420nm 
OJ.OJ [IJ.[IJ [IJ.OJ 
Expected vah..tes 11.0 - 33.6% 
[IJ.[D [IJ.[D [IJ.OJ [IJ.OJ [IJ.OJ [IJ.OJ 
Expected Vcilues 6,Q • 26.4% 
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VISIT 3: 
Date: [D 1[IJ 1I 11 1 1 
LRO Initials: [D Partici pant ID: I I I I 
Recent use of t anning products: 
Have you used any tanning products in the past month that may have 
affected the colour of your skin? 
1, Left inner upper arm 
2. Your fa ce 
Skin Reflectance: 
Left Inner 
Upper Arm 
Left Cheek 
Flash Numbet: 
[II] 
[ill 
[ill 
[ill 
[ill 
[II] 
YES 
□ 
□ 
400nm 
NO 
□ 
□ 
[]][D 
[D.[I] 
420nm 
0][0 
[JJ.[IJ 
[]][IJ [JJ.[IJ 
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Expected v<ilues 11.0 • JJ.6% 
[IJ[JJ 
[IJ[JJ 
[D.[[] 
[JJ.[IJ 
[D.[IJ 
[[].[D 
Expected v<tlues 6,0 • 26.4% 
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VISIT 4 
Date: DJ / [D / I I I I I 
LRO Initials: [D Participant ID: I I I I 
Skin test: Site: 
Comments: 
____________ Arm: □ Right 
□ Left 
Administered by: __________ _ Time: DJ:DJ 
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Date: [I] / [I] / I I I I I 
,;-J,.;, 
= JAMES COOK 
"":"" UNlVERSITY 
AU:S"rRA LIA. 
LRO Initials: [I] Participant ID: I I I I 
Result of Skin Test 
Horizontal Axis [I] llllll Time: [IJ:[IJ 
Long Axis [I] mm 
■ 
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AusUVI Sunburn Data Sheet 
StudyNumber: ITIJ 
Study Visit: 2 3 5 Circle 
Date/sofSunburn: ~ ~ ~ 
Day of study: (l - 30) [TI [TI [TI 
Site/s of Sunburn / redness I windburn (Shade all affected areas) 
FRONT BACK 
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Severity of w1mt affected 
area ( circle) 
I . Redness without peeling 
2. Burn with peeling 
3. Very painful with Blistering 
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THEAUSTRAJ.IAN HAl l()NAt ONIVEflSITY SUN EXPOSURE AND PHYSICAL ACTIVITY DIARY AUSTRA LIA 
Instructions for completing diary 
Please read the following instructions on how to complete your sun exposure and physical activity diary. 
Qj 
::I 
c.. 
"0 
;;:r 
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n 
Qj 
l> For each day, record the date and check that your participant study number is entered on each page (tc ~ 
hand corner) <' 
;:;: 
Time Spent Outside in the Sun - For each hour interval , put a cross in the box under the amount of tir < 
spent in the sun during that interval. Please do not leave any hour interval(s) not crossed; ie. Cross 'O minute, !:?.. 
you have not been exposed to the sun for that particular hour interval. ~ 
< 
• Sunscreen: Put a cross in the 'YES' or 'NO' box on the top right of the page to indicate whether you ha, 
applied sunscreen that day. If sunscreen was applied, shade in the area(s) on the diagram to reflect where yo, 
applied sunscreen on your body that day. Please also put a box under the "Did you apply sunscreen" colum1 
against the hour(s) of the day at wh ich you applied sunscreen. If you did not apply sunscreen that day, do not 
cross in any of the boxes under this column. 
Clothing worn: Use the 'Sun diary clothing guide' to fi ll in the type of clothing you wore for each hour 
interval that day. Insert the relevant number that matches the picture for upper and lower body, headwear and 
footwear. Please make sure that you have specified all clothing worn at each hour interval, and that you have 
written a number in every box in this section. Please put a cross against the hour(s) that gloves have been , 
that day. If no gloves have been worn, do not put a cross in any of the boxes in the gloves column. 
Level of physical activity: Referring to the coding guide (0 = No activity; 2=moderate activity; 3 = Vigo, 
activity), specify your level of physical activity for every hour interval throughout the day. If you have complete, 
indoor and outdoor activities within an hour interval , for example, 30 minutes of moderate physical activity bet\ 
5-6am, in which 10 minutes was spent indoors warming-up, and 20 minutes outdoor jogging; write '2' in both in 
and outdoors box. 
* NB: Please do not include driving as a physical activity. 
w 
N 
00 
er to the following EXAMPLE as a guide to filling out the Sun Exposur, 
lCtivity diary 
- 01 -2009 
t ID - 103 (Will be assigned to you once enrolled) 
1: applied at 7am on face, neck, upper and lower limbs (excluding hands ar 
: noon 
1t outside in the sun and type of physical activity: 
40 minutes of slow jogging , outdoor 
1 0 minutes of walking to the bus stop and to work 
10 minutes of walking to restaurant, outdoor 
10 minutes of walking to work place; outdoor 
10 minutes of walking to the bus stop and to home 
30 minutes swimming; indoor 
othing worn: 
Short sleeved top with shorts, cap , enclosed shoes and gloves 
Long sleeved top with long trousers, no headwear. enclosed shoes worn u 
w 
N 
V) 
HO CLOTHING 
DY ON UPPER 
BODY 
-- ---o 
Ho upper 
' 
clothin11 
I HO CLOTHING 
►DY . j ON LOWER 
BODY 
• 
_I 
- o--I No lower 
clothinH 
R HO HEADWEAR 
' 
- ~ o 
Ho he,,dwem 
R NO FOOlWEARJ 
HANDWEAR 
!- 0 
No footwem 
SUN DIARY CLOTHING GUIDE 
11 ~ □ LJ u l v 1 -- 2 --r · 4-- - 5 - ·-
Bikini Swimst1it Cro1> top Singlet 1011 Sho11-sleeved Lo , 
1011 
V GJ [jJ ill □ D - f - - 2-- - 3-- ~-- 4- ;-- -- -· 5-·- - · 
Spee1los/luiefs Sho1ts or sholl Medium sholls Long 1rouse1s/ "1edM1111 skin 
skil1 01 ¾ uauts ieans 
Q jJ) ~ <0 ~ ( 
1 "/. j 4 ~ 
Beanie Cap Le!liom1t1ire's Buckel hat Wi de-luimme d I 
cal) hat 
~~ 
~" 
~ d7! l t7 ~ 
-- J 
~7 '~I __ ) "'-"""' 
., 
"/. J 4 ~ t 
Thong/open Semi.en dosed Enclosed Wo1kboots Long socks 
samk1ls shoes shoes 
w 
w 
0 
■ DAY1 FROITT 
Date OJ / [I] / I I I I 
TIME OUTDOORS DID YOU APPLY 
(Cross Oie boJc wtuct1 be:51 represenl s tte amoon1 of tme )'Ol 
$pCf1.1 001dOCl'.s dumg· each oocnoor E 1-c:t¥al ~ """' bc::k::ffl) SUNSCREEN 
0 <15 15-30 30,45 45-60 Oou;as ma;i,y 
minutes minutes minutes minutes minutes 8$ apptieable 
Momlno 
5-6am □ □ □ □ □ □ 
6-7am □ □ □ □ □ □ 
7 • Barn □ □ □ □ □ □ 
8 - 9am □ □ □ □ ,□ □ 
9-10am □ □ □ □ □ □ 
10- 11 am □ □ □ □ □ □ 
11 • 12am □ □ □ □ □ □ 
Aftemo-on 
12- 1 pm □ □ □ □ □ □ 
1 -2pm □ □ □ □ □ □ 
2 - 3pm □ □ □ □ □ □ 
3 - 4pm □ □ □ □ □ □ 
4 -Spm □ □ □ □ □ □ 
5-6pm □ □ □ □ □ □ 
6 -7pm □ □ □ □ □ □ 
BACK 
Participant ID: I I I I ■ 
Did you app ly any sunscreen today? 
§~ 1-- □ Yes □ No '" 
\
(;\ IF YES, SHADE THE D1/\GRMI ON THE LEFT TO SHOW THE PARTS ~ OF THE BODY THAT YOU AP PUE D SUNSCREEN TO TODAY 
DID YOU MAKE SURETHATYOUR WRISTBAND WAS NOT 
COVERED BY CLOTHING TODAY? 
□ Yes □ No 
INSERT 1NUMBER DENOTING TYPE OF SELECT NIJlillleR OE.NOllNG LEVE.OF CLOTH.ING WORN 
(You lllnl ~ Oflenl,IJrlberln e«1'I b0'.11) PKYSICAL ACTIVITY 
o,.,..,. O• No pll)Oleal-llj, Upper tower Head Footwear t• Milclphy■lcoi-y 
body body wear (croaa all 2 •M-• phyolcoi -~ 
.... _) 3•---· Indoors OUtdoors 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
■ 
Pka&C dOCufl11:fl1 any probknru; you had w:i'h ltw UV badge i:c .g . The badljjc ~ covered ·11y cbftll,g b approx 30 mrn.11es 'Mlilo I wa; OU15k!e a'I mi;1day ; 'hO b.lidge foil ofl" a1 3pm; tic bad''i1C gol wc1 etc). 
■ 
Appendix I: Electronic UVR dosimeter error checking 
This important phase of data cleaning was designed and conducted by James Liley who was 
based at the National Institute for Water and Atmospheric Research, New Zealand. This 
section is an adaptation of the methods described by him. 
1. Construction of a maximum-UVR model 
This part of the analysis sought to identify badge UVR readings which exceeded the maximum 
possible UVR available. Abnormally high readings of this type can occur due to electrical 
interference or similar phenomena, and can cause a falsely high value of aggregate UVR to be 
calculated . To identify such readings, a model of the UVR level attainable under a clear sky at a 
given hour was produced for the Canberra and Townsville sites. Individual dosimeter badge 
readings were then compared to this theoretical maximum, and badge readings exceeding 
twice the clear-sky UVR were marked as noise. 
The estimate of maximum available UVR assuming a clear sky was made for each daylight hour 
during the study period using a database of column ozone levels over each city and solar zenith 
angles for each time. 
An estimate of maximum available UVR under cloud cover was also made for each daylight 
hour during the study period using a composite of two databases and clear-sky available UVR 
adjusted for cloud data. Data from the first and second (non-overlapping) databases were 
used preferentially, with the third being used in areas where data was absent. 
Both the maximum potential clear-sky UVR and maximum potential cloudy-sky UVR were 
plotted along with data for each participant, although only clear-sky UVR was used for filtering 
data. This was due to the possibility that the contributing sensors (outdoor 
spectroradiometers) may have been exposed to clouds while the participants of the study 
were not (i.e. the participants were not assumed to always be close enough to the sensor site 
to experience cloud cover at exactly the same time as the sensor). 
2. Removal of repeats, oscillations, and baseline errors 
This part of the analysis located and removed known types of errors in data. These errors 
included 'repeat sequences', in which identical series of data readings of significant length 
were found to occur at more than one time, 'oscillations', in which readings would change 
erratically but remain bounded at a low value for a period of time, and 'baseline drift', in which 
the badge 'returns to a non-zero steady level. 
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A repeat sequence in a sequence of badge readings {time[i], data[i]) was formally defined as 
the presence of indices a, b with a<b, and integer n>30 such that 
1. data[a+ j] = data[b + j] for all O :S,.J < n 
2. At least 10 of {data[a] ,data[a+l] .. . data[a+n- lJ} are nonzero 
2. At least 5 of 
-Odata[a + l] -data[a]i ,ldata[a + 2]-data[a + a]! ... !data[a + n- l]-data[a+ n- 2)1} 
are non-zero. 
An exhaustive search was conducted for repeat sequences . Only one sequence of significant 
length was found to be present. An example is shown in figure 1.1. 
A baseline drift was deemed to be present in a sequence of badge readings {time[i], data[i]) if 
the moving median of the values of order 100 was nonzero; that is 
median(data[i - 50],data[i - 49] .... data[i + 50]) > 0 for all i in the sequence 
Several instances of baseline drift were found that were logged in an 'Error Log' file. 
Oscillations were not formally defined but were found easily by observation . Several instances 
were found, which are logged in the 'Error Log' file . 
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Appendix J: Development of the interpolation algorithm for missing or 
erroneous UVR dosimeter data 
James Liley (based at NIWA, NZ) developed the interpolation algorithm to replace missing or 
erroneous data obtained from the electronic dosimeters. This section is an adaptation of the 
methods described by him. 
Participant-specific data obtained from UVR dosimeters was sometimes unreliable for periods 
of time. Removal of such unreliable data meant that data series for each participant frequently 
had 'holes' during which data was unavailable. An interpolant function was constructed for 
each participant to estimate the amount of UVR to which they were exposed each hour. This 
interpolant could be used to 'fill' the holes, with the interpolant value being used as a 
substitute to the measured value when the latter was unavailable. 
The interpolant estimated individual UVR exposure for a participant at a given hour from the 
maximum cloud-adjusted UVR available during that hour, a diary entry recording the amount 
ohime the participant spend outside during that hour, and the participant's valid data 
measurements from other hours. When diary entries or maximum cloudless UVR 
measurements were unavailable, they were estimated. This meant that some interpolant 
values were more 'reliable' than others, in that they were more likely to represent the true 
measurement. The way in which each interpolant value was calculated yvas logged in order to 
quantify this. 
The calculation of the interpolant was based on the approximation that the proportion of 
maximum available cloud-adjusted UVR attained by a participant while outside (denoted F, for 
factor) was constant at a given hour. To illustrate this, assume a participant P had a measured 
UVR dose of u3 between 10:00 and 11:00 on Day 3, having recorded spending 15 minutes 
outside, during which the maximum available UVR was m 3 . If P recorded spending 30 minutes 
outside between 10:00 and 11:00 on Day 5 during which the maximum available UVR was m5 , 
the assumption is thatu 5 , the actual UVR attained by Pon Day 5, satisfies: 
~ 60 = !!._s__ 60 
m3 15 m5 30 
This is justified by the assumption that, had P spent 60 minutes outside on Day 3 instead of 15, 
the amount of UVR attained would be four (60/15) times the amount measured for the time 
( u3 ). The LHS of the above equation is thus the proportion of the maximum UVR available 
during that hour which would have been attained had P spent the whole hour outside, which is 
assumed to be consistent for all Days during the hour 10:00-11:00. 
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The above equation gives: 
30 u, 60 30 
u = m ---=m -F 5 5 60 m 3 15 
5 60 
where Fis assumed to be constant for a given participant at a given hour. 
In this case 
F=!!..l_ 60 
m3 15 
In practice, however, Fis defined as an average of values for at least four days; that is 
~ u 00 . . . . F = L, -'--- where d, 1s the time spent outside on day 1 
Ulu,defined} m; 15d; 
A similar strategy was used in the case where the participant recorded spending no time 
outside, with the equivalent of F (G) as the ratio of recorded UVR to maximum UVR while diary 
records were 0. 
As the interpolant required a complete diary record, in the sense of a workable estimate of 
time outside for each participant during each hour they were (meant to be) measuring UVR 
exposure, a 'complete' diary O' was constructed from recorded diary entries 0. Each missing 
diary entry D'(p0,d0 ,h0 ) for participant Po on Day d0 at hour h0 , was estimated from 
known values D(p,d,j)according to the formula 
, { 1-1(D(p0 ,d,h0 )) if at least four such values were available } D(p0A,ho)= . · 1-1(D(p,d,h0 )) 1fless than four values as above were available 
where 1-1(D(p0,d,h0)) denotes the mean of D(p0,d,h0) overall values of d for which it is 
defined (that is, the diary entries for that participant during that hour of the day) and 
µ(D(p,d,h0)) denotes the mean of D(p,d,h0) overall values of p,d for which it is defined 
(that is, the diary entries for any participant during that hour of the day) . 
Broadly, missing diary values were estimated from diary entries at similar times to those 
missing; if possible, from that participant during that hour on other days; if not, from all 
participants during that hour of the day. 
The interpolant also required a complete record M' of maximum UVR available for each hour 
during which participants were (meant to be) measuring UVR exposure, which was estimated 
from meas·ured records M. The value M'(d0 ,h0 ) for Day d0 at hour h0 was estimated if 
unknown as 
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{
p(M(d0 - 5,h0 ), M(d0 - 4,h0 ) ••• M(d0 + 5,h0 )) if at least four such values were avail able} M'(d ,h )= . 0 0 M(d0 ± 365,h0 ) if less than four values as above were available 
where ;1( .. . ) denotes the mean over available va lues, as before. The restriction of the 
contributing values to five days either side of d0 ensured that estimations of maximum UVR 
came from a similar time of year. 
Missing hourly values of maximum available cloud-adjusted UVR were estimated from values 
several days around it if possible, and if not, from those at a similar time and date on the 
previous year. 
The interpolant for participant Po on Day d0 at hour h0 , i(p0 ,d0 ,h0 ), was constructed in 
one of two ways according to whether the 'complete' diary entry D'(p0 ,d0 ,h0 ) was zero or 
nonzero. It required the use of the measured UVR values U(p0 ,d0 ,h0 ) where defined, as well 
as the arrays D' and M'. f(p0 ,d0 ,h0 ) was defined as: 
If D'(p0 ,d0 ,h0 ) ic O then 
l(p d h) = F M'(po.do ,ho) 
o, o, o D'(Po, do, ho) 
(a) p( U(po,d,ho) ) if at least four such values are avai lab le 
M'(p0,d,h0 )D'(p0,d,h0 ) 
h I U(p0,d,h) . . w ere F = \ (b) p(------"---":.._:__--'-----) 1f at least fo ur such Values are avmlable and (a) was undefined 
M'(p0,d,h)D'(p0,d,h) 
If D'(p0 ,d0 ,h0 ) = 0 then 
U(p ,d,h0 ) (c) p(-----C:...C--'-'--) if(a) and (b) were undefined 
M'(p,d,h0 )D'(p,d,h0 ) 
l (p0.do ,h0 ) = G · M'(p0 .do ,h0 ) 
) ( U(po,d,ho) ·r I ·1 bl (a JI ------'"---"-'----'-----'..:._) 1 at least four such va ues were ava1 a e 
M'(Po,d,ho) 
where G = ! (b) p( U(po,d,h) ) ifat least four such values were available and (a) was undefined 
M'(p0,d,h) 
( ) ( U(p,d,h0 ) ·r fi c JI ------'"----'--'------"-'-- ) 1 · (a) and (b) were unde med 
M'(p,d,h0 ) 
Broadly, th_e interpolant was set as a proportion of the maximum cloud-adjusted UVR 
according to the diary record of how much time was spent outside. The value was adjusted 
according to what proportion of maximum UVR was usually obtained when outside . If possible, 
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the adjustment factor was calculated to be specific for each participant at each hour. If this 
was not possible, it was calculated to be specific for each participant but non-specific for that 
hour. If this, too, was impossible, it was calculated to be specific for the hour, but non-specific 
for the participant (i.e. the average proportion attained by all participants at that hour) . 
The final dataset, M'(p0 ,d0 ,h0 ), was then simply defined as : 
{ 
M(p0 ,d0 ,h0 ) ifavailable } 
M'(Po.Jo,ho) = I(p d h ) ifM is unavai lable o, o, 0 
This form of interpolant has several useful features and several drawbacks. This interpolant 
has the advantage of being linear in Mand 1/D. Thus for two different days on which the 
maximum available UVR was identical at a given hour and a participant recorded spending 15 
minutes outside on the first day and 30 on the second, the interpolant would have twice the 
value on the second day as on the first. Likewise, if the participant spent 15 minutes outside on 
both days but the maximum available UVR was twice as high on the second, the value on the 
second day would be twice as high . 
Where possible, it is only assumed that a constant proportion of available UVR was attained by 
each participant during a given hour of the day, rather than consistently over the entire 
duration they were measuring. This allowance was made based on empirical evidence that the 
proportion of maximum available UVR attained while outside changes through the day. 
It is not assumed that when a participant recorded a diary entry of O they were exposed to no 
UVR during that hour. This was based on empirical evideace from existing measurements . 
Possibly this could be attributed to participants going outside for short periods (e.g. 30s -1 
min) such that the badge recorded a non-zero value, but the total length was not long enough 
for them to have considered they were going outside for 15 min . 
Diary values of 1-4 were individually too sparse to be treated in the same way as 'O' values 
(that is, the interpolant formed by averaging over normalised measured values during which 
the diary entry was O). Likewise, the method which was used to interpolate hours with a 
nonzero diary entry degenerated when the diary entries were O (as it involved dividing by the 
diary entry). 
Because the interpolant was constructed from measured data, interpolant values cannot be 
simply compared to measured values against a null hypothesis of being unrelated 
The interpolant tends to be more uniform in appearance than measured data, although 
average values over most indices are similar. 'Spikes' in measured data are very difficult to 
predict, and for this reason the interpolant tends to be much lower than measured values at 
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points where the measured value is very high, and slightly higher when the measured value is 
at a 'baseline' level. 
The interpolation procedure when the diary value is non-zero assumes that attained UVR over 
one hour is proportional to time spent outside during that hour. However, this assumption 
would lead to expecting the interpolant value at 0 whenever the diary entry was 0, which did 
not hold empirically. This meant that two different assumptions were used for the relation of 
attained UVR to time spent outside, according to whether or not the time outside was 
recorded as 0. 
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Appendix K: Peripheral blood mononuclear cell separation, storage and 
lymphocyte assays 
This section provides the standardised protocols used to collect, isolate, freeze and thaw 
peripheral blood mononuclear cells (PBMCs). Assays to delineate T-helper cell sub-populations 
by characteristic cytokine markers and cell surface markers are also described here . These 
protocols were developed from existing laboratory protocols and/ or manufacturers 
guidelines (e.g. PBMC separation using Ficoll gradient (397)) . 
Separation of PBMCs from whole blood 
Commence separation procedures within 12 hours (maximum of 16 hours) of blood being 
taken from the study participant. 
Preparation of Sample: 
1. Prepare sample at room temperature (18 -20°C) 
2. Ensure blood samples (in Acid -citrate-dextrose tubes; lnterpath services Cat No: 455055) are 
clearly labelled 
3. Label 10 ml glass test tubes (2 for every blood sample) 
4. Add 2ml of blood sample to a 10ml test-tube with a transfer pipette 
5. Add an equal amount of RPMI (lnvitrogen Cat. No 21870-092) (final volume 4ml) 
6. Mix by drawing the blood and the buffer in and out with transfer pipette. Avoid bubbles. 
Gently swirl mixture. 
Procedure for isolation of Lymphocytes : 
1. Label centrifuge tubes (2 for each blood sample) 
2. Remove blue cap on the bottle of Ficoll Paque PLUS (GE Healthcare Cat No: 17-1440-03) (Fig 
1) 
3. Invert the Ficoll bottle several times to ensure mixing 
4. Using aseptic technique, pierce the septum of the Ficoll bottle with syringe & attached 
needle; withdraw 3ml for each centrifuge tube from the inverted bottle (Fig 2). 
5. Add 3ml Ficoll to each centrifuge tube 
6. With Pasteur pipette, carefully layer diluted blood sample (4ml) onto the Ficoll. DO NOT mix 
the Ficoll and the diluted blood sample. Screw caps on securely. (Fig 3) 
7. Centrifuge at 400g" for 30 min at 18- 20°C. No b(ake. 
338 
8. Draw off the upper layer (plasma) using a clean Pasteur pipette leaving the lymphocyte layer 
undisturbed at the interface. Care should be taken not to disturb the lymphocyte layer. (Fig 4 
and 5) 
Figure: Steps involved in step-gradient separation of PBMCs from whole blood 
Fig I. 
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1. With a clean Pasteur pipette with pipette bulb, transfer the lymphocyte layer to a clean 
centrifuge tube. It is critical to remove all the material at the interface but in a minimal 
volume. Removing excess Ficoll causes granulocyte contamination; removing excess 
supernatant results in platelet contamination . 
2. Suspend the lymphocytes in 6 - 8ml of RPMI by gently drawing in and out of a transfer 
pipette . 
3. Centrifuge at 300g,, for 10 minutes at 18 - 20°C. 
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4. Remove from centrifuge. Carefully tip out and discard supernatant. 
5. Repeat steps 2 - 4. 
6. Suspend the lymphocytes in 6-8ml of RPMI by gently drawing in and out of a transfer 
pipette. Prior to last spin, remove 250µL and place in a micro-tube . Perform cell count. 
7. Final wash - repeat steps 3-4 
6. The lymphocytes are now washed, and ready for freezing. 
For larger blood sample volumes 
Larger volumes of blood may be processed with the same efficiency of separation by using 
centrifuge tubes of increased diameter while maintaining approximately the same heights of 
Ficoll (2.4cm) and blood sample (3.0cm) as in the above standard method. Increasing the tube 
diameter does not affect the separation time required . 
Typical Results Expected from this Method 
Lymphocytes 60+/-20% recovery of lymphocytes from the original sample 
95+/-5% of cells present in the lymphocyte fraction are mononuclear 
leukocytes 
-
>90% viability (measure by tryptan blue exclusion) 
Other cells 3 +/- 2% granulocytes 
5+/- 2% erythrocytes 
<0.5% of the total platelet count of the original blood sample 
Protocol for cell freezing 
Preparing the freezing medium 
The freezing medium is made at least several hours before it is required and is placed in the 
fridge. Usually there is a bottle already prepared waiting in the fridge. The freezing medium is 
made up as follows. 
1. Use a 50ml Falcon tube as a measuring cylinder, and transfer 70ml of RPMI into a 100 ml 
glass bottle . 
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2. Add 20ml of heat inactivated foetal calf serum (Serana Cat No: FCS-500). Mix well by 
swirling. 
3. Add 10 ml of DMSO. It is important to add the DMSO drop by drop whilst gently swirling 
the FCS medium at the same time. This is because there is an exothermic reaction, 
generating heat which can precipitate protein from the FCS. 
4. When above steps complete, cover glass cylinder with foil; Label with today's date; Place 
in fridge . Ensure that there is always a stock of freezing solution ready. 
Freezing lymphocytes 
1. Place ice in an Esky™ 
2. Label the cryovials with all the details of the cells - cell number, study code, date. 
3. Place the required number of cryovials on ice . 
4. Tip the required amount of freezing medium from the stock bottle of freezing medium 
into an appropriate size tube and place on ice. 
5. Place the centrifuge tube containing lymphocyte pellet on ice . Cells are to be frozen in 
aliquots of 2 x 106• 
6. Allow everything to pre-cool on ice for 15 mins. 
7. Place the ice Esky under the biohazard hood. Turn off the gas flame -the pipette is not to 
be flamed and the gas generates heat. 
8. Place no more than 5 vials in the rack at any one time. Loosen the lids. 
9. Rub up the cell pellet in the centrifuge tube, and then add pre-cooled freezing mixt ure (1 
ml per vial) with a 3mL transfer pipette and mix gently. 
10. Twist offthe loosened lid of a cryovial, add cell suspension and immediately recap the 
vial. When all vials are filled and capped, transfer them back onto ice . 
11. Immediately take the ice Esky with cryovials and isopropanol freezing container (Mr 
Frosty (Sigma)); lsopropanol (Sigma Cat No: 19516) to the -80°C freezer in the liquid 
nitrogen freezer room . 
12. Transfer the cryovials into the Mr Frosty and place in the -80°C freezer. 
13. Leave overnight, or over the weekend before transferring the vials to liquid nitrogen. 
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Protocol for recovering frozen cells from liquid nitrogen 
1. Remove the cryovial containing the frozen cells from liquid nitrogen storage and 
immediately place it into a 37°C water bath . 
2. Quickly thaw the ce lls(< 1 minute) by gently swirling the vial in the 37°C water bath until 
there is just a small amount of ice left in the vial. 
3. Transfer the vial into a laminar flow hood. Before opening, wipe the outside of the vial 
with 70% ethanol. 
4. Transfer thawed cells into a labelled 15ml tube and while agitating the cell suspension 
(swirling) add 10ml of cold RPMI (made up as 500ml RPMI + 50ml FCS + 10ml Hepes + 
5ml Pen Strep/Glutamine solution) drop-wise. 
5. Spin cell suspension at 4 degrees, 300g for 5mins and t hen decant. 
6. Resuspend the ce ll pellet and repeat steps 4 and 5 
7. Gently resuspend the cells in 2ml of RPMI, and transfe r into a 10ml test tube. Count the 
cell concentration using a Tryptan Blue stain .. 
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Lymphocyte assays 
Intracellular cytokine staining far lnterferon-v, IL-4, IL-10 and /L-17 
1. On a 24 well plate (BD Biosciences; Cat No 351147), label one well 'unstimulated' and one 
well 'stimulated' . Place lx106 thawed participant cells into each of these wells and top up 
to lmL with RPMI. 
2. Thaw a pre-aliquoted vial of Leukocyte Activation Cocktail (LAC) solution with BD Golgi 
Plug (BD Biosciences Cat No: 550583) and transfer into the well that is labelled stimulated . 
3. Incubate for 4hrs at 37degrees, 100% humidity, 5%CO2. 
4. In a 96 well plate (BD Biosciences; Cat No 353227) label 2 wells each for Thl/17 
unstimulated, Thl/17 stimulated, Th2 unstimulated and Th2 stimulated . These are the 
experiment wells. Also label a well for unstained control and one well for each single 
stained control (PerCP, FITC, PE and APC) . These act as the control wells. 
5. After incubation, add lO0µL of unstimulated cells to the four unstimulated labelled wells in 
the 96 well plate. Do the same for the stimulated cells. 
6. Add 40µL of stimulated cells to each of the control wells. 
7. Top up each well with lO0µL of cold FACS buffer (PBS+ 2% FCS + Sodium Azide) and spin at 
300g for 5mins. 
8. Decant the supernatant, vortex, and wash again with lO0µL FACS buffer. 
9. Decant, vortex and add 25µL of surface staining antibody cocktail (See below) to all of the 
experimental wells. 
10. Add 25µL of single dilutions of the surface antibodies (see below) to the appropriate 
control well and 25µL of FACS buffer to the unstained well. 
11. Incubate on ice for 20mins in the dark. 
12. Add 150µL of FACS buffer to all of the wells and spin at 300g for 5mins. 
13. Decant, vortex, and spin again in l00µL FACS buffer. 
14. Decant, vortex, add lO0µL of CytoFix/CytoPerril solution (BD Biosciences; Cat No 554714) 
to every well. 
15. Incubate for 20mins on ice. 
16. Add lO0µL of Perm wash (BD Biosciences, 1:10 in MQ water) and spin at 300g for 5mins. 
17. Decant, vortex and repeat step 16. 
343 
18. Decant, vortex, and add 25µL ofThl/17 intracellular stain ing antibodies (see below) to 
each of the experimental we lls. The contro l wells can be left without re-suspending. 
19. Incubate on ice for 20mins in the dark. 
20. Repeat steps 12 and 13. 
21. For the experiment wel l resuspend cell pellets in lO0µL of FACS buffer and combine the 
duplicate experiment wel ls into a labelled FACS tube for a final volume of 200µL. For the 
control wells, resuspend cell pellets in 150µL of FACS buffer and transfer into labelled FACS 
tubes. Samples are now ready for FACS ana lysis. 
Antibody cocktail 
Cell surface staining antibodies 
In FACS buffer make up the following dilution of antibodies. Calculate the volume needed by 
mu ltiplying the number of wells by 25µL. 
• CD3 FITC (BD Biosciences; Cat No 555339) 1:100 
• CD4 PerCP (BD Biosciences; Cat No 347324) 1:20 
For example: 8 wel ls x 25µL = 200µL, therefore add 2µL of CD3 FITC and lOµL of CD4 PerCP to 
178µL of FACS buffer. 
Intracellular cytokines staining antibodies 
In Permwash, make up the fo llowing di lutions of antibodies. Ca lcu la te the volume needed by 
mu ltiplying the number of we lls by 25µL. 
• IL-17 PE (BD Biosciences; Cat No 560436) 1:6 
• IFNy APC (BD Biosciences; Cat No 341117) 1:50 
• IL-4 PE (Miltenyi; Cat No 130-091-647) 1:30 
• IL-10 APC (BD Biosciences; Cat No 554707) 1:100 
Treg surface staining antibody cocktail 
In FACS buffer make up the following dilution of antibodies. Ca lcu late the vo lume needed by 
mu ltiplying the number of we lls by 25µL 
• CD4 PerCP (BD Biosciences; Cat No 347324) 1:50 
• CD25 APC (BD Biosciences; Cat No 340939) 1:6 
• CD127 FITC (eBioscience; Cat No 11-1278-42) 1:20 
Staining for T-helper cells by Foxp3 status 
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1. In a 96 well plate add lx105 thawed cells into 2 wells. 
2. Add lOOµL of FACS buffer and centrifuge for 5mins at 300g. 
3. Decant and vortex gently. 
4. Add 25µL surface staining antibodies (see below) to each well. 
5. Incubate on ice for 30mins in the dark. 
6. While incubating prepare fix and perm buffers. Fix buffer is made by diluting FoxP3 
buffer A (BD Bioscience) 1:10 in MQ water. Perm buffer is made by diluting FoxP3 
buffer B (BD Bioscience; Cat No 560098) 1:50 in Fix buffer. For one patient 200µL of 
Perm buffer and 400µL of fix buffer is required. 
7. After incubation add 150µL of FACS buffer and spin at 300g. Decant, vortex, and wash 
again with lOOµL of FACS buffer. 
8. Decant, vortex and then fix the cells by adding lOOµL of fix buffer to each well and 
incubate for 10mins in the dark at room temperature. 
9. Repeat step 7 only using lOOµL of FACS each time. 
10. Add 50µL of Perm buffer to each well and incubate for 30mins in the dark at room 
temperature. 
11. Repeat step 7. 
12. Add 25µL of FoxP3 PE antibody (made as a 1:6 dilution in Perm buffer) to each well. 
13. Incubate for 30mins in the dark at room temperature. 
14. Wash twice with 150µL of FACS buffer. 
15. Resuspend in lOOµL of FACS buffer and combine into a labelled FASC tube. 
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Appendix L: KLH vaccine-associated adverse event report 
The following report was sent to the Australian Therapeutic Goods Administration as 
notification of a possible adverse reaction related to the KLH vaccination . 
Participant Details 
Gender: 
Date of Birth: 
Ethnicity: 
Occupation: 
Medical History: 
Medications: 
Female 
17 Nov 1990 Age: 20 years 
Caucasian 
University student (physiotherapy) 
Coeliac disease, lgA deficiency, seasonal allergic rhinitis 
1. Juliet Oral contraceptive pill 
Previous Adverse Events to Vaccination: Nil 
Study Participation Details 
Study Number: 509 
Study Site: 
Date of First Visit: 
Date of Vaccination: 
Date of Skin test: 
Completed Study: 
Details of Adverse event 
Townsville 
10th August 2010 
17'h August 2010 
7'h September 2010 
Yes 
Site: L forearm 
Site: L forearm 
On day 10 (Aug 27) post-vaccination, participant 509 describes developing lesions over the 
dorsal aspect of her fingers bilaterally (R>L) . She describes the lesions as small (<3mm) that 
appeared like an "oil splashback burn - red outside with a white raised middle" . 
By day 15 (Sept 2) post vaccination, she describes over 20 lesions over her fingers and 
knuckles, with spread to her elbows. Her palms were involved by this stage with 'blisters' up 
to 5-6mm in diameter. Pain felt on applying pressure to lesions. 
On day 21(Sept 7) post vaccination, the blisters were resolving though she consulted a general 
practitioner at this stage. A punch biopsy was conducted. 
On day 24_(Sept 10) post vaccination, the skin biopsy revealed "spongiform dermatitis". No 
treatment was initiated. 
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On day 28 (Sept 14) post vaccination, participant reports resolution of lesions on the dorsum 
of her hands, with the palmar lesions also resolving. AusUVI Study doctor (AS) notified by 
Townsville Local Research Officer. 
On day 29 (Sept 15) post vaccination, participant was contacted by AusUVI Study doctor to 
review events. Participant did not describe use of new medications, soaps, cosmetics, hand 
rubs, animal exposures, new work or home environment. She denies having had a fever or 
systemic symptoms associated with blistering rash. There were no mouth or mucosal 
involvement and feet were spared. She denies having this type of rash previously. Rash had 
completely resolved. 
AusUVI Study Doctor's Impression 
The skin lesions followed the vaccination by 10 days. The lesions occurred only on the hands 
and forearms and were bilateral. The rash self-resolved without need for treatment. A biopsy 
revealed non-specific spongiform dermatitis. 
Spongiform dermatitis is a non-specific histological finding characterized by inter- and intra-
cellular oedema within the epidermis, elongation of the intercellular bridges and inflammatory 
cells within the dermis. This reaction can occur secondary to primary dermatological 
conditions, atopic precipitants or contact irritant, infection or drugs. 
Individuals with lgA deficiency are at increased risk of atopic and allergic reactions. 
This participant did not list any known drug allergies or previous reactions to vaccination. 
This reaction has not been previously described in the literature describing KLH use and is not 
current ly listed in the Invest igator's Brochure. No sim ilar reaction has occurred to others in 
the AusUVI Study (currently 44 enrolled - as of 19 October 2010), or in the Pilot study 
(conducted in 2009, n=21). The vaccine has been very well tolerated - transient mild redness 
at injection site, the only reported adverse effect in 2 participants in the AusUVI Study. 
Classification of Adverse Event: Unexpected adverse drug reaction 
Conclusion: Skin reaction is temporally related to vaccination - a causal relationship between 
KLH vaccination and skin reaction remains a possibility in the absence of another explanation. 
Action: 
• Therapeutic Goods Administration notified -ADRAC blue card submitted 
• Human Research Ethics Committee and Safety Monitoring Board notified 
• lgA deficiency to be added to list of exclusion criteria 
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• Importance of timely notification of study medical officer re-affirmed when a 
participant presents with potential vaccine-associated adverse reactions 
Picture taken September 14, 2010 (Day 28 post vaccination) 
Safety Monitoring Board comment 
From Report 1 (July 2010 - 14 October 2010) 
"There has been one non-serious unexpected adverse event, a self-resolving non-specific rash 
(spongiotic dermatitis) 10 days post vaccination, not at t~e si t e of vaccination but distally 
affecting the hands and forearms bilaterally. In reviewing the clinical and histological details of 
this case, we agree with the classification of this event as 'mild' and the relationship to the 
vaccination as 'possible'. We recommend that the AusUVI Study continue according to the 
current ethically-approved protocol." 
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